<PAGE>
   AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON             , 1997
                                                        REGISTRATION NO.
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
 
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549
                            ------------------------
                                   FORM SB-2
                             REGISTRATION STATEMENT
                        UNDER THE SECURITIES ACT OF 1933
                            ------------------------
                                ANTIVIRALS INC.
          (Name of small business issuer as specified in its charter)
 

<TABLE>
<S>                              <C>                            <C>
            OREGON                           2834                  93-0797222
 (State or other jurisdiction    (Primary Standard Industrial    (IRS Employer
              of                 Classification Code Number)     Identification
incorporation or organization)                                      Number)
</TABLE>

 
                          ONE SW COLUMBIA, SUITE 1105
                             PORTLAND, OREGON 97201
                                 (503) 227-0554
 
  (Address, including zip code, and telephone number, including area code, of
                   registrant's principal executive offices)
 
                             DENIS R. BURGER, PH.D.
                            CHIEF EXECUTIVE OFFICER
                                ANTIVIRALS INC.
                         ONE S.W. COLUMBIA, SUITE 1105
                             PORTLAND, OREGON 97258
                                 (503) 227-0554
 
 (Name, address, including zip code, and telephone number, including area code,
                             of agent for service)
                         ------------------------------
 
                                   COPIES TO:
 

<TABLE>
<S>                                       <C>
  JACK W. SCHIFFERDECKER, JR., ESQ.              MARK A. VON BERGEN, ESQ.
       BYRON W. MILSTEAD, ESQ.                    SUSAN L. PRESTON, ESQ.
 ATER WYNNE HEWITT DODSON & SKERRITT          WEISS, JENSEN, ELLIS & HOWARD
                 LLP
     222 SW COLUMBIA, SUITE 1800                 2300 U.S. BANCORP TOWER
        PORTLAND, OREGON 97201                    PORTLAND, OREGON 97204
      TELEPHONE: (503) 226-1191                 TELEPHONE: (503) 243-2300
</TABLE>

 
                         ------------------------------
 
        APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC:
  As soon as practicable after this Registration Statement becomes effective.
                         ------------------------------
 
    If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. / /
 
    If this Form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. / /
 
    If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box. If any of the securities being registered on
this form are to be offered on a delayed or continuous basis pursuant to Rule
415 under the Securities Act, check the following. /X/
 
                        CALCULATION OF REGISTRATION FEE

<TABLE>
<CAPTION>
                                                                                                                PROPOSED MAXIMUM
                              TITLE OF EACH CLASS OF                                       AMOUNT TO             OFFERING PRICE
                           SECURITIES TO BE REGISTERED                                 BE REGISTERED(1)            PER UNIT(1)
<S>                                                                                 <C>                      <C>
 (a) Units (2) each consisting of:................................................         1,725,000                 $10.00
     (i) One share of Common Stock, $.0001 par value, and
    (ii) Warrant to Purchase One Share of Common Stock
 (b) Units (3) each consisting of:................................................          150,000                   12.00
     (i) One share of Common Stock, $.0001 par value, and
    (ii) Warrant to Purchase One Share of Common Stock
 (c) Common Stock, $.0001 par value (4)...........................................         1,725,000                  15.00
 (d) Common Stock, $.0001 par value (5)...........................................          150,000                   15.00
Total.............................................................................
 
<CAPTION>
                                                                                       PROPOSED MAXIMUM
                              TITLE OF EACH CLASS OF                                       AGGREGATE                AMOUNT OF
 
                           SECURITIES TO BE REGISTERED                                 OFFERING PRICE(1)        REGISTRATION FEE
 
<S>                                                                                 <C>                      <C>
 (a) Units (2) each consisting of:................................................        $17,250,000               $5,948.28
 
     (i) One share of Common Stock, $.0001 par value, and
    (ii) Warrant to Purchase One Share of Common Stock
 (b) Units (3) each consisting of:................................................         1,800,000                 620.69
 
     (i) One share of Common Stock, $.0001 par value, and
    (ii) Warrant to Purchase One Share of Common Stock
 (c) Common Stock, $.0001 par value (4)...........................................        25,875,000                8,922.42
 
 (d) Common Stock, $.0001 par value (5)...........................................         2,250,000                 775.87
 
Total.............................................................................        $47,175,000              $16,267.26
 
</TABLE>

 
(1) Estimated solely for the purpose of calculating the registration fee
    pursuant to Rule 457.
 
(2) Includes 225,000 Units that the Underwriters have the option to purchase to
    cover overallotments, if any.
 
(3) Issuable upon exercise of a warrant to be granted to the representative of
    the Underwriters to purchase up to 10% of the Units sold in the Offering,
    excluding any overallotments, at 120% of the Unit Offering Price.
 
(4) Issuable upon exercise of the Common Stock Purchase Warrants registered
    hereby at 150% of the Unit Offering Price. The exercise price of such Common
    Stock Warrants is estimated solely for the purpose of determining the
    registration fee. An indeterminate number of additional shares of Common
    Stock are registered hereunder that may be issued, as provided in the Common
    Stock Purchase Warrants, if provisions in such warrants against dilution
    become operative. No additional registration fee is included for such
    shares.
 
(5) Issuable upon exercise of the Common Stock Purchase Warrants which are
    issuable upon exercise of the warrant to be granted to the representative of
    the Underwriters to purchase up to 10% of the Units sold in the Offering,
    excluding any overallotments, at 120% of the Unit Offering Price.
                         ------------------------------
 
    THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR
DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL
FILE A FURTHER AMENDMENT THAT SPECIFICALLY STATES THAT THIS REGISTRATION
STATEMENT SHALL HEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(A) OF
THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME
EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(A),
MAY DETERMINE.
 
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------

<PAGE>
INFORMATION CONTAINED HEREIN IS SUBJECT TO COMPLETION OR AMENDMENT. A
REGISTRATION STATEMENT RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION. THESE SECURITIES MAY NOT BE SOLD NOR MAY
OFFERS TO BUY BE ACCEPTED PRIOR TO THE TIME THE REGISTRATION STATEMENT BECOMES
EFFECTIVE. THIS PROSPECTUS SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE
SOLICITATION OF AN OFFER TO BUY NOR SHALL THERE BE ANY SALE OF THESE SECURITIES
IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR
TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH STATE.

<PAGE>
                  SUBJECT TO COMPLETION, DATED JANUARY   ,1997
 
PROSPECTUS
 
                                1,500,000 UNITS
 
                                     [LOGO]
 
               EACH UNIT CONSISTING OF ONE SHARE OF COMMON STOCK
                     AND ONE COMMON STOCK PURCHASE WARRANT
 
    ANTIVIRALS INC. ("ANTIVIRALS" or the "Company") is hereby offering 1,500,000
units ("Units"), each Unit consisting of one share (the "Shares") of the
Company's common stock, $.0001 par value (the "Common Stock"), and one warrant
to purchase one share of Common Stock (the "Warrants"). The Units will separate
immediately upon issuance, and Common Stock and Warrants that make up the Units
will trade only as separate securities. Each Warrant initially entitles the
holder thereof to purchase one share of Common Stock at a price of $      per
share (150% of the initial public offering price of the Units), subject to
adjustment under certain circumstances. The Warrants are exercisable at any
time, unless previously redeemed, until the fifth anniversary of this
Prospectus, subject to certain conditions. The Company may redeem the Warrants,
in whole or in part, at any time upon at least 30 days prior written notice to
the registered holders thereof, at a price of $.25 per Warrant, provided that
the closing bid price of the Common Stock has been at least 200% of the
then-current Warrant exercise price for each of the 20 consecutive trading days
immediately preceding the date of the notice of redemption.
 
    Prior to this offering, there has been no public market for the Units,
Common Stock or Warrants, and there can be no assurance that an active trading
market will develop or be maintained following the offering. See "Underwriting"
for the factors to be considered in determining the initial public offering
price. It currently is anticipated that the initial public offering price will
be between $8.00 and $10.00 per Unit. The initial public offering price of the
Units will be determined by negotiation between the Company and Paulson
Investment Company, Inc., the representative of several Underwriters (the
"Representative").
 
    Application has been made to have the Common Stock and Warrants approved for
quotation on the Nasdaq National Market under the symbols "AVII" and "AVIIW,"
respectively.
 
    THE SECURITIES OFFERED HEREBY INVOLVE A HIGH DEGREE OF RISK. SEE "RISK
FACTORS" BEGINNING AT PAGE 6.
                             ---------------------
 
 THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES
     AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS
           THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE
              SECURITIES COMMISSION PASSED UPON THE ACCURACY
                    OR ADEQUACY OF THIS PROSPECTUS. ANY
                         REPRESENTATION TO THE CONTRARY
                          IS A CRIMINAL OFFENSE.
 

<TABLE>
<CAPTION>
                                                       UNDERWRITING          PROCEEDS TO
                               PRICE TO PUBLIC         DISCOUNT (1)          COMPANY (2)
<S>                          <C>                   <C>                   <C>
Per Unit...................           $                     $                     $
Total (3)..................           $                     $                     $
</TABLE>

 
(SEE ACCOMPANYING FOOTNOTES ON NEXT PAGE)
 
    The Units offered by this Prospectus are offered by the several Underwriters
subject to prior sale, when and if delivered to and accepted by the
Underwriters, and subject to the right to reject any order in

<PAGE>
whole or in part and to certain other conditions. It is expected that delivery
of the Units will be made in New York, New York on or about            , 1997.
 
                            ------------------------
 
                        PAULSON INVESTMENT COMPANY, INC.
                                ----------------
 
               THE DATE OF THIS PROSPECTUS IS            , 1997.

<PAGE>
(FOOTNOTES CONTINUED FROM FRONT COVER PAGE)
 
(1) Excludes a non-accountable expense allowance equal to 2.5% of the gross
    proceeds of this offering payable to the Representative, and the value of
    the five-year warrant (the "Representative's Warrant") entitling the
    Representative to purchase up to 150,000 Units at a price of $    per Unit
    (120% of the initial public offering price of the Units). The Company has
    agreed to indemnify the Underwriters against certain liabilities, including
    liabilities under the Securities Act of 1933, as amended (the "Securities
    Act"). See "Underwriting."
 
(2) Before deducting estimated expenses payable by the Company estimated at
    $812,500, including the Representative's non-accountable expense allowance.
 
(3) The Company has granted the Underwriters a 45-day option (the "Overallotment
    Option") to purchase up to 225,000 additional Units on the same terms as set
    forth above to cover overallotments, if any. If the Underwriters exercise
    such option in full, the total Price to Public, Underwriting Discount and
    Proceeds to Company will be $         , $         and $         ,
    respectively. See "Underwriting."
 
    The Company has not previously been subject to the reporting requirements of
the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The
Company intends to furnish its shareholders with annual reports containing
financial statements audited by its independent auditors and quarterly reports
containing unaudited financial information for each of the first three quarters
of each fiscal year.
 
    IN CONNECTION WITH THIS OFFERING, THE UNDERWRITERS MAY OVER-ALLOT OR EFFECT
TRANSACTIONS WHICH STABILIZE OR MAINTAIN THE MARKET PRICE OF THE COMMON STOCK OR
WARRANTS AT A LEVEL ABOVE THAT WHICH MIGHT OTHERWISE PREVAIL IN THE OPEN MARKET.
SUCH TRANSACTIONS MAY BE EFFECTED ON THE NASDAQ NATIONAL MARKET OR OTHERWISE.
SUCH STABILIZING, IF COMMENCED, MAY BE DISCONTINUED AT ANY TIME.
 
                            ------------------------
 
    This prospectus includes trademarks and registered trademarks of the
Company, including NEU-GENE-REGISTERED TRADEMARK- and CYTOPORTER-TM-, and
trademarks and registered trademarks of other companies.
 
                                       2

<PAGE>
                               PROSPECTUS SUMMARY
 
    THE FOLLOWING SUMMARY IS QUALIFIED IN ITS ENTIRETY BY, AND SHOULD BE READ IN
CONJUNCTION WITH THE MORE DETAILED INFORMATION AND THE FINANCIAL STATEMENTS AND
NOTES THERETO APPEARING ELSEWHERE IN THIS PROSPECTUS. EXCEPT AS OTHERWISE NOTED,
ALL INFORMATION IN THIS PROSPECTUS ASSUMES (I) NO EXERCISE OF THE OVERALLOTMENT
OPTION, THE WARRANTS OR THE REPRESENTATIVE'S WARRANT, (II) A 1-FOR-3 REVERSE
SPLIT OF THE COMMON STOCK WHICH WAS COMPLETED ON NOVEMBER 4, 1996 AND (III)
EXCEPT AS OTHERWISE INDICATED, NO SHARES OF COMMON STOCK WILL BE TENDERED TO THE
COMPANY IN CONNECTION WITH THE RESCISSION OFFERING TO BE UNDERTAKEN BY THE
COMPANY IMMEDIATELY PRIOR TO THIS OFFERING. SEE "RISK FACTORS--POTENTIAL
LIABILITY ARISING FROM RESCISSION RIGHTS OF CERTAIN SHAREHOLDERS," "DESCRIPTION
OF SECURITIES" AND "UNDERWRITING."
 
    THIS PROSPECTUS CONTAINS, IN ADDITION TO HISTORICAL INFORMATION,
FORWARD-LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES. THE COMPANY'S
ACTUAL RESULTS OR EXPERIENCE COULD DIFFER SIGNIFICANTLY FROM THOSE DISCUSSED IN
THE FORWARD-LOOKING STATEMENTS. FACTORS THAT COULD CAUSE OR CONTRIBUTE TO SUCH
DIFFERENCES INCLUDE, BUT ARE NOT LIMITED TO, THOSE DISCUSSED IN "RISK FACTORS"
AS WELL AS THOSE ELSEWHERE IN THIS PROSPECTUS.
 
                                  THE COMPANY
 
    ANTIVIRALS is a pioneer company in the field of gene-inactivating technology
referred to as antisense and has developed a patented class of antisense
compounds which may be useful in the treatment of a wide range of human
diseases. The Company also has developed new drug delivery technology which may
be useful with many FDA-approved drugs as well as with its antisense compounds.
The Company's drug development program has two areas of near-term focus:
 
    - NEU-GENE antisense compounds for selected applications, and
 
    - CYTOPORTER drug delivery engines for enhanced delivery of FDA-approved
      drugs with delivery problems.
 
    The Company's long-term product development program combines its NEU-GENE
and CYTOPORTER technologies to produce combination drugs with potential
applications for many human diseases. The Company has 19 issued patents and
several patent applications covering the basic compositions of matter, methods
of synthesis, and medical uses of NEU-GENE and CYTOPORTER compounds.
 
    Antisense technology has the potential to provide safe and effective
treatment for a broad range of diseases that previously have been difficult to
address, including viral and host diseases. The Company's new approach uses
synthetic compounds designed to inactivate selected genetic sequences that
underlie the disease process and thereby halt the disease. Targeting genetic
sequences with antisense compounds provides the selectivity that is not
available in conventional drug development which typically targets proteins
directly. The antisense approach specifically inhibits the mechanisms which
underlie the production of disease-producing proteins.
 
    To reach their therapeutic targets, many drugs must cross tissue and
cellular barriers. Drugs that have an intracellular site of action must cross
the lipid (fat-like) barrier of cellular membranes to move from the aqueous
environment in blood into the interior of target cells. Therefore, these drugs
must achieve solubility in both water and lipids. Since few compounds have these
solubility characteristics, many drug candidates are a compromise between
inherent solubility and effective delivery. This trade-off reduces efficacy and
may significantly heighten toxicity of many drug candidates, as well as many
FDA-approved drugs.
 
    The Company has developed two distinct technologies to address the critical
issues in drug development: selectivity for the target and delivery to the
target. The Company's NEU-GENE antisense technology addresses the issue of drug
selectivity and its CYTOPORTER drug delivery technology addresses delivery
problems with FDA-approved drugs and antisense compounds. The patented structure
of the Company's NEU-GENE compounds distinguishes its antisense technology from
competing technologies and provides
 
                                       3

<PAGE>
the selectivity for a single disease target that is the hallmark of antisense
drug development. The Company's molecular engine, CYTOPORTER, is designed to
transport drugs with delivery problems across the lipid barrier of cellular
membranes into the interior of cells to reach their targets.
 
    The first application of the Company's NEU-GENE antisense technology is
designed to treat restenosis, a cardiovascular disease. The Company is currently
in pre-clinical development with this compound and expects to file an IND to
begin clinical trials in 1997. The Company's first planned drug delivery
products combine its CYTOPORTER delivery engine with two FDA-approved drugs that
have delivery problems. These drugs, paclitaxel (Taxol-Registered Trademark-)
and cyclosporin, will both be off patent by late 1997 and could have much
broader usage if their delivery problems were reduced. The Company expects to
file an IND to begin clinical trials with its enhanced form of paclitaxel and to
initiate pre-clinical studies with its enhanced form of cyclosporin in 1997.
 
    The Company plans to market its initial products through marketing
agreements or other licensing arrangements with large pharmaceutical companies.
The Company intends to retain manufacturing rights to all products incorporating
its technology, whether such products are marketed directly by the Company or
through collaborative agreements with industry partners.
 
    The Company's principal executive office is located at One S.W. Columbia,
Suite 1105, Portland, Oregon 97258, where the telephone number is (503)
227-0554.
 
                                  THE OFFERING
 

<TABLE>
<S>                                 <C>
Securities offered................  1,500,000 Units, each consisting of one share of Common
                                    Stock and one Warrant to purchase one share of Common
                                    Stock. The Common Stock and Warrants will be separately
                                    tradeable immediately following this offering. See
                                    "Description of Securities."
 
Common Stock to be outstanding
  after this offering.............  10,279,763 shares(1)
 
Use of proceeds...................  To fund research and development, and for working
                                    capital, and other general corporate purposes. See "Use
                                    of Proceeds".
 
Proposed Nasdaq National Market
  symbols.........................  Common Stock--AVII
 
                                    Warrants--AVIIW
</TABLE>

 
- ------------------------
 
(1) Excludes an aggregate of 1,126,886 shares of Common Stock issuable upon
    exercise of stock options outstanding at December 31, 1996, and an aggregate
    of 432,498 shares of Common Stock issuable upon exercise of outstanding
    warrants as of December 31, 1996. An additional 206,447 shares are reserved
    for issuance under the Company's Stock Incentive Plan. See "Capitalization
    and Management--Stock Incentive Plan."
 
                                       4

<PAGE>
                             SUMMARY FINANCIAL DATA
 

<TABLE>
<CAPTION>
                                         YEARS ENDED DECEMBER
                                                 31,
                                        ----------------------
                                           1994        1995
                                        ----------  ----------    NINE MONTHS ENDED      PERIOD
                                                                    SEPTEMBER 30,       FROM JULY
                                                                ----------------------  22, 1980
                                                                   1995        1996     (INCEPTION)
                                                                ----------  ----------   THROUGH
                                                                                        SEPTEMBER
                                                                (UNAUDITED) (UNAUDITED) 30, 1996
                                                                                        ---------
                                                                                        (UNAUDITED)
<S>                                     <C>         <C>         <C>         <C>         <C>
STATEMENTS OF OPERATIONS DATA:
Revenues, from grants and research
  contracts...........................  $   --      $   82,500  $  82,500   $  16,827   $679,097
                                        ----------  ----------  ----------  ----------  ---------
Operating expenses:
  Research and development............   1,631,130   2,097,796  1,640,906   1,177,157   8,459,177
  General and administrative..........     678,705     609,723    437,159     432,252   4,368,023
                                        ----------  ----------  ----------  ----------  ---------
    Total operating expenses..........   2,309,835   2,707,519  2,078,065   1,609,409   12,827,200
                                        ----------  ----------  ----------  ----------  ---------
Other income..........................      63,563      68,133     54,888     177,616    395,016
                                        ----------  ----------  ----------  ----------  ---------
Net loss..............................  $(2,246,272) $(2,556,886) $(1,940,677) $(1,414,966) $(11,753,087)
                                        ----------  ----------  ----------  ----------  ---------
                                        ----------  ----------  ----------  ----------  ---------
Net loss per share(1).................  $    (0.33) $    (0.37) $   (0.28 ) $   (0.18 )
                                        ----------  ----------  ----------  ----------
                                        ----------  ----------  ----------  ----------
Shares used in per share
  calculation(1)......................   6,726,625   6,982,459  6,966,583   8,051,477
                                        ----------  ----------  ----------  ----------
                                        ----------  ----------  ----------  ----------
</TABLE>

 

<TABLE>
<CAPTION>
                                                                    DECEMBER
                                                                    31, 1995
                                                                   ----------        SEPTEMBER 30, 1996
                                                                                ----------------------------
                                                                                 ACTUAL     AS ADJUSTED(2)
                                                                                --------  ------------------
                                                                                (UNAUDITED)    (UNAUDITED)
<S>                                                                <C>          <C>       <C>
BALANCE SHEET DATA:
Working capital..................................................   $646,814    $3,455,651    15$,063,151
Total assets.....................................................  2,324,736    4,788,878    16,396,378
Common stock subject to rescission...............................  3,121,965    3,121,965     3,121,965
Deficit accumulated during the development stage.................  (10,338,121) (11,753,087)   (11,753,087)
Total shareholders' equity (deficit).............................  (1,051,293)  1,465,290    13,072,790
</TABLE>

 
- ------------------------------
 
(1) See Note 2 of Notes to Financial Statements for an explanation of the
    determination of the number of shares used in computing net loss per share.
 
(2) Adjusted to give effect to the application of the estimated net proceeds of
    this offering based upon an assumed initial public offering price of $9.00
    per Unit. See "Use of Proceeds" and "Management's Discussion and Analysis of
    Financial Condition and Results of Operations."
 
                                       5

<PAGE>
                                  RISK FACTORS
 
    IN EVALUATING THE COMPANY AND ITS BUSINESS, PROSPECTIVE INVESTORS SHOULD
CAREFULLY CONSIDER THE FOLLOWING RISKS IN ADDITION TO THE OTHER INFORMATION
CONTAINED ELSEWHERE HEREIN. BECAUSE ANY INVESTMENT IN THE COMPANY'S CAPITAL
STOCK INVOLVES A HIGH DEGREE OF RISK, ONLY INVESTORS WHO CAN ACCOMMODATE SUCH
RISKS, INCLUDING A COMPLETE LOSS OF THEIR INVESTMENT, SHOULD PURCHASE THE UNITS.
 
    DEVELOPMENT STAGE COMPANY; HISTORY OF OPERATING LOSSES.  The Company is a
development stage biotechnology company. Since its inception in 1980 through
September 30, 1996, the Company had incurred losses of $11,753,087,
substantially all of which resulted from expenditures related to research and
development and general and administrative expenses. The Company has not
generated any material revenues from product sales to date, and there can be no
assurance that material revenues from product sales will ever be achieved.
Moreover, even if the Company does realize revenues from product sales, the
Company nevertheless expects to incur significant operating losses over the next
several years. The financial statements accompanying this Prospectus have been
prepared assuming that the Company will continue as a going concern. The
Company's ability to achieve a profitable level of operations in the future will
depend in large part on the completion of product development of its antisense
and/or drug delivery products, obtaining regulatory approvals for such products
and bringing several of these products to market. The likelihood of the
long-term success of the Company must be considered in light of the expenses,
difficulties and delays frequently encountered in the development and
commercialization of new pharmaceutical products, competitive factors in the
marketplace as well as the burdensome regulatory environment in which the
Company operates. There can be no assurance that the Company will ever achieve
significant revenues or profitable operations. See "Selected Financial Data" and
"Management's Discussion and Analysis of Results of Operations and Financial
Condition."
 
    TECHNOLOGICAL UNCERTAINTY; EARLY STAGE OF PRODUCT DEVELOPMENT; NO ASSURANCE
OF REGULATORY APPROVALS. The Company's proposed products are in the pre-clinical
stage of development and will require significant further research, development,
clinical testing and regulatory clearances. The Company has no products
available for sale other than research reagents and does not expect to have any
products resulting from its research efforts commercially available for at least
several years. None of the Company's proposed products has been tested in
humans, nor has the Company filed an Investigational New Drug Application
("IND") with the United States Food and Drug Administration ("FDA") on any of
its products currently under research and development. The Company's proposed
products are subject to the risks of failure inherent in the development of
products based on innovative technologies. These risks include the possibilities
that some or all of the proposed products could be found to be ineffective or
toxic, or otherwise fail to receive necessary regulatory clearances; that the
proposed products, although effective, will be uneconomical to manufacture or
market; that third parties may now or in the future hold proprietary rights that
preclude the Company from marketing its products; or that third parties will
develop and market a superior or equivalent products. Accordingly, the Company
is unable to predict whether its research and development activities will result
in any commercially viable products or applications. Furthermore, due to the
extended testing and regulatory review process required before marketing
clearance can be obtained, the Company does not expect to be able to
commercialize any therapeutic drug for at least several years, either directly
or through any potential corporate partners or licensees. Although the Company
and others have demonstrated the effectiveness of antisense compounds in living
cells and, in some cases, in animal models, none of the Company's proposed
products has been tested in humans and there can be no assurance that the
Company's proposed products will prove to be safe or effective in humans or will
receive the regulatory approvals that are required for commercial sale.
 
    NEED FOR ADDITIONAL FUNDING; UNCERTAINTY OF ACCESS TO CAPITAL.  The Company
will require substantial funds for further development of its potential products
and to commercialize any products that may be developed. The Company's capital
requirements depend on numerous factors, including the progress of its research
and development programs, the progress of pre-clinical and clinical testing, the
time and cost
 
                                       6

<PAGE>
involved in obtaining regulatory approvals, the cost of filing, prosecuting,
defending and enforcing patent claims and other intellectual property rights,
competing technological and market developments and the ability of the Company
to establish collaborative arrangements. The Company has no current anticipated
sources of funding beyond the proceeds from this offering. The Company believes
that its existing capital resources, including the estimated net proceeds of
this offering, will be sufficient to satisfy its current and projected funding
requirements for at least 24 months from the date of this Prospectus. The
Company anticipates that after 24 months, it will require substantial additional
capital. Moreover, if the Company experiences unanticipated cash requirements
during the next 24 months, the Company could require additional capital to fund
its operations, continue research and development programs and to continue the
pre-clinical and clinical testing of its potential products and to commercialize
any products that may be developed. The Company may seek such additional funding
through public or private financings, collaborative arrangements, or other
arrangements with third parties. There can be no assurance that additional funds
will be available on acceptable terms, if at all. The Company may receive
additional funds upon the exercise from time to time of the Warrants and other
outstanding warrants and stock options, but there can be no assurance that any
such warrants or stock options will be exercised or that the amounts received
will be sufficient for the Company's purposes. If additional funds are raised by
issuing equity securities, further substantial dilution to existing
shareholders, including purchasers of the Units offered hereby, may result. If
adequate funds are not available, the Company may be required to delay, scale
back or eliminate one or more of its development programs, or to obtain funds by
entering into arrangements with collaborative partners or others that may
require the Company to relinquish rights to certain of its products or
technologies that the Company would not otherwise relinquish. See "Use of
Proceeds" and "Management's Discussion and Analysis of Financial Condition and
Results of Operations."
 
    LACK OF OPERATING EXPERIENCE.  To date, the Company has engaged exclusively
in the development of pharmaceutical technology. Although members of the
Company's management have experience in biotechnology company operations, the
Company has no experience in manufacturing or procuring products in commercial
quantities or selling pharmaceutical products and has only limited experience in
negotiating, setting up and maintaining strategic relationships, conducting
clinical trials and other later-stage phases of the regulatory approval process.
There can be no assurance that the Company will successfully engage in any of
these activities. See "Management."
 
    MANUFACTURING.  The Company intends to undertake the manufacture of its
products through the clinical development phase. The Company has not previously
manufactured pharmaceutical products of any kind, nor has it manufactured
antisense or drug delivery compounds in commercial quantities. Establishing
manufacturing facilities will require the retention of experienced personnel and
compliance with complex regulations relating to the manufacture of
pharmaceutical products. There is no assurance that the Company will be
successful in establishing and operating a manufacturing facility. See
"Business-- Manufacturing."
 
    DEPENDENCE ON THIRD PARTIES FOR CLINICAL TESTING, MANUFACTURING AND
MARKETING.  The Company does not have the resources and does not currently
intend to conduct later-stage human clinical trials itself or to manufacture all
of its proposed products for commercial sale. The Company therefore intends to
seek larger pharmaceutical company partners to conduct such activities for most
or all of its proposed products and to contract with third parties for the
manufacture of its proposed products for commercial sale. In connection with its
efforts to secure corporate partners, the Company will seek to retain certain
co-marketing rights to certain of its proposed products, so that it may promote
such products to selected medical specialists while its corporate partner
promotes these products to the general medical market. There can be no assurance
that the Company will be able to enter into any such partnering arrangements on
this or any other basis. In addition, there can be no assurance that either the
Company or its prospective corporate partners can successfully introduce its
proposed products, that they will achieve acceptance by patients, health care
providers and insurance companies, or that they can be manufactured and marketed
at prices that would permit the Company to operate profitably. With respect to
the
 
                                       7

<PAGE>
Company's products, the Company may seek to enter into joint venture, sublicense
or other marketing arrangements with another party that has an established
marketing capability. There can be no assurance that the Company will be able to
enter into any such marketing arrangements with third parties, or that such
marketing arrangements would be successful. Failure to market its products
successfully would have a material adverse effect on the Company's business and
results of operations. In addition, the Company has no current joint venture,
strategic partnering or other similar agreements with pharmaceutical companies,
and there can be no assurance that the Company could negotiate any such
arrangements, on an acceptable basis or at all, if it chose to do so.
Accordingly, the commercial viability of the Company's proposed products has not
been independently evaluated by any independent pharmaceutical company. See
"Business--Manufacturing" and "--Marketing Strategy."
 
    NEED TO COMPLY WITH GOVERNMENTAL REGULATION AND TO OBTAIN PRODUCT
APPROVALS.  The testing, manufacturing, labeling, distribution, marketing and
advertising of products such as the Company's proposed products and its ongoing
research and development activities are subject to extensive regulation by
governmental regulatory authorities in the United States and other countries.
The FDA and comparable agencies in foreign countries impose substantial
requirements on the introduction of new pharmaceutical products through lengthy
and detailed clinical testing procedures and other costly and time-consuming
compliance procedures. The Company's compounds require substantial clinical
trials and FDA review as new drugs. The Company cannot predict with certainty
when it might submit its products currently under development for regulatory
review. Once the Company submits its potential products for review, there can be
no assurance that FDA or other regulatory approvals for any pharmaceutical
products developed by the Company will be granted on a timely basis or at all. A
delay in obtaining or failure to obtain such approvals would have a material
adverse effect on the Company's business and results of operations. Failure to
comply with regulatory requirements could subject the Company to regulatory or
judicial enforcement actions, including, but not limited to, product recalls or
seizures, injunctions, civil penalties, criminal prosecution, refusals to
approve new products and withdrawal of existing approvals, as well as
potentially enhanced product liability exposure. Sales of the Company's products
outside the United States will be subject to regulatory requirements governing
clinical trials and marketing approval. These requirements vary widely from
country to country and could delay introduction of the Company's products in
those countries. See "Business--Drug Approval Process and Other Government
Regulation."
 
    DEPENDENCE ON KEY PERSONNEL.  The success of the Company's business will
depend to a large extent on the abilities and continued participation of certain
key employees, including Drs. Denis Burger, James Summerton, and Dwight Weller,
upon each of whom the Company holds key man life insurance. The loss of any of
these persons or of other key employees could significantly delay the
achievement of the Company's planned development objectives. Competition for
qualified personnel among pharmaceutical companies is intense, and the loss of
key personnel, or the inability to attract and retain the additional, highly
skilled personnel required for the expansion of the Company's activities, could
have a material adverse effect on the Company's business and results of
operations. See "Management."
 
    COMPETITION.  Competition in the area of pharmaceutical products is intense.
There are many companies, both public and private, including well-known
pharmaceutical companies, that are engaged in the development of products for
certain of the applications being pursued by the Company. The Company's probable
competitors in the antisense and drug delivery fields include Glaxo Ltd.
("Glaxo"), Boehringer Ingelheim Inc. ("Boehringer Ingelheim"), Gilead Sciences
Inc. ("Gilead"), Hybridon Inc. ("Hybridon"), ISIS Pharmaceuticals, Inc.
("ISIS"), Lynx Therapeutics Inc. ("Lynx"), Cygnus, Inc. ("Cygnus"), Biovail
Corporation International ("Biovail"), and Noven Pharmaceuticals, Inc.
("Noven"), among others. Most of these companies have substantially greater
financial, research and development, manufacturing and marketing experience, and
resources than the Company does and represent substantial long-term competition
for the Company. Such companies may succeed in developing pharmaceutical
products that are more effective or less costly than any that may be developed
by the Company.
 
                                       8

<PAGE>
    Factors affecting competition in the pharmaceutical industry vary depending
on the extent to which the competitor is able to achieve a competitive advantage
based on patented or proprietary technology. If the Company is able to establish
and maintain a significant patent position with respect to its antisense
compounds and drug delivery technology, its competition will likely depend
primarily on the effectiveness of the products and the number, gravity and
severity of unwanted side effects, if any, with its products as compared with
alternative products.
 
    The industry in which the Company competes is characterized by extensive
research and development efforts and rapid technological progress. Although the
Company believes that its patent position may give it a competitive advantage
with respect to its proposed antisense compounds and drug delivery products, new
developments are expected to continue and there can be no assurance that
discoveries by others will not render the Company's potential products
noncompetitive. The Company's competitive position also depends on its ability
to attract and retain qualified scientific and other personnel, develop
effective products, implement development and marketing plans, obtain patent
protection, and secure adequate capital resources. See "Business--Competition."
 
    PATENTS AND PROPRIETARY RIGHTS.  The Company believes that its ultimate
success will depend in part on the strength of its existing patents and
additional patents that it files in the future. Patent applications have been
filed covering the basic compositions of matter, methods of synthesis and
medical uses of NEU-GENES. These applications were filed in the United States,
Canada, Europe, Australia, and Japan. Certain of the Company's patents were
issued in the United States from 1991 through the present. Additionally, patents
on NEU-GENE chemistry and CYTOPORTER drug delivery systems have recently been
filed or are near filing. There can be no assurance, however, that any
additional patents will ultimately issue. Although the Company believes that its
technology is adequately protected, there is no assurance that any existing or
future patents will survive a challenge or will otherwise provide meaningful
protection from competition. There is also no assurance that the Company will
have the financial resources to provide a vigorous defense of its patent
position, if challenged, or that the practice of its patented and proprietary
technology will not infringe third-party patents. If an actual infringement were
instituted against the Company, there can be no assurance that the Company would
have the financial ability to defend the action or that the action would not
have an adverse effect on the Company. The Company's success will also depend on
its ability to avoid infringement of patent or other proprietary rights of
others or that it will be able to obtain any technology licenses it may require
in the future. See "Business--Patent and Proprietary Rights."
 
    RISK OF PRODUCT LIABILITY.  Clinical trials or marketing of any of the
Company's potential pharmaceutical products may expose the Company to liability
claims from the use of these products. The Company currently intends to obtain
product liability insurance at the appropriate time; however, there can be no
assurance that the Company will be able to obtain or maintain insurance on
acceptable terms for its clinical and commercial activities or that such
insurance would be sufficient to cover any potential product liability claim or
recall. Failure to have sufficient coverage could have a material adverse effect
on the Company's business and results of operations.
 
    ANTI-TAKEOVER EFFECTS OF CERTAIN CHARTER PROVISIONS AND OREGON LAW.  Certain
provisions of the Company's Second Restated Articles of Incorporation and Bylaws
could discourage potential acquisition proposals, could delay or prevent a
change in control of the Company and could make removal of management more
difficult. Such provisions could diminish the opportunities for a shareholder to
participate in tender offers, including tender offers that are priced above the
then-current market value of the Common Stock. The provisions may also inhibit
increases in the market price of the Common Stock and Warrants that could result
from takeover attempts. For example, the Board of Directors of the Company,
without further shareholder approval, may issue up to 2,000,000 shares of
Preferred Stock, in one or more series, with such terms as the Board of
Directors may determine, including rights such as voting, dividend and
conversion rights which could adversely affect the voting power and other rights
of the holders of Common Stock. Preferred Stock thus may be issued quickly with
terms calculated to delay or
 
                                       9

<PAGE>
prevent a change in control of the Company or make removal of management more
difficult. Additionally, the issuance of Preferred Stock may have the effect of
decreasing the market price of the Common Stock. The Oregon Control Share Act
and Business Combination Act limit the ability of parties who acquire a
significant amount of voting stock to exercise control over the Company. These
provisions may have the effect of lengthening the time required for a person to
acquire control of the Company through a proxy contest or the election of a
majority of the Board of Directors and may deter efforts to obtain control of
the Company. Finally, the Company's Board of Directors is divided into two
classes, each of which serves for a staggered two-year term, which may make it
more difficult for a third party to gain control of the Company's Board of
Directors. See "Description of Securities."
 
    CONTROL BY EXISTING SHAREHOLDERS.  Upon the closing of this offering, the
Company's officers, directors and five-percent shareholders and their affiliates
will beneficially own approximately 38% of the Company's outstanding shares of
Common Stock. The Company's existing shareholders will own approximately 85% of
the Company's outstanding shares of Common Stock. Accordingly, these
shareholders, if they were to act as a group, may be able to elect all of the
Company's directors and otherwise control matters requiring approval by the
shareholders of the Company, including approval of significant corporate
transactions. Such concentration of ownership may also have the effect of
delaying or preventing a change in control of the Company. See "Principal
Shareholders."
 
    NO PRIOR PUBLIC MARKET; POSSIBLE VOLATILITY OF COMMON STOCK PRICE.  Prior to
this offering, there has been no public market for the Company's Common Stock or
Warrants. There can be no assurance that an active public market for the Common
Stock or Warrants will develop or be sustained after this offering. The initial
public offering price of the Units has been determined by negotiations between
the Company and the Representative and may not be indicative of future market
prices. The trading price of the Company's Common Stock and Warrants could be
subject to significant fluctuations in response to such factors as variations in
the Company's anticipated or actual results of operations, announcements of new
products or technological innovations by the Company or its competitors, FDA and
foreign regulatory actions, developments with respect to patents and proprietary
rights, public concern as to the safety of products developed by the Company or
others, changes in health care policy in the United States and in foreign
countries, changes in stock market analyst recommendations regarding the
Company, the pharmaceutical industry in general and overall market conditions.
Moreover, the stock market has from time to time experienced extreme price and
volume fluctuations which have particularly affected the market prices for
emerging growth companies and which have often been unrelated to the operating
performance of such companies. These broad market fluctuations may adversely
affect the market price of the Company's Common Stock and Warrants. In the past,
following periods of volatility in the market price of a company's common stock,
securities class action litigations have occurred against the issuing company.
There can be no assurance that such litigation will not occur in the future with
respect to the Company. Such litigation could result in substantial costs and a
diversion of management's attention and resources, which could have a material
adverse effect on the Company's business and results of operations. Any adverse
determination in such litigation could also subject the Company to significant
liabilities. See "Management--Stock Incentive Plan" and "Underwriting."
 
    ADVERSE EFFECT ON MARKET PRICE DUE TO SHARES ELIGIBLE FOR FUTURE
SALE.  Sales of a substantial number of shares of the Common Stock in the public
market following this offering could adversely affect the market price of the
Common Stock and the Company's ability to raise capital in the future in the
equity markets. Upon completion of this offering, there will be 10,279,763
shares of Common Stock outstanding, assuming no exercise of the Overallotment
Option or of outstanding warrants or outstanding options under the Company's
Stock Incentive Plan after the date of this Prospectus. In addition to the
1,500,000 shares of Common Stock sold in this offering, approximately
shares not subject to lock-up agreements will be eligible for immediate resale
without restriction under Rule 144(k) of the Securities Act. An additional
          shares held for more than two but less than three years by
shareholders who are not affiliates of the Company and who are not subject to
lock-up agreements are eligible for sale under
 
                                       10

<PAGE>
Rule 144 of the Securities Act, subject to the volume and other limitations
thereunder. Upon expiration of lock-up agreements three months after the date of
this Prospectus (or earlier with the consent of the Representative),
shares will be eligible for immediate resale subject to the limitations of Rule
144 and           shares will be eligible for resale immediately without
restriction pursuant to Rule 144(k). Upon expiration of lock-up agreements six
months after the date of this Prospectus (or earlier with the consent of the
Representative),           shares will be eligible for immediate resale subject
to the limitations of Rule 144 and           shares will be eligible for resale
immediately without restriction pursuant to Rule 144(k). Upon expiration of
lock-up agreements nine months after the date of this Prospectus (or earlier
with the consent of the Representative),           shares will be eligible for
immediate resale subject to the limitations of Rule 144 and           shares
will be eligible for resale immediately without restriction pursuant to Rule
144(k). Upon expiration of lock-up agreements one year after the date of this
Prospectus (or earlier with the consent of the Representative),           shares
will be eligible for immediate resale subject to the limitations of Rule 144 and
          shares will be eligible for resale immediately without restriction
pursuant to Rule 144(k). As of the date of this Prospectus, options to purchase
          shares of Common Stock have been granted under the Stock Incentive
Plan, which shares, if acquired pursuant to the exercise of options, are subject
to lock-up agreements which expire one year after the date of this Prospectus
(or earlier with the consent of the Representative). See "Management--Stock
Incentive Plan," "Underwriting," "Description of Securities" and "Shares
Eligible for Future Sale."
 
    REDEMPTION OF WARRANTS.  As described in greater detail elsewhere in this
Prospectus, the Warrants are subject to redemption at $.25 per Warrant on 30
days written notice provided that the closing bid price of the Common Stock for
each of the 20 consecutive trading days immediately preceding the date of the
notice of redemption equals or exceeds 200% of the then-current warrant exercise
price. If the Company exercises the right to redeem the Warrants, a holder would
be forced either to exercise the Warrant or accept the redemption price. See
"Description of Securities--Warrants."
 
    CURRENT PROSPECTUS AND STATE BLUE SKY REGISTRATION REQUIRED TO EXERCISE THE
WARRANTS.  Purchasers of Units will be able to exercise the Warrants included
therein only if a current prospectus relating to the Common Stock underlying the
Warrants is then in effect, and only if the Common Stock is qualified for sale
or exempt from qualification under applicable state securities law of the state
in which such holders of the Warrants reside. Although the Company has
undertaken to maintain the effectiveness of a current prospectus covering the
Common Stock underlying the Warrants, there can be no assurance that the Company
will be able to do so. The value of the Warrants may be impaired if a current
prospectus covering the Common Stock issuable upon exercise of the Warrants is
not kept effective, or if such Common Stock is not qualified or exempt from
qualification in the states in which the holders of Warrants reside.
 
    The Warrants are separately transferable immediately upon issuance. Although
the Units will not knowingly be sold to purchasers in jurisdictions in which the
Units are not registered or otherwise qualified for sale, purchasers may buy
Warrants in the after market in, or may move to, jurisdictions in which the
shares underlying the Warrants are not so registered or qualified during the
period that the Warrants are exercisable. In this event, the Company would be
unable to issue shares to those persons desiring to exercise their warrants, and
holders of Warrants would have no choice but to attempt to sell the Warrants in
a jurisdiction where such sale is permissible or allow them to expire
unexercised. See "Description of Securities--Warrants."
 
    DILUTION.  Investors acquiring shares of Common Stock included in the Units
offered hereby will incur immediate and substantial net tangible value dilution
of $7.47 per share, assuming no value is attributed to the Warrant included in a
Unit. To the extent that currently outstanding options and warrants to purchase
the Company's Common Stock are exercised, there will be further dilution. See
"Dilution."
 
    ABSENCE OF DIVIDENDS.  The Company has never paid cash dividends on its
Common Stock and does not anticipate paying cash dividends in the foreseeable
future. See "Dividend Policy."
 
                                       11

<PAGE>
    BROAD DISCRETION OF MANAGEMENT TO ALLOCATE OFFERING PROCEEDS.  The Company
expects that the proceeds of this offering will be used for the construction of
a Good Manufacturing Practices ("GMP") facility, research and development,
including clinical development of the Company's near-term therapeutic products,
for working capital and general corporate purposes. The Company is not currently
able to estimate precisely the allocation of the proceeds among such uses, and
the timing and amount of expenditures will vary, depending upon numerous
factors. The Company's management will have broad discretion to allocate the
proceeds of this offering and to determine the timing of expenditures. See "Use
of Proceeds."
 
    POTENTIAL LIABILITY ARISING FROM RESCISSION RIGHTS OF CERTAIN
SHAREHOLDERS.  Throughout its existence, the Company has financed its activities
through periodic offerings of equity securities. During 1992, the Company's
management conducted a review of its past operations, including capital-raising
activities. At that time, although management did not identify any specific,
material failures to comply with obligations imposed on the Company by
applicable federal and state securities laws, management concluded that the
record with respect to such activities was sufficiently incomplete that a
conclusion could not be drawn with substantial certainty that such obligations
were complied with in all material respects. Although the Company believes that,
as of the date of this Prospectus, any potential rescission liability to
shareholders for failure to comply with these obligations has been effectively
eliminated by the running of applicable statutes of limitation, a review of the
Company's securities offering documents prepared in connection with certain
sales of Common Stock during 1991, 1992, 1993 and 1994 and an exchange offering
during 1993 indicated that the Company had omitted to disclose or provided only
limited disclosure with respect to its then potential rescission liability to
prospective purchasers of its Common Stock. As a result of this omission or
limited disclosure, the Company has been unable to conclude that sales of the
Company's Common Stock made in accordance with those offering documents complied
in all material respects with federal and state securities laws.
 
    Immediately prior to this offering, as a condition to this offering, the
Company intends to offer to each holder of 1,292,973 shares of its Common Stock
and who reside in the states of Alabama, Colorado, Illinois, Massachusetts,
Montana, New Jersey, Ohio, Oregon, Texas, Utah, Washington and Wisconsin the
right to rescind the holder's purchase of shares of the Company's Common Stock.
If all such offerees elect to rescind their purchases, the Company will be
required to pay these holders $3,121,965 and 568.67 units of limited partnership
interest in the Anti-Gene Development Group, plus approximately $2,129,000 in
statutory interest.
 
    The Company believes that its potential liability to shareholders who
receive the rescission offer for possible violations of federal law and the laws
of the states of Alabama, Colorado, Illinois, Massachusetts, Montana, New
Jersey, Ohio, Oregon, Texas, Utah, Washington and Wisconsin will be effectively
eliminated as a result of the rescission offer or the running of applicable
statutes of limitation. The Securities and Exchange Commission, however, takes
the position that liabilities under the federal securities laws are not
terminated by the making of a rescission offer.
 
    In addition, the rescission offer will not be made to holders of 22,021
shares of the Company's Common Stock who reside in Florida, the laws of which do
not permit rescission offerings to cure omissions in securities offering
documents. These holders of 22,021 shares of Common Stock originally purchased
such shares from the Company at prices ranging from $4.56 to $4.95 per share or
through the exchange of one unit of limited partnership interest in the
Anti-Gene Development Group. There can be no assurance that claims asserting
violations of federal or state securities laws will not be asserted by any of
these shareholders against the Company or that certain holders will not prevail
against the Company in the assertion of such claims, thereby compelling the
Company to repurchase their shares. If all of the holders of the 22,021 shares
successfully asserted claims against the Company, the Company would be required
to pay these holders $100,000, plus one unit of limited partnership interest in
Anti-Gene Development Group, plus approximately $44,000 in statutory interest.
The rescission offer also will not be made to holders of 192,603 shares of the
Company's Common Stock who reside in the states of California and
 
                                       12

<PAGE>
Nevada because the Company believes that its potential liability to these
shareholders has been eliminated by the running of applicable statutes of
limitation. There can be no assurance, however, that claims asserting violations
of federal or state securities laws will not be asserted by any of those
shareholders or that certain holders will not prevail against the Company in the
assertion of such claims, compelling the Company to repurchase their shares. If
all of the holders of the 192,603 shares successfully asserted claims against
the Company, the Company would be required to pay these holders $218,450, plus
54 units of limited partnership interest in the Anti-Gene Development Group,
plus approximately $193,000 in statutory interest. Even if the Company were
successful in defending any securities laws claims, the assertion of such claims
against the Company additionally could result in costly litigation and
significant diversions of effort by the Company's management.
 
                                       13

<PAGE>
                                USE OF PROCEEDS
 
    The net proceeds to the Company from the sale of the Units offered hereby,
based on an assumed initial public offering price of $9.00 per Unit, are
estimated to be $11,607,500 ($13,419,875 if the Overallotment Option is
exercised in full) after deducting the estimated underwriting discount and
offering expenses and assuming no exercise of the Warrants.
 
    The Company expects to apply up to $5 million of the net proceeds of this
offering to fund the construction of a Good Manufacturing Practices ("GMP")
manufacturing facility for the manufacture of its compounds required for the
pre-clinical and clinical trial phases. The Company expects to use approximately
$5 million to fund future research and development, of which approximately $2
million will be expended for the clinical development of the Company's near-term
therapeutic products. The balance of the net proceeds of this offering will be
used for working capital and general corporate purposes. Where appropriate,
proceeds of this offering also may be used to acquire products or technologies
that complement the Company's business, although there are no present
understandings, agreements or commitments with respect to any such acquisitions.
The cost, timing and amount of funds required for such uses by the Company will
be based on the timing of regulatory approvals, the results of clinical testing
and trials, and the results of the Company's research and development programs.
The amounts actually expended on any particular project may vary significantly
from the Company's current plans, particularly given the Company's early stage
of development and the uncertainty of the drug development process.
 
    Pending application of the net proceeds as described above, the Company
intends to invest the net proceeds in short-term, interest-bearing securities,
including government obligations and money market instruments.
 
                                DIVIDEND POLICY
 
    The Company has not declared or paid cash dividends on its Common Stock. The
Company currently intends to retain all future earnings to fund the operation of
its business and, therefore, does not anticipate paying dividends in the
foreseeable future. Future cash dividends, if any, will be determined by the
Board of Directors.
 
                                       14

<PAGE>
                                 CAPITALIZATION
 
    The following table sets forth the capitalization of the Company as of
September 30, 1996 (i) on an actual basis and (ii) as adjusted to reflect the
receipt and application of the estimated net proceeds from the sale of the
1,500,000 Units offered hereby at an assumed initial offering price of $9.00 per
Unit.
 

<TABLE>
<CAPTION>
                                                                                          SEPTEMBER 30, 1996
                                                                                    ------------------------------
                                                                                        ACTUAL       AS ADJUSTED
                                                                                    --------------  --------------
                                                                                     (UNAUDITED)     (UNAUDITED)
<S>                                                                                 <C>             <C>
Common stock subject to rescission, $.0001 par value:
  1,292,973 issued and outstanding................................................  $    3,121,965  $    3,121,965
                                                                                    --------------  --------------
Shareholders' equity:
  Preferred Stock, $.0001 par value: 2,000,000 shares authorized; no shares issued
    and outstanding, actual and as adjusted(1)....................................        --              --
  Common Stock, $.0001 par value: 50,000,000 shares authorized; 7,486,790 shares
    issued and outstanding, actual; 8,986,790 shares issued and outstanding, as
    adjusted(2)...................................................................             749             899
  Additional paid-in capital......................................................      13,217,628      24,824,978
  Deficit accumulated during the development stage................................     (11,753,087)    (11,753,087)
                                                                                    --------------  --------------
  Total shareholders' equity......................................................       1,465,290      13,072,790
                                                                                    --------------  --------------
Total capitalization..............................................................  $    1,465,290  $   13,072,790
                                                                                    --------------  --------------
                                                                                    --------------  --------------
</TABLE>

 
- ------------------------
 
(1) Reflects an amendment to the Company's Articles of Incorporation that was
    effective November 4, 1996, authorizing the issuance of up to 2,000,000
    shares of Preferred Stock.
 
(2) Excludes 1,559,384 shares of Common Stock issuable upon exercise of stock
    options and warrants outstanding as of September 30, 1996, at a weighted
    average exercise price of $4.63 per share. Also excludes 206,447 shares
    reserved for future issuance pursuant to the Company's Stock Incentive Plan.
    See "Management--Stock Incentive Plan" and Note 3 of Notes to Financial
    Statements.
 
                                       15

<PAGE>
                                    DILUTION
 
    The net tangible book value of the Company as of September 30, 1996, was
$4,116,087 or $0.47 per share of Common Stock. Net tangible book value per share
is determined by dividing the net tangible book value of the Company (total
tangible assets less total liabilities) by the total number of outstanding
shares of Common Stock. After giving effect to the sale of the 1,500,000 Units
offered by the Company hereby and the receipt of the estimated net proceeds
therefrom (after deducting the estimated underwriting discount and other
estimated expenses of the offering and attributing no portion of the value of a
Unit to the Warrant), the net tangible book value of the Company at September
30, 1996, would have been $15,723,587 or $1.53 per share. This represents an
immediate increase in the net tangible book value of $11,607,500 or $1.06 per
share to existing holders of Common Stock and an immediate dilution (i.e., the
difference between the initial public offering price and the net tangible book
value after the offering) to new investors purchasing Units in this offering of
$7.47 per share. The following table illustrates the per share dilution to new
investors purchasing Units in this offering:
 

<TABLE>
<S>                                                             <C>        <C>
Initial public offering price per share.......................             $    9.00
  Net tangible book value per share at September 30, 1996.....  $    0.47
  Increase per share attributable to new investors............       1.06
Pro forma net tangible book value per share after this
  offering....................................................                  1.53
                                                                           ---------
Net tangible book value dilution per share to new investors...             $    7.47
                                                                           ---------
                                                                           ---------
</TABLE>

 
    The following table summarizes on a pro forma basis as of September 30,
1996, the number of shares of Common Stock purchased, the percentage of total
cash consideration paid, and the average price per share (i) paid by present
shareholders and (ii) paid by investors purchasing Units in this offering. The
calculation in this table with respect to shares of Common Stock to be purchased
by new investors in this offering excludes shares of Common Stock issuable upon
exercise of the Warrants (after deducting the estimated underwriting discount
and other estimated expenses of this offering payable by the Company and
ascribing no portion of the value of a Unit to the Warrant).
 

<TABLE>
<CAPTION>
                                     SHARES PURCHASED          TOTAL CONSIDERATION        AVERAGE
                                 -------------------------  --------------------------   PRICE PER
                                    NUMBER       PERCENT       AMOUNT        PERCENT       SHARE
                                 ------------  -----------  -------------  -----------  -----------
<S>                              <C>           <C>          <C>            <C>          <C>
Existing Shareholders..........     8,779,763         85%      16,340,342         55%    $    1.86
New Investors..................     1,500,000         15%      13,500,000         45%    $    9.00
                                 ------------       -----   -------------       -----
  Total........................    10,279,763        100%      29,840,342        100%
                                 ------------       -----   -------------       -----
                                 ------------       -----   -------------       -----
</TABLE>

 
    The above computations assume no exercise of outstanding options or
warrants. As of September 30, 1996, there were options and warrants outstanding
to purchase a total of 1,559,384 shares of Common Stock at a weighted average
exercise price of $4.63 per share. The exercise of such options or warrants will
result in further dilution to new investors. See "Capitalization."
 
                                       16

<PAGE>
                            SELECTED FINANCIAL DATA
 
    The Selected Financial Data set forth below for the years ended December 31,
1995 and 1994 and with respect to the Balance Sheet Data at December 31, 1995
are derived from, and are qualified by reference to, the audited Financial
Statements and related Notes thereto included elsewhere in this Prospectus and
should be read in conjunction with those audited Financial Statements and Notes
thereto. The Statements of Operations Data with respect to the nine-month
periods ended September 30, 1995 and September 30, 1996 and the period from July
22, 1980 (inception) through September 30, 1996, and the Balance Sheet Data at
September 30, 1996 are unaudited, but have been prepared on the same basis as
the audited financial statements and in the opinion of management contain all
adjustments (consisting only of normal recurring adjustments) necessary to
present fairly the information set forth therein. The Selected Financial Data
set forth below are qualified by reference to, and should be read in conjunction
with, "Management's Discussion and Analysis of Financial Condition and Results
of Operations" and the Financial Statements and Notes thereto included elsewhere
in this Prospectus.
 

<TABLE>
<CAPTION>
                                         YEARS ENDED DECEMBER
                                                 31,
                                        ----------------------
                                           1994        1995
                                        ----------  ----------    NINE MONTHS ENDED       PERIOD
                                                                    SEPTEMBER 30,       FROM JULY
                                                                ----------------------   22, 1980
                                                                   1995        1996     (INCEPTION)
                                                                ----------  ----------   THROUGH
                                                                                        SEPTEMBER
                                                                (UNAUDITED) (UNAUDITED)  30, 1996
                                                                                        ----------
                                                                                        (UNAUDITED)
<S>                                     <C>         <C>         <C>         <C>         <C>
STATEMENTS OF OPERATIONS DATA:
Revenues, from grants and research
  contracts...........................  $   --      $   82,500  $  82,500   $  16,827   $ 679,097
                                        ----------  ----------  ----------  ----------  ----------
Operating expenses:
  Research and development............   1,631,130   2,097,796  1,640,906   1,177,157   8,459,177
  General and administrative..........     678,705     609,723    437,159     432,252   4,368,023
                                        ----------  ----------  ----------  ----------  ----------
    Total operating expenses..........   2,309,835   2,707,519  2,078,065   1,609,409   12,827,200
                                        ----------  ----------  ----------  ----------  ----------
Other income..........................      63,563      68,133     54,888     177,616     395,016
                                        ----------  ----------  ----------  ----------  ----------
Net loss..............................  $(2,246,272) $(2,556,886) $(1,940,677) $(1,414,966) $(11,753,087)
                                        ----------  ----------  ----------  ----------  ----------
                                        ----------  ----------  ----------  ----------  ----------
Net loss per share(1).................  $    (0.33) $    (0.37) $   (0.28 ) $   (0.18 )
                                        ----------  ----------  ----------  ----------
                                        ----------  ----------  ----------  ----------
Shares used in per share
  calculation(1)......................   6,726,625   6,982,459  6,966,583   8,051,477
                                        ----------  ----------  ----------  ----------
                                        ----------  ----------  ----------  ----------
</TABLE>

 

<TABLE>
<CAPTION>
                                                                    DECEMBER
                                                                    31, 1995
                                                                   ----------        SEPTEMBER 30, 1996
                                                                                ----------------------------
                                                                                 ACTUAL     AS ADJUSTED(2)
                                                                                --------  ------------------
                                                                                (UNAUDITED)    (UNAUDITED)
<S>                                                                <C>          <C>       <C>
BALANCE SHEET DATA:
Working capital..................................................   $646,814    $3,455,651    15$,063,151
Total assets.....................................................  2,324,736    4,788,878    16,396,378
Common stock subject to rescission...............................  3,121,965    3,121,965     3,121,965
Deficit accumulated during the development stage.................  (10,338,121) (11,753,087)   (11,753,087)
Total shareholders' equity (deficit).............................  (1,051,293)  1,465,290    13,072,790
</TABLE>

 
- ------------------------------
 
(1) See Note 2 of Notes to Financial Statements for an explanation of the
    determination of the number of shares used in computing net loss per share.
 
(2) Adjusted to give effect to the application of the estimated net proceeds of
    this offering based upon an assumed initial public offering price of $9.00
    per Unit. See "Use of Proceeds" and "Management's Discussion and Analysis of
    Financial Condition and Results of Operations."
 
                                       17

<PAGE>

                    MANAGEMENT'S DISCUSSION AND ANALYSIS OF
                 FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
OVERVIEW
 
    From its inception in July 1980, the Company has devoted its resources
primarily to fund its research and development efforts. The Company has been
unprofitable since inception and, other than limited interest and grant
revenues, has had no revenues from the sale of products or other sources. The
Company does not expect material revenues in the near term and expects to
continue to incur losses for the foreseeable future as it expands its research
and development efforts. As of September 30, 1996, the Company's accumulated
deficit was $11,753,087.
 
    The Company intends to use the net proceeds of this offering to expand its
research and administrative operations. See "Use of Proceeds." The Company plans
to build a GMP pilot manufacturing facility and is exploring all available
options with regard to building, leasing or contracting for this facility. The
Company intends to increase its research staff as it prepares to initiate
pre-clinical studies and file INDs for Resten-NG and Paclitaxol-CP. The
Company's administrative staff will be supplemented as needed to support the
research and development activities, to assure compliance with governmental
regulatory requirements, and to develop and establish strategic pharmaceutical
alliances.
 
RESULTS OF OPERATIONS
 
    NINE MONTHS ENDED SEPTEMBER 30, 1996, COMPARED WITH NINE MONTHS ENDED
SEPTEMBER 30, 1995.  The Company had revenues from grants and research contracts
of $16,827 and $82,500 for the nine months ended September 30, 1996 and
September 30, 1995, respectively. Revenues for both periods were derived from
research collaborations with outside organizations, and the decrease between the
current and prior periods was due primarily to the completion of a collaborative
research program. Operating expenses were $1,609,409 and $2,078,065 for the nine
months ended September 30, 1996 and September 30, 1995, respectively. The
decrease in operating expenses was due to a reduction in staff and other
efficiencies that resulted from a shift in focus of the Company's research.
General and administrative expenses remained relatively constant at $432,252 and
$437,159 over the 1996 and 1995 comparable nine-month periods, respectively.
Other income increased to $177,616 from $54,888 for the nine-month periods ended
September 30, 1996, and September 30, 1995, respectively, primarily due to
realized gains on the sale of short-term investments in 1996.
 
    YEAR ENDED DECEMBER 31, 1995 COMPARED WITH YEAR ENDED DECEMBER 31,
1994.  Revenues from grants and research contracts of $82,500 for 1995 were
derived from a research contract. The Company did not have research contracts or
grants in 1994. Operating expenses increased to $2,707,519 in 1995 from
$2,309,835 in 1994, primarily due to increased use of contract research and
additional personnel and supplies associated with the development of the
CYTOPORTER drug delivery engine. General and administrative expenses declined to
$609,723 in 1995 from $678,705 in 1994 principally due to a reduction in
personnel. Other income, consisting primarily of interest income, was $68,133 in
1995 and $63,563 in 1994.
 
LIQUIDITY AND CAPITAL RESOURCES
 
    The Company has financed its operations since inception primarily through
private equity sales totaling $16,340,342 and revenues from grants and contract
research totaling $679,097. The Company's cash and cash equivalents were
$3,614,724 at September 30, 1996 and $680,892 at December 31, 1995. The increase
of $2,933,832 from December 31, 1995 to September 30, 1996 was principally due
to the use of $1,168,026 for operations offset by net proceeds from the sale of
the Company's Common Stock of $4,028,299.
 
    The Company's future expenditures and capital requirements will depend on
numerous factors, including, without limitation, the progress of its research
and development programs, the progress of its
 
                                       18

<PAGE>
preclinical and clinical trials, the time and costs involved in obtaining
regulatory approvals, the cost of filing, prosecuting, defending and enforcing
any patent claims and other intellectual property rights, competing
technological and market developments, the ability of the Company to establish
collaborative arrangements and the terms of any such arrangements, and the costs
associated with commercialization of its products. The Company's cash
requirements are expected to continue to increase significantly each year as it
expands its activities and operations. There can be no assurance, however, that
the Company will ever be able to generate product revenues or achieve or sustain
profitability. See "Risk Factors."
 
    The proceeds of this offering are the only source of capital currently
available to the Company, other than its existing cash and cash equivalents. See
"Use of Proceeds." The Company believes that the estimated net proceeds from
this offering, and existing cash and cash equivalents will satisfy its budgeted
cash requirements for at least the next 24 months based upon the Company's
current operating plan. The Company's current operating plan shows that, at the
end of the 24-month period, the Company will require substantial additional
capital. Moreover, if the Company experiences unanticipated cash requirements
during the 24-month period, including without limitation cash required to pay
the holders of a significant number of shares of Common Stock in connection with
the Company's proposed rescission offering, the Company could require additional
capital to fund operations, continue research and development programs,
pre-clinical and clinical testing of its potential antisense and drug delivery
compounds, and commercialize any products that may be developed. See "Risk
Factors--Potential Liability Arising from Rescission Rights of Certain
Shareholders." The Company may seek such additional funding through public or
private financings or collaborative or other arrangements with third parties.
There can be no assurance, however, that additional funds will be available on
acceptable terms, if at all. See "Risk Factors--Additional Financing
Requirements."
 
                                       19

<PAGE>
 
                                   BUSINESS
 
GENERAL OVERVIEW
 
    ANTIVIRALS is a pioneer in the field of the gene-inactivating technology
referred to as ANTISENSE and has developed a patented class of antisense
compounds which may be useful in the treatment of a wide range of human
diseases. The Company also has developed new drug delivery technology which may
be useful with many FDA-approved drugs as well as with its antisense compounds.
The Company's drug development program has two areas of near-term focus:
 
    - NEU-GENE antisense compounds for selected applications, and
 
    - CYTOPORTER drug delivery engines for enhanced delivery of FDA-approved
      drugs with delivery problems.
 
The Company's long-term product development program combines its NEU-GENE and
CYTOPORTER technologies to produce combination drugs with potential applications
for many diseases. The Company has 19 issued patents and several patent filings
covering the basic compositions of matter, methods of synthesis and medical uses
of its NEU-GENE and CYTOPORTER technology.
 
    The first application of the Company's antisense technology is designed to
treat restenosis, a cardiovascular disease. The Company is currently in
pre-clinical development with this compound and expects to file an IND to begin
clinical trials in 1997. The Company's first planned drug delivery products
combine its CYTOPORTER delivery engine with two FDA-approved drugs that have
delivery problems. These drugs, paclitaxel (Taxolr) and cyclosporin, will both
be off patent by late 1997 and could have much wider use if their delivery
problems are reduced. The Company expects to file an IND to begin clinical
trials with its enhanced form of paclitaxel and to initiate pre-clinical studies
with its enhanced form of cyclosporin in 1997. See "Drug Approval Process and
Other Government Regulations."
 
    DRUG DESIGN AND DEVELOPMENT.  Most conventional drugs are chemicals designed
to induce or inhibit the function of a target protein molecule with as few side
effects as possible. Conventional drugs are not available for many diseases due
to their low level of selectivity for the specific disease target or because
they are difficult to deliver to their targets. These two issues, lack of
selectivity and poor delivery, may contribute to poor efficacy, unwanted side
effects or high toxicity, even at a suboptimal dosages. Moreover, the
development of conventional drugs is usually time consuming and expensive, since
thousands of compounds must be produced and analyzed to find one with an
acceptable balance between efficacy and toxicity. Safe and effective
therapeutics for viral and host diseases have been particularly difficult to
develop because these diseases use the patient's own cellular machinery and
therefore provide few specific targets for therapeutic intervention that will
not prove toxic to the patient.
 
    Antisense technology has the potential to provide safe and effective
treatment for a wide range of diseases, including viral and host diseases. This
new approach uses synthetic compounds, or polymers, designed to inactivate
selected genetic sequences, thereby halting the disease process. Targeting these
genetic sequences provides the selectivity that is not available in conventional
drug development which typically targets proteins directly. The antisense
approach inhibits at the genetic level the mechanisms which underlie the
production of disease-producing proteins.
 
    To reach their therapeutic targets, many drugs must cross tissue and
cellular barriers. Drugs that have an intracellular site of action must cross
the lipid barrier of cellular membranes to move from the aqueous environment in
blood into the interior of target cells. Therefore, these drugs must achieve
solubility in both water and lipids. Since few compounds have these solubility
characteristics, many drug candidates are a compromise between inherent
solubility and effective delivery. This trade-off greatly reduces efficacy and
may significantly heighten toxicity of many drug candidates as well as many
FDA-approved drugs.
 
    The Company has developed two distinct technologies designed to address the
critical issues in drug development. The Company's NEU-GENE antisense technology
addresses the issue of drug selectivity, and
 
                                       20

<PAGE>
its CYTOPORTER drug delivery technology addresses delivery problems with both
FDA-approved drugs and antisense compounds. The characteristics of the patented
structure of the Company's NEU-GENE compounds distinguish its antisense
technology from competing technologies and provide the selectivity for a single
disease target that is the hallmark of all antisense technology. The Company's
molecular engine, CYTOPORTER, is designed to transport certain drugs with poor
delivery characteristics across the lipid barrier of cellular membranes into the
interior of cells to reach their targets.
 
NEAR-TERM PRODUCT DEVELOPMENT SUMMARY
 
    The first application of the Company's antisense technology is designed to
treat restenosis. The Company's first planned drug delivery products combine its
CYTOPORTER delivery engine with two FDA-approved drugs, paclitaxel (Taxol) and
cyclosporin, each of which the Company believes could have much broader usage if
their delivery problems are reduced.
 

<TABLE>
<CAPTION>
                                                       POTENTIAL
COMPOUND                              DRUG             INDICATION                 DEVELOPMENT STATUS
- ------------------------------  -----------------  ------------------  ----------------------------------------
<S>                             <C>                <C>                 <C>
AVI-2221 NEU-GENE.............  Resten-NG          Restenosis          Pre-clinical studies and IND filing
                                                                         expected in 1997
 
AVI-2301 CYTOPORTER...........  Paclitaxel-CP      Cancer              IND filing expected in 1997
 
AVI-2401 CYTOPORTER...........  Cyclosporin-CP     Transplantation     Pre-clinical studies expected in 1997
</TABLE>

 
ANTISENSE--NEU-GENE
 
    TECHNICAL OVERVIEW
 
    GENETIC STRUCTURE AND FUNCTION.  All life forms contain genetic information
in molecules called DNA and RNA which comprise the operating instructions for
all life processes. The specific instructions are called genes, which are long
chains or strands of the four genetic bases: adenine, cytosine, guanine and
thymine, represented by the letters, A, C, G and T, respectively. The molecular
structures of these letters are complementary, such that A pairs with T, and C
pairs with G. Consequently, each genetic strand has the unique ability to bind
specifically to its complementary strand to form a duplex.
 
                                       21

<PAGE>
    The information encoded in the DNA by its sequence of genetic letters is
used to make proteins. To accomplish this, one strand (called the template
strand) of the duplex DNA is copied to make a new complementary strand, referred
to as messenger RNA. This messenger RNA is referred to as the SENSE strand
because it carries the information used to assemble a specific protein. See
"Figure 1" below. An ANTISENSE compound is a synthetic strand that is
complementary to a small portion of the messenger RNA. Antisense compounds pair
with their complementary messenger RNA sense strand to form a duplex, preventing
the message from initiating protein assembly. See "Figure 2" below.
 
                           FIGURE 1--GENETIC FUNCTION
 
                             [Genetic Function Diagram]
 
    GENE-TARGETED THERAPEUTICS.  Most human diseases arise from the function or
dysfunction of genes within the body, either those of pathogens, such as
viruses, or of one's own genes. New techniques in molecular biology have led to
the identification of the genes associated with most of the major human diseases
and to the determination of the sequence of their genetic letters. Using modern
methods of chemical synthesis, a genetic compound can be prepared that is
complementary to a critical SENSE sequence in a pathogen or pathogenic process.
When this complementary ANTISENSE compound binds tightly to the disease-causing
sequence, the selected protein is inhibited, and thus the pathogen or pathogenic
process is disabled. See "Figure 2" below.
 
               FIGURE 2--ANTISENSE INHIBITION OF GENETIC FUNCTION
 
                           [Antisense Inhibition Diagram]
 
    Antisense compounds are composed of repeating structures or subunits that
are linked together forming a polymer, referred to as the antisense BACKBONE.
Each subunit carries a genetic letter (A, C, G, or T) that pairs with its
corresponding letter in the genetic target. Although the genetic letters are a
feature
 
                                       22

<PAGE>
common to all antisense compounds, the structure of the subunits and the linkage
groups that string them together may differ greatly. These differences in the
subunits and the linkages define the different types of antisense backbones and
their corresponding physical and biological properties. The Company is
distinguished from all other antisense companies by the characteristics of its
patented antisense backbone. The subunits which carry the genetic letters on the
Company's backbone are synthetic products rather than modified natural
materials. In addition, the linkages used to string the subunits together carry
no charge in the Company's backbone. The Company believes these differences may
provide pharmaceutical advantages that are critical for antisense drug
development to meet the challenges of broad clinical utility.
 
    FIRST-GENERATION COMPOUNDS.  The first gene-inactivating compounds had
backbones composed of natural genetic materials and linkages. Development of
these compounds began in the late 1960s. As work continued in this new field, it
became increasingly clear that there were significant problems with these
structures. These natural compounds were degraded or broken down by enzymes in
the blood and within cells and had difficulty crossing cellular membranes to
enter the cells that contained their genetic target.
 
    SECOND-GENERATION COMPOUNDS.  To overcome these problems of degradation and
permeability, several research groups developed modified backbones in the late
1970s which were designed to resist degradation by enzymes and to enter tissues
and cells more efficiently. The most common of these types, the phosphorothioate
backbones used by ISIS Pharmaceuticals and Hybridon, use natural DNA subunits
linked together by a sulfur-containing, charged linkage. The Company was also
extensively involved in developing second-generation backbones through the
mid-1980s. After extensive investigation, however, the Company concluded that
even after optimization, these second-generation compounds might lack the
combination of properties desirable for broad clinical utility. For this reason,
the Company abandoned development of second-generation backbones in the
mid-1980s and started development of third-generation backbones designed to
address these drawbacks. Today, in spite of extensive progress in the field, the
Company believes that there remain serious limitations to second-generation
compounds due to problems with the stability, specificity, cost effectiveness,
and delivery of these compounds.
 
    NEU-GENE THIRD-GENERATION TECHNOLOGY.  By the mid-1980s, the limitations of
the second-generation compounds led the Company to pursue the development of
antisense technology with improved pharmaceutical properties which could be
produced in a cost-effective manner. This effort culminated in the Company's
development of a new class of compounds having a backbone of synthetic subunits
carrying each genetic letter, with each subunit linked together by a patented
uncharged linkage group. The synthetic subunits and linkages are not found in
nature, but rather were designed and synthesized to meet specific pharmaceutical
parameters. These patented third-generation agents, known as NEU-GENE compounds,
display advantageous pharmaceutical properties (stability, neutral charge, high
binding affinity and specificity). Moreover, they are made from less expensive,
more abundant materials, and the Company believes that they will cost
significantly less to produce than second-generation compounds.
 
    The Company and others have shown in cell culture and animal studies that
NEU-GENE compounds inhibit targeted genetic sequences. With these scientific
benchmarks in place, the Company's objective is to develop its third-generation
antisense compounds into effective and affordable therapeutics for major
infectious and host diseases.
 
    PHARMACEUTICAL PROPERTIES OF ANTISENSE COMPOUNDS.  If antisense compounds
are to become widely applicable pharmaceutical compounds, the following
challenges must be addressed.
 
    - Stability: resistance to enzymatic degradation both in blood and inside
      cells
 
    - Efficacy: ability to inhibit expression of the target gene
 
    - Specificity: binding restricted to the selected target, reducing toxicity
 
    - Cost effectiveness: manufacturing efficiency which allows a broad range of
      applications
 
    - Delivery: ability to cross tissue and cellular barriers in order to reach
      targeted genetic sequences
 
                                       23

<PAGE>
    The Company's core technology differentiates it from others developing
gene-inactivating compounds. The Company believes its principal competitive
advantage in the antisense area is the chemical structure of the NEU-GENE
backbone which was developed to address all of the above parameters.
 
    STABILITY.  Biological stability is principally determined by the degree of
resistance to enzymatic degradation. Because the NEU-GENE backbone is a unique
synthetic structure, the Company believes that there are no enzymes found in man
to degrade it. The Company has conducted studies indicating that these agents
are stable in blood and are stable to a broad range of degradative enzymes.
 
    EFFICACY AND SPECIFICITY.  Efficacy refers to the efficiency with which the
antisense compounds block selected protein production. In a direct comparison
with second-generation compounds conducted by the Company, its NEU-GENE
compounds exhibited significantly better binding to both RNA and DNA, as well as
substantially greater inhibition of the activity of targeted genetic sequences.
Specificity can be assessed by comparing target inactivation of perfectly paired
sequences and mispaired sequences. In the Company's direct comparison studies,
NEU-GENE compounds exhibited substantially greater specificity than all other
backbone types tested.
 
    COST EFFECTIVENESS.  The difficulty of synthesizing antisense compounds has
been a concern in the field since its inception. The cost of producing
gene-inactivating polymers depends to a considerable extent on the cost of the
subunits from which they are constructed. The Company believes that because of
abundant, low-cost materials, simpler production techniques and higher yields,
the subunits used for NEU-GENE synthesis will cost substantially less than those
used in the synthesis of second-generation backbones. After the genetic subunits
are prepared, they must be assembled in a defined order to form the desired
gene-inactivating polymer. The Company believes that the total cost of
production of commercial quantities of NEU-GENES will be significantly less than
that of gene-inactivating compounds prepared from natural or modified subunits
by competitors.
 
    DELIVERY.  To reach their targets, antisense compounds must cross tissue and
cellular barriers, including cellular and nuclear membranes. Preliminary
research indicates that antisense compounds, including those of the Company, may
face delivery problems when addressing many diseases. Accordingly, the Company
has devoted substantial research effort to develop technology for delivering
NEU-GENES to the interior of the cell. See "Drug Delivery--CYTOPORTER."
 
    NEAR-TERM ANTISENSE PRODUCT DEVELOPMENT--RESTENOSIS
 
    The first application of the Company's antisense technology is designed to
treat restenosis, a cardiovascular disease. Restenosis results from the failure
of balloon angioplasty due to a rapid growth of smooth muscle cells leading to a
second blockage of a coronary artery. There are approximately 400,000 balloon
angioplasties done in the United States each year with a failure rate of
approximately 30% - 40%. Although balloon angioplasty may avoid expensive bypass
surgery if successful, restenosis may ultimately require the patient to undergo
bypass surgery. The Company has selected restenosis as its first antisense
product opportunity because the Company believes that delivery of NEU-GENE
compounds is achievable in this disease setting, NEU-GENE compounds have the
combination of properties to address this disease, and because the restenosis
market is estimated at more than $1 billion annually in the United States.
 
    When a patient has a blocked coronary artery, a procedure called balloon
angioplasty is frequently used to remove the blockage. In this procedure a
balloon catheter is inserted in the artery up to the blockage and the balloon is
inflated to open the artery. The balloon scrapes away the blockage as it
interfaces with the blocked portion of the artery. During this process, vascular
cells, including smooth muscle cells which underlie the blockage, may be
damaged. This process may result in rapid cell division leading to closure of
the artery a second time. Restenosis occurs in approximately 30% - 40% of these
procedures and cannot be predicted from patient to patient. The precise
mechanisms which cause this reaction are not known. However, scientific evidence
suggests that, if the smooth muscle cells can be
 
                                       24

<PAGE>
prevented from dividing for a few days until the integrity of the artery is
reestablished, restenosis could be prevented in a significant number of cases.
Although there are a few new clinical approaches that attempt to prevent
restenosis, none is very effective and all have significant risks associated
with them.
 
    There is scientific evidence that antisense compounds readily enter
scrape-damaged artery cells, and the Company has demonstrated that its NEU-GENE
antisense compounds readily enter and function in scraped cells in the
laboratory. The Company has selected target genetic sequences, has produced drug
candidates, and has demonstrated that its NEU-GENE compounds inhibit cell
division in laboratory models for this disease. Compound AVI-2221, Resten-NG, is
now in pre-clinical development for restenosis, and the Company expects to file
an IND to begin clinical trials in 1997. See "Drug Approval Process and Other
Government Regulations." The Company intends to co-develop its NEU-GENE
restenosis compound with a pharmaceutical partner. There can be no assurance,
however, that the Company will be able to enter into any partnerships or
establish any such relationship on favorable terms.
 
DRUG DELIVERY--CYTOPORTER
 
    Since NEU-GENES are large molecules that do not readily make their way into
cells, the Company has been developing a delivery mechanism that would allow
NEU-GENES, as well as other drugs, to be transported directly into their
intercellular site of action. The Company has developed and has filed a patent
for a molecular engine, called CYTOPORTER, to transport drugs across the lipid
layers of cellular and endosomal membranes into the interior of cells. This
engine is powered by the acidic differential (pH gradient) across the endosomal
membrane, does not disrupt the membrane, and is disassembled into harmless
byproducts after carrying out its transport function.
 
    TECHNICAL OVERVIEW
 
    The body has protective barriers that shield it from penetration by foreign
agents. Two of these barriers, cell membranes and the outermost layer of the
skin, are composed of lipid layers (fat-like substances). The lipid composition
of these barriers prevents aqueous or water-soluble agents from the environment
or in the blood from penetrating into the interior of cells and interfering with
critical cellular functions. These lipid layers are the principal barriers to
effective drug delivery for many drugs that have an intracellular site of
action.
 
    For optimal delivery, a drug should penetrate readily into both the aqueous
compartments of the body (body fluids and the interior of cells) and into the
lipid layers which enclose those compartments. This is rarely achieved because
when lipid solubility is increased, water solubility is decreased, and vice
versa. In the past, to achieve delivery, the structure of a selected drug
candidate was chemically adjusted to produce a compromise in the solubility
profile (i.e., less than ideal water solubility in order to achieve some level
of lipid solubility). This trade-off has been successful with many drugs, but
markedly less successful for many others. Currently, about one-third of all
FDA-approved drugs have delivery problems, and many others never make it into
clinical development due to delivery problems.
 
    Small substances of low polarity can usually pass directly through the lipid
layers of cell membranes. This appears to be the principal route of entry for
most drugs without delivery problems. In contrast, substances with greater
polarity and/or larger molecular size generally enter cells by being taken up
and sequestered in a closed cellular compartment, or endosome, in a process
called endocytosis. In this process, the interior of the endosome is acidified
and the contents are exposed to degradative enzymes resulting in their
breakdown. This is a natural cellular mechanism that protects the interior of
the cell from exposure to foreign material.
 
    Drugs that are polar in nature or are of a larger molecular size must cross
the lipid membrane of the endosome before being degraded in order to gain entry
into the interior of the cell. Many drugs in this category fail to achieve entry
rapidly enough to be practical for pharmaceutical purposes.
 
                                       25

<PAGE>
    CYTOPORTER DRUG DELIVERY SOLUTION.  The Company believes it has developed an
effective drug delivery engine, called CYTOPORTER, to facilitate the transport
of polar and larger size drugs across the lipid barriers of the skin, cell
membranes, and endosomes into the interior of cells at a rate that is practical
to achieve pharmaceutical results. When drugs in this category are taken up by
cells, they are sequestered within an endosome surrounded by a lipid barrier.
The Company's CYTOPORTER drug delivery engine is designed to transport these
problem drugs from the endosome into the interior of cells without disruption of
the lipid membrane that traps them. CYTOPORTER is a synthetic peptide containing
specifically positioned acidic groups along its structure. In neutral
conditions, CYTOPORTER exists as a water-soluble random form with its acidic
groups exposed and hydrated. On acidification in the endosome, CYTOPORTER
undergoes a transition to a lipid-soluble, needle-like form where the acidic
groups are masked by associating as mated pairs, and other polar groups are
shielded from the environment. As the engine becomes lipid soluble, it
penetrates across the surrounding lipid membrane. As it enters into the interior
of the cell, it encounters a neutral environment which induces a transition back
to a water-soluble form resulting in movement of the engine and drug into the
interior of the cell. See "Figure 3" below.
 
            FIGURE 3--CYTOPORTER DRUG DELIVERY AT THE CELLULAR LEVEL
 
                              [Drug Delivery Diagram]
 
    CYTOPORTER DRUG TRANSPORT MECHANISM.  In preparation for enhanced drug
delivery, the selected drug is chemically linked to the CYTOPORTER engine. This
process will be unique for each drug and must take into account each drug's mode
and site of action. Several steps are involved in the transport of the selected
drug from the blood or body fluids across lipid barriers into the interior of
target cells. After the drug is taken up by endocytosis, the endosome is
acidified as the cell attempts to degrade its contents. As this acidification
takes place, the engine converts from a water-soluble random form into a
lipophilic, needle-like form. As the engine converts to its lipophilic form, it
is PUSHED into the lipid membrane. Because the engine is longer than the
membrane is thick, continued entry pushes the leading end of the engine into the
interior of the cell. As the engine enters the neutral environment of the
interior of the cell, it reverts automatically to its random, water-soluble
form. This provides the motive force to PULL more of the engine across the
membrane. Finally, ionization and solvation of the engine as it enters the
interior pull the attached drug into the interior of the cell. The interior of
the cell contains enzymes which rapidly break down the engine into harmless
by-products. This is a natural process that results in freeing the drug to react
with its intracellular target.
 
    The Company believes that its CYTOPORTER delivery engine can be chemically
adjusted to accommodate a range of delivery challenges. The transition from
water to lipid solubility can be manipulated to afford a wide range of
transitions to accommodate various endosome characteristics. Moreover, the
Company believes that its CYTOPORTER can be adjusted to accommodate various drug
loads from modest polar drugs to the more challenging large polymers like
uncharged antisense compounds.
 
                                       26

<PAGE>
    CYTOPORTER APPLICATIONS.  The Company believes its CYTOPORTER molecular
engines may provide improved pharmaceutical properties for a wide variety of
drugs, including:
 
    - Improved aqueous solubility for lipophilic drugs, such as Taxol.
 
    - Improved transport of peptides from endosomes into the interior of cells
      (e.g., Cyclosporin) and transport of antisense polymers, particularly
      non-charged types such as NEU-GENES.
 
    - Protection of polymer drugs from degradation by virtue of transport out of
      endosomes prior to the start of the degradation process.
 
    - Improved transport of drugs into cells of the brain by specialized
      CYTOPORTER engines designed to provide both transport across the
      blood/brain barrier and subsequent entry into the interior of the brain.
 
    - Delivery of highly cytotoxic drugs into bacteria living in an acidic
      environment, specifically H. PYLORI, a major cause of ulcers in the
      stomach.
 
    - Transdermal delivery of lipophilic drugs.
 
    TRANSDERMAL DRUG DELIVERY.  The Company believes that its CYTOPORTER drug
delivery engine may have the potential for transdermal delivery of selected
substances. Placing an acidic, lipid-soluble form of the engine with an attached
drug in contact with the surface of the skin results in the diffusion of the
drug-engine through the lipid layers of the outer barrier of the skin (the
extracellular matrix of the stratum corneum). Upon contact with the aqueous
compartment underlying the stratum corneum, the drug-engine is drawn actively
into this compartment through progressive ionization and solvation of the engine
in the neutral conditions of this environment. This results in delivery of the
attached drug into the underlying tissues, with subsequent distribution
throughout the body.
 
    NEAR-TERM DRUG DELIVERY PRODUCTS
 
    The Company has selected paclitaxel (Taxol) and cyclosporin as the initial
drugs to be combined with its CYTOPORTER delivery engine for its enhanced drug
products. Additionally, the Company plans to apply its drug delivery technology
to current drugs used to treat inflammation, pain, and infectious diseases. The
Company plans to work with pharmaceutical collaborators to bring its drug
delivery technology to the market in a timely fashion. The Company has not,
however, entered into any arrangements with pharmaceutical collaborators, and
there can be no assurance that the Company will be able to do so or that, if
entered into, the arrangements will be successful in bringing the technology to
the market in a timely fashion.
 
    PACLITAXEL-CP.  Taxol is a Bristol-Myers Squibb drug whose patent life
expires in 1997. It is the largest selling cancer therapeutic worldwide, with an
estimated market size of $1 billion. However, severe solubility and delivery
problems greatly limit its use and effectiveness.
 
    Paclitaxel is indicated to treat ovarian cancer and is being used
experimentally to treat numerous cancers including breast cancer. The current
paclitaxel formulation is not readily soluble in aqueous solutions, requiring
the use of the solvent Cremophor-Registered Trademark-EL. Injection of the
drug/solvent combination causes hypersensitivity reactions, leaching of
plasticizer from PVC infusion bags, haziness of diluted solutions and the need
for in-line filters. The Company believes that combining its CYTOPORTER delivery
engine with paclitaxel (Paclitaxel-CP) could eliminate the need for solvent in
the formulation, thereby eliminating solvent-associated problems. This
development could result in more optimized dosing, a reduction in side effects,
and broader usage. The Company expects to file an IND to begin clinical trials
of Paclitaxel-CP in 1997. There can be no assurance that the Company will be
able to file or obtain approval for an IND in 1997 or at all.
 
                                       27

<PAGE>
    CYCLOSPORIN-CP.  Cyclosporin is a drug marketed by Sandoz AG whose patent
life expired in 1996. It is the transplantation anti-rejection drug of choice
worldwide, with an estimated market size of $1 billion. Difficulties with
delivery prevent broader systemic use and topical applications.
 
    Cyclosporin is an immunosuppressive drug that inhibits the function of
lymphocytes involved in mounting a rejection response in patients undergoing
organ transplantation. It has both poor solubility and poor delivery to its site
of action. Consequently, larger doses of the drug are required in order to
achieve a clinical level of effectiveness than if the drug readily reached its
site of action. These higher dosages lead to renal toxicity and other problems
that limit broader use. The Company believes that combining its CYTOPORTER drug
delivery engine with cyclosporin (Cyclosporin-CP) potentially would eliminate
these delivery difficulties, resulting in lower dosages, fewer side effects, and
broader usage.
 
LONG-TERM PRODUCT DEVELOPMENT PROGRAM--NEU-GENE/CYTOPORTER DRUG COMBINATIONS
 
    The following table summarizes the Company's broader drug development
program. These programs combine the Company's NEU-GENE antisense technology with
its CYTOPORTER drug delivery technology. For each indication, NEU-GENES have
been designed to target the disease process at the genetic level. The Company
has designed CYTOPORTER to deliver the NEU-GENE drugs to their intracellular
site of action. Although NEU-GENES may display clinical efficacy on their own,
the Company believes that broad use of NEU-GENES and other antisense compounds
will require a drug delivery strategy. CYTOPORTER drug delivery engines were
developed to facilitate the delivery of the NEU-GENE backbone and are currently
being optimized for that purpose.
 
    All of the development programs listed below are in the research or lead
compound stage. Disease targets have been identified and NEU-GENE compounds have
been produced and tested in laboratory and/ or animal models. In some cases,
lead compounds have been produced which are undergoing optimization prior to
pre-clinical development. The Company believes that several of these compounds
may move into pre-clinical development in the next two years.
 

<TABLE>
<CAPTION>
                                                                HOST DISEASE TARGETS
             INFECTIOUS DISEASE TARGETS               -----------------------------------------
- ----------------------------------------------------                             POTENTIAL
  DEVELOPMENT PROGRAM       POTENTIAL INDICATIONS     DEVELOPMENT PROGRAM       INDICATIONS
- ------------------------  --------------------------  --------------------  -------------------
<S>                       <C>                         <C>                   <C>
HIV                       AIDS, HIV-I infection       TNF Alpha             Inflammation
 
Hepatitis B, C            Hepatitis, Liver Cancer     ICAM-I                Inflammation
 
Herpes Simplex Virus      Ocular, Genital Herpes      Telomerase            Cancer
 
Cytomegalovirus           Retinitis
</TABLE>

 
    INFECTIOUS DISEASE TARGETS
 
    HUMAN IMMUNODEFICIENCY VIRUS ("HIV").  The Company has initiated a program
to produce and evaluate NEU-GENE agents directed at HIV targets. The Centers for
Disease Control ("CDC") estimated that, by the end of 1995, there were one
million HIV-infected persons in the United States and the cumulative number of
diagnosed AIDS cases approximated 500,000. The World Health Organization ("WHO")
estimated that worldwide there were approximately 20 million individuals
infected with HIV by the end of 1995. Currently, there are few FDA-approved
therapies for the treatment of HIV-infected individuals and drugs that are
available have significant toxic side effects.
 
    HEPATITIS B ("HBV").  The Company has initiated a program to produce and
evaluate NEU-GENE compounds directed at HBV targets. HBV is a major health
problem throughout the world, with epidemic infection levels in certain less
developed countries. HBV was estimated in 1995 to be the second leading cause of
death in the world. There are an estimated 200,000 to 300,000 new hepatitis
infections in the United States each year and approximately one million people
with chronic infection. Although there are
 
                                       28

<PAGE>
effective vaccines against HBV, there are currently no FDA-approved therapies
for the treatment of chronic or acute HBV infection.
 
    HEPATITIS C ("HCV").  The Company has initiated a program to produce and
evaluate NEU-GENE compounds directed at HCV targets. HCV is a major health
problem in many parts of the world, including the United States where there are
approximately 150,000 new infections each year (about 40% of all acute hepatitis
cases). The mechanism of transmission may involve the exchange of blood,
although the route of transmission in many cases is obscure. There are no
FDA-approved vaccines or therapeutic drugs for the treatment of HCV.
 
    HERPES SIMPLEX VIRUS ("HSV").  The Company is developing HSV NEU-GENE
compounds for the treatment of HSV type I and type II. Primary herpes infections
are usually severe and may involve skin, mucous membranes, conjunctivae or the
central nervous system. After remission of the initial infection, the virus
establishes a latent phase which is interrupted periodically by outbreaks or
herpetic lesions. Newborns can be infected at birth, which results in 50%
mortality, and survivors may suffer from permanent neurological damage.
Approximately 500,000 new cases each of genital herpes and oral herpes infection
occur annually in the United States. It is estimated that approximately 10
million Americans suffer from some form of primary or recurrent herpes infection
each year, and about 100 million people are chronically infected with type I and
25 million with type II.
 
    CYTOMEGALOVIRUS ("CMV").  The Company is developing NEU-GENE compounds for
the treatment of CMV infections. CMV is a member of the herpes family of viruses
and is the most common cause of intrauterine and congenital infections in
newborns of infected mothers. CMV retinitis is a severe problem in transplant
patients and patients with immunosuppression (e.g., AIDS), often leading to
blindness and pneumonitis, one of the most lethal viral syndromes. Current
FDA-approved treatments for CMV retinitis suffer from dose-limiting side effects
and have been associated with the emergence of drug-resistant CMV strains.
 
    HOST DISEASE TARGETS
 
    The Company is evaluating NEU-GENES for the treatment of inflammatory
diseases and cancer, two major host diseases. Inflammation is a crucial
component of a number of acute and chronic diseases. Although inflammation is a
key part of the normal physiological response to injury, alterations to the
normal inflammatory process often lead to inflammatory diseases. These
inflammatory disorders can affect practically every organ system in the body.
The interactions at the molecular level that cause inflammation are becoming
better understood and provide targets for intervention by antisense approaches.
Two families of potential targets include cellular mediators (TNF alpha) and
cellular adhesion molecules (ICAM-I), which are proteins involved in various
stages of the inflammatory process. The Company believes that by targeting
messenger RNA with NEU-GENE compounds, control of these mediators of
inflammation may be possible.
 
    TNF ALPHA.  TNF alpha has been implicated as a significant factor in
psoriasis, arthritis and other inflammatory disorders. Psoriasis is a serious
chronic, recurring skin disease that involves proliferation of keratinocytes
within the epidermal layer of the skin. Approximately four million individuals
in the United States are afflicted by psoriasis and approximately 200,000 new
cases are diagnosed annually. Current psoriasis therapies are varied but offer
limited results. The Company has demonstrated that its NEU-GENE compounds are
effective in inhibiting TNF alpha in laboratory and animal models of
inflammation.
 
    ICAM-I.  ICAM-1 facilitates the migration of immune cells involved in both
acute and chronic inflammation. Over-production of ICAM-1 is specifically
implicated in a wide variety of inflammatory disorders, such as rheumatoid
arthritis, asthma, psoriasis, organ transplant rejection, and inflammatory bowel
disease. The Company has targeted NEU-GENES against the adhesion molecule ICAM-I
and is testing these compounds in models of inflammation.
 
                                       29

<PAGE>
    TELOMERASE.  Telomerase is an enzyme found in cancer cells but rarely in
normal cells and the Company believes that inhibiting it may provide a broad
general approach to treat most cancers. There are approximately one million new
cases of cancer of all types reported in the United States annually. This leads
to about 500,000 deaths in the United States attributed to cancer each year,
making it the country's second leading cause of death. The Company has developed
NEU-GENE compounds that block telomerase activity in model systems in the
laboratory.
 
COLLABORATIVE AGREEMENTS
 
    The Company believes that antisense and drug delivery technologies are
broadly applicable for the potential development of pharmaceutical products in
many therapeutic areas. To exploit its core technologies as fully as possible,
the Company's strategy is to enter into collaborative research agreements with
major pharmaceutical companies directed at specific molecular targets. It is
anticipated that collaborative research agreements may provide the Company with
funding for programs conducted by the Company aimed at discovering and
developing antisense compounds to inhibit the production of individual molecular
targets. Partners may be granted options to obtain licenses to co-develop and to
market drug candidates resulting from its collaborative research programs. The
Company intends to retain manufacturing rights to its antisense products. There
can be no assurance, however, it will be able to enter into collaborative
research agreements with large pharmaceutical companies on terms and conditions
satisfactory to the Company.
 
MANUFACTURING
 
    The Company believes that it has developed significant proprietary
manufacturing techniques which will allow large-scale, low-cost synthesis and
purification of NEU-GENES. Because the Company's NEU-GENE compounds are based
upon a malleable backbone chemistry, the Company believes that NEU-GENE
synthesis will be more cost-effective than those of competing technologies. The
Company has established sufficient manufacturing capacity to meet immediate
research and development needs.
 
    The Company currently intends to retain manufacturing rights to all products
incorporating its proprietary and patented technology, whether such products are
sold directly by the Company or through collaborative agreements with industry
partners. The Company's current production capacity is insufficient for the
requirements of human clinical studies. Consequently, the Company intends to
construct, or contract for, a GMP manufacturing facility beginning in 1997 at an
estimated cost for construction of $5 million. The Company expects to finance
this facility using proceeds of this offering and possibly funds from
collaborative agreements, commercial debt and/or leasing arrangements. See "Use
of Proceeds." Before a production facility is built, and to satisfy the need for
compounds for clinical trials, the Company intends to work with contract
manufacturing firms to provide GMP-quality NEU-GENE and CYTOPORTER compounds.
There is no assurance, however, that the Company's plans will not change as a
result of unforeseen contingencies, nor is there any assurance that the Company
will have a need for a manufacturing facility, that such a facility can be built
at a cost and on a schedule as described above, or that financing will be
available on acceptable terms for such a project.
 
    In March 1993, the Company moved to its present laboratory facility. This
facility and the laboratory procedures followed by the Company have not been
formally inspected by the FDA and will have to be approved as products move from
the research phase through the clinical testing phase to commercialization. The
Company will need to comply with FDA requirements for GMP in connection with
human clinical trials and commercial production. See "Drug Approval Process and
Other Government Regulations."
 
                                       30

<PAGE>
MARKETING STRATEGY
 
    The Company plans to market the initial products for which it obtains
regulatory approval, through marketing arrangements or other licensing
arrangements with large pharmaceutical companies. Implementation of this
strategy will depend on many factors, including the market potential of any
products the Company develops and the Company's financial resources. The Company
does not expect to establish a direct sales capability for therapeutic compounds
for at least the next several years. To market products that will serve a large,
geographically diverse patient population, the Company expects to enter into
licensing, distribution, or partnering agreements with pharmaceutical companies
that have large, established sales organizations. See "Risk Factors--Dependence
on Third Parties for Clinical Testing, Manufacturing and Marketing."
 
PATENTS AND PROPRIETARY RIGHTS
 
    The proprietary nature of, and protection for, the Company's product
candidates, processes and know-how are important to its business. The Company
plans to prosecute and defend aggressively its patents and proprietary
technology. The Company's policy is to patent the technology, inventions, and
improvements that are considered important to the development of its business.
The Company also relies upon trade secrets, know-how, and continuing
technological innovation to develop and maintain its competitive position.
 
    The Company has 19 issued patents and several patent applications covering
the basic compositions of matter, methods of synthesis and medical uses of
NEU-GENES and CYTOPORTER compounds. These applications were filed in the United
States, Canada, Europe, Australia, and Japan. Certain of the Company's patents
were issued in the United States from 1991 through the present. Additional
applications have been filed to cover numerous improvements and advances in
these technologies. The Company feels that its patent protection is broad in
scope and expects to continue to protect its proprietary technology with
additional filings as appropriate.
 
    There can be no assurance that any patents applied for will be granted or
that patents held by the Company will be valid or sufficiently broad to protect
the Company's technology or provide a significant competitive advantage, nor can
the Company provide assurance that practice of the Company's patents or
proprietary technology will not infringe third-party patents.
 
    Although the Company believes that it has independently developed its
technology and attempts to ensure that its technology does not infringe the
proprietary rights of others, if infringement were alleged and proven, there can
be no assurance that the Company could obtain necessary licenses on terms and
conditions that would not have an adverse effect on the Company. The Company is
not aware of any asserted or unasserted claims that its technology violates the
proprietary rights of any person. See "Risk Factors--Patents and Proprietary
Rights."
 
DRUG APPROVAL PROCESS AND OTHER GOVERNMENT REGULATION
 
    The production and marketing of the Company's products and its research and
development activities are subject to regulation for safety, efficacy and
quality by numerous governmental authorities in the United States and other
countries. In the United States, drugs are subject to rigorous regulation. The
Federal Food, Drug and Cosmetics Act, as amended, and the regulations
promulgated thereunder, as well as other federal and state statutes and
regulations, govern, among other things, the testing, manufacture, safety,
efficacy, labeling, storage, record keeping, approval, advertising and promotion
of the Company's proposed products. Product development and approval within this
regulatory framework take a number of years and involve the expenditure of
substantial resources. In addition to obtaining FDA approval for each product,
each drug manufacturing establishment must be registered with, and approved by
the FDA. Domestic manufacturing establishments are subject to regular
inspections by the FDA and must comply with GMP. To supply products for use in
the United States, foreign manufacturing establishments must also
 
                                       31

<PAGE>
comply with GMP and are subject to periodic inspection by the FDA or by
regulatory authorities in certain of such countries under reciprocal agreement
with the FDA.
 
    NEW DRUG DEVELOPMENT AND APPROVAL.  The United States system of new drug
approval is the most rigorous in the world. According to a February 1993 report
by the Congressional Office of Technology Assessment, it cost an average of $359
million and took an average of 15 years from discovery of a compound to bring a
single new pharmaceutical product to market. Approximately one in 1,000
compounds that enter the pre-clinical testing stage eventually makes it to human
testing and only one-fifth of those are ultimately approved for
commercialization. In recent years, societal and governmental pressures have
created the expectation that drug discovery and development costs can be reduced
without sacrificing safety, efficacy and innovation. The need to significantly
improve or provide alternative strategies for successful pharmaceutical
discovery, research and development remains a major health care industry
challenge.
 
    DRUG DISCOVERY.  In the initial stages of drug discovery, before a compound
reaches the laboratory, typically tens of thousands of potential compounds are
randomly screened for activity in an assay assumed to be predictive of a
particular disease process. This drug discovery process can take several years.
Once a "screening lead" or starting point for drug development is found,
isolation and structural determination are initiated. Numerous chemical
modifications are made to the screening lead (called "rational synthesis") in an
attempt to improve the drug properties of the lead. After a compound emerges
from the above process, it is subjected to further studies on the mechanism of
action and further IN VITRO animal screening. If the compound passes these
evaluation points, animal toxicology is performed to begin to analyze the toxic
effect of the compound, and if the results indicate acceptable toxicity
findings, the compound emerges from the basic research mode and moves into the
pre-clinical phase.
 
    PRE-CLINICAL TESTING.  During the pre-clinical testing stage, laboratory and
animal studies are conducted to show biological activity of the compound against
the targeted disease, and the compound is evaluated for safety. These tests can
take up to three years or more to complete.
 
    INVESTIGATIONAL NEW DRUG APPLICATION.  After pre-clinical testing, an IND is
filed with the FDA to begin human testing of the drug. The IND becomes effective
if the FDA does not reject it within 30 days. The IND must indicate the results
of previous experiments, how, where and by whom the new studies will be
conducted, how the chemical compound is manufactured, the method by which it is
believed to work in the human body, and any toxic effects of the compound found
in the animal studies. In addition, the IND must be reviewed and approved by an
Institutional Review Board consisting of physicians at the hospital or clinic
where the proposed studies will be conducted. Progress reports detailing the
results of the clinical trials must be submitted at least annually to the FDA.
 
    PHASE I CLINICAL TRIALS.  After an IND becomes effective, Phase I human
clinical trials can begin. These studies, involving usually between 20 and 80
healthy volunteers, can take up to one year or more to complete. The studies
determine a drug's safety profile, including the safe dosage range. The Phase I
clinical studies also determine how a drug is absorbed, distributed, metabolized
and excreted by the body, as well as the duration of its action.
 
    PHASE II CLINICAL TRIALS.  In Phase II clinical trials, controlled studies
of approximately 100 to 300 volunteer patients with the targeted disease assess
the drug's effectiveness. These studies are designed primarily to evaluate the
effectiveness of the drug on the volunteer patients as well as to determine if
there are any side effects on these patients. These studies can take up to two
years or more and may be conducted concurrently with Phase I clinical trials. In
addition, Phase I/II clinical trials may be conducted that evaluate not only the
efficacy but also the safety of the drug on the patient population.
 
    PHASE III CLINICAL TRIALS.  This phase typically lasts up to three years or
more and usually involves 1,000 to 3,000 patients with the targeted disease.
During the Phase III clinical trials, physicians monitor the
 
                                       32

<PAGE>
patients to determine efficacy and to observe and report any adverse reactions
that may result from long-term use of the drug.
 
    NEW DRUG APPLICATION ("NDA").  After the completion of all three clinical
trial phases, the data are analyzed and if the data indicate that the drug is
safe and effective an NDA is filed with the FDA. The NDA must contain all of the
information on the drug that has been gathered to date, including data from the
clinical trials. NDAs are often over 100,000 pages in length. The average NDA
review time for new pharmaceuticals approved in 1995 was approximately 19
months.
 
    FAST TRACK REVIEW.  In December 1992, the FDA formalized procedures for
accelerating the approval of drugs to be marketed for the treatment of certain
serious diseases for which no satisfactory alternative treatment exists, such as
Alzheimer's disease and AIDS. If it is demonstrated that the drug has a positive
effect on survival or irreversible morbidity during Phase II clinical trials,
then the FDA may approve the drug for marketing without completion of Phase III
testing.
 
    APPROVAL.  If the FDA approves the NDA, the drug becomes available for
physicians to prescribe. The Company must continue to submit periodic reports to
the FDA, including descriptions of any adverse reactions reported. For certain
drugs which are administered on a long-term basis, the FDA may request
additional clinical studies (Phase IV) after the drug has begun to be marketed
to evaluate long-term effects.
 
    In addition to regulations enforced by the FDA, the Company also is subject
to regulation under the Occupational Safety and Health Act, the Environmental
Protection Act, the Toxic Substances Control Act, the Resource Conservation and
Recovery Act and other present and future federal, state or local regulations.
The Company's research and development activities involve the controlled use of
hazardous materials, chemicals, viruses and various radioactive compounds.
Although the Company believes that its safety procedures for handling and
disposing of such materials comply with the standard prescribed by state and
federal regulations, the risk of accidental contamination or injury from these
materials cannot be completely eliminated. In the event of such an accident, the
Company could be held liable for any damages that result, and any such liability
could exceed the resources of the Company.
 
    For marketing outside the United States, the Company or its prospective
licensees will be subject to foreign regulatory requirements governing human
clinical trials and marketing approval for drugs and devices. The requirements
governing the conduct of clinical trials, product licensing, pricing and
reimbursement vary widely from country to country.
 
COMPETITION
 
    Several companies are pursuing the development of antisense technology,
including Glaxo, Boehringer Ingelheim, Gilead, Hybridon, ISIS, and Lynx. All of
these companies are in development stages, and, in some cases, are in human
trials with antisense compounds generally similar to the Company's NEU-GENE
compounds. While the Company believes that none of these companies is likely to
introduce an antisense compound into the commercial market in the immediate
future, many pharmaceutical and biotechnology companies, including all of those
listed above, have financial and technical resources greater than those
currently available to the Company and have more established collaborative
relationships with industry partners than does the Company. Lynx has recently
announced that it plans to begin clinical trials with an antisense compound for
restenosis and that it will co-develop this potential application with Schwarz
Pharma AG. The Company believes that the combination of pharmaceutical
properties of its NEU-GENE compounds for restenosis afford it competitive
advantages when compared to the antisense compounds of competitors. Many
companies are pursuing drug delivery technology, including Biovail, Cellegy
Pharmaceuticals, Cygnus, and Noven, among others. If the Company's antisense and
drug delivery technologies attain regulatory and commercial acceptance as the
basis for the commercial pharmaceutical products, it is to be expected that
additional companies, including large, multinational pharmaceutical
 
                                       33

<PAGE>
companies, will choose to compete in the Company's markets, either directly or
through collaborative arrangements.
 
    The Company can also expect to compete with other companies exploiting
alternative technologies that address the same therapeutic needs as does the
Company's technology. The biopharmaceutical market is subject to rapid
technological change, and it can be expected that competing technologies will
emerge and will present a competitive challenge to the Company.
 
FACILITIES
 
    The Company occupies 18,400 square feet of leased laboratory and office
space at 4575 S.W. Research Way, Suite 200, Corvallis, Oregon 97333. The
Company's executive office is located in 2,400 square feet of leased space at
One S.W. Columbia, Suite 1105, Portland, Oregon 97258.
 
EMPLOYEES
 
    As of December 31, 1996, the Company had 28 employees, 14 of whom hold
advanced degrees. Twenty-three employees are engaged directly in research and
development activities, and five are in administration. None of the Company's
employees is covered by collective bargaining agreements, and management
considers relations with its employees to be good.
 
LEGAL MATTERS
 
    The Company is not currently involved in any litigation or legal proceedings
and is not aware of any litigation or proceedings threatened against it.
 
                                       34

<PAGE>
                                   MANAGEMENT
 
DIRECTORS AND EXECUTIVE OFFICERS
 
    The directors and officers of the Company and their ages are as follows:
 

<TABLE>
<CAPTION>
NAME                                               AGE                                POSITION
- ---------------------------------------------      ---      -------------------------------------------------------------
<S>                                            <C>          <C>
John A. Beaulieu(1,2)........................          61   Chairman of the Board
 
Denis R. Burger, Ph.D.(1)....................          53   Chief Executive Officer, Director
 
James E. Summerton, Ph.D.(1).................          52   President, Chief Scientific Officer, Director
 
Alan P. Timmins..............................          37   Chief Operating Officer, Chief Financial Officer
 
Dwight D. Weller, Ph.D.......................          45   Vice President of Research and Development, Director
 
Nick Bunick..................................          59   Director
 
Donald R. Johnson, Ph.D.(1)..................          67   Director
 
James E. Reinmuth, Ph.D.(2)..................          56   Director
 
Joseph Rubinfeld, Ph.D.(2)...................          64   Director
</TABLE>

 
- ------------------------
 
(1) Member of the Executive Committee
 
(2) Member of the Compensation and Audit Committees
 
    JOHN A. BEAULIEU has served as a director at the Company since 1991 and was
elected Chairman in January 1996. He is the Managing Partner of Cascadia Pacific
Management, LLC. ("CPM"). CPM is the contract manager for the Oregon Resource
and Technology Development Fund, a state-funded venture capital fund. Mr.
Beaulieu is also a general partner in Seed Management, a Vancouver B.C.-based
venture capital firm. Mr. Beaulieu is a director of TCC Communications, Biozyme
Inc., Virtual Corp., EPC Inc., and Purphonics LLC. Mr. Beaulieu received his
BS&C degree in Accounting and an M.B.A. from the University of Santa Clara.
 
    DENIS R. BURGER, PH.D. has served as Chief Executive Officer of the Company
since January 1996 and as a director of the Company since 1991. From 1992 to
1995, he was President and Chief Operating Officer of the Company. He co-founded
Epitope, Inc., a biotechnology company, and served as Chairman from 1981 to
1990. Dr. Burger has also been a member of Sovereign Ventures, LLC, a
biotechnology consulting and merchant banking venture since 1991. Dr. Burger is
a member of the Board of Directors of Cellegy Pharmaceuticals, Inc., an emerging
pharmaceutical company focused on drug delivery, SuperGen, Inc., a
pharmaceutical company focused on life-threatening diseases, and Trinity
Biotech, plc., an Irish diagnostics company. Dr. Burger held the positions of
Assistant Professor, Associate Professor and Professor at the Oregon Health
Sciences University ("OHSU") from 1969 to 1986. Dr. Burger received a B.A. in
Bacteriology and Immunology from the University of California, Berkeley, and his
M.S. and Ph.D. degrees in Microbiology and Immunology from the University of
Arizona.
 
    JAMES E. SUMMERTON, PH.D. has been President and Chief Scientific Officer
since January 1996. He founded the Company in 1980 and was its Chairman and
Chief Executive Officer until January 1996. He held the position of assistant
professor of Biochemistry-Biophysics at Oregon State University from 1978 to
1980. He is the inventor or co-inventor on all of the Company's patents and
pending applications. Dr. Summerton received a B.S. in Chemistry from Northern
Arizona University and a Ph.D. from the University of Arizona. Dr. Summerton
first conceived of the concept of sequence-specific gene-inactivation in 1969.
 
    ALAN P. TIMMINS has served as Chief Operating Officer and Chief Financial
Officer of the Company since October 1996 and Executive Vice President and Chief
Financial Officer since 1992. From 1981 to 1991, he served in a variety of
positions at the firm of Price Waterhouse, LLP, most recently as a Senior
 
                                       35

<PAGE>
Manager specializing in high technology and emerging growth companies. Mr.
Timmins received a B.B.A. in Accounting and Management from the University of
Portland and an M.B.A. from Stanford University. He is a Certified Public
Accountant.
 
    DWIGHT D. WELLER, PH.D. has served as Vice President of Research and
Development of the Company since 1992 and as a director of the Company since
1991. He joined the faculty of Oregon State University in 1978 as Assistant
Professor and was an Associate Professor in the Chemistry Department from 1984
to 1992. He is co-inventor on all but one of the Company's issued patents and
patent applications. Dr. Weller received a B.S. in Chemistry from Lafayette
College and a Ph.D. in Chemistry from the University of California at Berkeley,
followed by postdoctoral work in Bio-organic Chemistry at the University of
Illinois.
 
    NICK BUNICK has served as a director of the Company since 1992. Mr. Bunick
is the President and Chairman of the Board of three real estate development
companies and one investment management company. From 1987 to 1990, he was a
Vice President of In-Focus Systems, Inc., a company that specializes in the
design and manufacturing of flat panel display products. Mr. Bunick received a
B.S. in Business Administration and Marketing from the University of Florida.
 
    DONALD R. JOHNSON, PH.D. has served as a director of the Company since 1991.
He founded Technology Conversion, a research and new product development
consulting firm in 1986, and has served as its President since that time. Dr.
Johnson was Director, New Technology Research, Diagnostic and Bioresearch
Products at E. I. du Pont de Nemours and Company, Inc. from 1983 to 1986. Dr.
Johnson received a B.A. in Chemistry from the University of Minnesota and a
Ph.D. in Analytical Chemistry from the University of Wisconsin.
 
    JAMES E. REINMUTH, PH.D. has served as a director of the Company since 1991.
He was Dean of the College of Business Administration at the University of
Oregon from 1976 to 1994 and since 1995 has been the Charles H. Lundquist
Distinguished Professor of Business at University of Oregon. Dr. Reinmuth is the
Chairman of the Board of Directors and Chief Executive Officer of Athena Medical
Corp., a feminine health care company. He is also the President and Chief
Executive Officer of Fuji Advanced Filtration, Inc. Dr. Reinmuth is a general
partner in Rubicon Asset Management Corp. Dr. Reinmuth received a B.S. in
Mathematics from the University of Washington and his M.S. and Ph.D. degrees in
Statistics from Oregon State University.
 
    JOSEPH RUBINFELD, PH.D. has served as a director of the Company since 1996.
He has served as Chief Executive Officer, President, Chief Scientific Officer
and a director of SuperGen, Inc. since its inception in 1991. Dr. Rubinfeld was
one of the four initial founders of Amgen, Inc. in 1980 and served as Vice
President and Chief of Operations until 1983. From 1987 to 1990, he was Senior
Director at Cetus Corporation. From 1968 to 1980, Dr. Rubinfeld was employed at
Bristol-Myers Squibb (formerly Bristol-Myers International Corporation) in a
variety of positions, most recently as Vice President and Director of Research
and Development. He received his B.S. in Chemistry from C.C.N.Y., and his M.A.
and Ph.D. degrees in Chemistry from Columbia University.
 
DIRECTOR COMPENSATION
 
    Directors who are not employees of the Company receive a non-qualified
option to purchase 33,333 shares of Common Stock at an exercise price equal to
the fair market value of the Common Stock on the date of the grant pursuant to
the Company's Stock Incentive Plan, which vest over four years. See "Stock
Incentive Plan." Drs. Johnson and Rubinfeld are reimbursed for expenses for
attendance at board meetings.
 
                                       36

<PAGE>
SCIENTIFIC ADVISORY COMMITTEE
 
    The Company has established relationships with a group of scientific
advisors with expertise in their respective fields that complement the Company's
product research and development. The following individuals serve on the
Scientific Advisory Committee to the Company's Board of Directors:
 
    CHRISTOPHER K. MATHEWS, PH.D. is Chairman of the Scientific Advisory
Committee. He is the Chairman of the Biochemistry-Biophysics Department at
Oregon State University. Dr. Mathews received a B.A. from Reed College and a
Ph.D. in Biochemistry from the University of Washington. He performed
postdoctoral work in Biochemistry at the University of Pennsylvania. Dr. Mathews
joined the Scientific Advisory Committee in 1994 and was a director of the
Company from 1991 to 1994.
 
    STEVEN H. HEFENEIDER, PH.D. has been a staff immunologist at the Veterans
Administration Medical Center in Portland, Oregon since 1985 and Research
Associate Professor in the Department of Medicine at OHSU since 1987. He
received a B.S. in biology from the University of Oregon, an M.S. in genetics
from the University of Minnesota and a Ph.D. in Microbiology and Immunology from
OHSU in 1981.
 
    DAVID J. HINRICHS, PH.D. is a Research Scientist at the Veterans
Administration Medical Center in Portland, Oregon and a Professor of
Microbiology and Immunology at OHSU. From 1976 to 1985 he was a Professor of
Microbiology at Washington State University. He received a Ph.D. in Microbiology
from the University of Arizona in 1967.
 
    JEFFREY D. HOSENPUD, M.D. has been Chief of Cardiology and a Professor of
Medicine at the Medical College of Wisconsin in Milwaukee since 1994. Dr.
Hosenpud was Professor of Medicine and Head of the Cardiac Transplant Medicine
at OHSU from 1980 to 1994, and Medcal Director for the Registry of the
International Society for Heart & Lung Transplantation since 1993. Dr. Hosenpud
completed his M.D. at the University of California, Los Angeles.
 
EXECUTIVE COMPENSATION
 
    SUMMARY COMPENSATION TABLE.  The following table sets forth compensation
received in the fiscal year ended December 31, 1995, certain summary information
concerning compensation of the Company's Chief Executive Officer (the "Named
Officer"). No other executive officer received compensation exceeding $100,000.
 
                           SUMMARY COMPENSATION TABLE
 

<TABLE>
<CAPTION>
                                                                                              LONG-TERM
                                                                                            COMPENSATION
                                                                                           ---------------
                                                                ANNUAL COMPENSATION          SECURITIES
                                                          -------------------------------    UNDERLYING        ALL OTHER
                                                            YEAR      SALARY      BONUS        OPTIONS       COMPENSATION
                                                          ---------  ---------  ---------  ---------------  ---------------
<S>                                                       <C>        <C>        <C>        <C>              <C>
James E. Summerton, Ph.D.,
  Chairman and Chief Executive Officer..................       1995  $  90,400     --            --               --
</TABLE>

 
                                       37

<PAGE>
AGGREGATE OPTION EXERCISES IN LAST FISCAL YEAR AND FISCAL YEAR-END OPTION VALUES
 
    The following table sets forth information concerning the value of
unexercised options as of December 31, 1995, held by the Named Officer. No
options were exercised by the Named Officer during the year ended December 31,
1995.
 

<TABLE>
<CAPTION>
                                                            NUMBER OF SECURITIES
                                                           UNDERLYING UNEXERCISED       VALUE OF UNEXERCISED
                                                          OPTIONS AT DECEMBER 31,     IN-THE-MONEY OPTIONS AT
                                                                  1995 (#)            DECEMBER 31, 1995 ($)(1)
                                                         --------------------------  --------------------------
NAME                                                     EXERCISABLE  UNEXERCISABLE  EXERCISABLE  UNEXERCISABLE
- -------------------------------------------------------  -----------  -------------  -----------  -------------
<S>                                                      <C>          <C>            <C>          <C>
James E. Summerton, Ph.D.(2)...........................     132,220        93,334       144,502        125,418
</TABLE>

 
- ------------------------
 
(1) Based upon the difference between the fair market value of the securities
    underlying the options at December 31, 1995 ($6.00 per share as determined
    by the Board of Directors) and the exercise price of the options.
 
(2) Dr. Summerton resigned as the Chairman and Chief Executive Officer in
    February 1996 and is now the Company's President and Chief Scientific
    Officer.
 
EMPLOYMENT AGREEMENTS
 
    The Company has entered into employment contracts with Drs. Burger and
Summerton that provide for annual base salaries for Drs. Burger and Summerton of
$120,000 and $90,000, respectively, that increase to $225,000 and $150,000,
respectively, on January 1, 1997. The employment agreements also provide for the
payment to Drs. Burger and Summerton of one additional year of base salary and
the immediate and full vesting of all options granted to them under the
Company's Stock Incentive Plan in the event of the termination of their
respective employment for reasons, other than cause, or upon their voluntary
termination upon a change in control of the Company. In addition, the employment
agreements prevent Drs. Burger and Summerton from competing with the Company for
a period of two years following termination of their employment for any reason.
Dr. Summerton's agreement also provides that the Company shall engage him as a
consultant for a term of one year following the termination of his employment at
the rate of $75,000 per year and grants the Company the option to engage him as
a consultant on the same terms for a second year. Drs. Burger and Summerton are
deferring their January 1, 1997, salary increases until completion of the
Company's initial public offering.
 
STOCK INCENTIVE PLAN
 
    The Stock Incentive Plan was adopted by the Board of Directors and was
approved by the shareholders in 1992. The purposes of the Stock Incentive Plan
are to attract and retain the best available personnel for positions of
substantial responsibility, to provide additional incentive to the employees and
consultants of the Company and to promote the success of the Company's business.
 
    The Stock Incentive Plan is administered by the Compensation Committee (the
"Committee"). Transactions under the Stock Incentive Plan are intended to comply
with all applicable conditions of Rule 16b-3 promulgated under the Securities
Exchange Act of 1934. In addition to determining who will be granted options,
the Committee has the authority and discretion to determine when options will be
granted and the number of options to be granted. The Committee may determine
which options may be intended to qualify ("Incentive Stock Options") for special
treatment under the Internal Revenue Code of 1986, as amended from time to time
(the "Code"), or whether options are Non-Qualified Options ("Non-Qualified Stock
Options") which are not intended to so qualify. The Committee also may determine
the time or times when each option becomes exercisable, the duration of the
exercise period for options and the form or forms of the instruments evidencing
options granted under the Stock Incentive Plan. The Committee may adopt, amend
and rescind such rules and regulations as in its opinion may be advisable for
the administration of the Stock Incentive Plan. The Committee also may construe
the Stock Incentive Plan and
 
                                       38

<PAGE>
the provisions in the instruments evidencing option granted under Stock
Incentive Plan to employee and officer participants and is empowered to make all
other determinations deemed necessary or advisable for the administration of the
Stock Incentive Plan.
 
    The Stock Incentive Plan contains provisions for proportionate adjustment of
the number of shares for outstanding options and the option price per share in
the event of stock dividends, recapitalizations resulting in stock splits or
combinations or exchanges of shares. In addition, the Stock Incentive Plan
provides for adjustments in the purchase price and exercise period by the
Committee in the event of a proposed dissolution or liquidation of the Company,
or any corporate separation or division, including, but not limited to,
split-up, split-off or spin-off, or a merger or consolidation of the Company
with another corporation, or in the event there is a change in constitution of
the Common Stock of the Company.
 
    Participants in the Stock Incentive Plan may be selected by the Committee
from employees, officers, directors and consultants of the Company. In
determining the persons to whom options will be granted and the number of shares
to be covered by each option, the Committee will take into account the duties of
the respective persons, their present and potential contributions to the success
of the Company and such other factors as the Committee deems relevant to
accomplish the purposes of the Stock Incentive Plan.
 
    Only employees of the Company as the term "employees" is defined for the
purposes of Code will be entitled to receive Incentive Stock Options. Incentive
Stock Options granted under the Stock Incentive Plan are intended to satisfy all
requirements for incentive stock options under Section 422 of the Code and the
Treasury Regulations thereunder.
 
    Each option granted under the Stock Incentive Plan will be evidenced by a
written option agreement between the Company and the optionee. The option price
of any Incentive Stock Option may be not less than 100% of the fair market value
per share on the date of grant of the option; provided, however, that any
Incentive Stock Option granted under the Stock Incentive Plan to a person owning
more than 10% of the total combined voting power of the Common Stock will have
an option price of not less than 110% of the fair market value per share on the
date of grant of the Incentive Stock Option. Each Non-Qualified Stock Option
granted under the Stock Incentive Plan will be at an exercise price as
determined by the Board of Directors. Fair market value on the date of grant is
defined as a value determined in the discretion of the Board; provided, however,
that where there is a public market for the Common Stock, the fair market value
per share shall be the closing price of the Common Stock for the date of grant
or authorization of sale, as reported in THE WALL STREET JOURNAL.
 
    The exercise period of Incentive Stock Options granted under the Stock
Incentive Plan generally may not exceed 10 years from the date of grant thereof.
Incentive Stock Options granted to a person owning more than 10 percent of the
total combined voting power of the Common Stock of the Company will be for no
more than five years. The Committee will have the authority to accelerate or
extend the exercisability of any outstanding option at such time and under such
circumstances as it, in its sole discretion, deems appropriate. However, no
exercise period may be extended to increase the term of an Incentive Stock
Option beyond 10 years from the date of grant.
 
    To exercise an option, the optionee must pay the full exercise price in
whole or in part consisting of cash or transfer to the Company of shares having
a fair market value at the time of such exercise equal to the option exercise
price.
 
    An option may not be exercised unless the optionee then is an employee,
officer, director or consultant of the Company, and unless the optionee has
remained continuously as an employee, officer, director or consultant of the
Company since the date of grant of the option. If the optionee ceases to be an
employee, officer, director or consultant of the Company, all options which are
not vested under the Stock Incentive Plan by the time of death, disability,
retirement or termination of employment, immediately terminate. All options
granted to such optionee that are fully vested to such optionee but not yet
exercised, will terminate (i) 12 months after the date the optionee ceases to be
an employee, officer or director of the
 
                                       39

<PAGE>
Company by reason of death or disability; or (ii) 30 days after termination of
employment for any other reason.
 
    If an optionee dies while an employee, officer, director or consultant, or
is terminated by reason of disability, all options theretofore granted to such
optionee, unless earlier terminated in accordance with their terms, may be
exercised at any time within one year after the date of death or disability of
said optionee, by the optionee or by the optionee's estate or by a person who
acquired the right to exercise such options by request or inheritance, but only
to the extent of the right to exercise as of the date of death or disability.
 
    Options granted under the Stock Incentive Plan are not transferable other
than by will or by the laws of descent and distribution. Options may be
exercised during the lifetime of the optionee only by the optionee. An optionee
has no rights as a shareholder with respect to any shares covered by an option
until the option has been exercised.
 
    The Company, to the extent permitted by law, may deduct a sufficient number
of shares due to the optionee upon exercise of the option to allow the Company
to pay federal, state and local taxes of any kind required by law to be withheld
upon the exercise otherwise due to the optionee. The Company is not obligated to
advise any optionee of the existence of any tax or the amount which the Company
will be required to withhold.
 
    As of the date of this Prospectus, options to purchase 1,126,886 shares of
the Company's Common Stock have been granted and are outstanding under the Stock
Incentive Plan, at a weighted average exercise price of $4.73 per share, and
206,447 shares were available for future grants.
 
LIMITATION OF LIABILITY AND INDEMNIFICATION
 
    The Company's Third Restated Articles of Incorporation eliminate, to the
fullest extent permitted by Oregon law, liability of a director to the Company
or its shareholders for monetary damages for conduct as a director. While
liability for monetary damages has been eliminated, equitable remedies such as
injunctive relief or rescission remain available. In addition, a director is not
relieved of his or her responsibilities under any other law, including the
federal securities laws.
 
    The Company's Third Restated Articles of Incorporation require the Company
to indemnify its directors to the fullest extent not prohibited by law. The
Company believes that the limitation of liability provisions in its Third
Restated Articles may enhance the Company's ability to attract and retain
qualified individuals to serve as directors.
 
                                       40

<PAGE>
                              CERTAIN TRANSACTIONS
 
    James E. Summerton, Ph.D., the President, Chief Scientific Officer, and a
director of the Company, is the general partner of Anti-Gene Development Group
("AGDG"), and was the general partner of NEU-GENE Development Group ("NGDG").
AGDG was founded in 1981 and NGDG was founded in 1984 to own and fund the
Company's development of gene-targeted therapeutics and NEU-GENE technology.
NGDG and AGDG were combined in 1989, with AGDG as the surviving entity. The
Company entered into numerous research and development contracts with AGDG and
NGDG, all of which were completed or were superseded by the Technology Transfer
Agreement described below.
 
    On February 9, 1993, the Company and AGDG entered into a Technology Transfer
Agreement wherein effective May 19, 1993, AGDG conveyed all intellectual
property in its control related to antisense technology (the "Intellectual
Property") to the Company. As part of the conveyance, the Company tendered to
AGDG for liquidation all partnership units received pursuant to an exchange
offer and received a 49.37% undivided interest in the intellectual property. The
Company then purchased the remaining undivided interest in the Intellectual
Property in consideration of payments of 4.05% of gross revenues in excess of
$200 million, if any, sales of products by the Company which would, in the
absence of the Technology Transfer Agreement, infringe a valid claim under any
patent transferred to the Company (the "Technology Fees"). The Company's
obligation to make payments of the Technology Fees with respect to a particular
product terminates upon the expiration of all patents transferred to the Company
pursuant to the Technology Transfer Agreement related to that product.
 
    Pursuant to a License and Option Agreement by and between AGDG and the
Company dated February 9, 1993 (the "License Agreement"), the Company granted to
AGDG a royalty-free non-exclusive license to use the Intellectual Property for
internal research and development and to sell small quantities of products
incorporating the Intellectual Property. In addition, if AGDG develops any
specific prototype products which incorporate any of the Intellectual Property,
the Company has the right to commercialize and market such products in
consideration of payments of 4.05% of gross revenues, in excess of the $200
million exemption for all products utilizing the Intellectual Property, to AGDG.
If the Company elects not to commercialize the proposed AGDG product or fails to
meet certain product development milestones, the Company is required to grant
AGDG a license to develop and market the proposed product (an "AGDG License").
The Company is entitled to payments for the AGDG License but only if the
proposed product incorporates patented improvements developed by the Company to
the Intellectual Property. The amount of the license fee payable to the Company
by AGDG pursuant to an AGDG License, if any, is equal to the percentage payable
to AGDG for products sold by the Company and covered by the Technology Transfer
Agreement. AGDG also has the right to obtain an exclusive royalty-free license
to use, develop, make, sell, distribute and sublicense products utilizing the
Intellectual Property at such time as the Company has less than 10 full-time
employees engaged in developing, testing or marketing products based upon the
Intellectual Property for a period of at least 180 consecutive days.
 
    On January 20, 1997, AGDG and the Company amended the Technology Transfer
Agreement to reduce the Technology Fees arising from the sale of diagnostic
products from 4.05% to 2% and to remove the $200 million exemption with respect
to sales of such diagnostic products. The Company also granted to AGDG
royalty-bearing licenses to make, use and sell certain quantities of product
derived from the Intellectual Property.
 
    Pursuant to an August 4, 1992 restatement of earlier agreements between
Oregon Resource and Technology Development Fund ("ORTDF"), the Company, AGDG and
Dr. Summerton, warrants to purchase 600,000 shares of the Company's Common Stock
were issued to ORTDF. John A. Beaulieu was president of ORTDF and a director of
the Company at that time. In connection with this issuance to ORTDF, they
acquired certain rights to register such shares under the Securities Act. See
"Description of Securities--Registration Rights." In May 1993, ORTDF acquired
warrants to purchase an additional 357,500 shares in exchange for 325
partnership units in AGDG conveyed to the Company. Such warrants
 
                                       41

<PAGE>
carry no registration rights. In March 1996, ORTDF exercised its warrants in a
cashless exercise for which ORTDF acquired 957,452 shares of the Company's
Common Stock.
 
    Effective July 1, 1992, the Company entered into a consulting arrangement
with a former director of the Company, pursuant to which the Company agreed to
pay $3,500 per month for 24 months, and agreed to issue 11,000 shares of Common
Stock of the Company for no additional consideration. Under this arrangement,
and for services rendered prior to such date, the former director received
$10,500 in 1994, $52,500 in 1993 (including a $10,500 advance on 1994 payments),
and $69,500 in 1992.
 
    Donald R. Johnson, Ph.D., a director of the Company, performed consulting
services and incurred reimbursable expenses for the Company for which he was
paid approximately $7,000 in 1995, $13,500 in 1994, and $6,500 in 1993.
 
                                       42

<PAGE>
                             PRINCIPAL SHAREHOLDERS
 
    The following table sets forth certain information with respect to the
beneficial ownership of the Company's Common Stock as of February 28, 1997, and
as adjusted to give effect to the sale by the Company of the shares of Common
Stock offered (assuming no exercise of the Overallotment Option or the Warrants)
by (i) each person (or group of affiliated persons) who is known by the Company
to own beneficially 5% or more of the Common Stock, (ii) each of the Company's
directors, (iii) the Named Officer, and (iv) all executive officers and
directors of the Company as a group. The information as to each person or entity
has been furnished by such person or entity, and unless otherwise indicated, the
persons named in the table have sole voting and sole investment power with
respect to all shares beneficially owned, subject to community property laws
where applicable.
 

<TABLE>
<CAPTION>
                                                                                                PERCENT OF SHARES
                                                                                                   OUTSTANDING
                                                                                  SHARES     ------------------------
                                                                                BENEFICIALLY   BEFORE        AFTER
NAME AND ADDRESS OF BENEFICIAL OWNER(1)                                          OWNED(1)     OFFERING    OFFERING(1)
- ------------------------------------------------------------------------------  -----------  -----------  -----------
<S>                                                                             <C>          <C>          <C>
James E. Summerton, Ph.D.(2)..................................................   2,553,473        24.8%        21.6%
  ANTIVIRALS INC.
  4575 S.W. Research Way, Suite 200
  Corvallis, OR 97333
 
John A. Beaulieu(3)...........................................................     990,785         9.7%         8.5%
  4370 N.E. Halsey, Suite 233
  Portland, OR 97213
 
Oregon Resource and Technology(4).............................................     990,785         9.7%         8.5%
  Development Fund
  4370 N.E. Halsey, Suite 233
  Portland, OR 97213
 
Denis R. Burger, Ph.D.(5).....................................................     406,886         3.9%         3.4%
  ANTIVIRALS INC.
  1 S.W. Columbia, Suite 1105
  Portland, OR 97258
 
Dwight D. Weller, Ph.D(6).....................................................     370,178         3.6%         3.1%
  ANTIVIRALS INC.
  4575 S.W. Research Way, Suite 200
  Corvallis, OR 97333
 
Nick Bunick(7)................................................................     200,733         2.0%         1.7%
  ANTIVIRALS INC.
  1 S.W. Columbia, Suite 1105
  Portland, OR 97258
 
Alan P. Timmins(8)............................................................      68,825        *            *
  ANTIVIRALS INC.
  1 S.W. Columbia, Suite 1105
  Portland, OR 97258
 
Donald R. Johnson, Ph.D.(9)...................................................      64,333        *            *
  ANTIVIRALS INC.
  1 S.W. Columbia, Suite 1105
  Portland, OR 97258
</TABLE>

 
                                       43

<PAGE>

<TABLE>
<CAPTION>
                                                                                                PERCENT OF SHARES
                                                                                                   OUTSTANDING
                                                                                  SHARES     ------------------------
                                                                                BENEFICIALLY   BEFORE        AFTER
NAME AND ADDRESS OF BENEFICIAL OWNER(1)                                          OWNED(1)     OFFERING    OFFERING(1)
- ------------------------------------------------------------------------------  -----------  -----------  -----------
<S>                                                                             <C>          <C>          <C>
James E. Reinmuth, Ph.D.(10)..................................................      51,817        *            *
  ANTIVIRALS INC.
  1 S.W. Columbia, Suite 1105
  Portland, OR 97258
 
Joseph Rubinfeld, Ph.D.(11)...................................................       8,334        *            *
  ANTIVIRALS INC.
  1 S.W. Columbia, Suite 1105
  Portland, OR 97258
 
All executive officers and directors as a group (10 persons)..................   4,715,365        53.7%        45.9%
</TABLE>

 
- ------------------------
 
*   Less than 1%.
 
 (1) Beneficial ownership is determined in accordance with the rules of the
    Securities and Exchange Commission and generally includes voting or
    investment power with respect to securities. Shares of Common Stock subject
    to options and warrants currently exercisable or convertible, or exercisable
    or convertible within 60 days of February 28, 1997, are deemed beneficially
    owned and outstanding for computing the percentage of the person holding
    such securities, but are not considered outstanding for computing the
    percentage of any other person.
 
 (2) Includes 158,886 shares subject to options exercisable as of February 28,
    1997, and 727,154 shares held jointly or by others over which Dr. Summerton
    exercises voting and investment power. Does not include 66,667 shares
    subject to options exercisable after February 28, 1997.
 
 (3) Includes 33,334 shares subject to options exercisable as of February 28,
    1997, of which Mr. Beaulieu is the record owner. ORTDF is the beneficial
    owner of all of the 33,334 options for which Mr. Beaulieu is the record
    owner. Includes 957,452 shares of common stock issued to Cascadia Pacific
    Management, LLC for the benefit of ORTDF.
 
 (4) Includes 33,334 shares subject to options held of record by Mr. Beaulieu
    and exercisable as of February 28, 1997 and 957,452 shares issued to
    Cascadia Pacific Management, LLC for the benefit of ORTDF. See Note 3 above.
 
 (5) Includes 34,434 shares held by Sovereign Ventures, LLC, a limited liability
    company in which Dr. Burger is a general partner. Also includes 365,735
    shares subject to options exercisable as of February 28, 1997.
 
 (6) Includes 247,634 shares held jointly or by others over which Dr. Weller
    exercises voting and investment power, 94,018 shares subject to options
    exercisable by Dr. Weller and 1,860 shares subject to options exercisable by
    Dr. Weller's spouse as of February 28, 1997, and 25,000 shares subject to
    warrants exercisable as of February 28, 1997. Does not include 25,000 shares
    subject to warrants exercisable after February 28, 1997.
 
 (7) Includes 50,667 shares held jointly or by others over which Mr. Bunick
    exercises voting and investment power. Includes 33,334 shares subject to
    options exercisable as of February 28, 1997.
 
 (8) Includes 68,825 shares subject to options exercisable as of February 28,
    1997. Does not include 38,333 shares subject to options exercisable after
    February 28, 1997.
 
 (9) Includes 33,334 shares subject to options and 16,667 shares subject to
    warrants exercisable as of February 28, 1997.
 
(10) Includes 33,334 shares subject to options exercisable as of February 28,
    1997. Also includes 5,051 shares held jointly with others over which Dr.
    Reinmuth exercises voting and investment power.
 
(11) Includes 8,334 shares subject to options exercisable as of February 28,
    1997. Does not include 25,000 shares subject to options exercisable after
    February 28, 1997.
 
                                       44

<PAGE>
                           DESCRIPTION OF SECURITIES
 
    The authorized capital stock of the Company consists of 50,000,000 shares of
Common Stock and 2,000,000 shares of Preferred Stock.
 
UNITS
 
    Each Unit consists of one share of Common Stock and one redeemable Warrant.
The Units will separate immediately upon issuance, and the Common Stock and
Warrants that comprise the Units will trade as separate securities.
 
COMMON STOCK
 
    The Company is authorized to issue 50,000,000 shares of Common Stock. As of
December 31, 1996, 8,779,763 shares of Common Stock were outstanding, held of
record by 881 shareholders. The holders of Common Stock are entitled to one vote
for each share held of record on all matters submitted to a vote of shareholders
(and do not have any cumulative voting rights). Subject to preferences that may
be applicable to outstanding shares of Preferred Stock, if any, the holders of
Common Stock are entitled to receive ratably such dividends as may be declared
by the Company's Board of Directors out of funds legally available therefor.
Holders of Common Stock have no preemptive, subscription or redemption rights,
and there are no redemption, conversion or similar rights with respect to such
shares. In the event of a liquidation, dissolution or winding up of the Company,
holders of the Common Stock are entitled to share equally and ratably in the
assets of the Company, if any, remaining after the payment of all liabilities of
the Company and the liquidation preference of any outstanding class or series of
Preferred Stock. The outstanding shares of Common Stock are fully paid and
nonassessable. The rights, preferences and privileges of holders of Common Stock
are subject to any series of Preferred Stock that the Company may issue in the
future, as described below.
 
PREFERRED STOCK
 
    The Company is authorized to issue up to 2,000,000 shares of undesignated
Preferred Stock. No shares of Preferred Stock have been issued. The Board of
Directors has the authority to issue the undesignated Preferred Stock in one or
more series and to fix the rights, preferences, privileges and restrictions
granted to or imposed upon any wholly unissued shares of undesignated Preferred
Stock, as well as to fix the number of shares constituting any series and the
designation of such series, without any further vote or action by the
shareholders. The Board of Directors, without shareholder approval, may issue
Preferred Stock with voting and conversion rights which could materially
adversely affect the voting power of the holders of Common Stock. The issuance
of Preferred Stock could also decrease the amount of earnings and assets
available for distribution to holders of Common Stock. In addition, the issuance
of Preferred Stock may have the effect of delaying, deferring or preventing a
change in control of the Company. At present, the Company has no plans to issue
any shares of Preferred Stock. See "Risk Factors--Anti-Takeover Effects of
Certain Charter Provisions and Oregon Law" and "Certain Provisions of the
Company's Articles of Incorporation and Bylaws."
 
WARRANTS
 
    REPRESENTATIVE'S WARRANT.  In connection with this offering, the Company has
authorized the issuance of the Representative's Warrant and has reserved 300,000
shares of Common Stock for issuance upon exercise of such warrant (including the
warrants issuable upon exercise of the Representative's Warrant). The
Representative's Warrant will entitle the holder to acquire up to 150,000 Units
at an exercise price of $          per Unit (120% of the initial public offering
price for the Units). The Representative's Warrant will be exercisable at any
time from the first anniversary of the date of this Prospectus until the fifth
anniversary of the date of this Prospectus.
 
                                       45

<PAGE>
    THE WARRANTS.  Each Warrant will entitle the holder to purchase one share of
Common Stock at a price of $          per share (150% of the initial public
offering price for the Units). The Warrants will, subject to certain conditions,
be exercisable at any time until the fifth anniversary of the date of this
Prospectus, unless earlier redeemed. The Warrants are redeemable by the Company
at $.25 per Warrant, upon 30 days written notice, if the closing bid price (as
defined in the Warrant Agreement described below) per share of the Common Stock
for each of the 20 consecutive trading days immediately preceding the date
notice of redemption is given equals or exceeds 200% of the then-current Warrant
exercise price. If the Company gives notice of its intention to redeem, a holder
would be forced either to exercise his or her Warrant before the date specified
in the redemption notice or accept the redemption price.
 
    The Warrants will be issued in registered form under a Warrant Agreement
(the "Warrant Agreement") between the Company and                     , as
warrant agent (the "Warrant Agent"). The shares of Common Stock underlying the
Warrants, when issued upon exercise of a Warrant, will be fully paid and
nonassessable, and the Company will pay any transfer tax incurred as a result of
the issuance of Common Stock to the holder upon its exercise.
 
    The Warrants and the Representative's Warrant contain provisions that
protect the holders against dilution by adjustment of the number of shares that
may be purchased by the holders. Such adjustments will occur in the event, among
others, that the Company makes certain distributions to holders of its Common
Stock. The Company is not required to issue fractional shares upon the exercise
of a Warrant or Representative's Warrant. The holder of a Warrant or
Representative's Warrant will not possess any rights as a shareholder of the
Company until such holder exercises the Warrant or Representative's Warrant.
 
    A Warrant may be exercised upon surrender of the Warrant Certificate on or
before the expiration date of the Warrant at the offices of the Warrant Agent,
with the form of "Election To Purchase" on the reverse side of the Warrant
Certificate completed and executed as indicated, accompanied by payment of the
exercise price (by certified or bank check payable to the order of the Company
or by wire transfer of good funds) for the number of shares with respect to
which the Warrant is being exercised.
 
    For a holder to exercise the Warrants, there must be a current registration
statement in effect with the Commission and qualification in effect under
applicable state securities laws (or applicable exemptions from state
qualification requirements) with respect to the issuance of shares or other
securities underlying the Warrants. The Company has agreed to use all
commercially reasonable efforts to cause a registration statement with respect
to such securities under the Securities Act to be filed and to become and remain
effective in anticipation of and prior to the exercise of the Warrants and to
take such other actions under the laws of various states as may be required to
cause the sale of Common Stock (or other securities) issuable upon exercise of
Warrants to be lawful. If a current registration statement is not in effect at
the time a Warrant is exercised, the Company may at its option redeem the
Warrant by paying to the holder cash equal to the difference between the market
price of the Common Stock on the exercise date and the exercise price of the
Warrant. The Company will not be required to honor the exercise of Warrants if,
in the opinion of the Company's Board of Directors upon advice of counsel, the
sale of securities upon exercise would be unlawful.
 
    The foregoing discussion of certain terms and provisions of the Warrants and
Representative's Warrant is qualified in its entirety by reference to the
detailed provisions of the Warrant Agreement and Representative's Warrant
Certificate, the form of each of which has been filed as an exhibit to the
Registration Statement of which this Prospectus is a part.
 
    For the life of the Warrants and Representative's Warrant, the holders
thereof have the opportunity to profit from a rise in the market price of the
Common Stock without assuming the risk of ownership of the shares of Common
Stock issuable upon the exercise of the warrants. The warrant holders may be
expected to exercise their warrants at a time when the Company would, in all
likelihood, be able to obtain any needed capital by an offering of Common Stock
on terms more favorable than those provided for by the
 
                                       46

<PAGE>
warrants. Further, the terms on which the Company could obtain additional
capital during the life of the warrants may be adversely affected.
 
    OTHER WARRANTS.  The Company has outstanding certain warrants to purchase
147,902 shares of Common Stock, of which warrants to purchase 25,000 shares are
not presently exercisable. Of these warrants, 38,001 are exercisable through the
period ending 90 days after the expiration of lock-up agreements entered into in
connection with this offering, of which 27,001 are exercisable at a price of
$0.0003 per share and 11,000 are exercisable at a price of $1.14 per share.
Warrants to purchase 14,467 shares are exercisable through July 17, 1997, at an
exercise price of $0.0003 per share. Warrants to purchase 25,000 shares are
exercisable through December 31, 1997, at an exercise price of $0.0003 per
share. Warrants to purchase 1,100 shares are exercisable through August 8, 2001,
at an exercise price of $4.56 per share. Warrants to purchase 44,334 shares are
currently exercisable and do not have a termination date; warrants to purchase
11,000 of these shares are exercisable at a price of $1.14 per share and
warrants to purchase 33,334 of these shares are exercisable at $0.0003 per
share.
 
    The Company also has outstanding a warrant to purchase 219,331 shares of
Common Stock, exercisable through May 14, 2002, at an exercise price of $4.56
per share. The exercise price is subject to adjustment to make the price paid by
the warrant holder equivalent to the price paid by certain independent
third-party purchasers buying after the issue date of the warrant. The Company
has agreed to register the shares underlying this warrant under certain
circumstances. See "Registration Rights."
 
    The Company additionally has outstanding warrants to purchase 60,200 shares
of Common Stock at an exercise price of $9.00 per share. These warrants are
exercisable through the earlier of August 30, 2001 or three years from the date
of closing by the Company of an initial public offering.
 
CERTAIN FEDERAL INCOME TAX CONSIDERATIONS
 
    The following discussion sets forth certain federal income tax consequences,
under current law, relating to the purchase and ownership of the Units and the
Common Stock and Warrants constituting the Units. The discussion is a summary
and does not purport to deal with all aspects of federal taxation that may be
applicable to an investor, nor does it consider specific facts and circumstances
that may be relevant to a particular investor's tax position. Certain holders
(such as dealers in securities, insurance companies, tax exempt organizations,
foreign persons and those holding Common Stock or Warrants as part of a straddle
or hedge transaction) may be subject to special rules that are not addressed in
this discussion. This discussion is based on current provisions of the Internal
Revenue Code of 1986, as amended, and on administrative and judicial
interpretations as of the date hereof, all of which are subject to change. ALL
INVESTORS SHOULD CONSULT THEIR OWN TAX ADVISORS AS TO THE SPECIFIC TAX
CONSEQUENCES TO THEM OF THIS OFFERING, INCLUDING THE APPLICABILITY OF FEDERAL,
STATE, LOCAL AND FOREIGN TAX LAWS.
 
    ALLOCATION OF PURCHASE PRICE.  Each Unit as a whole will have a tax basis
equal to the cost of the Unit. The measure of income or loss from certain
transactions described below depends upon the tax basis in each of the Warrants
and the Common Stock comprising the Unit. The tax basis for each of the Warrants
and the Common Stock will be determined by allocating the cost of the Unit among
the securities which comprise the Unit in proportion to the relative fair market
values of those elements at the time of acquisition.
 
    U.S. HOLDERS OF COMMON STOCK OR WARRANTS. The following discussion concerns
the material U.S. federal income tax consequences of the ownership and
disposition of Common Stock or Warrants applicable to a U.S. Holder of such
Common Stock or Warrants. In general, a "U.S. Holder" is (i) a citizen or
resident of the U.S., (ii) a corporation or partnership created or organized in
the U.S. or under the laws of the U.S. or any state, or (iii) an estate or trust
whose income is includable in gross income for U.S. federal income tax purposes
regardless of its source.
 
                                       47

<PAGE>
    DIVIDENDS.  Dividends, if any, paid to a U.S. Holder generally will be
includable in the gross income of such U.S. Holder as ordinary income to the
extent of such U.S. Holder's share of the Company's current or accumulated
earnings and profits. See "Dividend Policy."
 
    SALE OF COMMON STOCK.  The sale of Common Stock should generally result in
the recognition of gain or loss to a U.S. Holder thereof in an amount equal to
the difference between the amount realized and such U.S. Holder's tax basis in
the Common Stock. If the Common Stock constitutes a capital asset in the hands
of a U.S. Holder, gain or loss upon the sale of the Common Stock will be
characterized as long-term or short-term capital gain or loss, depending on
whether the Common Stock has been held for more than one year.
 
    EXERCISE AND SALE OF WARRANTS.  No gain or loss will be recognized by a U.S.
Holder of a Warrant on the purchase of shares of Common Stock for cash pursuant
to an exercise of a Warrant (except that gain will be recognized to the extent
cash is received in lieu of fractional shares). The tax basis of Common Stock
received upon the exercise of a Warrant will equal the sum of the U.S. Holder's
tax basis for the exercised Warrant and the exercise price. The holding period
of the Common Stock acquired upon the exercise of the Warrant will begin on the
date the Warrant is exercised and the Common Stock is purchased (i.e., it does
not include the period during which the Warrant was held).
 
    Gain or loss from the sale or other disposition of a Warrant (or loss in the
event that the Warrant expires unexercised as discussed below), other than
pursuant to a redemption by the Company, will be capital gain or loss to its
U.S. Holder if the Common Stock to which the Warrant relates would have been a
capital asset in the hands of such holder. Such capital gain or loss will be
long-term capital gain or loss if the U.S. Holder has held the Warrant for more
than one year at the time of the sale, disposition or lapse. It is unclear
whether the redemption of a Warrant by the Company would generate ordinary or
capital income or loss.
 
    EXPIRATION OF WARRANTS WITHOUT EXERCISE.  If a holder of a Warrant allows it
to expire without exercise, the expiration will be treated as a sale or exchange
of the Warrant on the expiration date. The U.S. Holder will have a taxable loss
equal to the amount of such U.S. Holder's tax basis in the lapsed Warrant. If
the Warrant constitutes a capital asset in the hands of the U.S. Holder, such
taxable loss will be characterized as long-term or short-term capital loss
depending upon whether the Warrant was held for the required long-term holding
period.
 
    BACKUP WITHHOLDING.  A shareholder who is a U.S. Holder may be subject to
backup withholding at the rate of 31% in connection with distributions received
with respect to his or her shares, unless the shareholder (i) is a corporation
or comes within certain other exempt categories and, when required, demonstrates
this fact or (ii) provides a correct taxpayer identification number, certifies
as to no loss of exemption for backup withholding and otherwise complies with
applicable requirements of the backup withholding rules. Any amount paid as
backup withholding will be creditable against such shareholder's income tax
liability. The Company will report to the shareholders and the I.R.S. the amount
of any "reportable payments" distributed and the amount of tax withheld, if any,
with respect to the shares.
 
    NON-U.S. HOLDERS OF COMMON STOCK OR WARRANTS. The following discussion
concerns the material U.S. federal income and estate tax consequences of the
ownership and disposition of shares of Common Stock or Warrants applicable to
Non-U.S. Holders of such shares of Common Stock or Warrants. In general, a
"Non-U.S. Holder" is any holder other than a U.S. Holder, as defined in the
preceding section.
 
    DIVIDENDS.  Dividends, if any, paid to a Non-U.S. Holder generally will be
subject to U.S. with holding tax at a 30% rate (or a lower rate as may be
prescribed by an applicable tax treaty) unless the dividends are effectively
connected with a trade or business of the Non-U.S. Holder within the United
States. See "Dividend Policy." Dividends effectively connected with such a trade
or business will generally not be subject to withholding (if the Non-U.S. Holder
properly files an executed IRS Form 4224 with the payor of the dividend) and
generally will be subject to federal income tax on a net income basis at regular
graduated
 
                                       48

<PAGE>
rates. In the case of a Non-U.S. Holder which is a corporation, such effectively
connected income also may be subject to the branch profits tax (which is
generally imposed on a foreign corporation on the repatriation from the U.S. of
effectively connected earnings and profits). The branch profits tax may not
apply if the recipient is a qualified resident of certain countries with which
the U.S. has an income tax treaty. To determine the applicability of a tax
treaty providing for a lower rate of withholding, dividends paid to an address
in a foreign country are presumed, under the current I.R.S. position, to be paid
to a resident of that country, unless the payor had definite knowledge that such
presumption is not warranted or an applicable tax treaty (or U.S. Treasury
Regulations thereunder) requires some other method for determining a Non-U.S.
Holder's treaty status. The Company must report annually to the I.R.S. and to
each Non-U.S. Holder the amount of dividends paid to, and the tax withheld with
respect to, each Non-U.S. Holder. These reporting requirements apply regardless
of whether withholding was reduced or eliminated by an applicable tax treaty.
Copies of these information returns also may be made available under the
provisions of a specific treaty or agreement to the tax authorities in the
country in which the Non-U.S. Holder resides.
 
    SALE OF COMMON STOCK.  Generally, a Non-U.S. Holder will not be subject to
federal income tax on any gain realized upon the disposition of such holder's
shares of Common Stock unless (i) the gain is effectively connected with a trade
or business carried on by the Non-U.S. Holder within the U.S. (in which case the
branch profits tax may apply); (ii) the Non-U.S. Holder is an individual who
holds the shares of Common Stock as a capital asset and is present in the U.S.
for 183 days or more in the taxable year of the disposition and to whom such
gain is U.S. source; (iii) the Non-U.S. Holder is subject to tax pursuant to the
provisions of U.S. tax law applicable to certain former U.S. citizens or
residents; or (iv) the Company is or has been a "U.S. real property holding
corporation" for federal income tax purposes (which the Company does not believe
that it is or is likely to become) at any time during the five-year period
ending on the date of disposition (or such shorter period that such shares were
held) and, subject to certain exceptions, the Non-U.S. Holder held, directly or
indirectly, more than 5% of the Common Stock.
 
    EXERCISE AND SALE OF WARRANTS.  Generally, a Non-U.S. Holder who recognizes
capital gain from the sale of a Warrant, other than pursuant to a redemption by
the Company, will not be subject to U.S. federal income tax unless (i) the gain
is effectively connected with a trade or business carried on by the Non-U.S.
Holder within the United States (in which case the branch profits tax may
apply); (ii) the Non-U.S. Holder is an individual who is present in the U.S. for
183 days or more in the taxable year of sale and to whom the gain is U.S.
source; (iii) the Non-U.S. Holder is subject to tax pursuant to the provisions
of U.S. law applicable to certain former U.S. citizens or residents; or (iv) the
Company is or has been a "U.S. real property holding corporation" for federal
income tax purposes (which the Company does not believe it is or is likely to
become) at any time during the five-year period ending on the date of sale (or
such shorter period such Warrants were held) and, subject to certain exceptions,
the Non-U.S. Holder held, directly or indirectly, more than 5% of the Warrants.
 
    ESTATE TAX.  Shares of Common Stock and Warrants owned or treated as owned
by an individual who is not a citizen or resident (as specially defined for U.S.
federal estate tax purposes) of the U.S. at the time of death will be includable
in the individual's gross estate for U.S. federal estate tax purposes, unless an
applicable tax treaty provides otherwise, and may be subject to U.S. federal
estate tax.
 
    BACKUP WITHHOLDING AND INFORMATION REPORTING.  Under current U.S. federal
income tax law, backup withholding tax (which generally is a withholding tax
imposed at the rate of 31% on certain payments to persons that fail to furnish
certain required information) and information reporting apply to payments of
dividends (actual and constructive) made to certain non-corporate U.S. persons.
The backup withholding tax and information reporting requirements applicable to
U.S. persons will generally not apply to dividends paid on Common Stock to a
Non-U.S. Holder at an address outside the U.S., although dividends paid to
Non-U.S. Holders will be reported and taxed as described above under
"Dividends."
 
                                       49

<PAGE>
    The payment of the proceeds.from the disposition of shares of Common Stock
or Warrants through the U.S. office of a broker will be subject to information
reporting and backup withholding unless the holder, under penalties of perjury,
certifies, among other things, its status as a Non-U.S. Holder or otherwise
establishes an exemption. Generally, the payment of the proceeds from the
disposition of shares of Common Stock or Warrants to or through a non-U.S.
office of a broker will not be subject to backup withholding and will not be
subject to information reporting. In the case of the payment of proceeds from
the disposition of shares of Common Stock or Warrants through a non-U.S. office
of a broker that is a U.S. person or a "U.S.-related person," existing
regulations require information reporting (but not backup withholding) on the
payment unless the broker receives a statement from the owner, signed under
penalties of perjury, certifying, among other things, its status as a non-U.S.
Holder or the broker has documentary evidence in its files that the owner is a
Non-U.S. Holder and the broker has no actual knowledge to the contrary. For this
purpose, a "U.S.-related person" is (i) a "controlled foreign corporation" for
U.S. federal income tax purposes or (ii) a foreign person 50% or more of whose
gross income from all sources for the three-year period ending with the close of
its taxable year preceding the payment (or for such part of the period that the
broker has been in existence) is derived from activities that are effectively
connected with the conduct of a U.S. trade or business.
 
    Any amounts withheld from a payment to a Non-U.S. Holder under the backup
withholding rules will be allowed as a credit against such holder's U.S. federal
income tax liability and may entitle such holder to a refund, provided that the
required information is furnished to the I.R.S. Non-U.S. Holders should consult
their tax advisors regarding the application of these rules to their particular
situations, the availability of an exemption therefrom and the procedure for
obtaining such an exemption, if available.
 
REGISTRATION RIGHTS
 
    REPRESENTATIVE'S WARRANT.  The Representative's Warrant provides certain
rights with respect to the registration under the Securities Act of the 300,000
shares issuable upon exercise thereof (including shares of Common Stock issuable
upon the exercise of the Warrants included therein). The Company has agreed that
during the entire period between the first anniversary and fifth anniversary
after the date of this Prospectus it will register the issuance of such shares
upon the exercise of the Representative's Warrant (and, if necessary, their
resale) so as to permit their public resale without restriction. These
registration rights could result in substantial future expense to the Company
and could adversely affect the Company's ability to complete future equity or
debt financings. Furthermore, the registration and sale of Common Stock of the
Company held by or issuable to the holders of registration rights, or even the
potential of such sales, could have an adverse effect on the market price of the
securities offered hereby.
 
    OTHER REGISTRATION RIGHTS.  Holders of 834,568 shares of Common Stock, or
their transferees, are entitled to certain rights with respect to the
registration of such shares under the Securities Act. Under the terms of an
Agreement to Purchase Limited Partnership Interests dated as of August 4, 1992
among AGDG, the Company and ORTDF, if the Company proposes to register any of
its Common Stock for sale to the public, ORTDF may require the Company to
include in such registration any shares of Common Stock issued or issuable upon
the exercise of certain warrants to purchase Common Stock of the Company held by
ORTDF subject to certain conditions and limitations. As of the date of this
Prospectus, ORTDF held 599,970 shares of Common Stock which enjoy registration
rights. ORTDF will not participate in this offering.
 
    Under the terms of a Registration Rights Agreement dated as of May 20, 1992
between the Company and Ice Bear, Inc., an Alaska corporation ("Ice Bear"), if
the Company proposes to register any of its stock or other securities under the
Act in connection with a public offering of those securities for cash, Ice Bear
may require the Company to include in such registration any shares of Common
Stock held or issued or issuable upon the exercise of certain warrants to
purchase Common Stock of the Company held by Ice Bear subject to certain
conditions and limitations. As of the date of this Prospectus, Ice Bear holds
21,930
 
                                       50

<PAGE>
shares of Common Stock and warrants to purchase 219,334 shares of Common Stock,
all of which enjoy registration rights. Ice Bear will not participate in this
offering.
 
CERTAIN PROVISIONS OF THE COMPANY'S ARTICLES OF INCORPORATION AND BYLAWS
 
    Certain provisions of the Company's Third Restated Articles of Incorporation
and Bylaws could make more difficult the acquisition of the Company by means of
a tender offer, a proxy contest or otherwise and the removal of incumbent
officers and directors. These provisions include authorization of the issuance
of up to 2,000,000 shares of Preferred Stock, with such characteristics, and
potential effects on the acquisition of the Company, as are described in
"Preferred Stock" above. This provision is expected to discourage certain types
of coercive takeover practices and inadequate takeover bids and to encourage
persons seeking to acquire control of the Company to negotiate first with the
Company. The Company believes that the benefits of increased protection of the
Company's potential ability to negotiate with the proponent of an unfriendly or
unsolicited proposal to acquire or restructure the Company outweigh the
disadvantages of discouraging such proposals because, among other things,
negotiation of such proposals could result in an improvement of their terms. See
"Risk Factors--Anti-Takeover Effects of Certain Charter Provisions and Oregon
Law."
 
OREGON CONTROL SHARE AND BUSINESS COMBINATION STATUTES
 
    Upon completion of this offering, the Company will become subject to the
Oregon Control Share Act (the "Control Share Act"). The Control Share Act
generally provides that a person (the "Acquiring Person") who acquires voting
stock of an Oregon corporation in a transaction that results in the Acquiring
Person holding more than 20%, 33 1/3% or 50% of the total voting power of the
corporation (a "Control Share Acquisition") cannot vote the shares it acquires
in the Control Share Acquisition ("control shares") unless voting rights are
accorded to the control shares by (i) a majority of each voting group entitled
to vote and (ii) the holders of a majority of the outstanding voting shares,
excluding the control shares held by the Acquiring Person and shares held by the
Company's officers and inside directors. The term "Acquiring Person" is broadly
defined to include persons acting as a group.
 
    The Acquiring Person may, but is not required to, submit to the Company a
statement setting forth certain information about the Acquiring Person and its
plans with respect to the Company. The statement may also request that the
Company call a special meeting of shareholders to determine whether voting
rights will be accorded to the control shares. If the Acquiring Person does not
request a special meeting of shareholders, the issue of voting rights of control
shares will be considered at the next annual meeting or special meeting of
shareholders. If the Acquiring Person's control shares are accorded voting
rights and represent a majority or more of all voting power, shareholders who do
not vote in favor of voting rights for the control shares will have the right to
receive the appraised "fair value" of their shares which may not be less than
the highest price paid per share by the Acquiring Person for the control shares.
 
    Upon completion of this offering, the Company will become subject to certain
provision of the Oregon Business Corporation Act that govern business
combinations between corporations and interested shareholders (the "Business
Combination Act"). The Business Combination Act generally provides that if a
person or entity acquires 15% or more of the voting stock of an Oregon
corporation (an "Interested Shareholder"), the corporation and the Interested
Shareholder, or any affiliated entity of the Interested Shareholder, may not
engage in certain business combination transactions for three years following
the date the person became an Interested Shareholder. Business combination
transactions for this purpose include (a) a merger or plan of share exchange,
(b) any sales, lease, mortgage or other disposition of 10% or more of the assets
of the corporation and (c) certain transactions that result in the issuance of
capital stock of the corporation to the Interested Shareholder. These
restrictions do not apply if (i) the Interested Shareholder, as a result of the
transaction in which such person became an Interested Shareholder, owns at least
85% of the outstanding voting stock of the corporation (disregarding shares
owned by directors who are also officers and certain employee benefit plans),
(ii) the board of directors approves the share
 
                                       51

<PAGE>
acquisition or business combination before the Interested Shareholder acquires
15% or more of the corporation's outstanding voting stock or (iii) the board of
directors and the holders of at least two-thirds of the outstanding voting stock
of the corporation (disregarding shares owned by the Interested Shareholder)
approve the transaction after the Interested Shareholder acquires 15% or more of
the corporation's voting stock. See "Risk Factors--Anti-Takeover Effects of
Certain Charter Provisions and Oregon Law."
 
TRANSFER AGENT AND REGISTRAR
 
    The Transfer Agent and Registrar for the Company's securities is ChaseMellon
Shareholder Services.
 
                        SHARES ELIGIBLE FOR FUTURE SALE
 
    Prior to this offering, there has been no public market for the Units,
Common Stock or Warrants. No prediction can be made of the effect, if any, that
future market sales of shares of Common Stock or the availability of such shares
for sale will have on the prevailing market price of the Common Stock following
this offering. Nevertheless, sales of substantial amounts of such shares in the
open market following this offering could adversely affect the prevailing market
price of the Common Stock.
 
    Upon completion of this offering and assuming no exercise of outstanding
options and warrants to purchase Common Stock after December 31, 1996, the
Company will have 10,279,763 outstanding shares of Common Stock. See
"Description of Securities." The 1,500,000 shares of Common Stock which are
included in the Units and sold in this offering (or 1,725,000 shares if the
Overallotment Option is exercised in full) by the Company and, subject to
certain conditions, up to 1,725,000 shares of Common Stock issuable upon
exercise of the Warrants (including Warrants subject to the Overallotment
Option, and, commencing approximately 12 months after the date of this
Prospectus, up to 300,000 shares of Common Stock that are issuable upon exercise
of the Representative's Warrant (including the Warrants included therein), will,
subject to any applicable state law restrictions on secondary trading (see "Risk
Factors-- Possible Illiquidity of Trading Market"), be freely tradeable without
restriction under the Securities Act, except that any shares purchased by an
"affiliate" of the Company (as that term is defined in Rule 144 under the
Securities Act) will be subject to the resale limitations of Rule 144.
 
    The remaining 8,779,763 shares of Common Stock are "restricted" shares
within the meaning of Rule 144 under the Securities Act (the "Restricted
Shares"). Of this number, approximately           shares not subject to lock-up
agreements will be eligible for immediate resale without restriction under Rule
144(k) of the Securities Act. An additional           shares held for more than
two but less than three years by shareholders who are not affiliates of the
Company and who are not subject to lock-up agreements are eligible for sale
under Rule 144 of the Securities Act, subject to the volume and other
limitations thereunder. Upon expiration of lock-up agreements with the
Representative three months after the date of this Prospectus (or earlier with
the consent of the Representative),           shares will be eligible for
immediate resale subject to the limitations of Rule 144 and           shares
will be eligible for resale immediately without restriction pursuant to Rule
144(k). Upon expiration of lock-up agreements with the Representative six months
after the date of this Prospectus (or earlier with the consent of the
Representative),           shares will be eligible for immediate resale subject
to the limitations of Rule 144 and           shares will be eligible for resale
immediately without restriction pursuant to Rule 144(k). Upon expiration of
lock-up agreements with the Representative nine months after the date of this
Prospectus (or earlier with the consent of the Representative),           shares
will be eligible for immediate resale subject to the limitations of Rule 144 and
          shares will be eligible for resale immediately without restriction
pursuant to Rule 144(k). Upon expiration of lock-up agreements with the
Representative one year after the date of this Prospectus (or earlier with the
consent of the Representative),           shares will be eligible for immediate
resale subject to the limitations of Rule 144 and           shares will be
eligible for resale immediately without restriction pursuant to Rule 144(k). As
of the date of this Prospectus, options to purchase           shares of Common
Stock have been granted
 
                                       52

<PAGE>
under the Stock Incentive Plan, which shares, if acquired pursuant to the
exercise of options, are subject to lock-up agreements which expire one year
after the date of this Prospectus (or earlier with the consent of the
Representative).
 
    In general, under Rule 144, as currently in effect, any person (or persons
whose shares are aggregated) who has beneficially owned Restricted Shares for at
least two years, is entitled to sell, within any three-month period, a number of
shares that does not exceed the greater of (i) 1% of the then outstanding shares
of the Company's Common Stock (approximately 102,798 shares immediately after
this offering) or (ii) the average weekly trading volume of the Company's Common
Stock in the Nasdaq National Market during the four calendar weeks immediately
preceding the date on which notice of the sale is filed with the Securities and
Exchange Commission. Sales pursuant to Rule 144 are also subject to certain
requirements relating to manner of sale, notice and availability of current
public information about the Company. A person who is not deemed to have been an
affiliate of the Company at any time during the 90 days immediately preceding
the sale and whose Restricted Shares have been fully-paid for three years since
the later of the date they were acquired from the Company or the date they were
acquired from an affiliate of the Company may sell such Restricted Shares under
Rule 144(k) without regard to the limitations and requirements described above.
Under Rule 701, shares privately issued under certain compensatory stock-based
plans, such as the Stock Incentive Plan, may be resold under Rule 144 by
non-affiliates, subject only to the manner of sale requirements, and by
affiliates without regard to the two-year holding period requirement, commencing
90 days after the Company becomes subject to certain periodic reporting
requirements.
 
    Shortly after this offering, the Company intends to file a registration
statement under the Securities Act covering shares of Common Stock reserved for
issuance under the Company's outstanding stock options and Stock Incentive Plan
(other than shares issued upon the exercise of options prior to the effective
date of such registration statement). Based on the number of options outstanding
and options and shares reserved for issuance, such registration statement would
cover approximately 1,333,333 shares. Such registration statement will
automatically become effective upon filing. All shares issuable under the
Company's Stock Incentive Plan are subject to a six-month lock-up period
following the date of this Prospectus.
 
    Prior to this offering, there has been no established public market for the
Common Stock. No prediction can be made of the effect, if any, that sales of
shares under Rule 144 or the availability of shares for sale will have on the
market price of the Common Stock prevailing from time to time after the
offering. The Company is unable to estimate the number of shares that may be
sold in the public market under Rule 144, because such amount will depend on the
trading volume in, and market price for, the Common Stock and other factors.
Nevertheless, sales of substantial amounts of shares in the public market, or
the perception that such sales could occur, could adversely affect the market
price of the Common Stock of the Company. See "Underwriting."
 
                                       53

<PAGE>
                                  UNDERWRITING
 
    The underwriters named below (the "Underwriters"), for whom Paulson
Investment Company, Inc. is acting as representative, have severally agreed
subject to the terms and conditions of the Underwriting Agreement between the
Company and the several Underwriters (the "Underwriting Agreement"), to purchase
from the Company, and the Company has agreed to sell to the Underwriters, the
number of Units set forth in the table below at the price set forth on the cover
page of this Prospectus.
 

<TABLE>
<CAPTION>
UNDERWRITER                                                                    NUMBER OF UNITS
- -----------------------------------------------------------------------------  ---------------
<S>                                                                            <C>
Paulson Investment Company, Inc..............................................
 
                                                                               ---------------
    Total....................................................................      1,500,000
                                                                               ---------------
                                                                               ---------------
</TABLE>

 
    The Underwriting Agreement provides that the obligations of the Underwriters
to purchase such Units are subject to certain conditions. The Underwriters are
committed to purchase all the 1,500,000 Units offered by this Prospectus, but
not the 225,000 Units subject to the Overallotment Option, if any are purchased.
 
    The Representative has advised the Company that the Underwriters propose to
offer the Units to the public at the initial public offering price set forth on
the cover page of this Prospectus and to selected dealers at such price less a
concession within the discretion of the Representative, and that the
Underwriters and such dealers may reallow a concession to other dealers,
including the Underwriters, within the discretion of the Representative. After
the initial public offering of the Units, the public offering price, the
concessions to selected dealers and the reallowance to other dealers may be
changed by the Representative.
 
    The Company has granted the Underwriters the Overallotment Option, expiring
at the close of business 45 days after the date of this Prospectus, to purchase
up to 225,000 additional Units from the Company on the same terms as apply to
the sale of the Units set forth above. The Underwriters may exercise the
Overallotment Option only to cover overallotments, if any, incurred in the sale
of Units.
 
    The Company has agreed that if it elects to redeem the Warrants at any time
commencing one year after the date of this Prospectus, it will retain the
Representative as the Company's solicitation agent ("Warrant Solicitation
Agent"). The Company has agreed to pay the Warrant Solicitation Agent for its
services a solicitation fee equal 2% of the total amount paid by the holders of
the Warrants whom the Warrant Solicitation Agent solicited to exercise the
Warrants. The exercise will be presumed to be unsolicited unless the customer
states in writing that the transaction was solicited by the Warrant Solicitation
Agent and designates in writing the registered representative at the Warrant
Solicitation Agent entitled to receive compensation for the exercise. The fee is
not payable for the exercise of any Warrant held by a Warrant Solicitation Agent
in a discretionary account at the time of exercise, unless the Warrant
Solicitation Agent receives from the customer prior specific written approval of
such exercise.
 
    The Representative has informed the Company that it does not expect the
Underwriters to confirm sales of Units offered by this Prospectus to any account
on a discretionary basis.
 
    The Underwriting Agreement provides for indemnification between the Company
and the Underwriters against certain liabilities, including liabilities under
the Securities Act, and for contribution by the Company and the Underwriters to
payments that may be required to be made in respect thereof.
 
                                       54

<PAGE>
    The Company has agreed to pay the Representative a nonaccountable expense
allowance equal to 2.5% of the gross proceeds from the sale of Units offered
hereby, of which $35,000 has already been paid.
 
    The Company has agreed to issue to the Representative the Representative's
Warrant to purchase from the Company up to 150,000 Units at an exercise price
per Unit equal to $          (120% of the initial offering price of the Units).
The Representative's Warrant is exercisable for a period of four years beginning
one year from the date of this Prospectus, and is not transferable for a period
of one year from the date of this Prospectus except to one of the Underwriters
or to any individual who is either a partner or an officer of an Underwriter, or
by will or by the laws of descent and distribution. The Representative's Warrant
is not redeemable by the Company. The Company has agreed to maintain an
effective registration statement with respect to the issuance of securities
underlying the Representative's Warrant (and, if necessary, to allow their
public resale without restriction) at all times during the period in which the
Representative's Warrant is exercisable. Such securities are being registered on
the Registration Statement of which this Prospectus is a part.
 
    The Company has agreed that, for a period of 1 year following the closing of
this offering, it will not, subject to certain exceptions, offer, sell, contract
to sell, grant any option for the sale or otherwise dispose of any securities of
the Company without the Representative's consent. The Company's officers and
directors and certain other shareholders have agreed that for a period of one
year following the closing of this offering, they will not offer, sell, contract
to sell, grant any option for the sale or otherwise dispose of any securities of
the Company (other than intra-family transfer or transfers to trusts for estate
planning purposes), without the Representative's consent. See "Shares Eligible
For Future Sale."
 
    Prior to this offering, there has been no public market for the Units,
Common Stock or Warrants. Accordingly, the initial public offering price has
been determined by negotiations between the Company and the Representative.
Among the factors considered in determining the initial public offering price
were the history and the prospects of the Company and the industry in which it
operates, the status and development prospects for the Company's proposed
products and the trends of such results, the experience and qualifications of
the Company's executive officers and the general condition of the securities
markets at the time of this offering.
 
                                 LEGAL MATTERS
 
    The validity of the Units offered hereby will be passed upon for the Company
by Ater Wynne Hewitt Dodson & Skerritt, LLP, Portland, Oregon. Certain legal
matters with respect to patents and proprietary rights of the Company, as
described in this Prospectus, are being passed upon for the Company by Peter
Dehlinger & Associates, Palo Alto, California, patent counsel to the Company.
Certain legal matters relating to this offering will be passed upon for the
Underwriters by Weiss, Jensen, Ellis & Howard, P.C., Portland, Oregon.
 
                                    EXPERTS
 
    The financial statements of the Company as of December 31, 1995 and for each
of the two years in the period ended December 31, 1995 appearing in this
Prospectus have been audited by Arthur Andersen LLP, independent auditors, as
set forth in their report thereon appearing elsewhere herein, and are included
in reliance upon such report given upon the authority of such firm as experts in
accounting and auditing.
 
    The information contained in "Risk Factors--Patents and Proprietary Rights"
and in "Business-- Patents and Proprietary Rights" have been reviewed and
approved by Peter Dehlinger & Associates, Palo Alto, California, patent counsel
to the Company, as experts in such matters, and are included in reliance upon
their review and approval.
 
                                       55

<PAGE>
                             ADDITIONAL INFORMATION
 
    The Company has filed with the Securities and Exchange Commission (the
"Commission") a Registration Statement on Form SB-2 under the Securities Act
with respect to the Units offered hereby, of which this Prospectus forms a part.
This Prospectus does not contain all of the information set forth in the
Registration Statement and the exhibits and schedules thereto. For further
information with respect to the Company and the Units, Common Stock and
Warrants, reference is made to the Registration Statement and such exhibits and
schedules. Statements contained in this Prospectus as to the contents of any
contract or other documents referred to are not necessarily complete and, in
each instance, if such contract or document is filed as an exhibit to the
Registration Statement, reference is made to the copy of such contract or
document filed as an exhibit, each such statement being qualified in all
respects by such reference to such exhibit. The Registration Statement and the
exhibits and schedules thereto may be inspected without charge at the
Commission's principal office in Washington, D.C., and copies of all or any part
thereof may be obtained from the Public Reference Section of the Commission, 450
Fifth Street, N.W., Washington, D.C. 20549, upon payment of certain fees
prescribed by the Commission. The Commission also maintains a site on the World
Wide Web that contains reports, proxy and information statements and other
information regarding registrants that file electronically with the Commission.
The address of such site is http://www.sec.gov.
 
                                       56

<PAGE>
                                ANTIVIRALS INC.
 
                         INDEX TO FINANCIAL STATEMENTS
 

<TABLE>
<S>                                                                        <C>
Report of Independent Public Accountants.................................   F-2
Balance Sheets as of December 31, 1994 and 1995 and September 30, 1996...   F-3
Statements of Operations for the two years ended December 31, 1995 and
 the nine months ended September 30, 1995 and 1996.......................   F-4
Statements of Shareholders' Equity for the sixteen years ended December
 31, 1995 and the nine months ended September 30, 1996...................   F-5
Statements of Cash Flows for the two years ended December 31, 1995 and
 the nine months ended September 30, 1995 and 1996.......................   F-8
Notes to Financial Statements............................................   F-9

</TABLE>

 
                                      F-1

<PAGE>

                    REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS
 
To the Board of Directors and Shareholders of
ANTIVIRALS INC.
 
    We have audited the accompanying balance sheets of ANTIVIRALS INC. (an
Oregon corporation in the development stage) as of December 31, 1995 and 1994,
and the related statements of operations, shareholders' equity and cash flows
for the years ended December 31, 1995 and 1994 and for the period from inception
(July 22, 1980) to December 31, 1995. These financial statements are the
responsibility of the Company's management. Our responsibility is to express an
opinion on these financial statements based on our audits.
 
    We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
 
    In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of ANTIVIRALS INC. as of
December 31, 1995 and 1994, and the results of its operations and its cash flows
for the years ended December 31, 1995 and 1994 and for the period from inception
(July 22, 1980) to December 31, 1995, in conformity with generally accepted
accounting principles.
 
Portland, Oregon,
March 22, 1996 (except with respect to
  the matters discussed in Note 7 as

to
  which the date is January 13, 1997)
 
                                      F-2

<PAGE>
                                ANTIVIRALS INC.
                         (A DEVELOPMENT STAGE COMPANY)
                                 BALANCE SHEETS
                                     ASSETS
 

<TABLE>
<CAPTION>
                                                                            DECEMBER 31,
                                                                    -----------------------------
                                                                        1994            1995
                                                                    -------------  --------------  SEPTEMBER 30,
                                                                                                        1996
                                                                                                   --------------
                                                                                                    (UNAUDITED)
<S>                                                                 <C>            <C>             <C>
CURRENT ASSETS:
  Cash and cash equivalents.......................................  $   1,850,369  $      680,892  $    3,614,724
  Short-term securities--available-for-sale.......................        192,000         212,750          30,000
  Other current assets............................................         15,881           7,236          12,550
                                                                    -------------  --------------  --------------
      Total current assets........................................      2,058,250         900,878       3,657,274
                                                                    -------------  --------------  --------------
PROPERTY AND EQUIPMENT, at cost:
  Laboratory equipment............................................        587,935         677,728         719,349
  Office equipment................................................        181,003         181,803         182,459
  Leasehold improvements..........................................      1,464,603       1,464,603       1,464,603
                                                                    -------------  --------------  --------------
                                                                        2,233,541       2,324,134       2,366,411
  Less--Accumulated depreciation and amortization.................       (926,587)     (1,379,377)     (1,735,822)
                                                                    -------------  --------------  --------------
                                                                        1,306,954         944,757         630,589
                                                                    -------------  --------------  --------------
PATENT COSTS, net.................................................        321,814         449,254         471,168
OTHER ASSETS......................................................         29,847          29,847          29,847
                                                                    -------------  --------------  --------------
                                                                    $   3,716,865  $    2,324,736  $    4,788,878
                                                                    -------------  --------------  --------------
                                                                    -------------  --------------  --------------
 
                                      LIABILITIES AND SHAREHOLDERS' EQUITY
 
CURRENT LIABILITIES:
  Accounts payable................................................  $      52,061  $       85,298  $      100,684
  Accrued payroll.................................................        123,586         149,715          81,888
  Deferred payments...............................................         20,225          19,051          19,051
  Deferred rent...................................................          4,874        --              --
                                                                    -------------  --------------  --------------
    Total current liabilities.....................................        200,746         254,064         201,623
                                                                    -------------  --------------  --------------
COMMON STOCK SUBJECT TO RESCISSION, $.0001 par value, 1,292,973
 issued and outstanding...........................................      3,121,965       3,121,965       3,121,965
                                                                    -------------  --------------  --------------
SHAREHOLDERS' EQUITY:
  Preferred stock, $.0001 par value, 2,000,000 shares authorized;
    none issued and outstanding...................................       --              --              --
  Common stock, $.0001 par value, 50,000,000 shares authorized;
    5,670,655, 5,816,838 and 7,486,790 shares issued and
    outstanding, respectively.....................................            567             582             749
  Additional paid-in capital......................................      8,113,822       9,189,496      13,217,628
  Unrealized gain on available-for-sale securities................         61,000          96,750        --
  Deficit accumulated during the development stage................     (7,781,235)    (10,338,121)    (11,753,087)
                                                                    -------------  --------------  --------------
      Total shareholders' equity (deficit)........................        394,154      (1,051,293)      1,465,290
                                                                    -------------  --------------  --------------
                                                                    $   3,716,865  $    2,324,736  $    4,788,878
                                                                    -------------  --------------  --------------
                                                                    -------------  --------------  --------------
</TABLE>

 
                            See accompanying notes.
 
                                      F-3

<PAGE>
                                ANTIVIRALS INC.
                         (A DEVELOPMENT STAGE COMPANY)
 
                            STATEMENTS OF OPERATIONS
 

<TABLE>
<CAPTION>
                                                              JULY 22, 1980        NINE MONTHS ENDED        JULY 22, 1980
                                  YEAR ENDED DECEMBER 31,     (INCEPTION) TO         SEPTEMBER 30,          (INCEPTION) TO
                                ----------------------------   DECEMBER 31,   ----------------------------  SEPTEMBER 30,
                                    1994           1995            1995           1995           1996            1996
                                -------------  -------------  --------------  -------------  -------------  --------------
                                                                                      (UNAUDITED)            (UNAUDITED)
<S>                             <C>            <C>            <C>             <C>            <C>            <C>
REVENUES, from grants and
 research contracts...........  $    --        $      82,500  $      662,270  $      82,500  $      16,827  $      679,097
                                -------------  -------------  --------------  -------------  -------------  --------------
 
OPERATING EXPENSES:
  Research and development....      1,631,130      2,097,796       7,282,020      1,640,906      1,177,157       8,459,177
  General and
    administrative............        678,705        609,723       3,935,771        437,159        432,252       4,368,023
                                -------------  -------------  --------------  -------------  -------------  --------------
    Total operating
      expenses................      2,309,835      2,707,519      11,217,791      2,078,065      1,609,409      12,827,200
                                -------------  -------------  --------------  -------------  -------------  --------------
 
OTHER INCOME..................         63,563         68,133         217,400         54,888        177,616         395,016
                                -------------  -------------  --------------  -------------  -------------  --------------
NET LOSS......................  $  (2,246,272) $  (2,556,886) $  (10,338,121) $  (1,940,677) $  (1,414,966) $  (11,753,087)
                                -------------  -------------  --------------  -------------  -------------  --------------
                                -------------  -------------  --------------  -------------  -------------  --------------
 
NET LOSS PER SHARE............  $       (0.33) $       (0.37)                 $       (0.28) $       (0.18)
                                -------------  -------------                  -------------  -------------
                                -------------  -------------                  -------------  -------------
SHARES USED IN PER SHARE
 CALCULATION..................      6,726,625      6,982,459                      6,966,583      8,051,477
                                -------------  -------------                  -------------  -------------
                                -------------  -------------                  -------------  -------------
</TABLE>

 
                            See accompanying notes.
 
                                      F-4

<PAGE>
                                ANTIVIRALS INC.
                         (A DEVELOPMENT STAGE COMPANY)
 
                       STATEMENTS OF SHAREHOLDERS' EQUITY

<TABLE>
<CAPTION>
                                                                                                    UNREALIZED     DEFICIT
                                                                                                      GAIN ON    ACCUMULATED
                                                                    COMMON STOCK        ADDITIONAL  AVAILABLE-    DURING THE
                                                  PARTNERSHIP  -----------------------   PAID-IN     FOR-SALE    DEVELOPMENT
                                                     UNITS       SHARES      AMOUNT      CAPITAL    SECURITIES      STAGE
                                                  -----------  ----------  -----------  ----------  -----------  ------------
<S>                                               <C>          <C>         <C>          <C>         <C>          <C>
BALANCE AT JULY 22, 1980 (inception)............      --           --       $  --       $   --       $  --        $   --
  No activity
                                                  -----------  ----------       -----   ----------  -----------  ------------
BALANCE AT OCTOBER 31, 1980.....................      --           --          --           --          --            --
  Issuance of partnership units and common stock
    in October 1981 for equipment and supplies
    valued at $3,500 and technology.............       1,000    1,666,667         167        3,333      --            --
  Issuance of partnership units and common stock
    for cash, $500 per unit.....................         150      250,000          25       75,055      --            --
  Issuance of partnership units for consulting
    services, $500 per unit.....................          10       --          --            5,000      --            --
  Issuance of common stock in connection with
    financing agreement.........................      --           33,333           3            7      --            --
  Net loss......................................      --           --          --           --          --            (9,224)
                                                  -----------  ----------       -----   ----------  -----------  ------------
BALANCE AT OCTOBER 31, 1981.....................       1,160    1,950,000         195       83,395      --            (9,224)
  Issuance of common stock for consulting
    services....................................      --           54,600           5           11      --            --
  Net loss......................................      --           --          --           --          --           (57,962)
                                                  -----------  ----------       -----   ----------  -----------  ------------
BALANCE AT OCTOBER 31, 1982.....................       1,160    2,004,600         200       83,406      --           (67,186)
  Issuance of partnership units and common stock
    for cash, $550 per unit.....................          60      100,000          10       33,020      --            --
  Issuance of common stock for consulting
    services....................................      --           21,733           2            5      --            --
  Net loss......................................      --           --          --           --          --           (27,475)
                                                  -----------  ----------       -----   ----------  -----------  ------------
BALANCE AT OCTOBER 31, 1983.....................       1,220    2,126,333         212      116,431      --           (94,661)
  Issuance of partnership units and common stock
    for cash, $600 per unit.....................          10       16,667           2        6,003      --            --
  Issuance of partnership units and common stock
    forconsulting services and $1,000 cash, $550
    to $600 per unit............................          20       16,667           2       11,503      --            --
  Issuance of common stock for consulting
    services....................................      --            2,533      --                1      --            --
  Issuance of common stock for donation to
    charitable organizations....................      --          100,000          10           20      --            --
  Net loss......................................      --           --          --           --          --           (21,463)
                                                  -----------  ----------       -----   ----------  -----------  ------------
BALANCE AT OCTOBER 31, 1984.....................       1,250    2,262,200         226      133,958      --          (116,124)
  Issuance of partnership units and common stock
    in December 1984 for technology.............       1,000      166,667          16          (16)     --            --
  Issuance of partnership units and common stock
    for cash, $50 to $100 per unit..............         460       78,333           8       23,515      --            --
  Issuance of partnership units for cash, $50 to
    $550 per unit...............................         140       --          --           17,000      --            --
  Issuance of common stock for consulting
    services....................................      --            6,733           1            1      --            --
  Net loss......................................      --           --          --           --          --            (8,469)
                                                  -----------  ----------       -----   ----------  -----------  ------------
BALANCE AT OCTOBER 31, 1985.....................       2,850    2,513,933         251      174,458      --          (124,593)
  Issuance of partnership units and common stock
    for cash, $50 to $500 per unit..............          90      105,000          11       31,521      --            --
  Issuance of common stock forconsulting
    services....................................      --            8,500           1            1      --            --
  Net loss......................................      --           --          --           --          --           (32,353)
                                                  -----------  ----------       -----   ----------  -----------  ------------
BALANCE AT OCTOBER 31, 1986.....................       2,940    2,627,433         263      205,980      --          (156,946)
  Issuance of partnership units and common stock
    for cash, $500 per unit.....................          20       33,333           3       10,007      --            --
  Issuance of partnership units and warrants to
    purchase 400,000 shares of common stock
    forcash, $500 to $2,500 per unit............          80       --          --          100,000      --            --
  Issuance of common stock forconsulting
    services....................................      --           28,533           3            6      --            --
  Net loss......................................      --           --          --           --          --           (71,616)
                                                  -----------  ----------       -----   ----------  -----------  ------------
BALANCE AT OCTOBER 31, 1987.....................       3,040    2,689,299         269      315,993      --          (228,562)
 
<CAPTION>
 
                                                      TOTAL
                                                  SHAREHOLDERS'
                                                     EQUITY
                                                  -------------
<S>                                               <C>
BALANCE AT JULY 22, 1980 (inception)............   $   --
  No activity
                                                  -------------
BALANCE AT OCTOBER 31, 1980.....................       --
  Issuance of partnership units and common stock
    in October 1981 for equipment and supplies
    valued at $3,500 and technology.............         3,500
  Issuance of partnership units and common stock
    for cash, $500 per unit.....................        75,080
  Issuance of partnership units for consulting
    services, $500 per unit.....................         5,000
  Issuance of common stock in connection with
    financing agreement.........................            10
  Net loss......................................        (9,224)
                                                  -------------
BALANCE AT OCTOBER 31, 1981.....................        74,366
  Issuance of common stock for consulting
    services....................................            16
  Net loss......................................       (57,962)
                                                  -------------
BALANCE AT OCTOBER 31, 1982.....................        16,420
  Issuance of partnership units and common stock
    for cash, $550 per unit.....................        33,030
  Issuance of common stock for consulting
    services....................................             7
  Net loss......................................       (27,475)
                                                  -------------
BALANCE AT OCTOBER 31, 1983.....................        21,982
  Issuance of partnership units and common stock
    for cash, $600 per unit.....................         6,005
  Issuance of partnership units and common stock
    forconsulting services and $1,000 cash, $550
    to $600 per unit............................        11,505
  Issuance of common stock for consulting
    services....................................             1
  Issuance of common stock for donation to
    charitable organizations....................            30
  Net loss......................................       (21,463)
                                                  -------------
BALANCE AT OCTOBER 31, 1984.....................        18,060
  Issuance of partnership units and common stock
    in December 1984 for technology.............       --
  Issuance of partnership units and common stock
    for cash, $50 to $100 per unit..............        23,523
  Issuance of partnership units for cash, $50 to
    $550 per unit...............................        17,000
  Issuance of common stock for consulting
    services....................................             2
  Net loss......................................        (8,469)
                                                  -------------
BALANCE AT OCTOBER 31, 1985.....................        50,116
  Issuance of partnership units and common stock
    for cash, $50 to $500 per unit..............        31,532
  Issuance of common stock forconsulting
    services....................................             2
  Net loss......................................       (32,353)
                                                  -------------
BALANCE AT OCTOBER 31, 1986.....................        49,297
  Issuance of partnership units and common stock
    for cash, $500 per unit.....................        10,010
  Issuance of partnership units and warrants to
    purchase 400,000 shares of common stock
    forcash, $500 to $2,500 per unit............       100,000
  Issuance of common stock forconsulting
    services....................................             9
  Net loss......................................       (71,616)
                                                  -------------
BALANCE AT OCTOBER 31, 1987.....................        87,700
</TABLE>

 
                            See accompanying notes.
 
                                      F-5

<PAGE>
                                ANTIVIRALS INC.
                         (A DEVELOPMENT STAGE COMPANY)
 
                 STATEMENTS OF SHAREHOLDERS' EQUITY (CONTINUED)

<TABLE>
<CAPTION>
                                                                                                   UNREALIZED     DEFICIT
                                                                                                     GAIN ON    ACCUMULATED
                                                                   COMMON STOCK        ADDITIONAL  AVAILABLE-   DURING THE
                                                 PARTNERSHIP  -----------------------   PAID-IN     FOR-SALE    DEVELOPMENT
                                                    UNITS       SHARES      AMOUNT      CAPITAL    SECURITIES      STAGE
                                                 -----------  ----------  -----------  ----------  -----------  -----------
<S>                                              <C>          <C>         <C>          <C>         <C>          <C>
BALANCE AT OCTOBER 31, 1987....................       3,040    2,689,299   $     269   $  315,993   $  --        $(228,562)
  Issuance of partnership units and common
    stock for cash, $500 per unit..............         100      166,667          17       50,033      --           --
  Issuance of partnership units and common
    stock for cash, $1,250 per unit............          20       33,333           3       25,007      --           --
  Issuance of partnership units for cash, $50
    per unit...................................          20       --          --            1,000      --           --
  Issuance of partnership units and warrants to
    purchase 400,000 shares of common for cash,
    $1,250 per unit............................          80       --          --          100,000      --           --
  Compensation expense related to issuance of
    warrants forpartnership units                    --           --          --           10,000      --           --
  Issuance of common stock for consulting
    services and employee compensation.........      --           47,014           5            9      --           --
  Net loss.....................................      --           --          --           --          --         (266,194)
                                                 -----------  ----------         ---   ----------  -----------  -----------
BALANCE AT OCTOBER 31, 1988....................       3,260    2,936,313   $     294   $  502,042   $  --        $(494,756)
 
  Exercise of warrants for common stock........      --          141,667          14           28      --           --
  Issuance of partnership units and common
    stock for cash, $1,250 per unit............          10       16,667           1       12,504      --           --
  Issuance of partnership units and warrants to
    purchase 800,000 shares of common stock for
    cash, $1,250 per unit......................         160       --          --          200,000      --           --
  Issuance of common stock for consulting
    services and employee compensation.........      --           17,733           2            4      --           --
  Compensation expense related to issuance of
    warrants forpartnership units..............      --           --          --            2,500      --           --
  Net loss.....................................      --           --          --           --          --         (243,926)
                                                 -----------  ----------         ---   ----------  -----------  -----------
 
BALANCE AT OCTOBER 31, 1989....................       3,430    3,112,380         311      717,078      --         (738,682)
 
  Exercise of warrants forcommon stock.........      --           33,333           3            7      --           --
  Issuance of partnership units and common
    stock for cash, $1,250 per unit............          74      123,334          12       92,525      --           --
  Issuance of partnership unitfor cash, $5,000
    per unit...................................           1       --          --            5,000      --           --
  Issuance of common stock for cash, $4.56 per
    share......................................      --            1,100      --            5,000      --           --
  Issuance of partnership units and warrants to
    purchase 200,000 shares of common stock for
    cash, $1,250 per unit......................          40       --          --           50,000      --           --
  Issuance of common stock for consulting
    services and employee compensation.........      --           11,400           2       51,678      --           --
  Compensation expense related to issuance of
    warrants for partnership units.............      --           --          --           40,000      --           --
  Exercise of warrant for partnership units....          10       --          --           12,500      --           --
  Net loss.....................................      --           --          --           --          --         (351,772)
                                                 -----------  ----------         ---   ----------  -----------  -----------
 
BALANCE AT OCTOBER 31, 1990....................       3,555    3,281,547         328      973,788      --       (1,090,454)
 
  Issuance of partnership units for cash,
    $5,000 per unit............................        23.5       --          --          117,500      --           --
  Exercise of warrants for partnership unit and
    common stock...............................           1        1,100      --            1,250      --           --
  Issuance of common stock for cash, $4.56 per
    share......................................      --           24,750           3      112,505      --           --
  Compensation expense related to issuance of
    warrants for common stock..................      --           --          --            1,520      --           --
  Issuance of common stock for consulting
    services, $4.56 per share..................      --            1,657      --            7,547      --           --
  Common stock subject to rescission...........      --           (7,127)         (1)     (32,499)     --           --
  Net loss.....................................      --           --          --           --          --         (274,844)
                                                 -----------  ----------         ---   ----------  -----------  -----------
BALANCE AT OCTOBER 31, 1991....................     3,579.5    3,301,927         330    1,181,611      --       (1,365,298)
 
<CAPTION>
 
                                                    TOTAL
                                                 SHAREHOLDERS'
                                                    EQUITY
                                                 ------------
<S>                                              <C>
BALANCE AT OCTOBER 31, 1987....................   $   87,700
  Issuance of partnership units and common
    stock for cash, $500 per unit..............       50,050
  Issuance of partnership units and common
    stock for cash, $1,250 per unit............       25,010
  Issuance of partnership units for cash, $50
    per unit...................................        1,000
  Issuance of partnership units and warrants to
    purchase 400,000 shares of common for cash,
    $1,250 per unit............................      100,000
  Compensation expense related to issuance of
    warrants forpartnership units                     10,000
  Issuance of common stock for consulting
    services and employee compensation.........           14
  Net loss.....................................     (266,194)
                                                 ------------
BALANCE AT OCTOBER 31, 1988....................   $    7,580
  Exercise of warrants for common stock........           42
  Issuance of partnership units and common
    stock for cash, $1,250 per unit............       12,505
  Issuance of partnership units and warrants to
    purchase 800,000 shares of common stock for
    cash, $1,250 per unit......................      200,000
  Issuance of common stock for consulting
    services and employee compensation.........            6
  Compensation expense related to issuance of
    warrants forpartnership units..............        2,500
  Net loss.....................................     (243,926)
                                                 ------------
BALANCE AT OCTOBER 31, 1989....................      (21,293)
  Exercise of warrants forcommon stock.........           10
  Issuance of partnership units and common
    stock for cash, $1,250 per unit............       92,537
  Issuance of partnership unitfor cash, $5,000
    per unit...................................        5,000
  Issuance of common stock for cash, $4.56 per
    share......................................        5,000
  Issuance of partnership units and warrants to
    purchase 200,000 shares of common stock for
    cash, $1,250 per unit......................       50,000
  Issuance of common stock for consulting
    services and employee compensation.........       51,680
  Compensation expense related to issuance of
    warrants for partnership units.............       40,000
  Exercise of warrant for partnership units....       12,500
  Net loss.....................................     (351,772)
                                                 ------------
BALANCE AT OCTOBER 31, 1990....................     (116,338)
  Issuance of partnership units for cash,
    $5,000 per unit............................      117,500
  Exercise of warrants for partnership unit and
    common stock...............................        1,250
  Issuance of common stock for cash, $4.56 per
    share......................................      112,508
  Compensation expense related to issuance of
    warrants for common stock..................        1,520
  Issuance of common stock for consulting
    services, $4.56 per share..................        7,547
  Common stock subject to rescission...........      (32,500)
  Net loss.....................................     (274,844)
                                                 ------------
BALANCE AT OCTOBER 31, 1991....................     (183,357)
</TABLE>

 
                            See accompanying notes.
 
                                      F-6

<PAGE>
                                ANTIVIRALS INC.
                         (A DEVELOPMENT STAGE COMPANY)
 
                 STATEMENTS OF SHAREHOLDERS' EQUITY (CONTINUED)

<TABLE>
<CAPTION>
                                                                                                   UNREALIZED     DEFICIT
                                                                                                     GAIN ON    ACCUMULATED
                                                                   COMMON STOCK        ADDITIONAL  AVAILABLE-   DURING THE
                                                 PARTNERSHIP  -----------------------   PAID-IN     FOR-SALE    DEVELOPMENT
                                                    UNITS       SHARES      AMOUNT      CAPITAL    SECURITIES      STAGE
                                                 -----------  ----------  -----------  ----------  -----------  -----------
 
<S>                                              <C>          <C>         <C>          <C>         <C>          <C>
  BALANCE AT OCTOBER 31, 1991..................     3,579.5    3,301,927   $     330   $1,181,611   $  --       ($1,365,298)
  Issuance of partnership units for cash,
    $5,000 per unit............................        15.5       --          --           77,500      --           --
  Issuance of common stock for cash, $4.56 per
    share......................................      --           17,050           2       77,498      --           --
  Compensation expense related to issuance of
    warrants forcommon stock...................      --           --          --            7,500      --           --
  Common stock subject to rescission...........      --          (32,486)         (3)    (148,135)     --           --
  Net loss.....................................      --           --          --           --          --          (91,588)
                                                 -----------  ----------         ---   ----------  -----------  -----------
 
BALANCE AT DECEMBER 31, 1991...................       3,595    3,286,491         329    1,195,974      --       (1,456,886)
 
  Issuance of partnership units for cash,
    $5,000 per unit............................        30.5       --          --          152,500      --           --
  Exercise of warrants for partnership units
    and common stock...........................          22        2,200      --           28,750      --           --
  Conversion of debt into common stock and
    partnership units..........................           9        9,634           1       87,859      --           --
  Issuance of common stock for cash, $4.56 per
    share......................................      --          868,906          87    3,954,625      --           --
  Issuance of common stock for consulting
    services, $4.56 per share..................      --           22,872           2      104,167      --           --
  Compensation expense related to issuance of
    warrants for common stock and partnership
    units......................................      --           --          --          262,833      --           --
  Common stock subject to rescission...........      --         (410,099)        (41)  (1,870,008)     --           --
  Net loss.....................................      --           --          --           --          --       (1,731,138)
                                                 -----------  ----------         ---   ----------  -----------  -----------
 
BALANCE AT DECEMBER 31, 1992...................     3,656.5    3,780,004         378    3,916,700      --       (3,188,024)
 
  Exercise of warrants for partnership units...           9       --          --            4,500      --           --
  Issuance of common stock in exchange for
    partnership units..........................    (1,809.5)   1,632,950         163         (163)     --           --
  Withdrawal of partnership net assets upon
    conveyance of technology...................      (1,856)      --          --         (176,642)     --           --
  Issuance of common stock for cash and
    short-term investments, $4.95 per share....      --          507,084          50    2,510,014      --           --
  Exercise of warrants for common stock........      --            3,844           1        9,999      --           --
  Common stock subject to rescission...........      --         (808,902)        (81)    (901,119)     --           --
  Net loss.....................................      --           --          --           --          --       (2,346,939)
                                                 -----------  ----------         ---   ----------  -----------  -----------
BALANCE AT DECEMBER 31, 1993...................      --        5,114,980   $     511   $5,363,289   $  --       ($5,534,963)
  Issuance of common stock for cash, $4.95 per
    share......................................      --          565,216          57    2,797,761      --           --
  Exercise of warrants for common stock........      --           24,667           2      122,098      --           --
  Issuance of common stock for consulting
    services, $4.95 per share..................      --              151      --              749      --           --
  Unrealized gain on available-for-sale
    securities.................................      --           --          --           --          61,000       --
  Common stock subject to rescission...........      --          (34,359)         (3)    (170,075)     --           --
  Net loss.....................................      --           --          --           --          --       (2,246,272)
                                                 -----------  ----------         ---   ----------  -----------  -----------
BALANCE AT DECEMBER 31, 1994...................      --        5,670,655         567    8,113,822      61,000   (7,781,235)
  Issuance of common stock for cash, $6.00 per
    share......................................      --          146,183          15      862,674      --           --
  Compensation expense related to issuance of
    warrants for common stock..................      --           --          --          213,000      --           --
  Unrealized gain on available-for-sale
    securities.................................      --           --          --           --          35,750       --
  Net loss.....................................      --           --          --           --          --       (2,556,886)
                                                 -----------  ----------         ---   ----------  -----------  -----------
BALANCE AT DECEMBER 31, 1995...................      --        5,816,838         582    9,189,496      96,750   (10,338,121)
  Exercise of warrants for common stock........      --          957,452          96          (96)     --           --
  Issuance of common stock for cash, $6.00 per
    share (net of commission)..................      --          712,500          71    4,028,228      --           --
  Liquidation of available-for-sale
    securities.................................      --           --          --           --         (96,750)      --
  Net loss.....................................      --           --          --           --          --       (1,414,966)
                                                 -----------  ----------         ---   ----------  -----------  -----------
BALANCE AT SEPTEMBER 30, 1996 (UNAUDITED)......      --        7,486,790         749   13,217,628      --       (11,753,087)
                                                 -----------  ----------         ---   ----------  -----------  -----------
                                                 -----------  ----------         ---   ----------  -----------  -----------
 
<CAPTION>
 
                                                    TOTAL
                                                 SHAREHOLDERS'
                                                    EQUITY
                                                 ------------
<S>                                              <C>
  BALANCE AT OCTOBER 31, 1991..................   $ (183,357)
  Issuance of partnership units for cash,
    $5,000 per unit............................       77,500
  Issuance of common stock for cash, $4.56 per
    share......................................       77,500
  Compensation expense related to issuance of
    warrants forcommon stock...................        7,500
  Common stock subject to rescission...........     (148,138)
  Net loss.....................................      (91,588)
                                                 ------------
BALANCE AT DECEMBER 31, 1991...................     (260,583)
  Issuance of partnership units for cash,
    $5,000 per unit............................      152,500
  Exercise of warrants for partnership units
    and common stock...........................       28,750
  Conversion of debt into common stock and
    partnership units..........................       87,860
  Issuance of common stock for cash, $4.56 per
    share......................................    3,954,712
  Issuance of common stock for consulting
    services, $4.56 per share..................      104,169
  Compensation expense related to issuance of
    warrants for common stock and partnership
    units......................................      262,833
  Common stock subject to rescission...........   (1,870,049)
  Net loss.....................................   (1,731,138)
                                                 ------------
BALANCE AT DECEMBER 31, 1992...................      729,054
  Exercise of warrants for partnership units...        4,500
  Issuance of common stock in exchange for
    partnership units..........................       --
  Withdrawal of partnership net assets upon
    conveyance of technology...................     (176,642)
  Issuance of common stock for cash and
    short-term investments, $4.95 per share....    2,510,064
  Exercise of warrants for common stock........       10,000
  Common stock subject to rescission...........     (901,200)
  Net loss.....................................   (2,346,939)
                                                 ------------
BALANCE AT DECEMBER 31, 1993...................   $ (171,163)
  Issuance of common stock for cash, $4.95 per
    share......................................    2,797,818
  Exercise of warrants for common stock........      122,100
  Issuance of common stock for consulting
    services, $4.95 per share..................          749
  Unrealized gain on available-for-sale
    securities.................................       61,000
  Common stock subject to rescission...........     (170,078)
  Net loss.....................................   (2,246,272)
                                                 ------------
BALANCE AT DECEMBER 31, 1994...................      394,154
  Issuance of common stock for cash, $6.00 per
    share......................................      862,689
  Compensation expense related to issuance of
    warrants for common stock..................      213,000
  Unrealized gain on available-for-sale
    securities.................................       35,750
  Net loss.....................................   (2,556,886)
                                                 ------------
BALANCE AT DECEMBER 31, 1995...................   (1,051,293)
  Exercise of warrants for common stock........       --
  Issuance of common stock for cash, $6.00 per
    share (net of commission)..................    4,028,299
  Liquidation of available-for-sale
    securities.................................      (96,750)
  Net loss.....................................   (1,414,966)
                                                 ------------
BALANCE AT SEPTEMBER 30, 1996 (UNAUDITED)......    1,465,290
                                                 ------------
                                                 ------------
</TABLE>

 
                            See accompanying notes.
 
                                      F-7

<PAGE>
                                ANTIVIRALS INC.
                         (A DEVELOPMENT STAGE COMPANY)
 
                            STATEMENTS OF CASH FLOWS
 

<TABLE>
<CAPTION>
                                                                     FOR THE PERIOD                            FOR THE PERIOD
                                             YEAR ENDED DECEMBER     JULY 22, 1980      NINE MONTHS ENDED       JULY 22, 1980
                                                     31,             (INCEPTION) TO       SEPTEMBER 30,        (INCEPTION) TO
                                            ----------------------    DECEMBER 31,    ----------------------    SEPTEMBER 30,
                                               1994        1995           1995           1995        1996           1996
                                            ----------  ----------  ----------------  ----------  ----------  -----------------
                                                                                           (UNAUDITED)           (UNAUDITED)
<S>                                         <C>         <C>         <C>               <C>         <C>         <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
  Net loss................................  $(2,246,272) $(2,556,886)   $(10,338,121) $(1,940,677) $(1,414,966)    $(11,753,087)
  Adjustments to reconcile net loss to net
    cash used in operating activities--
    Depreciation and amortization.........     539,122     503,340       1,541,138       355,939     401,445       1,942,583
    Realized gain on sale of short-term
      investments available for sale......      --          --             --             --         (96,750)        (96,750)
    Compensation expense on issuance of
      common stock and partnership
      units...............................      --          --             182,392        --          --             182,392
    Compensation expense on issuance of
      warrants to purchase common stock or
      partnership units...................      --         213,000         562,353        --          --             562,353
    Conversion of interest accrued to
      common stock........................      --          --               7,860        --          --               7,860
  Changes in operating assets and
    liabilities:
    Decrease (increase) in other current
      assets..............................      10,814       8,645          (7,236)       (5,511)     (5,314)        (12,550)
    Increase in other assets..............      --          --             (45,191)       --          --             (45,191)
    Net (decrease) increase in accounts
      payable, accrued payroll, deferred
      payments and deferred rent..........     (35,562)     53,318         257,827       254,892     (52,441)        205,673
                                            ----------  ----------  ----------------  ----------  ----------  -----------------
      Net cash used in operating
        activities........................  (1,731,898) (1,778,583)     (7,838,978)   (1,335,357) (1,168,026)     (9,006,717)
                                            ----------  ----------  ----------------  ----------  ----------  -----------------
 
CASH FLOWS FROM INVESTING ACTIVITIES:
  Proceeds from sale or redemption of
    short-- term investments..............      20,000      15,000          35,000        15,000     182,750         217,750
  Purchase of property and equipment......     (73,442)    (90,594)     (2,347,479)      (74,108)    (42,277)     (2,389,756)
  Patent costs............................    (110,763)   (177,989)       (576,089)     (111,377)    (66,914)       (643,003)
                                            ----------  ----------  ----------------  ----------  ----------  -----------------
      Net cash (used in) provided by
        investing activities..............    (164,205)   (253,583)     (2,888,568)     (170,485)     73,559      (2,815,009)
                                            ----------  ----------  ----------------  ----------  ----------  -----------------
CASH FLOWS FROM FINANCING ACTIVITIES:
  Proceeds from sale of common stock and
    partnership units.....................   2,920,667     862,689      11,505,080        --       4,028,299      15,533,092
  Withdrawal of partnership net assets....      --          --            (176,642)       --          --            (176,642)
  Issuance of convertible debt............      --          --              80,000        --          --              80,000
                                            ----------  ----------  ----------------  ----------  ----------  -----------------
      Net cash provided by financing
        activities........................   2,920,667     862,689      11,408,438        --       4,028,299      15,436,450
                                            ----------  ----------  ----------------  ----------  ----------  -----------------
INCREASE (DECREASE) IN CASH AND CASH
  EQUIVALENTS.............................   1,024,564  (1,169,477)        680,892    (1,505,842)  2,933,832       3,614,724
CASH AND CASH EQUIVALENTS:
  Beginning of period.....................     825,805   1,850,369         --          1,850,369     680,892         --
                                            ----------  ----------  ----------------  ----------  ----------  -----------------
  End of period...........................  $1,850,369  $  680,892    $    680,892    $  344,527  $3,614,724     $ 3,614,724
                                            ----------  ----------  ----------------  ----------  ----------  -----------------
                                            ----------  ----------  ----------------  ----------  ----------  -----------------
</TABLE>

 
                            See accompanying notes.
 
                                      F-8

<PAGE>
                                ANTIVIRALS INC.
                         (A DEVELOPMENT STAGE COMPANY)
 
                         NOTES TO FINANCIAL STATEMENTS
 
1. ORGANIZATION AND NATURE OF BUSINESS:
 
    ANTIVIRALS INC. (the Company) was incorporated in the State of Oregon on
July 22, 1980. The mission of the Company is to develop and commercialize
improved therapeutic products based upon antisense and drug delivery technology.
 
    Through May 1993, the financial statements include the combined accounts of
the Company and ANTI-GENE DEVELOPMENT GROUP, a limited partnership (AGDG or the
Partnership) founded in 1981 and registered in the State of Oregon.
Substantially all income generated and proceeds from the Partnership unit sales
have been paid to the Company under the terms of research and development
contracts entered into by the Partnership and the Company. Significant
transactions between the Company and the Partnership have been eliminated.
 
    In March 1993, the Company offered to all partners in the Partnership the
opportunity to exchange their partnership units or warrants to purchase
partnership units (unit warrants) for common stock or warrants to purchase
common stock. Under the terms of the offer, which was completed May 1, 1993,
each partner could elect to exchange each unit held or unit warrant held for
1,100 shares of common stock or warrants to purchase 1,100 shares of common
stock of the Company, respectively. One partner exchanged 325 partnership units
for warrants to purchase 357,500 shares of common stock. Total shares and
warrants to purchase shares issued in the exchange offer were 1,632,950 and
381,700, respectively.
 
    Effective May 19, 1993, the Company and the Partnership entered into a
Technology Transfer Agreement wherein the Partnership conveyed all intellectual
property in its control to the Company. As part of the conveyance, the Company
tendered to the Partnership for liquidation all partnership units received
pursuant to the exchange offer and received a 49.37 percent undivided interest
in the intellectual property. The Company then purchased the remaining undivided
interest in the intellectual property for rights to payments of 4.05 percent of
gross revenues in excess of $200 million, from sales of products which would, in
the absence of the Technology Transfer Agreement, infringe a valid claim under
any patent transferred to the Company.
 
    The remaining net assets of the Partnership, $176,642 of cash, were no
longer combined with those of the Company in May 1993. Under the terms of the
Technology Transfer Agreement, the Partnership ceased active sales of
partnership units and income generating activities and no longer will enter into
research and development contracts with the Company. The Partnership currently
exists primarily for the purpose of collecting potential future payments from
the Company as called for in the Technology Transfer Agreement.
 
    Beginning in 1991, the Company changed its fiscal year from a fiscal year
ending on October 31, to a calendar year. The new fiscal year was adopted
prospectively.
 
    The Company is in the development stage. Since its inception in 1980 through
September 30, 1996, the Company has incurred significant losses of approximately
$11.8 million, substantially all of which resulted from expenditures related to
research and development and general and administrative expenses. The Company
has not generated any material revenue from product sales to date, and there can
be no assurance that revenues from product sales will be achieved. Moreover,
even if the Company does achieve revenues from product sales, the Company
nevertheless expects to incur significant operating losses over the next several
years. The financial statements have been prepared assuming that the Company
will continue as a going concern. The Company's ability to achieve a profitable
level of operations in the future will depend in large part on its completing
product development of its antisense and/or drug delivery
 
                                      F-9

<PAGE>
                                ANTIVIRALS INC.
                         (A DEVELOPMENT STAGE COMPANY)
 
                   NOTES TO FINANCIAL STATEMENTS (CONTINUED)
 
1. ORGANIZATION AND NATURE OF BUSINESS: (CONTINUED)
products, obtaining regulatory approvals for such products and bringing several
of these products to market. During the period required to develop these
products, the Company will require substantial financing. There is no assurance
that such financing will be available when needed or that the Company's planned
products will be commercially successful. If necessary, the Company's management
will curtail expenditures in an effort to conserve operating funds. The
likelihood of the long-term success of the Company must be considered in light
of the expenses, difficulties and delays frequently encountered in the
development and commercialization of new pharmaceutical products, competitive
factors in the marketplace as well as the burdensome regulatory environment in
which the Company operates. There can be no assurance that the Company will ever
achieve significant revenues or profitable operations.
 
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:
 
USE OF ESTIMATES
 
    The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
 
CASH AND CASH EQUIVALENTS
 
    For purposes of the statements of cash flows, the Company considers all
highly liquid investments with an original maturity of three months or less to
be cash equivalents.
 
SHORT-TERM SECURITIES--AVAILABLE-FOR-SALE
 
    In January 1994, the Company adopted Statement of Financial Accounting
Standards No. 115, "Accounting for Certain Investments in Debt and Equity
Securities" (SFAS 115). In accordance with SFAS 115, the Company has classified
its investment securities as available-for-sale and, accordingly, such
investment securities are stated on the balance sheet at their fair market
value, which exceeds cost by $96,750. The unrealized difference between the cost
and the fair market value of these securities has been reflected as a separate
component of shareholders' equity. These short-term securities included common
stock with a fair value of $147,000 and $182,750 and state government
obligations with a cost, which approximated fair market value, of $45,000 and
$30,000 at December 31, 1994 and 1995, respectively.
 
PROPERTY AND EQUIPMENT
 
    Property and equipment is stated at cost and depreciated over the estimated
useful lives of the assets, generally five years, using the straight-line
method. Leasehold improvements are amortized over the shorter of the lease term
or life of the asset.
 
PATENT COSTS
 
    Patent costs consist primarily of legal and filing fees incurred to file
patents on proprietary technology developed by the Company. Patent costs are
amortized on a straight-line basis over the shorter of the
 
                                      F-10

<PAGE>
                                ANTIVIRALS INC.
                         (A DEVELOPMENT STAGE COMPANY)
 
                   NOTES TO FINANCIAL STATEMENTS (CONTINUED)
 
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: (CONTINUED)
estimated economic lives or the legal lives of the patents, generally 17 years.
Total accumulated amortization at December 31, 1994 and 1995 was $76,286 and
$126,835, respectively.
 
RESEARCH AND DEVELOPMENT
 
    Research and development costs are expensed as incurred.
 
INCOME TAXES
 
    The Company accounts for income taxes, in accordance with Statement of
Financial Accounting Standards No. 109, "Accounting for Income Taxes" (SFAS
109). Under SFAS 109, deferred tax assets and liabilities are recorded based on
the tax effected difference between the tax bases of assets and liabilities and
their carrying amount for financial reporting purposes, referred to as temporary
differences, using enacted marginal income tax rates.
 
NET LOSS PER SHARE
 
    Net loss per share is calculated using the weighted average number of shares
outstanding, including common stock subject to rescission. Common equivalent
shares (stock options and warrants) are excluded from the computation as their
effect is antidilutive, except that, pursuant to the Securities and Exchange
Commission ("SEC") Staff Accounting Bulletins, common and common equivalent
shares issued during the period commencing 12 months prior to the initial filing
of a proposed public offering at prices below the public offering price have
been considered in the calculation as if they were outstanding for all periods
presented (using the treasury stock method for stock options and warrants at the
estimated initial public offering price).
 
NEW PRONOUNCEMENTS
 
    In March 1995, the Financial Accounting Standards Board issued SFAS No. 121,
"Accounting for the Impairment of Long-Lived Assets and for Long Lived Assets to
be Disposed of," which requires the Company to review for impairment of its
long-lived assets and certain identifiable intangibles whenever events or
changes in circumstances indicate that the carrying amount of the asset may not
be recoverable. The Statement is effective for the Company in 1996. The Company
believes that adoption of this statement will not have a material effect on the
Company's financial position.
 
    Effective January 1, 1996, the Company is required to adopt SFAS No. 123,
"Accounting for Stock-Based Compensation." The statement requires, at a minimum,
new disclosures on an annual basis regarding employee and nonemployee
stock-based compensation plans. The Company intends to continue using the
measurement prescribed by the former standard and, accordingly, this
pronouncement will not have a material effect on the Company's financial
position or results of operations.
 
UNAUDITED INTERIM FINANCIAL INFORMATION
 
    The unaudited financial statements have been prepared pursuant to the rules
and regulations of the SEC. Certain information and note disclosures normally
included in annual financial statements prepared in accordance with generally
accepted accounting principles have been condensed or omitted pursuant to those
rules and regulations, although the Company believes that the disclosures made
are adequate to
 
                                      F-11

<PAGE>
                                ANTIVIRALS INC.
                         (A DEVELOPMENT STAGE COMPANY)
 
                   NOTES TO FINANCIAL STATEMENTS (CONTINUED)
 
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: (CONTINUED)
make the information presented not misleading. These unaudited financial
statements reflect, in the opinion of management, all adjustments (which include
only normal recurring adjustments) necessary to fairly present the results of
operations, changes in cash flows and financial position as of and for the
periods presented. These unaudited financial statement should be read in
conjunction with the audited financial statements and related notes thereto,
appearing elsewhere herein. The results for the interim periods presented are
not necessarily indicative of results to be expected for a full year.
 
3. SHAREHOLDERS' EQUITY:
 
STOCK INCENTIVE PLAN
 
    During 1992, the Company adopted the 1992 Stock Incentive Plan (the Plan)
which provides for the issuance of incentive stock options to its employees and
nonqualified stock options, stock appreciation rights and bonus rights to
employees, directors of the Company and consultants. The Company has reserved
1,333,333 shares of common stock for issuance under the Plan. Options issued
under the Plan generally vest ratably over four years or upon achievement of
certain financial or scientific goals, and expire five to ten years from the
date of grant. At December 31, 1995, options for 804,181 shares were exercisable
and 223,505 shares were available for future grant. At September 30, 1996,
options for 871,879 shares were exercisable and 206,447 shares were available
for future grant (unaudited). Activity within the Plan was as follows:
 

<TABLE>
<CAPTION>
                                                                                 PRICE PER
                                                                     SHARES        SHARE
                                                                   ----------  --------------
<S>                                                                <C>         <C>
Balance at December 31, 1992.....................................     911,428  $4.56 - $5.01
  Granted........................................................      43,103       4.95
  Canceled.......................................................     (10,331)      4.56
                                                                   ----------
 
Balance at December 31, 1993.....................................     944,200   4.56 - 5.01
  Granted........................................................      43,166       4.95
  Canceled.......................................................     (10,219)  4.65 - 4.95
                                                                   ----------
 
Balance at December 31, 1994.....................................     977,147   4.56 - 5.01
  Granted........................................................     137,400   4.95 - 6.00
  Canceled.......................................................      (4,719)  4.95 - 6.00
                                                                   ----------
 
Balance at December 31, 1995.....................................   1,109,828   4.56 - 6.00
  Granted........................................................      40,000       6.00
  Canceled.......................................................     (22,942)      6.00
                                                                   ----------
 
Balance at September 30, 1996 (unaudited)........................   1,126,886
                                                                   ----------
                                                                   ----------
</TABLE>

 
                                      F-12

<PAGE>
                                ANTIVIRALS INC.
                         (A DEVELOPMENT STAGE COMPANY)
 
                   NOTES TO FINANCIAL STATEMENTS (CONTINUED)
 
3. SHAREHOLDERS' EQUITY: (CONTINUED)
WARRANTS
 
    The Company has issued warrants for the purchase of common stock in
conjunction with financing and compensation arrangements. Outstanding warrants
for the purchase of common stock at December 31, 1992 and warrant activity
through September 30, 1996 are as follows:
 

<TABLE>
<CAPTION>
                                                NUMBER OF    EXERCISE PRICE
                                                  SHARES       PER SHARE                EXPIRATION DATE
                                                ----------  ----------------  -----------------------------------
<S>                                             <C>         <C>               <C>
Outstanding at December 31, 1992..............     946,877   $.0003 - $4.56   633,333 - None
                                                                              313,545 - Various through 2002
Issued in exchange for partnership units......     381,700       .0003        357,500 - None
                                                                              24,200 - Various through 2001
Granted.......................................      40,000        4.95        Various through 2001
Exercised.....................................      (3,844)   .0003 - 4.56
                                                ----------
 
Outstanding at December 31, 1993..............   1,364,733    .0003 - 4.95
 
Granted.......................................      18,000        4.95        1994
Exercised.....................................     (24,667)       4.56
Expired.......................................     (33,333)       4.56
                                                ----------
 
Outstanding at December 31, 1994..............   1,324,733    .0003 - 4.95
 
Granted.......................................      38,000    .0003 - 1.14    Various
Expired.......................................     (38,000)   .0003 - 1.14
                                                ----------
 
Outstanding at December 31, 1995..............   1,324,733    .0003 - 4.95
 
Granted.......................................      60,200        9.00
Exercised.....................................    (957,500)      .0003
                                                ----------
Outstanding at September 30, 1996
  (unaudited).................................     427,433   $.0003 - $9.00
                                                ----------
                                                ----------
Exercisable at December 31, 1995..............   1,299,733
                                                ----------
                                                ----------
 
Exercisable at September 30, 1996
  (unaudited).................................     407,450
                                                ----------
                                                ----------
</TABLE>

 
4. INCOME TAXES:
 
    At December 31, 1994 and 1995, the Company had federal and state tax net
operating loss carryforwards of approximately $5,504,000 and $7,731,000,
respectively. The difference between the operating loss carryforwards on a tax
basis and a book basis is due principally to differences in depreciation and
amortization. The federal and state carryforwards will begin to expire in 1997
and 2008, respectively, if not otherwise used. The Internal Revenue Code rules
under Section 382 could limit the future use of these losses based on ownership
changes in the value of the Company's stock. The Company believes, however, that
such a limitation would not have a material impact on the utilization of its
carryforwards.
 
                                      F-13

<PAGE>
                                ANTIVIRALS INC.
                         (A DEVELOPMENT STAGE COMPANY)
 
                   NOTES TO FINANCIAL STATEMENTS (CONTINUED)
 
4. INCOME TAXES: (CONTINUED)
    The Company had a net deferred tax asset of $2,613,000 and $3,808,000 at
years ended December 31, 1994 and 1995, primarily from net operating loss
carryforwards. A valuation allowance was recorded to reduce the net deferred tax
asset to zero. The net change in the valuation allowance for deferred tax assets
was an increase of approximately $913,000 and $1,195,000 for the years ended
December 31, 1994 and 1995, respectively, mainly due to the increase in the net
operating loss carryforwards.
 
    An analysis of the deferred tax assets and liabilities as of December 31,
1995, is as follows:
 

<TABLE>
<CAPTION>
                                                     DEFERRED TAX  DEFERRED TAX
                                                        ASSET       LIABILITY        TOTAL
                                                     ------------  ------------  -------------
<S>                                                  <C>           <C>           <C>
Net operating loss carryforwards...................   $3,092,000    $   --       $   3,092,000
Accrued expenses...................................      108,000        --             108,000
Depreciation.......................................      298,000        --             298,000
Research and development tax credit................      490,000        --             490,000
Patent costs.......................................       --          (180,000)       (180,000)
                                                     ------------  ------------  -------------
                                                      $3,988,000    $ (180,000)      3,808,000
                                                     ------------  ------------
                                                     ------------  ------------
Valuation allowance................................                                 (3,808,000)
                                                                                 -------------
                                                                                 $    --
                                                                                 -------------
                                                                                 -------------
</TABLE>

 
    An analysis of the deferred tax assets and liabilities as of December 31,
1994, is as follows:
 

<TABLE>
<CAPTION>
                                                     DEFERRED TAX  DEFERRED TAX
                                                        ASSET       LIABILITY        TOTAL
                                                     ------------  ------------  -------------
<S>                                                  <C>           <C>           <C>
Net operating loss carryforwards...................   $2,202,000    $   --       $   2,202,000
Accrued expenses...................................       24,000        --              24,000
Depreciation.......................................      136,000        --             136,000
Research and development tax credit................      380,000        --             380,000
Patent costs.......................................       --          (129,000)       (129,000)
                                                     ------------  ------------  -------------
                                                      $2,742,000    $ (129,000)      2,613,000
                                                     ------------  ------------
                                                     ------------  ------------
Valuation allowance................................                                 (2,613,000)
                                                                                 -------------
                                                                                 $    --
                                                                                 -------------
                                                                                 -------------
</TABLE>

 
5. LEASE OBLIGATIONS:
 
    The Company leases office and laboratory facilities under various
noncancelable operating leases through December 1997. Rent expense under these
leases was $179,000 and $168,000 for the years ended December 31, 1994 and 1995,
respectively, and $642,000 for the period from July 22, 1980 through December
31, 1995.
 
    In September 1996, the Company leased additional laboratory facilities and
extended the lease on its existing laboratory facilities through 2004. At
September 30, 1996, the aggregate noncancelable future minimum payments under
these leases were $269,000, $254,000, $242,000, $249,000 and $257,000 for the
 
                                      F-14

<PAGE>
                                ANTIVIRALS INC.
                         (A DEVELOPMENT STAGE COMPANY)
 
                   NOTES TO FINANCIAL STATEMENTS (CONTINUED)
 
5. LEASE OBLIGATIONS: (CONTINUED)
years ended December 31, 1997, 1998, 1999, 2000 and 2001, respectively, and
$817,000 thereafter (unaudited).
 
6. RELATED PARTY TRANSACTIONS:
 
    The Company paid $25,200, $8,000 and $220,800 to certain nonemployee
directors for financial consulting, scientific research services and
reimbursement for out-of-pocket costs of attending Board of Director meetings
during the years ended December 31, 1994 and 1995, and the period from July 22,
1980 through December 31, 1995, respectively.
 
7. SUBSEQUENT EVENTS:
 
    PRIVATE PLACEMENT
 
    In March 1996, the Company commenced a private offering wherein 712,500
shares of common stock were sold for net proceeds of $4,028,299, which included
warrants to purchase 65,217 shares of common stock at $9.00 per share. These
warrants are exercisable through the earlier of five years from issuance or
three years from the filing for an initial public offering.
 
    INITIAL PUBLIC OFFERING
 
    On October 3, 1996, the Board of Directors authorized management of the
Company to file a registration statement with the SEC offering to the public
1,500,000 units (the Units), each unit consisting of one share of the Company's
common stock, and one warrant to purchase one share of common stock. The Units
will separate immediately following issuance and thereafter the common stock and
warrants that make up the Units will trade only as separate securities.
 
    REVERSE STOCK SPLIT
 
    On October 3, 1996, the Board of Directors authorized, subject to
shareholder approval, a reverse split of the Company's outstanding Common Stock
on the basis of one share for each three shares of the then outstanding common
stock. The share information in the accompanying financial statements has been
retroactively restated to reflect the split. The Common Stock will continue to
have $.0001 par value. The Board of Directors also approved, subject to
shareholder confirmation, the authorization of a new class of preferred stock
which includes 2,000,000 shares of $0.0001 par value preferred stock.
 
    AMENDMENT TO TECHNOLOGY TRANSFER AGREEMENT
 
    On January 20, 1997, AGDG and the Company amended the Technology Transfer
Agreement to reduce the Technology Fees arising from the sale of diagnostic
products from 4.05% to 2% and to remove the $200 million exemption with respect
to sales of such diagnostic products. The Company also granted to AGDG a
royalty-bearing license to make, use and sell small quantities of product
derived from the Intellectual Property for research purposes only.
 
                                      F-15

<PAGE>
                                ANTIVIRALS INC.
                         (A DEVELOPMENT STAGE COMPANY)
 
                   NOTES TO FINANCIAL STATEMENTS (CONTINUED)
 
7. SUBSEQUENT EVENTS: (CONTINUED)
    COMMON STOCK RESCISSION OFFER
 
    In 1997, as a condition to its planned initial public offering, the Company
intends to offer to holders of 1,292,973 shares of its common stock, the right
to rescind their purchase of shares of the Company's common stock. If all such
offerees elect to rescind their purchases, the Company will be required to pay
these shareholders $3,121,965 and 568.67 units of limited partnership interests
in AGDG, plus statutory interest. To the extent these shareholders accept the
rescission offer, the Company will use up to $1,500,000 of its cash resources to
repurchase the shares. If any additional consideration is required to repurchase
the shares, the Company will issue unsecured promissory notes to the
shareholders on a pro rata basis. Such notes will bear interest at 9% per annum
and mature between 18 and 36 months. The Company believes that its potential
exposure to litigation for possible violations of securities laws will be
effectively eliminated by this rescission offer. All periods presented have been
restated to reflect the amount of common stock subject to the rescission offer
outside of shareholders' equity.
 
    The Company estimates that the total amount of its obligation for interest
to rescinding shareholders could aggregate approximately $2,129,000 if all
eligible shareholders accepted the rescission offer. Because of the contingent
nature of such liability and because the ultimate amount to be refunded is not
presently known, the potential interest liability has not been accrued but will
be recorded as an expense of the Company if and when the amount becomes an
actual liability.
 
    The rescission offer will not be made to holders of 22,021 shares of common
stock in Florida as state securities laws do not permit such offerings. The
rescission offer will also not be made to holders of 192,603 shares of common
stock who reside in California and Nevada because the Company believes its
potential liability to these holders has been eliminated by the running of
applicable statute of limitations. If all of the shareholders in Florida, Nevada
and California were to successfully assert claims against the Company, the
Company would be required to pay these holders approximately $318,000 and 55
units of limited partnership interests in AGDG, plus $237,000 in statutory
interest. Since no rescission offer has been made to these shareholders and
because of the contingent nature of such obligations, the potential liability
has not been reflected in the accompanying financial statements.
 
    The Company's cash flow and its financial position could be materially
affected by the results of the rescission offer. The financial statements do not
include any adjustments that might result from the outcome of the rescission
offer.
 
                                      F-16

<PAGE>
- -------------------------------------------
                                     -------------------------------------------
- -------------------------------------------
                                     -------------------------------------------
 
    NO DEALER, SALESPERSON OR OTHER PERSON HAS BEEN AUTHORIZED TO GIVE ANY
INFORMATION OR TO MAKE ANY REPRESENTATIONS NOT CONTAINED IN THIS PROSPECTUS IN
CONNECTION WITH THE OFFERING COVERED BY THIS PROSPECTUS. IF GIVEN OR MADE, SUCH
INFORMATION OR REPRESENTATIONS MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED
BY THE COMPANY OR ANY UNDERWRITER. THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER
TO SELL, OR A SOLICITATION OF ANY OFFER TO BUY, UNITS IN ANY JURISDICTION TO ANY
PERSON TO WHOM IT IS UNLAWFUL TO MAKE SUCH AN OFFER OR SOLICITATION IN SUCH
JURISDICTION. SUBJECT TO ANY DUTIES AND OBLIGATIONS UNDER APPLICABLE SECURITIES
LAWS TO UPDATE INFORMATION CONTAINED HEREIN OR INCORPORATED BY REFERENCE HEREIN,
NEITHER THE DELIVERY OF THIS PROSPECTUS NOR ANY SALE MADE HEREUNDER SHALL, UNDER
ANY CIRCUMSTANCES, CREATE ANY IMPLICATION THAT THE INFORMATION CONTAINED HEREIN
IS CORRECT AS OF ANY TIME SUBSEQUENT TO THE DATE HEREOF OR THAT THERE HAS BEEN
NO CHANGE IN THE AFFAIRS OF THE COMPANY SINCE THE DATE HEREOF.
 
                            ------------------------
 
 
                              TABLE OF CONTENTS
 

<TABLE>
<CAPTION>
                                                    PAGE
                                                    -----
<S>                                              <C>
Prospectus Summary.............................           3
The Company....................................           3
Risk Factors...................................           6
Use of Proceeds................................          14
Dividend Policy................................          14
Capitalization.................................          15
Dilution.......................................          16
Selected Financial Data........................          17
Management's Discussion and Analysis of
 Financial Condition and Results of
 Operation.....................................          18
Business.......................................          20
Management.....................................          35
Certain Transactions...........................          41
Principal Shareholders.........................          43
Description of Securities......................          45
Shares Eligible for Future Sale................          52
Underwriting...................................          54
Legal Matters..................................          55
Experts........................................          55
Additional Information.........................          56
Index to Financial Statements..................         F-1
</TABLE>

 
                         ------------------------------
 
    UNTIL                   , 1997 (25 DAYS AFTER THE DATE OF THIS PROSPECTUS),
ALL DEALERS EFFECTING TRANSACTIONS IN THE UNITS, COMMON STOCK OR THE WARRANTS,
WHETHER OR NOT PARTICIPATING IN THIS DISTRIBUTION, MAY BE REQUIRED TO DELIVER A
PROSPECTUS. THIS IS IN ADDITION TO THE OBLIGATIONS OF DEALERS TO DELIVER A
PROSPECTUS WHEN ACTING AS UNDERWRITERS AND WITH RESPECT TO THEIR UNSOLD
ALLOTMENTS OR SUBSCRIPTIONS.
 
                                1,500,000 UNITS
 
                             ---------------------
 
                                   PROSPECTUS
 
                             ---------------------
 
                               PAULSON INVESTMENT
                                 COMPANY, INC.
 
                                           , 1997
 
- -------------------------------------------
                                     -------------------------------------------
- -------------------------------------------
                                     -------------------------------------------

<PAGE>

                                    PART II
 
                     INFORMATION NOT REQUIRED IN PROSPECTUS
 
ITEM 24.  INDEMNIFICATION OF DIRECTORS AND OFFICERS.
 
    As an Oregon corporation the Company is subject to the Oregon Business
Corporation Act ("OBCA") and the exculpation from liability and indemnification
provisions contained therein. Pursuant to Section 60.047(2)(d) of the OBCA,
Article VI of the Company's Third Restated Articles of Incorporation (the
"Articles") eliminates the liability of the Company's directors to the Company
or its stockholders, except for any liability related to breach of the duty of
loyalty, actions not in good faith and certain other liabilities.
 
    Section 60.387 et seq. of the OBCA allows corporations to indemnify their
directors and officers against liability where the director or officer has acted
in good faith and with a reasonable belief that actions taken were in the best
interests of the corporation or at least not adverse to the corporation's best
interests and, if in a criminal proceeding, the individual had no reasonable
cause to believe the conduct in question was unlawful. Under the OBCA,
corporations may not indemnify against liability in connection with a claim by
or in the right of the corporation but may indemnify against the reasonable
expenses associated with such claims unless the party is adjusted liable to the
corporation. Corporations may not indemnify if the party is adjudged liable for
receiving improper personal benefit. The OBCA provides for mandatory
indemnification of directors against all reasonable expenses incurred in the
successful defense of any claim made or threatened whether or not such claim was
by or in the right of the corporation. Finally, a court may order
indemnification if it determines that the director or officer is fairly and
reasonably entitled to indemnification in view of all the relevant circumstances
whether or not the director or officer met the good faith and reasonable belief
standards of conduct set out in the statute.
 
    The OBCA also provides that the statutory indemnification provisions are not
deemed exclusive of any other rights to which directors or officers may be
entitled under a corporation's articles of incorporation or bylaws, any
agreement, general or specific action of the board of directors, vote of
stockholders or otherwise.
 
    Article VII of the Articles requires the Company to indemnify its directors
and officers to the fullest extent not prohibited by law. The Bylaws of the
Company also permit the Company to indemnify its directors and officers to the
fullest extent permitted by the OBCA.
 
ITEM 25.  OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION.
 
    The following table sets forth the costs and expenses, other than
underwriting discounts and commissions, expected to be incurred by the
Registrant in connection with the offering described in this Registration
Statement. All amounts, except the SEC registration fee, the NASD filing fee and
the NASDAQ National Market System listing fee, are estimates.
 

<TABLE>
<S>                                                                 <C>
SEC Registration Fee..............................................  $  16,267
NASD Filing Fee...................................................      5,218
NASDAQ Listing Fee................................................     50,000
Printing and Engraving Expenses...................................     65,000
Accounting Fees and Expenses......................................     40,000
Legal Fees and Expenses...........................................    200,000
Blue Sky Fees and Expenses (including fees of Counsel)............     50,000
Transfer Agent and Registrar Fees.................................     13,500
Miscellaneous Expenses............................................     35,015
                                                                    ---------
    Total.........................................................  $ 475,000
                                                                    ---------
                                                                    ---------
</TABLE>

 
                                      II-1

<PAGE>
ITEM 26.  RECENT SALES OF UNREGISTERED SECURITIES.
 
    Within the last three years, the Company has sold securities without
registration under the Securities Act of 1933, as amended (the "Act"), in the
transactions and in reliance on the exemptions from registration described
below.
 
        1.  Between November 1995 and October 1996, the Company sold an
    aggregate of 2,598,516 shares of its Common Stock at $2.00 per share to 208
    purchasers. The sale of these shares was exempt from registration pursuant
    to Section 4(2) of the Securities Act.
 
        2.  On March 15, 1996, the Company issued 2,852,356 shares of its Common
    Stock pursuant to the exercise of warrants that were issued to Oregon
    Resource and Technology Development Corporation. The issuance of the Common
    Stock upon the exercise of the Warrants was exempt from registration,
    pursuant to Section 4(2) of the Securities Act.
 
        3.  Between January 1994 and April 1995, the Company sold an aggregate
    of 2,258,914 shares of its Common Stock at $1.65 per share to 145
    purchasers. The sale of these shares was exempt from registration, pursuant
    to Section 4(2) of the Securities Act.
 
ITEM 27.  EXHIBITS.
 
(a) Exhibits
 

<TABLE>
<CAPTION>
  NUMBER     DESCRIPTION
- -----------  --------------------------------------------------------------------------------------------------
<C>          <S>
       1.0   Form of Underwriting Agreement
 
       3.1   Third Restated Articles of Incorporation of AntiVirals, Inc.
 
       3.2   Bylaws of AntiVirals, Inc.
 
       4.1   Form of Specimen Certificate for Common Stock*
 
       4.2   Form of Warrant for Purchase of Common Stock
 
       4.3   Form of Warrant Agreement
 
       4.4   Form of Representative's Warrant
 
       4.5   Registration Rights Agreement between AntiVirals Inc. and Ice Bear, Inc., dated May 20, 1992.
 
       4.6   Purchase Warrants between AntiVirals Inc. and ORTDF, dated August 4, 1992.
 
       5.0   Opinion of Ater Wynne Hewitt Dodson & Skerritt, LLP as to the legality of the securities being
               registered*
 
      10.1   1992 Stock Incentive Plan
 
      10.2   Employment Agreement with Denis R. Burger, Ph.D. dated November 4, 1996
 
      10.3   Employment Agreement with James Summerton, Ph.D. dated November 4, 1996
 
      10.4   Employment Agreement with Alan P. Timmins dated November 4, 1996
 
      10.5   Employment Agreement with Dwight Weller, Ph.D. dated November 4, 1996
 
      10.6   Technology Transfer Agreement between Anti-Gene Development Group and AntiVirals Inc., dated
               February 9, 1992.
 
      10.7   Amendment to Technology Transfer Agreement between Anti-Gene Development Group and AntiVirals Inc.
               dated January 20, 1996.
 
      10.8   License and Option Agreement between Anti-Gene Development Group and AntiVirals Inc., dated
               February 9, 1993.
</TABLE>

 
                                      II-2

<PAGE>

<TABLE>
<CAPTION>
  NUMBER     DESCRIPTION
- -----------  --------------------------------------------------------------------------------------------------
<C>          <S>
      10.9   Commercial Lease between Research Way Investments, Landlord, and AntiVirals Inc., Tenant, dated
               June 15, 1992.
 
      10.10  Lease between Benjamin Franklin Plaza, Inc., Landlord, and AntiVirals Inc., Tenant, dated June 17,
               1992.
 
      10.11  First Amendment to Lease between Benjamin Franklin Plaza, Inc., Landlord, and AntiVirals Inc.,
               Tenant, dated July 24, 1995.
 
      23.1   Consent of Ater Wynne Hewitt Dodson & Skerritt, LLP (included in legal opinion filed as Exhibit
               5.0)*
 
      23.2   Consent of Arthur Andersen LLP
 
      23.3   Consent of Peter Dehlinger & Associates.*
 
      25.0   Powers of Attorney (included in signature page in Part II of the Registration Statement)
</TABLE>

 
- ------------------------
 
* To be filed by amendment.
 
(b) Financial Statement Schedules
 
ITEM 28.  UNDERTAKINGS.
 
    Insofar as indemnification for liabilities arising under the Securities Act
may be permitted to directors, officers and controlling persons of the
Registrant pursuant to the provisions described in Item 24, or otherwise, the
Registrant has been advised that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy as expressed in the
Securities Act and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the
Registrant of expenses incurred or paid by a director, officer or controlling
person of the Registrant in the successful defense of any action, suit or
proceeding) is asserted by such director, officer or controlling person in
connection with the securities being registered, the Registrant will, unless in
the opinion of its counsel the matter has been settled by controlling precedent,
submit to a court of appropriate jurisdiction the question of whether such
indemnification by it is against public policy as expressed in the Securities
Act and will be governed by the final adjudication of such issue.
 
    The undersigned registrant hereby undertakes:
 
    1.  To file, during any period in which it offers or sells securities, a
post-effective amendment to this registration statement to:
 
        (i) include any prospectus required by section 10(a)(3) of the
    Securities Act;
 
        (ii) reflect in the prospectus any facts or events which, individually
    or together, represent a fundamental change in the information set forth in
    the registration statement; and
 
       (iii) include any additional or changed material information on the plan
    of distribution.
 
    2.  That, for determining liability under the Securities Act, it will treat
each post-effective amendment as a new registration statement of the securities
offered, and the offering of the securities at that time to be the initial bona
fide offering.
 
    3.  To file a post-effective amendment to remove from registration any of
the securities that remain unsold at the end of the offering.
 
    4.  That, for determining any liability under the Securities Act, it will
treat the information omitted from the form of prospectus filed as part of this
registration statement in reliance upon Rule 430A and contained in a form of
prospectus filed by the Company pursuant to Rule 424(b)(1) or (4) or 497(h)
under the Securities Act as part of this registration statement as of the time
it was declared effective.
 
                                      II-3

<PAGE>
    5.  That, for determining any liability under the Securities Act, it will
treat each post-effective amendment that contains a form of prospectus as a new
registration statement for the securities offered therein, and the offering of
the securities at that time as the initial bona fide offering thereof.
 
                                      II-4

<PAGE>

                                   SIGNATURES
 
    In accordance with the requirements of the Securities Act of 1933, the
registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form SB-2 and authorized this registration
statement to be signed on its behalf by the undersigned in the city of Portland,
state of Oregon, on January 22, 1997.
 

<TABLE>
<S>                             <C>  <C>
                                ANTIVIRALS INC.
 
                                By:             /s/ DENIS R. BURGER
                                     -----------------------------------------
                                                  Denis R. Burger,
                                              CHIEF EXECUTIVE OFFICER
</TABLE>

 
                               POWER OF ATTORNEY
 
    KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears
below constitutes and appoints Denis R. Burger and Alan P. Timmins and each of
them singly, as true and lawful attorneys-in-fact and agents with full power of
substitution and resubstitution, for him and in his name, place and stead, in
any and all capacities to sign the Registration Statement filed herewith and any
or all amendments to said Registration Statement (including post-effective
amendments), and to file the same, with all exhibits thereto, and other
documents in connection therewith, with the Securities and Exchange Commission
granting unto said attorneys-in-fact and agents and full power and authority to
do and perform each and every act and thing requisite and necessary to be done
in and about the foregoing, as full to all intents and purposes as he or she
might or could do in person, hereby ratifying and confirming all that said
attorneys-in-fact and agents or any of them, or his substitute, may lawfully do
or cause to be done by virtue hereof.
 
    Witness our hands on the date set forth below.
 
    In accordance with the requirements of the Securities Act of 1933, this
registration statement has been signed by the following persons in the capacity
stated on January 22, 1997.
 

<TABLE>
<CAPTION>
          SIGNATURE                       TITLE
- ------------------------------  --------------------------
 
<C>                             <S>
     /s/ DENIS R. BURGER        Chief Executive Officer
- ------------------------------    and Director (Principal
       Denis R. Burger            Executive Officer)
 
    /s/ JAMES E. SUMMERTON      President, Chief
- ------------------------------    Scientific Officer and
      James E. Summerton          Director
 
                                Chief Operating Officer
     /s/ ALAN P. TIMMINS          and Chief Financial
- ------------------------------    Officer (Principal
       Alan P. Timmins            Financial and Accounting
                                  Officer)
</TABLE>

 
                                      II-5

<PAGE>

<TABLE>
<CAPTION>
          SIGNATURE                       TITLE
- ------------------------------  --------------------------
 
<C>                             <S>
     /s/ DWIGHT D. WELLER       Vice President of Research
- ------------------------------    and Development and
       Dwight D. Weller           Director
 
     /s/ JOHN A. BEAULIEU
- ------------------------------  Chairman of the Board
       John A. Beaulieu
 
       /s/ NICK BUNICK
- ------------------------------  Director
         Nick Bunick
 
    /s/ DONALD R. JOHNSON
- ------------------------------  Director
      Donald R. Johnson
 
    /s/ JAMES E. REINMUTH
- ------------------------------  Director
      James E. Reinmuth
 
     /s/ JOSEPH RUBINFELD
- ------------------------------  Director
       Joseph Rubinfeld
</TABLE>

 
                                      II-6





<PAGE>

                                 1,500,000 UNITS

                                 ANTIVIRALS INC.
                                        

                             UNDERWRITING AGREEMENT


                                                      ____________________, 1997



Paulson Investment Company, Inc.
As Representative of the
  Several Underwriters
811 SW Front Avenue
Portland, Oregon 97204

Gentlemen:

     AntiVirals Inc., an Oregon corporation (the "Company"), proposes to sell to
the several underwriters (the "Underwriters") named in Schedule I hereto for
whom you are acting as Representative (the "Representative") an aggregate of
1,500,000 Units (the "Firm Units").  Each Units will consist of one share of the
Company's Common Stock, $.0001 par value ("Common Stock"), and one Common Stock
Purchase Warrant substantially in the form filed as an exhibit to the
Registration Statement (hereinafter defined) (the "Warrants").  The respective
amounts of the Firm Units to be so purchased by the several Underwriters are set
forth opposite their names in Schedule I hereto.  The Company also proposes to
grant to the Underwriters an option to purchase in the aggregate up to 225,000
additional Units (the "Option Units"), identical to the Firm Units, as set forth
below.  The offer and sale of the Firm Units and the Option Units pursuant to
this Agreement is referred to as the "Offering."

     As the Representative, you have advised the Company (a) that you are
authorized
 to enter into this Agreement for yourself as Representative and on
behalf of the several Underwriters, and (b) that the several Underwriters are
willing, acting severally and not jointly, to purchase the numbers of Firm Units
set forth opposite their respective names in Schedule I.  The Firm Units and the
Option Units (to the extent the aforementioned option is exercised) are herein
collectively called the "Units."

     In consideration of the mutual agreements contained herein and of the
interests of the parties in the transactions contemplated hereby, the parties
hereto agree as follows:

Page 1 of 27


<PAGE>

     1.   REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

          The Company represents and warrants to each of the Underwriters as
follows:

          (a)       A registration statement on Form SB-2 (File No. __________)
with respect to the Units has been carefully prepared by the Company in
conformity with the requirements of the Securities Act of 1933, as amended (the
"Act"), and the Rules and Regulations (the "Rules and Regulations") of the
Securities and Exchange Commission (the "Commission") thereunder and has been
filed with the Commission.  Copies of such registration statement, including any
amendments thereto, the preliminary prospectuses (meeting the requirements of
the Rules and Regulations) contained therein and the exhibits, financial
statements and schedules, as finally amended and revised, have heretofore been
delivered by the Company to you.  Such registration statement, together with any
registration statement filed by the Company pursuant to Rule 462(b) of the Act,
herein referred to as the "Registration Statement," which shall be deemed to
include all information omitted therefrom in reliance upon Rule 430A and
contained in the Prospectus referred to below, has become effective under the
Act and no post-effective amendment to the Registration Statement has been filed
as of the date of this Agreement.  "Prospectus" means (a) the form of prospectus
first filed with the Commission pursuant to Rule 424(b) or (b) the last
preliminary prospectus included in the Registration Statement filed prior to the
time it becomes effective or filed pursuant to Rule 424(a) under the Act that is
delivered by the Company to the Underwriters for delivery to purchasers of the
Units, together with the term sheet or abbreviated term sheet filed with the
Commission pursuant to Rule 424(b)(7) under the Act.  Each preliminary
prospectus included in the Registration Statement prior to the time it becomes
effective is herein referred to as a "Preliminary Prospectus."

          (b)       The Company has been duly organized and is validly existing
as a corporation in good standing under the laws of the state of Oregon, with
corporate power and authority to own or lease its properties and conduct its
business as described in the Registration Statement.  Except as described in the
Prospectus, the Company does not own and never has owned a controlling interest
in any corporation or other business entity that has or ever has had any
material assets, liabilities or operations.  The Company is duly qualified to
transact business in all jurisdictions in which the conduct of its business
requires such qualification.

          (c)       The outstanding shares of Common Stock of the Company have
been duly authorized and validly issued and are fully paid and non-assessable
and have been issued and sold by the Company in compliance in all material
respects with applicable securities laws; the Common Stock and Warrants to be
included in the Units have been duly authorized and when issued and paid for as
contemplated herein will be validly issued, fully paid and non-assessable; and
no preemptive rights of stockholders exist with respect to any security of the
Company or the issue and sale thereof.  Neither the filing of the Registration
Statement nor the offering or sale of the Units as contemplated by this
Agreement gives rise to any rights, other than those which have been waived or
satisfied, for or relating to the registration of any shares of Common Stock or
other securities of the Company.

Page 2 of 27


<PAGE>

          (d)       The information set forth under the caption "Capitalization"
in the Prospectus is true and correct.  The Common Stock and the Warrants
conform to the description thereof contained in the Registration Statement.  The
forms of certificates for the Common Stock and Warrants conform to the corporate
law of the jurisdiction of the Company's incorporation.

          (e)       The Commission has not issued an order preventing or
suspending the use of any Prospectus relating to the proposed offering of the
Units and has not instituted proceedings for that purpose.  The Registration
Statement contains, and the Prospectus and any amendments or supplements thereto
will contain, all statements which are required to be stated therein by, and
will conform, to the requirements of the Act and the Rules and Regulations.  The
Registration Statement and any amendment thereto do not contain, and will not
contain, any untrue statement of a material fact and do not omit, and will not
omit, to state any material fact required to be stated therein or necessary to
make the statements therein not misleading.  The Prospectus and any amendments
and supplements thereto do not contain, and will not contain, any untrue
statement of material fact; and do not omit, and will not omit, to state any
material fact required to be stated therein or necessary to make the statements
therein, in the light of the circumstances under which they were made, not
misleading; provided, however, that the Company makes no representations or
warranties as to information contained in or omitted from the Registration
Statement or the Prospectus, or any such amendment or supplement, in reliance
upon, and in conformity with, written information furnished to the Company by or
on behalf of any Underwriter through the Representative, specifically for use in
the preparation thereof.

          (f)       The financial statements of the Company, together with
related notes and schedules as set forth in the Registration Statement, present
fairly the financial position and the results of operations and cash flows of
the Company at the indicated dates and for the indicated periods.  Such
financial statements and related schedules have been prepared in accordance with
generally accepted principles of accounting, consistently applied throughout the
periods involved, except as disclosed herein, and all adjustments necessary for
a fair presentation of results for such periods have been made.  The summary
financial and statistical data of the Company included in the Registration
Statement present fairly the information shown therein and such data have been
compiled on a basis consistent with the financial statements presented therein
and the books and records of the Company.

          (g)       Arthur Andersen LLP, who have audited certain of the
financial statements filed with the Commission as part of the Registration
Statement, are independent public accountants as required by the Act and the
Rules and Regulations.

          (h)       There is no action, suit, claim or proceeding pending or, to
the knowledge of the Company, threatened against the Company before any court or
administrative agency or otherwise which if determined adversely to the Company
might result in any material adverse change in the earnings, business,
management, properties, assets, rights, operations, condition (financial or
otherwise) or prospects of the Company or

Page 3 of 27


<PAGE>

to prevent the consummation of the transactions contemplated hereby, except 
as set forth in the Registration Statement.

          (i)       The Company has good and marketable title to all of the
properties and assets reflected in the financial statements (or as described in
the Registration Statement) hereinabove described, subject to no lien, mortgage,
pledge, charge or encumbrance of any kind except those reflected in such
financial statements (or as described in the Registration Statement) or which
are not material in amount.  The Company occupies its leased properties under
valid and binding leases conforming in all material respects to the description
thereof set forth in the Registration Statement.

          (j)       The Company has filed all federal, state, local and foreign
income tax returns which have been required to be filed and has paid all taxes
indicated by said returns and all assessments received by it to the extent that
such taxes have become due and are not being contested in good faith.  All tax
liabilities have been adequately provided for in the financial statements of the
Company.

          (k)       Since the respective dates as of which information is given
in the Registration Statement, as it may be amended or supplemented, there has
not been any material adverse change or any development involving a prospective
material adverse change in or affecting the earnings, business, management,
properties, assets, rights, operations, condition (financial or otherwise), or
prospects of the Company, whether or not occurring in the ordinary course of
business, and there has not been any material transaction entered into or any
material transaction that is probable of being entered into by the Company,
other than transactions in the ordinary course of business and changes and
transactions described in the Registration Statement, as it may be amended or
supplemented.  The Company has no material contingent obligations which are not
disclosed in the Company's financial statements included in the Registration
Statement or elsewhere in the Prospectus.

          (l)       The Company is not, nor, with the giving of notice or lapse
of time or both, will it be, in violation of or in default under its articles of
incorporation or bylaws or under any agreement, lease, contract, indenture or
other instrument or obligation to which it is a party or by which it, or any of
its properties, is bound and which default is of material significance in
respect of the condition, financial or otherwise of the Company or the business,
management, properties, assets, rights, operations, condition (financial or
otherwise) or prospects of the Company.  The execution and delivery of this
Agreement and the consummation of the transactions herein contemplated and the
fulfillment of the terms hereof will not conflict with or result in a breach of
any of the terms or provisions of, or constitute a default under, any indenture,
mortgage, deed of trust or other agreement or instrument to which the Company is
a party, or of the articles of incorporation or bylaws of the Company or any
order, rule or regulation applicable to the Company of any court or of any
regulatory body or administrative agency or other governmental body having
jurisdiction.

          (m)       Each approval, consent, order, authorization, designation,
declaration or filing by or with any regulatory, administrative or other
governmental body necessary in

Page 4 of 27


<PAGE>

connection with the execution and delivery by the Company of this Agreement 
and the consummation of the transactions herein contemplated (except such 
additional steps as may be required by the Commission, the National 
Association of Securities Dealers, Inc. (the "NASD") or such additional steps 
as may be necessary to qualify the Units for public offering by the 
Underwriters under state securities or Blue Sky laws) has been obtained or 
made and is in full force and effect.

          (n)       The Company holds all material patents, patent rights
trademarks, trade names, copyrights, trade secrets and licenses of any of the
foregoing (collectively, "Intellectual Property Rights") that are necessary to
the conduct of its business; there is no claim pending or, to the best knowledge
of the Company, threatened against the Company alleging any infringement of
Intellectual Property Rights, or any violation of the terms of any license
relating to Intellectual Property Rights, nor does the Company know of any basis
for any such claim.  The Company knows of no material infringement by others of
Intellectual Property Rights owned by or licensed to the Company.  The Company
has obtained, is in compliance in all material respects with and maintains in
full force and effect all material licenses, certificates, permits, orders or
other, similar authorizations granted or issued by any governmental agency
(collectively, "Government Permits") required to conduct its business as it is
presently conducted.  All applications for additional Government Permits
described in the Prospectus as having been made by the Company have been
properly and effectively made in accordance with the applicable laws and
regulations with respect thereto and such applications constitute, in the best
judgment of the Company's management, those reasonably required to have been
made in order to carry out the Company's business plan as described in the
Prospectus. No proceeding to revoke, limit or otherwise materially change any
Government Permit has been commenced or, to the Company's best knowledge, is
threatened against the Company or any supplier to the Company with respect to
materials supplied to the Company, and the Company has no reason to anticipate
that any such proceeding will be commenced against the Company or any such
supplier.  Except as disclosed or contemplated in the Prospectus, the Company
has no reason to believe that any pending application for a Government Permit
will be denied or limited in a manner inconsistent with the Company's business
plan as described in the Prospectus.

          (o)       The Company is in all material respects in compliance with
all applicable Environmental Laws.  The Company has no knowledge of any past,
present or, as anticipated by the Company, future events, conditions,
activities, investigation, studies, plans or proposals that (i) would interfere
with or prevent compliance with any Environmental Law by the Company or
(ii) could reasonably be expected to give rise to any common law or other
liability, or otherwise form the basis of a claim, action, suit, proceeding,
hearing or investigation, involving the Company and related in any way to
Hazardous Substances or Environmental Laws.  Except for the prudent and safe use
and management of Hazardous Substances in the ordinary course of the Company's
business, (i) no Hazardous Substance is or has been used, treated, stored,
generated, manufactured or otherwise handled on or at any Facility and (ii) to
the Company's best knowledge, no Hazardous Substance has otherwise come to be
located in, on or under any Facility.  No Hazardous Substances are stored at any
Facility except in quantities necessary to satisfy the reasonably anticipated
use or consumption

Page 5 of 27


<PAGE>

by the Company.  No litigation, claim, proceeding or governmental 
investigation is pending regarding any environmental matter for which the 
Company has been served or otherwise notified or, to the knowledge of the 
Company threatened or asserted against the Company, or the officers or 
directors of the Company in their capacities as such, or any Facility or the 
Company's business.  There are no orders, judgments or decrees of any court 
or of any governmental agency or instrumentality under any Environmental Law 
which specifically apply to the Company, any Facility or any of the Company's 
operations.  The Company has not received from a governmental authority or 
other person (i) any notice that it is a potentially responsible person for 
any Contaminated site or (ii) any request for information about a site 
alleged to be Contaminated or regarding the disposal of Hazardous Substances. 
 There is no litigation or proceeding against any other person by the Company 
regarding any environmental matter.  The Company has disclosed in the 
Prospectus or made available to the Underwriters and their counsel true, 
complete and correct copies of any reports, studies, investigations, audits, 
analysis, tests or monitoring in the possession of or initiated by the 
Company pertaining to any environmental matter relating to the Company, its 
past or present operations or any Facility. 

     For the purposes of the foregoing paragraph, "Environmental Laws" means any
applicable federal, state or local statute, regulation, code, rule, ordinance,
order, judgment, decree, injunction or common law pertaining in any way to the
protection of human health or the environment, including without limitation, the
Resource Conservation and Recovery Act, the Comprehensive Environmental
Response, Compensation and Liability Act, the Toxic Substances Control Act, the
Clean Air Act, the Federal Water Pollution Control Act and any similar or
comparable state or local law; "Hazardous Substance" means any hazardous, toxic,
radioactive or infectious substance, material or waste as defined, listed or
regulated under any Environmental Law; "Contaminated" means the actual existence
on or under any real property of Hazardous Substances, if the existence of such
Hazardous Substances triggers a requirement to perform any investigatory,
remedial, removal or other response action under any Environmental Laws or if
such response action legally could be required by any governmental authority;
"Facility" means any property currently owned, leased or occupied by the
Company.

          (p)       Neither the Company, nor to the Company's best knowledge,
any of its affiliates, has taken or intends to take, directly or indirectly, any
action designed to cause or result in, or which has constituted or which might
reasonably be expected to constitute, the stabilization or manipulation of the
price of the shares of Common Stock to facilitate the sale or resale of the
Units.

          (q)       The Company is not an "investment company" within the
meaning of such term under the Investment Company Act of 1940, as amended (the
"1940 Act"), and the rules and regulations of the Commission thereunder.

          (r)       The Company maintains a system of internal accounting
controls sufficient to provide reasonable assurances that (i) transactions are
executed in accordance with management's general or specific authorization;
(ii) transactions are recorded as

Page 6 of 27


<PAGE>

necessary to permit preparation of financial statements in conformity with 
generally accepted accounting principles and to maintain accountability for 
assets; (iii) access to assets is permitted only in accordance with 
management's general or specific authorization; and (iv) the recorded 
accountability for assets is compared with existing assets at reasonable 
intervals and appropriate action is taken with respect to any differences.

          (s)       The Company carries, or is covered by, insurance in such
amounts and covering such risks as is adequate for the conduct of its business
and the value of its properties and as is customary for companies engaged in
similar industries.

          (t)       The Company is in compliance in all material respects with
all presently applicable provisions of the Employee Retirement Income Security
Act of 1974, as amended, including the regulations and published interpretations
thereunder ("ERISA"); no "reportable event" (as defined in ERISA) has occurred
with respect to any "pension plan" (as defined in ERISA) for which the Company
would have any liability; the Company has not incurred and does not expect to
incur liability under (i) Title IV of ERISA with respect to termination of, or
withdrawal from, any "pension plan" or (ii) Section 412 or 4971 of the Internal
Revenue Code of 1986, as amended, including the regulations and published
interpretations thereunder (the "Code"); and each "pension plan" for which the
Company would have any liability that is intended to be qualified under
Section 401(a) of the Code is so qualified in all material respects and nothing
has occurred, whether by action or by failure to act, which would cause the loss
of such qualification.

          (u)       The Company confirms as of the date hereof that it is in
compliance with all provisions of Section 1 of Laws of Florida, Chapter 92-198,
AN ACT RELATING TO DISCLOSURE OF DOING BUSINESS WITH CUBA, and the Company
further agrees that if it commences engaging in business with the government of
Cuba or with any person or affiliate located in Cuba after the date the
Registration Statement becomes or has become effective with the Commission or
with the Florida Department of Banking and Finance (the "Department"), whichever
date is later, or if the information reported or incorporated by reference in
the Prospectus, if any, concerning the Company's business with Cuba or with any
person or affiliate located in Cuba changes in any material way, the Company
will provide the Department notice of such business or change, as appropriate,
in a form acceptable to the Department.

          (v)       The Company is in material compliance with all laws, rules,
regulations, orders of any court or administrative agency, operating licenses or
other requirements imposed by any governmental body applicable to it, including,
without limitation, all applicable laws, rules, regulations, licenses or other
governmental standards applicable to the industry in which the Company operates;
and the conduct of the business of the Company, as described in the Prospectus,
will not cause the Company to be in violation of any such requirements.

          (w)       The Warrants have been authorized for issuance to the
various purchasers of the Units and will, when issued, possess rights,
privileges, and characteristics

Page 7 of 27


<PAGE>

as represented in the most recent form of Warrants filed as an exhibit to the 
Registration Statement; the securities to be issued upon exercise of the 
Warrants, when issued and delivered against payment therefor in accordance 
with the terms of the Warrants, will be duly and validly issued, fully paid, 
nonassessable and free of preemptive rights, and all corporate action 
required to be taken for the authorization and issuance of the Warrants, and 
the securities to be issued upon their exercise, has validly and sufficiently 
taken.

          (x)       The Representative's Warrants (as defined in Paragraph (d)
of Section 2 hereof) have been authorized for issuance to the Representative and
will, when issued, possess rights, privileges, and characteristics as
represented in the most recent form of Representative's Warrants filed as an
exhibit to the Registration Statement; the securities to be issued upon exercise
of the Representative's Warrants, when issued and delivered against payment
therefor in accordance with the terms of the Representative's Warrants, will be
duly and validly issued, fully paid, nonassessable and free of preemptive
rights, and all corporate action required to be taken for the authorization and
issuance of the Representative's Warrants, and the securities to be issued upon
their exercise, have been validly and sufficiently taken.

          (y)       Except as disclosed in the Prospectus, neither the Company
nor any of its officers, directors or affiliates have caused any person, other
than the Underwriters, to be entitled to reimbursement of any kind, including,
without limitation, any compensation that would be includable as underwriter
compensation under the NASD's Corporate Financing Rule with respect to the
offering of the Units, as a result of the consummation of such offering based on
any activity of such person as a finder, agent, broker, investment adviser or
other financial service provider.

     2.   PURCHASE, SALE AND DELIVERY OF THE UNITS.

          (a)       On the basis of the representations, warranties and
covenants herein contained, and subject to the conditions herein set forth, the
Company agrees to sell to the Underwriters and each Underwriter agrees,
severally and not jointly, to purchase, at a price of $__________ per Unit, the
number of Firm Units set forth opposite the name of each Underwriter in Schedule
I hereof, subject to adjustments in accordance with Section 9 hereof.

          (b)       Payment for the Firm Units to be sold hereunder is to be
made in New York Clearing House funds and, at the option of the Representative,
by certified or bank cashier's checks drawn to the order of the Company or bank
wire to an account specified by the Company against either uncertificated
delivery of Firm Units or of certificates therefor (which delivery, if
certificated, shall take place in such location in New York, New York as may be
specified by the Representative) to the Representative for the several accounts
of the Underwriters.  Such payment is to be made at the offices of the
Representative at the address set forth on the first page of this Agreement, or
at such other place as you and the Company shall designate, at 7:00 a.m.,
Pacific time, on the third business day after the date of this Agreement or at
such other time and date not later than five business days after as you and the
Company shall agree upon, such time and date being herein referred to as the
"Closing

Page 8 of 27


<PAGE>

Date."  (As used herein, "business day" means a day on which the New York 
Stock Exchange is open for trading and on which banks in New York are open 
for business and not permitted by law or executive order to be closed.)  
Except to the extent uncertificated Firm Units are delivered at closing, the 
certificates for the Firm Units will be delivered in such denominations and 
in such registrations as the Representative request in writing not later than 
the second full business day prior to the Closing Date, and will be made 
available for inspection by the Representative at least one business day 
prior to the Closing Date.

          (c)       In addition, on the basis of the representations and
warranties herein contained and subject to the terms and conditions herein set
forth, the Company hereby grants an option to the Representative to purchase the
Option Units at the price per Unit as set forth in the first paragraph of this
Section 2. The option granted hereby may be exercised in whole or in part by
giving written notice (i) at any time before the Closing Date and (ii) only once
thereafter within 45 days after the date of this Agreement, by the
Representative to the Company setting forth the number of Option Units as to
which the Representative is exercising the option, the names and denominations
in which the Option Units are to be registered and the time and date at which
certificate representing such Units are to be delivered.  The time and date at
which certificates for Option Units are to be delivered shall be determined by
the Representative but shall not be earlier than three nor later than 10 full
business days after the exercise of such option, nor in any event prior to the
Closing Date (such time and date being herein referred to as the "Option Closing
Date").  If the date of exercise of the option is three or more days before the
Closing Date, the notice of exercise shall set the Closing Date as the Option
Closing Date.  The option with respect to the Option Units granted hereunder may
be exercised only to cover over-allotments in the sale of the Firm Units by the
Underwriters. The Representative may cancel such option at any time prior to its
expiration by giving written notice of such cancellation to the Company.  To the
extent, if any, that the option is exercised, payment for the Option Units shall
be made on the Option Closing Date in New York Clearing House funds and, at the
option of the Representative, by certified or bank cashier's check drawn to the
order of the Company for the Option Units to be sold by the Company or bank wire
to an account specified by the Company against delivery of certificates therefor
at the offices of Paulson Investment Company, Inc. set forth on the first page
of this Agreement.

          (d)       In addition to the sums payable to the Representative as
provided elsewhere herein, the Representative shall be entitled to receive at
the Closing, for itself alone and not as Representative of the Underwriters, as
additional compensation for its services, a purchase warrant (the
"Representative's Warrant") for the purchase of up to __________ Units at a
price of $__________ per Unit, upon the terms and subject to adjustment and
conversion as described in the form of Representative's Warrant filed as an
exhibit to the Registration Statement.

     3.   OFFERING BY THE UNDERWRITERS.

          It is understood that the several Underwriters are to make a public
offering of the Firm Units as soon as the Representative deems it advisable to
do so.  The Firm Units

Page 9 of 27


<PAGE>

are to be initially offered to the public at the initial public offering 
price set forth in the Prospectus.  The Representative may from time to time 
thereafter change the public offering price and other selling terms.  To the 
extent, if at all, that any Option Units are purchased pursuant to Section 2 
hereof, the Representative will offer them to the public on the foregoing 
terms.

          It is further understood that you will act as the Representative for
the Underwriters in the offering and sale of the Units in accordance with an
Agreement Among Underwriters entered into by you and the several other
Underwriters.

     4.   COVENANTS OF THE COMPANY.

     The Company covenants and agrees with the several Underwriters that:

          (a)       The Company will (i) use its best efforts to cause the
Registration Statement to become effective or, if the procedure in Rule 430A of
the Rules and Regulations is followed, to prepare and timely file with the
Commission under Rule 424(b) of the Rules and Regulations a Prospectus in a form
approved by the Representative containing information previously omitted at the
time of effectiveness of the Registration Statement in reliance on Rule 430A of
the Rules and Regulations, and (ii) not file any amendment to the Registration
Statement or supplement to the Prospectus of which the Representative shall not
previously have been advised and furnished with a copy or to which the
Representative shall have reasonably objected in writing or which is not in
compliance with the Rules and Regulations.

          (b)       The Company will advise the Representative promptly (i) when
the Registration Statement or any post-effective amendment thereto shall have
become effective, (ii) of receipt of any comments from the Commission, (iii) of
any request of the Commission for amendment of the Registration Statement or for
supplement to the Prospectus or for any additional information, and (iv) of the
issuance by the Commission of any stop order suspending the effectiveness of the
Registration Statement or the use of the Prospectus or of the institution of any
proceedings for that purpose.  The Company will use its best efforts to prevent
the issuance of any such stop order preventing or suspending the use of the
Prospectus and to obtain as soon as possible the lifting thereof, if issued.

          (c)       The Company will cooperate with the Representative in
endeavoring to qualify the Units for sale under the securities laws of such
jurisdictions as the Representative may reasonably have designated in writing
and will make such applications, file such documents, and furnish such
information as may be reasonably required for that purpose, provided the Company
shall not be required to qualify as a foreign corporation or to file a general
consent to service of process in any jurisdiction where it is not now so
qualified or required to file such a consent.  The Company will, from time to
time, prepare and file such statements, reports, and other documents, as are or
may be required to continue such qualifications in effect for so long a period
as the Representative may reasonably request for distribution of the Units.

Page 10 of 27


<PAGE>

          (d)      The Company will deliver to, or upon the order of, the
Representative, from time to time, as many copies of any Preliminary Prospectus
as the Representative may reasonably request.  The Company will deliver to, or
upon the order of, the Representative during the period when delivery of a
Prospectus is required under the Act, as many copies of the Prospectus in final
form, or as thereafter amended or supplemented, as the Representative may
reasonably request.  The Company will deliver to the Representative at or before
the Closing Date, four signed copies of the Registration Statement and all
amendments thereto including all exhibits filed therewith, and will deliver to
the Representative such number of copies of the Registration Statement
(including such number of copies of the exhibits filed therewith that may
reasonably be requested), and of all amendments thereto, as the Representative
may reasonably request.

          (e)       The Company will comply with the Act and the Rules and
Regulations, and the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), and the rules and regulations of the Commission thereunder, so as to
permit the completion of the distribution of the Units as contemplated in this
Agreement and the Prospectus.  If during the period in which a prospectus is
required by law to be delivered by an Underwriter or dealer, any event shall
occur as a result of which, in the judgment of the Company or in the reasonable
opinion of the Underwriters, it becomes necessary to amend or supplement the
Prospectus in order to make the statements therein, in the light of the
circumstances existing at the time the Prospectus is delivered to a purchaser,
not misleading, or, if it is necessary at any time to amend or supplement the
Prospectus to comply with any law, the Company promptly will prepare and file
with the Commission an appropriate amendment to the Registration Statement or
supplement to the Prospectus so that the Prospectus as so amended or
supplemented will not, in the light of the circumstances when it is so
delivered, be misleading, or so that the Prospectus will comply with the law.

          (f)       The Company will make generally available to its security
holders, as soon as it is practicable to do so, but in any event not later than
15 months after the effective date of the Registration Statement, an earnings
statement (which need not be audited) in reasonable detail, covering a period of
at least 12 consecutive months beginning after the effective date of the
Registration Statement, which earnings statement shall satisfy the requirements
of Section 11(a) of the Act and Rule 158 of the Rules and Regulations and will
advise you in writing when such statement has been so made available.

          (g)       The Company will, for a period of five years from the 
Closing Date, deliver to the Representative copies of annual reports and 
copies of all other documents, reports and information furnished by the 
Company to its stockholders or filed with any securities exchange pursuant to 
the requirements of such exchange or with the Commission pursuant to the Act 
or the Exchange Act. The Company will deliver to the Representative similar 
reports with respect to significant subsidiaries, as that term is defined in 
the Rules and Regulations, which are not consolidated in the Company's 
financial statements.

          (h)       No offering, sale, short sale or other disposition of any
shares of Common Stock of the Company or other securities convertible into or
exchangeable or

Page 11 of 27


<PAGE>

exercisable for shares of Common Stock or derivative of Common Stock (or 
agreement for such) will be made for a period of one year after the date of 
this Agreement, directly or indirectly, by the Company otherwise than 
hereunder or with the prior written consent of the Representative, which 
consent will not be unreasonably withheld.

          (i)       The Company will use its best efforts to list the Common
Stock and the Warrants, subject to notice of their issuance, on The Nasdaq Stock
Market.

          (j)       The Company has caused each officer and director and each
person who owns, beneficially or of record, 1% or more of the Common Stock
outstanding immediately prior to this offering (the "Insiders") to furnish to
you, on or prior to the date of this Agreement, a letter or letters, in form and
substance satisfactory to the Underwriters (the "Insider Lockup Agreements"),
pursuant to which each Insider shall agree not to offer to sell, sell, contract
to sell, sell short or otherwise dispose of any shares of Common Stock or other
capital stock of the Company, or any other securities convertible, exchangeable
or exercisable for Common Stock or derivatives of Common Stock owned by such
Insider, or request the registration for the offer or sale of any of the
foregoing (or as to which such Insider has the right to direct the disposition
of), for a period of one year after the date of this Agreement, directly or
indirectly, except with the prior written consent of the Representative, which
consent shall not be unreasonably withheld.  In addition, the Company has caused
persons (the "Non-insiders") who own in the aggregate at least 85% of the Common
Stock outstanding immediately prior to this offering remaining after subtracting
the shares owned by those who have executed Insider Lockup Agreements to enter
into a letter or letters, in form and substance satisfactory to the Underwriters
(the "Other Lockup Agreements"), pursuant to which each such Non-insider shall
agree not to offer to sell, sell, contract to sell, sell short or otherwise
dispose of any shares of Common Stock or other capital stock of the Company, or
any other securities convertible, exchangeable or exercisable for Common Stock
or derivatives of Common Stock owned by such Non-insider, or request the
registration for the offer or sale of any of the foregoing (or as to which such
Non-insider has the right, to direct the disposition of) for a period of one
year after the date of this Agreement, directly or indirectly, except with the
prior written consent of the Representative, which consent shall not be
unreasonably withheld, provided, however, that notwithstanding the foregoing, a
Non-insider may sell or otherwise dispose of up to 50% of the shares of Common
Stock or other capital stock of the Company held by such person during the
period beginning six months and ending one year after the date of this
Agreement.  The Insider Lockup Agreements and the Other Lockup Agreements shall
also provide that the holder shall give the Representative prior notice with
respect to any offers to sell, sales, contracts to sell, short sales or other
dispositions of Common Stock pursuant to Rule 144 under the Act or any similar
provisions enacted subsequent to the date of this Agreement, for as long as you
are a market maker in the Common Stock or for a period of five years from the
date of this Agreement, whichever period is shorter.

          (k)       The Company shall apply the net proceeds of its sale of the
Units as set forth in the Prospectus and shall file such reports with the
Commission with respect to the

Page 12 of 27


<PAGE>

sale of the Units and the application of the proceeds therefrom as may be 
required in accordance with Rule 463 under the Act.

          (l)       The Company shall not invest, or otherwise use the proceeds
received by the Company from its sale of the Units in such a manner as would
require the Company or any of the subsidiaries to register as an investment
company under the 1940 Act.

          (m)       The Company will maintain a transfer agent and, if necessary
under the jurisdiction of incorporation of the Company, a registrar for the
Common Stock.

          (n)       The Company will not take, directly or indirectly, any
action designed to cause or result in, or that has constituted or might
reasonably be expected to constitute, the stabilization or manipulation of the
price of any securities of the Company.

     5.   COSTS AND EXPENSES.

          (a)       The Representative shall be entitled to receive from the
Company, for itself alone and not as Representative of the Underwriters, a
nonaccountable expense allowance equal to 2.5% of the aggregate public offering
price of Units sold to the Underwriters in connection with the Offering.  The
Representative shall be entitled to withhold this allowance on the Closing Date
(less the $35,000 advance against such amount that has been paid by the Company)
with respect to Units delivered on the Closing Date and to require the Company
to make payment of this allowance on the Option Closing Date with respect to
Units delivered on the Option Closing Date.

          (b)       In addition to the payment described in Paragraph (a) of
this Section 5, the Company will pay all costs, expenses and fees incident to
the performance of the obligations of the Company under this Agreement,
including, without limiting the generality of the foregoing, the following: 
accounting fees of the Company; the fees and disbursements of counsel for the
Company; the cost of printing and delivering to, or as requested by, the
Underwriters copies of the Registration Statement, Preliminary Prospectuses, the
Prospectus, this Agreement, the Underwriters' Selling Memorandum, the
Underwriters' Invitation Letter, the Listing Application, the Blue Sky Survey
and any supplements or amendments thereto; the filing fees of the Commission;
the filing fees incident to securing any required review by the NASD of the
terms of the sale of the Units; the Listing Fee of The Nasdaq Stock Market;
reasonable costs of a due diligence investigation of the principals of the
Company by a firm acceptable to the Representative; and the expenses, including
the fees and disbursements of counsel for the Underwriters, incurred in
connection with the qualification of the Units under state securities or Blue
Sky laws.  Any transfer taxes imposed on the sale of the Units to the several
Underwriters will be paid by the Company.  The Company agrees to pay all costs
and expenses of the Underwriters, including the fees and disbursements of
counsel for the Underwriters, incident to the offer and sale of directed shares
of the Common Stock by the Underwriters to employees and persons having business
relationships with the Company.  The Company shall not, however, be required to
pay for any of the Underwriters' expenses (other than those related to
qualification under NASD regulation and state securities or Blue Sky

Page 13 of 27


<PAGE>

laws) except that, if this Agreement shall not be consummated, then the 
Company shall reimburse the several Underwriters for reasonable accountable 
out-of-pocket expenses, including fees and disbursements of counsel, 
reasonably incurred in connection with investigating, marketing and proposing 
to market the Units or in contemplation of performing their obligations 
hereunder (less the $35,000 advance that has been paid by the Company); but 
the Company shall not in any event be liable to any of the several 
Underwriters for damages on account of loss of anticipated profits from the 
sale by them of the Units.

          (c)       In the event the Company elects to redeem the Warrants at
any time commencing one year after the date of this Agreement, the Company shall
retain the Representative as the Company's solicitation agent (the "Warrant
Solicitation Agent").  The Company shall pay to the Warrant Solicitation Agent
for its services a solicitation fee equal to 2% of the total amount paid by the
holders of the Warrants whom the Warrant Solicitation Agent solicits to exercise
the Warrants.  The exercise will be presumed to be unsolicitated unless the
customer states in writing that the transaction was solicited by the Warrant
Solicitation Agent and designates in writing the registered representative of
the Warrant Solicitation Agent entitled to receive compensation for the
exercise.  The fee shall not be payable for the exercise of any Warrant held by
the Warrant Solicitation Agent in a discretionary account at the time of
exercise, unless the Warrant Solicitation Agent receives from the customer prior
specific written approval of such exercise.

     6.   CONDITIONS OF OBLIGATIONS OF THE UNDERWRITERS.

          The several obligations of the Underwriters to purchase the Firm Units
on the Closing Date and the Option Units, if any, on the Option Closing Date are
subject to the accuracy, as of the Closing Date or the Option Closing Date, as
the case may be, of the representations and warranties of the Company contained
herein, and to the performance by the Company of their covenants and obligations
hereunder and to the following additional conditions:

          (a)       The Registration Statement and all post-effective amendments
thereto shall have become effective and any and all filings required by Rule 424
and Rule 430A of the Rules and Regulations shall have been made, and any request
of the Commission for additional information (to be included in the Registration
Statement or otherwise) shall have been disclosed to the Representative and
complied with to its reasonable satisfaction.  No stop order suspending the
effectiveness of the Registration Statement, as amended from time to time, shall
have been issued and no proceedings for that purpose shall have been taken or,
to the knowledge of the Company, shall be contemplated by the Commission and no
injunction, restraining order, or order of any nature by a federal or state
court of competent jurisdiction shall have been issued as of the Closing Date
which would prevent the issuance of the Units.

          (b)       The Representative shall have received on the Closing Date
or the Option Closing Date, as the case may be, the opinion of Ater Wynne Hewitt
Dodson & Skerritt, counsel for the Company, dated the Closing Date or the Option
Closing Date, as the

Page 14 of 27


<PAGE>

case may be, addressed to the Underwriters (and stating that it may be relied 
upon by counsel to the Underwriters) to the effect that:

               (i)       The Company has been duly organized and is validly
existing as a corporation in good standing under the laws of the state of
Oregon, with corporate power and authority to own or lease its properties and
conduct its business as described in the Registration Statement; the Company is
duly qualified to transact business in all jurisdictions in which the conduct of
its business requires such qualification, or in which the failure to qualify
would have a materially adverse effect upon the business of the Company.

               (ii)      The Company has authorized and outstanding capital
stock as set forth under the caption "Capitalization" in the Prospectus; the
authorized shares of the Company's Common Stock have been duly authorized; the
outstanding shares of the Company's Common Stock have been duly authorized and
validly issued and are fully paid and non-assessable; all of the securities of
the Company conform to the description thereof contained in the Prospectus; the
certificates for the Common Stock and Warrants, assuming they are in the form
filed with the Commission, are in due and proper form; the shares of Common
Stock to be sold by the Company pursuant to this Agreement, including shares of
Common Stock to be sold as a part of the Option Units have been duly authorized
and, upon issuance and delivery thereof as contemplated in this Agreement and
the Registration Statement, will be validly issued, fully paid and non-
assessable; no preemptive rights of stockholders exist with respect to any of
the Common Stock of the Company or the issuance or sale thereof pursuant to any
applicable statute or the provisions of the Company's charter documents or, to
such counsel's best knowledge, pursuant to any contractual obligation. The
Warrants and the Representative's Warrants have been authorized for issuance to
the purchasers of Units or the Representative, as the case may be, and will,
when issued, possess rights, privileges, and characteristics as represented in
the most recent form of Warrants or Representative's Warrants, as the case may
be, filed as an exhibit to the Registration Statement; the securities to be
issued upon exercise of the Representative's Warrants, when issued and delivered
against payment therefor in accordance with the terms of the Representative's
Warrants, will be duly and validly issued, fully paid, nonassessable and free of
preemptive rights, and all corporate action required to be taken for the
authorization and issuance of the Warrants, the Representative's Warrants, and
the securities to be issued upon their exercise, has been validly and
sufficiently taken. 

               (iii)          Except as described in or contemplated by the
Prospectus, to the knowledge of such counsel, there are no outstanding
securities of the Company convertible or exchangeable into or evidencing the
right to purchase or subscribe for any shares of capital stock of the Company
and there are no outstanding or authorized options, warrants or rights of any
character obligating the Company to issue any shares of its capital stock or any
securities convertible or exchangeable into or evidencing the right to purchase
or subscribe for any shares of such stock; and except as described in the
Prospectus, to the knowledge of such counsel, no holder of any securities of the
Company or any other person has the right, contractual or otherwise, which has
not been satisfied or effectively waived, to cause the Company to sell or
otherwise issue to them, or to permit them to underwrite the sale of, any

Page 15 of 27


<PAGE>

of the Units or the right to have any Common Stock or other securities of the 
Company included in the Registration Statement or the right, as a result of 
the filing of the Registration Statement, to require registration under the 
Act of any shares of Common Stock or other securities of the Company.

               (iv)      The Registration Statement has become effective under
the Act and, to the best of the knowledge of such counsel, no stop order
proceedings with respect thereto have been instituted or are pending or
threatened under the Act.

               (v)       The Registration Statement, the Prospectus and each
amendment or supplement thereto comply as to form in all material respects with
the requirements of the Act and the applicable rules and regulations thereunder
(except that such counsel need express no opinion as to the financial statements
and related schedules therein). 

               (vi)      The statements under the captions "Shares Eligible for
Future Sale" and "Description of Securities" in the Prospectus and in Item 24 of
the Registration Statement, insofar as such statements constitute a summary of
documents referred to therein or matters of law, fairly summarize in all
material respects the information called for with respect to such documents and
matters.

               (vii)    Such counsel does not know of any contracts or 
documents required to be filed as exhibits to the Registration Statement or 
described in the Registration Statement or the Prospectus which are not so 
filed or described as required, and such contracts and documents as are 
summarized in the Registration Statement or the Prospectus are fairly 
summarized in all material respects.

               (viii)   Such counsel knows of no material legal or 
governmental proceedings pending or threatened against the Company.

               (ix)      The execution and delivery of this Agreement and the
consummation of the transactions herein contemplated do not and will not
conflict with or result in a breach of any of the terms or provisions of, or
constitute a default under, the articles of incorporation or bylaws of the
Company, or any agreement or instrument known to such counsel to which the
Company is a party or by which the Company may be bound.

               (x)       This Agreement has been duly authorized, executed and
delivered by the Company.

               (xi)      No approval, consent, order, authorization,
designation, declaration or filing by or with any regulatory, administrative or
other governmental body is necessary in connection with the execution and
delivery of this Agreement and the consummation of the transactions herein
contemplated (other than as may be required by the NASD or as required by state
securities and Blue Sky laws as to which such counsel need express no opinion)
except such as have been obtained or made, specifying the same.

Page 16 of 27


<PAGE>

               (xii)     The Company is not, and will not become, as a
result of the consummation of the transactions contemplated by this Agreement,
and application of the net proceeds therefrom as described in the Prospectus,
required to register as an investment company under the 1940 Act.

          In rendering such opinion, such counsel may rely as to matters
governed by the laws of states other than Oregon or federal laws on local
counsel in such jurisdictions, provided that in each case such counsel shall
state that they believe that they and the Underwriters are justified in relying
on such other counsel.  In addition to the matters set forth above, the opinion
of Ater Wynne Hewitt Dodson & Skerritt shall also include a statement to the
effect that nothing has come to the attention of such counsel that has caused
them to believe that (i) the Registration Statement, at the time it became
effective under the Act (but after giving effect to any modifications
incorporated therein pursuant to Rule 430A under the Act) and as of the Closing
Date or the Option Closing Date, as the case may be, contained an untrue
statement of a material fact or omitted to state a material fact required to be
stated therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading, and (ii) the
Prospectus, or any supplement thereto, on the date it was filed pursuant to the
Rules and Regulations and as of the Closing Date or the Option Closing Date, as
the case may be, contained an untrue statement of a material fact or omitted to
state a material fact necessary in order to make the statements, in the light of
the circumstances under which they are made, not misleading (except that such
counsel need express no view as to financial statements, schedules and
statistical information therein).

          (c)       The Representative shall have received from Weiss, 
Jensen, Ellis & Howard, counsel for the Underwriters, an opinion dated the 
Closing Date or the Option Closing Date, as the case may be, substantially to 
the effect specified in subparagraphs (i), (iv) and (v) of Paragraph (b) of 
this Section 6. In rendering such opinion Weiss, Jensen, Ellis & Howard may 
rely as to all matters governed other than by the laws of the State of Oregon 
or federal laws on the opinion of counsel referred to in Paragraph (b) of 
this Section 6.  In addition to the matters set forth above, such opinion 
shall also include a statement to the effect that nothing has come to the 
attention of such counsel that has caused them to believe that (i) the 
Registration Statement, or any amendment thereto, as of the time it became 
effective under the Act (but after giving effect to any modifications 
incorporated therein pursuant to Rule 430A under the Act) and as of the 
Closing Date or the Option Closing Date, as the case may be, contained an 
untrue statement of a material fact or omitted to state a material fact 
required to be stated therein or necessary to make the statements therein, in 
light of the circumstances under which they were made, not misleading, and 
(ii) the Prospectus, or any supplement thereto, on the date it was filed 
pursuant to the Rules and Regulations and as of the Closing Date or the 
Option Closing Date, as the case may be, contained an untrue statement of a 
material fact or omitted to state a material fact, necessary in order to make 
the statements, in the light of the circumstances under which they are made, 
not misleading (except that such counsel need express no view as to financial 
statements, schedules and statistical information therein).  With respect to 
such statement, Weiss, Jensen,

Page 17 of 27


<PAGE>

Ellis & Howard may state that their belief is based upon the procedures set 
forth therein, but is without independent check and verification.

          (d)       The Representative shall have received at the Closing Date
or the Option Closing Date, as the case may be, the opinion of Peter Dehlinger &
Associates, patent counsel to the Company, dated the Closing Date or the Option
Closing Date, as the case may be, addressed to the Underwriters (and stating
that it may be relied upon by counsel to the Underwriters) related to the
Company's patents and substantially in the form attached hereto as Schedule II
hereto.

          (e)       The Representative shall have received at or prior to the 
Closing Date from Weiss, Jensen, Ellis & Howard a memorandum or summary, in 
form and substance satisfactory to the Representative, with respect to the 
qualification for offering and sale by the Underwriters of the Units under 
the state securities or Blue Sky laws of such jurisdictions as the 
Representative may reasonably have designated to the Company.

          (f)       The Representative, on behalf of the several Underwriters,
shall have received, on each of the dates hereof, the Closing Date and the
Option Closing Date, as the case may be, a letter dated the date hereof, the
Closing Date or the Option Closing Date, as the case may be, in form and
substance satisfactory to the Representative, of Arthur Andersen LLP confirming
that they are independent public accountants within the meaning of the Act and
the applicable published Rules and Regulations thereunder and stating that in
their opinion the financial statements and schedules examined by them and
included in the Registration Statement comply in form in all material respects
with the applicable accounting requirements of the Act and the related published
Rules and Regulations and containing such other statements and information as
are ordinarily included in accountants' "comfort letters" to Underwriters with
respect to the financial statements and certain financial and statistical
information contained in the Registration Statement and Prospectus.

          (g)       The Representative shall have received on the Closing Date
or the Option Closing Date, as the case may be, a certificate or certificates of
the Chief Executive Officer and the Chief Financial Officer of the Company to
the effect that, as of the Closing Date or the Option Closing Date, as the case
may be, each of them severally represents as follows:

                    (i)   The Registration Statement has become effective under
the Act and no stop order suspending the effectiveness of the Registration
Statement has been issued, and no proceedings for such purpose have been taken
or are, to his knowledge, contemplated by the Commission;

                    (ii)  The representations and warranties of the Company
contained in Section 1 hereof are true and correct as of the Closing Date or the
Option Closing Date, as the case may be;

Page 18 of 27


<PAGE>


               (iii)     All filings required to have been made pursuant to
Rule 424 or Rule 430A under the Act have been made;

               (iv)      He or she has carefully examined the Registration
Statement and the Prospectus and, in his or her opinion, as of the effective
date of the Registration Statement, the statements contained in the Registration
Statement were true and correct, and such Registration Statement and Prospectus
did not omit to state a material fact required to be stated therein or necessary
in order to make the statements therein, in light of the circumstances under
which they were made, not misleading, and since the effective date of the
Registration Statement, no event has occurred which should have been set forth
in a supplement to or an amendment of the Prospectus which has not been so set
forth in such supplement or amendment; and 

               (v)       Since the respective dates as of which information is
given in the Registration Statement and Prospectus, there has not been any
material adverse change or any development involving a prospective material
adverse change in or affecting the condition, financial or otherwise, of the
Company or the earnings, business, management, properties, assets, rights,
operations, condition (financial or otherwise) or prospects of the Company,
whether or not arising in the ordinary course of business.
          
          (h)  The Company shall have furnished to the Representative such
further certificates and documents confirming the representations and
warranties, covenants and conditions contained herein and related matters as the
Representative may reasonably have requested.

          (i)  The Common Stock and Warrants have been approved for
designation on The Nasdaq Stock Market upon notice of issuance.

          (j)  The Lockup Agreements described in Section 4(j) are in full
force and effect.

          (k)  The Company shall have fully completed a rescission offer to
certain purchasers of the Company's Common Stock offering them the right to
rescind their prior acquisition of Common Stock as described in the registration
statement filed with the Commission on Form _____ (File No. _____) and declared
effective by the Commission on __________, 1997.

          The opinions and certificates mentioned in this Agreement shall be
deemed to be in compliance with the provisions hereof only if they are in all
material respects satisfactory to the Representative and to Weiss, Jensen,
Ellis & Howard, counsel for the Underwriters.

          If any of the conditions hereinabove provided for in this Section 6
shall not have been fulfilled when and as required by this Agreement to be
fulfilled, the obligations of the Underwriters hereunder may be terminated by
the Representative by notifying the

Page 19 of 27


<PAGE>

Company of such termination in writing or by telegram at or prior to the 
Closing Date or the Option Closing Date, as the case may be.

          In such event, the Company and the Underwriters shall not be under any
obligation to each other (except to the extent provided in Sections 5 and 8
hereof).

     7.   CONDITIONS OF THE OBLIGATIONS OF THE COMPANY.

          The obligations of the Company to sell and deliver the portion of the
Units required to be delivered as and when specified in this Agreement are
subject to the conditions that at the Closing Date or the Option Closing Date,
as the case may be, no stop order suspending the effectiveness of the
Registration Statement shall have been issued and in effect or proceedings
therefor initiated or threatened.

     8.   INDEMNIFICATION.

          (a)       The Company agrees to indemnify and hold harmless each
Underwriter and each person, if any, who controls any Underwriter within the
meaning of the Act, against any losses, claims, damages or liabilities to which
such Underwriter or any such controlling person may become subject under the Act
or otherwise, insofar as such losses, claims, damages or liabilities (or actions
or proceedings in respect thereof) arise out of or are based upon (i) any untrue
statement or alleged untrue statement of any material fact contained in the
Registration Statement, any Preliminary Prospectus, the Prospectus or any
amendment or supplement thereto, or (ii) the omission or alleged omission to
state therein a material fact required to be stated therein or necessary to make
the statements therein not misleading; and will reimburse each Underwriter and
each such controlling person upon demand for any legal or other expenses
reasonably incurred by such Underwriter or such controlling person in connection
with investigating or defending any such loss, claim, damage or liability,
action or proceeding or in responding to a subpoena or governmental inquiry
related to the offering of the Units, whether or not such Underwriter or
controlling person is a party to any action or proceeding; provided, however,
that the Company will not be liable in any such case to the extent that any such
loss, claim, damage or liability arises out of or is based upon an untrue
statement or alleged untrue statement, or omission or alleged omission made in
the Registration Statement, any Preliminary Prospectus, the Prospectus, or such
amendment or supplement, in reliance upon and in conformity with written
information furnished to the Company by or through the Representative
specifically for use in the preparation thereof.  This indemnity agreement will
be in addition to any liability which the Company may otherwise have.

          (b)       Each Underwriter severally and not jointly will indemnify
and hold harmless the Company, each of its directors, each of its officers who
have signed the Registration Statement and each person, if any, who controls the
Company within the meaning of the Act, against any losses, claims, damages or
liabilities to which the Company or any such director, officer or controlling
person may become subject under the Act or otherwise, insofar as such losses,
claims, damages or liabilities (or actions or proceedings in

Page 20 of 27


<PAGE>

respect thereof) arise out of or are based upon (i) any untrue statement or 
alleged untrue statement of any material fact contained in the Registration 
Statement, any Preliminary Prospectus, the Prospectus or any amendment or 
supplement thereto, or (ii) the omission or the alleged omission to state 
therein a material fact required to be stated therein or necessary to make 
the statements therein not misleading in the light of the circumstances under 
which they were made; and will reimburse any legal or other expenses 
reasonably incurred by the Company or any such director, officer or 
controlling person in connection with investigating or defending any such 
loss, claim, damage, liability, action or proceeding; provided, however, that 
each Underwriter will be liable in each case to the extent, but only to the 
extent, that such untrue statement or alleged untrue statement or omission or 
alleged omission has been made in the Registration Statement, any Preliminary 
Prospectus, the Prospectus or such amendment or supplement, in reliance upon 
and in conformity with written information furnished to the Company by or 
through the Representative specifically for use in the preparation thereof.  
This indemnity agreement will be in addition to any liability which such 
Underwriter may otherwise have.

          (c)       In case any proceeding (including any governmental
investigation) shall be instituted involving any person in respect of which
indemnity may be sought pursuant to this Section 8, such person (the
"indemnified party") shall promptly notify the person against whom such
indemnity may be sought (the "indemnifying party") in writing.  No
indemnification provided for in Section 8(a) or (b) shall be available to any
party who shall fail to give notice as provided in this Section 8(c) if the
party to whom notice was not given was unaware of the proceeding to which such
notice would have related and was materially prejudiced by the failure to give
such notice, but the failure to give such notice shall not relieve the
indemnifying party or parties from any liability which it or they may have to
the indemnified party for contribution or otherwise than on account of the
provisions of Section 8(a) or (b).  In case any such proceeding shall be brought
against any indemnified party and it shall notify the indemnifying party of the
commencement thereof, the indemnifying party shall be entitled to participate
therein and, to the extent that it shall wish, jointly with any other
indemnifying party similarly notified, to assume the defense thereof, with
counsel satisfactory to such indemnified party and shall pay as incurred the
fees and disbursements of such counsel related to such proceeding.  In any such
proceeding, any indemnified party shall have the right to retain its own counsel
at its own expense.  Notwithstanding the foregoing, the indemnifying party shall
pay as incurred (or within 30 days of presentation) the fees and expenses of the
counsel retained by the indemnified party in the event (i) the indemnifying
party and the indemnified party shall have mutually agreed to the retention of
such counsel, (ii) the named parties to any such proceeding (including any
impleaded parties) include both the indemnifying party and the indemnified party
and representation of both parties by the same counsel would be inappropriate
due to actual or potential differing interests between them or (iii) the
indemnifying party shall have failed to assume the defense and employ counsel
acceptable to the indemnified party within a reasonable period of time after
notice of commencement of the action.  It is understood that the indemnifying
party shall not, in connection with any proceeding or related proceedings in the
same jurisdiction, be liable for the reasonable fees and expenses of more than
one separate firm for all such indemnified parties.  Such firm shall be
designated in writing by

Page 21 of 27


<PAGE>

you in the case of parties indemnified pursuant to Section 8(a) and by the 
Company in the case of parties indemnified pursuant to Section 8(b).  The 
indemnifying party shall not be liable for any settlement of any proceeding 
effected without its written consent but if settled with such consent or if 
there be a final judgment for the plaintiff, the indemnifying party agrees to 
indemnify the indemnified party from and against any loss or liability by 
reason of such settlement or judgment.  In addition, the indemnifying party 
will not, without the prior written consent of the indemnified party, settle 
or compromise or consent to the entry of any judgment in any pending or 
threatened claim, action or proceeding of which indemnification may be sought 
hereunder (whether or not any indemnified party is an actual or potential 
party to such claim, action or proceeding) unless such settlement, compromise 
or consent includes an unconditional release of each indemnified party from 
all liability arising out of such claim, action or proceeding.

          (d)       If the indemnification provided for in this Section 8 is
unavailable to or insufficient to hold harmless an indemnified party under
Section 8(a) or (b) above in respect of any losses, claims, damages or
liabilities (or actions or proceedings in respect thereof) referred to therein,
then each indemnifying party shall contribute to the amount paid or payable by
such indemnified party as a result of such losses, claims, damages or
liabilities (or actions or proceedings in respect thereof) in such proportion as
is appropriate to reflect the relative benefits received by the Company on the
one hand and the Underwriters on the other from the offering of the Units.  If,
however, the allocation provided by the immediately preceding sentence is not
permitted by applicable law then each indemnifying party shall contribute to
such amount paid or payable by such indemnified party in such proportion as is
appropriate to reflect not only such relative benefits but also the relative
fault of the Company on the one hand and the Underwriters on the other in
connection with the statements or omissions which resulted in such losses,
claims, damages or liabilities, (or actions or proceedings in respect thereof),
as well as any other relevant equitable considerations.  The relative benefits
received by the Company on the one hand and the Underwriters on the other shall
be deemed to be in the same proportion as the total net proceeds from the
offering (before deducting expenses) received by the Company bears to the total
underwriting discounts and commissions received by the Underwriters, in each
case as set forth in the table on the cover page of the Prospectus.  The
relative fault shall be determined by reference to, among other things, whether
the untrue or alleged untrue statement of a material fact or the omission or
alleged omission to state a material fact relates to information supplied by the
Company on the one hand or the Underwriters on the other and the parties'
relative intent, knowledge, access to information and opportunity to correct or
prevent such statement or omission.

          The Company and the Underwriters agree that it would not be just and
equitable if contributions pursuant to this Section 8(d) were determined by pro
rata allocation (even if the Underwriters were treated as one entity for such
purpose) or by any other method of allocation which does not take account of the
equitable considerations referred to above in this Section 8(d).  The amount
paid or payable by an indemnified party as a result of the losses, claims,
damages or liabilities (or actions or proceedings in respect thereof) referred
to above in this Section 8(d) shall be deemed to include any legal or other
expenses

Page 22 of 27


<PAGE>

reasonably incurred by such indemnified party in connection with 
investigating or defending any such action or claim.  Notwithstanding the 
provisions of this subsection (d), (i) no Underwriter shall be required to 
contribute any amount in excess of the underwriting discounts and commissions 
applicable to the Units purchased by such Underwriter, and (ii) no person 
guilty of fraudulent misrepresentation (within the meaning of Section 11(f) 
of the Act) shall be entitled to contribution from any person who was not 
guilty of such fraudulent misrepresentation.  The Underwriters' obligations 
in this Section 8(d) to contribute are several in proportion to their 
respective underwriting obligations and not joint.

          (e)       In any proceeding relating to the Registration Statement,
any Preliminary Prospectus, the Prospectus or any supplement or amendment
thereto, each party against whom contribution may be sought under this Section 8
hereby consents to the jurisdiction of any court having jurisdiction over any
other contributing party, agrees that process issuing from such court may be
served upon him or it by any other contributing party and consents to the
service of such process and agrees that any other contributing party may join
him or it as an additional defendant in any such proceeding in which such other
contributing party is a party.

          (f)       Any losses, claims, damages, liabilities or expenses for
which an indemnified party is entitled to indemnification or contribution under
this Section 8 shall be paid by the indemnifying party to the indemnified party
as such losses, claims, damages, liabilities or expenses are incurred.  The
indemnity and contribution agreements contained in this Section 8 and the
representations and warranties of the Company set forth in this Agreement shall
remain operative and in full force and effect, regardless of (i) any
investigation made by or on behalf of any Underwriter or any person controlling
any Underwriter, the Company, its directors or officers or any persons
controlling the Company, (ii) acceptance of any Units and payment therefor
hereunder, and (iii) any termination of this Agreement.  A successor to any
Underwriter, or to the Company, its directors or officers, or any person
controlling the Company, shall be entitled to the benefits of the indemnity,
contribution and reimbursement agreements contained in this Section 8.

     9.   DEFAULT BY UNDERWRITERS.

          If on the Closing Date or the Option Closing Date, as the case may be,
any Underwriter shall fail to purchase and pay for the portion of the Units
which such Underwriter has agreed to purchase and pay for on such date
(otherwise than by reason of any default on the part of the Company), you, as
Representative of the Underwriters, shall use your reasonable efforts to procure
within 36 hours thereafter one or more of the other Underwriters, or any others,
to purchase from the Company such amounts as may be agreed upon and upon the
terms set forth herein, the Firm Units or Option Units, as the case may be,
which the defaulting Underwriter or Underwriters failed to purchase.  If during
such 36 hours you, as such Representative, shall not have procured such other
Underwriters, or any others, to purchase the Firm Units or Option Units, as the
case may be, agreed to be purchased by the defaulting Underwriter or
Underwriters, then (a) if the aggregate number of Units with respect to which
such default shall occur does not exceed 10% of the Firm

Page 23 of 27


<PAGE>

Units or Option Units, as the case may be, covered hereby, the other 
Underwriters shall be obligated, severally, in proportion to the respective 
numbers of Firm Units or Option Units, as the case may be, which they are 
obligated to purchase hereunder, to purchase the Firm Units or Option Units, 
as the case may be, which such defaulting Underwriter or Underwriters failed 
to purchase, or (b) if the aggregate number of Firm Units or Option Units, as 
the case may be, with respect to which such default shall occur equals or 
exceeds 10% of the Firm Units or Option Units, as the case may be, covered 
hereby, the Company or you as the Representative of the Underwriters will 
have the right, by written notice given within the next 36-hour period to the 
parties to this Agreement, to terminate this Agreement without liability on 
the part of the non-defaulting Underwriters or of the Company except to the 
extent provided in Section 8 hereof.  In the event of a default by any 
Underwriter or Underwriters, as set forth in this Section 9, the Closing Date 
or Option Closing Date, as the case may be, may be postponed for such period, 
not exceeding seven days, as you, as Representative, may determine in order 
that the required changes in the Registration Statement or in the Prospectus 
or in any other documents or arrangements may be effected. The term 
"Underwriter" includes any person substituted for a defaulting Underwriter.  
Any action taken under this Section 9 shall not relieve any defaulting 
Underwriter from liability in respect of any default of such Underwriter 
under this Agreement.

     10.  NOTICES.

          All communications hereunder shall be in writing and, except as
otherwise provided herein, will be mailed, delivered, telecopied or telegraphed
and confirmed as follows:  if to the Underwriters, to Paulson Investment
Company, Inc., 811 SW Front Avenue, Portland, Oregon 97204, Attention: Chester
L.F. Paulson; with a copy to Weiss, Jensen, Ellis & Howard, 2300 U.S. Bancorp
Tower, 111 Fifth Avenue, Portland, Oregon 97204, Attention: Mark A. von Bergen;
if to the Company, to AntiVirals Inc., One S.W. Columbia, Suite 1105, Portland,
Oregon  97258, Attention:  Denis R. Burger, Ph.D.; with a copy to Ater Wynne
Hewitt Dodson & Skerritt, Suite 1800, 222 SW Columbia, Portland, Oregon
97201-6618, Attention: Jack W. Schifferdecker, Jr.

     11.  TERMINATION.

          This Agreement may be terminated by you by notice to the Company as
follows:

          (a)       at any time prior to the earlier of (i) the time the Units
are released by you for sale by notice to the Underwriters, or (ii) 11:30 a.m.
on the first business day following the date of this Agreement;

          (b)       at any time prior to the Closing Date if any of the
following has occurred: (i) since the respective dates as of which information
is given in the Registration Statement and the Prospectus, any material adverse
change or any development involving a prospective material adverse change in or
affecting the condition, financial or otherwise, of the Company and its
subsidiaries taken as a whole or the earnings, business, management,

Page 24 of 27


<PAGE>

properties, assets, rights, operations, condition (financial or otherwise) or 
prospects of the Company and its subsidiaries taken as a whole, whether or 
not arising in the ordinary course of business, (ii) any outbreak or 
escalation of hostilities or declaration of war or national emergency or 
other national or international calamity or crisis or change in economic or 
political conditions if the effect of such outbreak, escalation, declaration, 
emergency, calamity, crisis or change on the financial markets of the United 
States would, in your reasonable judgment, make it impracticable to market 
the Units or to enforce contracts for the sale of the Units, (iii) the Dow 
Jones Industrial Average shall have fallen by 15 percent or more from its 
closing price on the day immediately preceding the date that the Registration 
Statement is declared effective by the Commission, (iv) suspension of trading 
in securities generally on the New York Stock Exchange or the American Stock 
Exchange or limitation on prices (other than limitations on hours or numbers 
of days of trading) for securities on either such Exchange, (v) the 
enactment, publication, decree or other promulgation of any statute, 
regulation, rule or order of any court or other governmental authority which 
in your opinion materially and adversely affects or may materially and 
adversely affect the business or operations of the Company, (vi) declaration 
of a banking moratorium by United States or New York State authorities, (vii) 
any downgrading in the rating of the Company's debt securities by any 
"nationally recognized statistical rating organization" (as defined for 
purposes of Rule 436(g) under the Exchange Act); (viii) the suspension of 
trading of the Common Stock by the Commission on The Nasdaq Stock Market or 
(ix) the taking of any action by any governmental body or agency in respect 
of its monetary or fiscal affairs which in your reasonable opinion has a 
material adverse effect on the securities markets in the United States; or

          (c)       as provided in Sections 6 and 9 of this Agreement.

     12.  SUCCESSORS.

          This Agreement has been and is made solely for the benefit of the
Underwriters, the Company and their respective successors, executors,
administrators, heirs and assigns, and the officers, directors and controlling
persons referred to herein, and no other person will have any right or
obligation hereunder.  No purchaser of any of the Units from any Underwriter
shall be deemed a successor or assign merely because of such purchase.

     13.  INFORMATION PROVIDED BY UNDERWRITERS.

          The Company and the Underwriters acknowledge and agree that the only
information furnished or to be furnished by any Underwriter to the Company for
inclusion in any Prospectus or the Registration Statement consists of the
information set forth in the last paragraph on the front cover page (insofar as
such information relates to the Underwriters), legends required by Item 502(d)
of Regulation S-B under the Act and the information under the caption
"Underwriting" in the Prospectus.

     14.  MISCELLANEOUS.

Page 25 of 27


<PAGE>

          The reimbursement, indemnification and contribution agreements
contained in this Agreement and the representations, warranties and covenants in
this Agreement shall remain in full force and effect regardless of (a) any
termination of this Agreement, (b) any investigation made by or on behalf of any
Underwriter or controlling person thereof, or by or on behalf of the Company or
its directors or officers and (c) delivery of and payment for the Units under
this Agreement.

          This Agreement may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

          This Agreement shall be governed by, and construed in accordance with,
the laws of the state of Oregon.  All disputes relating to this Underwriting
Agreement shall be adjudicated before a court located in Multnomah County,
Oregon to the exclusion of all other courts that might have jurisdiction.

     If the foregoing letter is in accordance with your understanding of our
agreement, please sign and return to us the enclosed duplicates hereof,
whereupon it will become a binding agreement among the Company and the several
Underwriters in accordance with its terms. 


                                            Very truly yours,
 
                                            ANTIVIRALS INC.
 
 
                                            By:
                                               ---------------------------
                                                 Denis R. Burger, Ph.D.
                                                 Chief Executive Officer

The foregoing Underwriting Agreement 
is hereby confirmed and accepted 
as of the date first above written.

PAULSON INVESTMENT COMPANY, INC.

As Representative of the several 
Underwriters listed on Schedule I



By:
   ---------------------------
     Authorized Officer

Page 26 of 27


<PAGE>

                                   SCHEDULE I


                            SCHEDULE OF UNDERWRITERS
 

                                                           NUMBER OF FIRM
                                                                UNITS
                   UNDERWRITER                             TO BE PURCHASED
- -------------------------------------------------         -----------------
Paulson Investment Company, Inc.
 
 
 
 
                                                           Total:
                                                          -----------------
                                                          -----------------



Schedule I




<PAGE>
              THIRD RESTATED AND AMENDED ARTICLES OF INCORPORATION
                                       OF
                                 ANTIVIRALS INC.



     Pursuant to ORS 60.451, the Board of Directors of Antivirals Inc. (the
"Corporation") hereby amends and restates its Second Restated Articles of
Incorporation dated November 20, 1992.

                                    ARTICLE I
                                      NAME

     The name of the Corporation is Antivirals Inc.

                                   ARTICLE II     
                                 SHARES OF STOCK

    1.   The authorized capital stock of the Corporation consists of 50,000,000
shares of common stock, $0.0001 par value ("Common Stock") and 2,000,000 
shares of preferred stock, $0.0001 par value ("Preferred Stock"). 

    2.   The Board of Directors shall have the power to issue, from time to
time, one or more series of Preferred Shares or special stock in any manner 
permitted by law and not inconsistent with these Articles or the Bylaws of 
the Corporation. The Board of Directors shall have the authority to fix and 
determine, subject to the provisions of these Articles, the rights and 
preferences of the shares of such additional series, which shall be 
established by a resolution or resolutions of the Board of Directors 
providing for the issuance of such series.

    3.   On the effective date of this Third Restated and Amended Articles of
Incorporation, each issued and outstanding share of Common
 Stock shall be 
combined and reconstituted as one-third (1/3) share.  Any fractional shares 
resulting from his reverse stock split (after aggregating all shares held by 
each holder) shall be rounded up to the next whole share.

                                   ARTICLE III    
                          STAGGERED TERMS OF DIRECTORS

    1.   When there are six or more positions on the Board of Directors,
those positions shall be divided into two equal or nearly equal groups, 
denoted Group I and Group II.  Beginning at the 1992 annual shareholders 
meeting, in even years shareholders will elect directors to fill all Group I 
positions and in odd years shareholders will elect directors to fill all 
Group II positions.

1


<PAGE>

    2.   This Article may not be amended, altered, changed or repealed in
any respect unless such action is approved by the affirmative vote of the 
holders of not less than 66-2/3 percent of the shares then entitled to vote 
at an election of directors.

                                    ARTICLE IV     
                              NO PREEMPTIVE RIGHTS

    The Corporation elects to waive preemptive rights.

                                   ARTICLE V
                             LIMITATION ON LIABILITY

    No director of the Corporation shall be personally liable to the
Corporation or its shareholders for monetary damages for conduct as a 
director, provided that this Article shall not eliminate the liability of a 
director for any act or omission for which such elimination of liability is 
not permitted under the Act.  No amendment to the Act that further limits the 
acts or omissions for which elimination of liability is permitted shall 
affect the liability of a director for any act or omission which occurs prior 
to the effective date of the amendment.

                                    ARTICLE VI     
                                 INDEMNIFICATION

    The Corporation shall indemnify to the fullest extent not prohibited by law
any current or former director of the Corporation who is made, or threatened 
to be made, a party to an action, suit or proceeding, whether civil, 
criminal, administrative, investigative or other (including an action, suit 
or proceeding by or in the right of the Corporation), by reason of the fact 
that such person is or was a director, officer, employee or agent of the 
Corporation or a fiduciary within the meaning of the Employee Retirement 
Income Security Act of 1974 with respect to any employee benefit plan of the 
Corporation, or serves or served at the request of the Corporation as a 
director, officer, employee or agent, or as a fiduciary of an employee 
benefit plan, of another corporation, partnership, joint venture, trust or 
other enterprise.  The Corporation shall pay for or reimburse the reasonable 
expenses incurred by any such current or former director in any such 
proceeding in advance of the final disposition of the proceeding if the 
person sets forth in writing (i) the person's good faith belief that the 
person is entitled to indemnification under this Article and (ii) the 
person's agreement to repay all advances if it is ultimately determined that 
the person is not entitled to indemnification under this Article.  No 
amendment to this Article that limits the Corporation's obligation to 
indemnify any person shall have any effect on such obligation for any act or 
omission that occurs prior to the later of the effective date of the 
amendment or the date notice of the amendment is given to the person.  This 
Article shall not be deemed exclusive of any other provisions for 
indemnification or advancement of expenses of directors, officers, employees, 
agents and fiduciaries that may be included in any statute, bylaw, agreement, 
general or specific action of the Board of Directors, vote of shareholders or 
other document or arrangement.

2


<PAGE>

                                  ARTICLE VII    
                               ADDRESS FOR NOTICES

    The mailing address for the Corporation for notices is One SW Columbia,
Suite 1105, Portland, OR 97258.


EXECUTED:  JANUARY 20, 1997

                             /s/ John A. Beaulieu
                             _____________________________________
                             John A. Beaulieu
                             Chairman of the Board
3


<PAGE>
Registry No. 145980-15

                            CERTIFICATE ACCOMPANYING
                    THIRD RESTATED ARTICLES OF INCORPORATION
                                       OF
                                 ANTIVIRALS INC.



    The Third Restated Articles of Incorporation to which this certificate is
attached contain amendments to the Restated Articles of Incorporation which 
require shareholder approval.

    Pursuant to ORS 60.451(4), the undersigned Chairman of the Board of
Directors of Antivirals Inc. hereby certifies that the Third Restated 
Articles of Incorporation were approved by the shareholders on 
November 4, 1996.  At that time, 26,319,281 shares of Common Stock, 
representing 26,319,281 votes, were outstanding and entitled to vote on the 
amendments and were cast as follows:

     1.   ARTICLE II - PREFERRED STOCK 
          Votes cast in favor:     15,055,737
          Votes cast against:      114,054   
          Votes abstaining:        3,030     

     2.   ARTICLE II - STOCK SPLIT
          Votes cast in favor:     15,058,767
          Votes cast against:      114,054
          Votes abstaining:        0

     2.   ARTICLE IV - CUMULATIVE VOTING REMOVAL
          Votes cast in favor:     15,557,737
          Votes cast against:      190,292
          Votes abstaining:        0



Dated:  January 20, 1997


                             ANTIVIRALS INC.

                             /s/ John A. Beaulieu
                             _____________________
                             John A. Beaulieu
                             Chairman of the Board



<PAGE>
                                                    ADOPTED: NOVEMBER 1, 1991
                                                    AMENDED:    JULY 20, 1993


                                     BYLAWS
                                       OF
                                 ANTIVIRALS INC.



                                    ARTICLE 1.     

                              STOCKHOLDERS' MEETING

    Section 1.01.  ANNUAL MEETING:  The annual meeting of the stockholders 
shall be held on the last Thursday in March of each year at a time and place 
set by the Board of Directors.  At such meeting the stockholders entitled to 
vote shall nominate candidates to fill positions to be vacated by members of 
the Board of Directors whose terms end March 31 of that year, and to fill any 
new positions due to expansion of the Board of Directors.

    Section 1.02.  SPECIAL MEETINGS:  Special meetings of the stockholders of 
this corporation may be held at any time on request of the President, or at 
the request of a majority of the Board of Directors, or on demand in writing 
by stockholders of record holding not less than one-tenth of the stock of the 
corporation entitled to vote.

    Section 1.03.  VOTING:  Each stockholder shall be entitled to one vote, 
in person or by proxy, for each share of stock entitled to vote outstanding 
in such stockholder's name on the books of the corporation.

    Section 1.04.  QUORUM:  A majority of the shares entitled to vote, 
represented in person or by proxy, shall constitute a quorum at any meeting 
of the stockholders.
  If a quorum is present, the affirmative vote of the 
majority of the shares entitled to vote on the subject matter shall be the 
act of the stockholders, unless the vote of a greater number is required by 
law, the Articles of Incorporation, or other provision of these Bylaws.

    Section 1.05.  NOTICE:  Written or printed notice stating the place, day 
and hour of the meeting, and, in case of a special meeting, the purpose or 
purposes for which the meeting is called, shall be delivered not less than 
ten nor more than fifty days before the date of the meeting, either 
personally or by mail, by or at the direction of the President, the 
Secretary, or the officer or person calling the meeting, to each stockholder 
of record entitled to vote at such meeting.  If mailed, such notice shall be 
deemed to be delivered when deposited in the United States Mail addressed to 
the stockholder at his address as it appears on the stock transfer books of 
the corporation, with postage thereon prepaid.

1


<PAGE>

                                   ARTICLE 2.     

                               BOARD OF DIRECTORS

    Section 2.01.  NUMBER AND ELECTION OF DIRECTORS:  The Board of Directors 
of this corporation shall be increased to nine (9) members.  Elected 
directors will be those candidates receiving the highest number of votes.  
Directors elected after 1991 will serve two-year terms beginning at the time 
of their formal qualification in the year of their election.  The number of 
directors may be subsequently increased or decreased by amendment to the 
Bylaws if said amendment is stockholder approved by a majority vote of the 
shares outstanding, but no decrease shall have the effect of shortening the 
term of any incumbent director. At each annual meeting of stockholders, the 
stockholders shall elect directors to fill the positions being vacated by 
directors whose terms will expire in the year of the meeting, and to fill 
positions created by any expansion of the Board of Directors.

    In the election of directors, each stockholder may cast his or her votes,
corresponding to the number of shares owned by that stockholder, for any 
number of candidates, with any desired proportion of those votes going to any 
given candidate.

    Section 2.02.  VACANCIES:  Any vacancy occurring in the Board of 
Directors shall be filled by election at a special meeting of directors.  A 
director so elected to fill a vacancy shall be elected for the unexpired term 
of his predecessor in office, subject to prior death, resignation or removal.

    Section 2.03.  ANNUAL MEETING:  The Board of Directors shall meet in 
April (or soon thereafter) of each year at such time and place as the board 
shall agree upon, and at several other times throughout the year as the Board 
shall deem necessary or desirable.

    Section 2.04.  SPECIAL MEETINGS:  Special Meetings of the Board of 
Directors can be called by the President or any member of the Board of 
Directors upon no less than 5 days notice to each director.  Special meetings 
of the directors may be held at any time when a majority of the members of 
the Board consent thereto. Special meetings of the directors may be held at 
any place agreed to by a majority of the Board of Directors, or by means of 
conference telephone or similar communications equipment by which all 
participating directors can hear each other at the same time.

    Section 2.05.  QUORUM:  A majority of the number of elected and qualified 
directors shall constitute a quorum for the transaction of business.

    Section 2.06.  VOTING:  The act of the majority of the directors shall be 
the act of the Board of Directors, unless the vote of a greater number is 
required by other provision of these Bylaws.

2


<PAGE>

    Section 2.07.  REMOVAL OF DIRECTORS:  The stockholders at any annual 
meeting of the stockholders, or at any special meeting of the stockholders 
called for that purpose, may remover any director from office, with or 
without cause.  Such removal requires an affirmative vote, represented in 
person or by proxy, of a majority of the shares outstanding.

    Section 2.08.  POWERS OF DIRECTORS:  The Board of Directors shall have 
sole responsibility for the entire management of the business of the 
corporation.  In the management and control of the property, business and 
affairs of the corporation, the Board of Directors is hereby vested with all 
of the powers possessed by the corporation, itself, so far as this delegation 
of authority is not inconsistent with the Oregon business Corporation Act, 
with the Articles of Incorporation of the corporation, or with these Bylaws.  
The Board of Directors shall have power to determine what constitutes net 
earnings, profits and surplus, respectively; what amount shall be reserved 
for working capital and for any other purpose and what amount shall be 
declared as dividends; and such determination by the Board of Directors shall 
be final and conclusive except as otherwise provided by the Oregon Business 
Corporation Act and the Articles of Incorporation.

    Section 2.09.  EXECUTIVE COMMITTEE:  The Board of Directors may appoint 
from among its members an Executive Committee of two or more members.  The 
Executive Committee shall have such powers and shall perform such duties as 
may be delegated and assigned to the Executive Committee from time to time by 
the Board of Directors.  A majority of the members of the Executive Committee 
may fix its rules of procedure.  All action by the Executive Committee shall 
be reported to the Board of Directors at the meeting succeeding such action 
and shall be subject to revision, alteration and approval by the Board of 
Directors. Meetings of the Executive Committee shall be called, from time to 
time, at the direction and upon the request of any member thereof.  Notice of 
such meetings, unless waived, shall in each instance be given to each member 
of the Committee at his last known business address at least 24 hours before 
such meeting, either orally or in writing.  All actions by the Executive 
Committee shall be by unanimous written approval, if taken without a meeting, 
or if taken at a meeting, by a majority of those then serving on the 
Committee.  The Executive Committee shall keep such record of its activities 
and proceedings as it shall deem appropriate.  All meetings shall be held 
upon consent of all members of the Committee, and may be held at any agreed 
upon place, or by telephone conference or similar communication equipment by 
means of which all participating members can hear each other at the same time.

                                   ARTICLE 3.     

                                   OFFICERS

    Section 3.01.  OFFICERS:  The elected officers of the Corporation may 
consist of the Chairman of the Board; Vice Chairman of the Board; Chief 
Executive Officer; the President; one or more Vice Presidents (who may be 
designated as "Executive" or "Senior" Vice Presidents or by such other title 
as the Board of Directors may establish); a Secretary; a Controller; and a 
Treasurer.  If the duties of the Controller and the Treasurer are vested in 
one individual, that individual shall have the title of Chief Financial 
Officer.

3


<PAGE>

    Section 3.02.  POWERS AND DUTIES:  The powers and duties of the 
respective officers of the Corporation (if appointed) are as follows, subject 
to any specific limitations on such powers and duties that may be effectuated 
by resolution of the Board of Directors:

    a.   CHAIRMAN OF THE BOARD:  The Chairman of the Board shall call and
conduct the Board of Directors meetings, and shall see that resolutions of 
the Board of Directors are carried into effect.  The Chairman shall make 
reports to the Board of Directors, as well as to the stockholders, and shall 
perform such further powers as may be assigned to him from time to time by 
the Board of Directors.

    b.   VICE CHAIRMAN OF THE BOARD:  The Vice Chairman shall, in the
absence of the Chairman, or in the event of his inability to act, perform the 
duties and exercise the powers of the Chairman of the Board described in 
Section 3.02(a) hereof.

    c.   CHIEF EXECUTIVE OFFICER:  The Chief Executive Officer, subject to
the power of the Board of Directors to manage the business and affairs of the 
Corporation or to delegate such power to other officers or employees, shall 
have general and active supervision of the business affairs of the 
corporation and shall see that resolutions of the Board of Directors are 
carried into effect. The Chief Executive Officer is authorized, subject to 
such limitations as may be established by resolution of the Board of 
Directors, to execute certificates, contracts, bonds, mortgages, notes, 
guaranties and other instruments and documents for and on behalf of the 
Corporation and under the seal of the Corporation where so required.  Subject 
to such limitations, he shall have authority to cause the employment of such 
employees of the Corporation, other than officers elected by the Board of 
Directors, as the conduct of the business of the corporation may require, 
and, within the limits of his authority as delegated by resolution of the 
Board of Directors, to fix their compensation and the compensation of all 
appointed officers of the corporation, except if any are members of the Board 
of Directors; to remove or suspend any employee who shall not have been 
appointed by the Board of Directors; and to suspend for cause, pending final 
action by the Board of Directors, any officer who shall have been appointed 
by the Board of Directors.  The Chief Executive Officer shall make reports to 
the Board of Directors, as well as the shareholders and shall perform such 
other duties and exercise such other powers as may be assigned to him from 
time to time by the Board of Directors.

    d.   PRESIDENT:  The President shall, in the absence of the Chief
Executive Officer, or in the event of his inability or refusal to act, 
perform the duties and exercise the powers of the Chief Executive Officer 
described in Section 3.02(c) hereof.  The President has the same power as the 
Chief Executive Officer to execute certificates, contracts, bonds, mortgages, 
notes, guaranties and other instruments and documents for and on behalf of 
the corporation and under the seal of the corporation where so required, and 
to act with respect to the employment and compensation of employees.  The 
President shall make reports to the Board of Directors as well as the 
shareholders and preside over all meetings of the shareholders, and shall 
perform such other duties as are incident to the office of President or are 
properly required of the President by the Board of Directors.

4


<PAGE>

    e.   VICE PRESIDENT:  The Vice Presidents shall, to the extent
authorized by the President or the Chairman of the Board (which authority may 
be specific or general in nature), be authorized to execute certificates, 
contracts, bonds, mortgages, notes, guaranties and other instruments and 
documents for and on behalf of the Corporation and under the seal of the 
Corporation.  They shall also be authorized to perform all duties that from 
time to time may be prescribed by the Board of Directors, the Chairman of the 
Board or the President.

    f.   CONTROLLER:  The Controller shall have the responsibility for
supervision and management of all accounting and bookkeeping functions of the 
Corporation and of all of its subsidiaries; shall keep or cause to be kept, 
such books or records of all the income, expenses, losses, gains, assets and 
liabilities of the Corporation; shall have custody of the accounting records 
of the Corporation; shall render to the Chairman of the Board, the President 
and the Board of Directors at meetings of the Board of Directors or whenever 
else it may be required, an account of all transactions and the financial 
condition of the Corporation, and shall perform all other duties and exercise 
all other powers usually pertaining to the office of controller of a 
corporation and shall perform such other duties and exercise such other 
powers as may be assigned by the Board of Directors, the Chairman of the 
Board or the President.  In the absence of the Controller or in the event of 
the Controller's inability to act or refusal to act, the duties of the 
Controller shall be performed by and the powers of the Controller may be 
exercised by the Treasurer.

    g.   TREASURER:  The Treasurer has custody of the corporate funds and
securities and shall deposit all monies and other valuable effects in the 
name and to the credit of the Corporation in any depositories that are 
authorized by the Board of Directors; shall disburse the funds of the 
Corporation as may be directed by the Board of Directors, taking proper 
vouchers therefor; and shall render to the Chairman of the Board, the 
President, and the Board of Directors, an account of all such transactions, 
at meetings of the Board of Directors, or whenever it shall be required.  The 
Treasurer shall perform all other duties incident to the office of Treasurer, 
and shall have all other duties that may be assigned by the Board of 
Directors the Chairman of the Board, or the President. The Treasurer may 
appoint, pursuant to Section 3.02 (with the approval of the Chairman of the 
Board), one or more assistant treasurers, who shall perform all duties 
delegated to them by the Treasurer, the President, the Chairman of the Board, 
or the Board of Directors.  In the absence of the Treasurer or in the event 
of inability or refusal to act, the duties of the Treasurer shall be 
performed and the powers of the Treasurer may be exercised by such Assistant 
Treasurer as shall be designated by the Chairman of the Board of Directors.

5


<PAGE>

    h.   SECRETARY:  The Secretary shall attend all meetings of the
shareholders and Board of Directors, and act as clerk thereof, and record all 
votes and minutes of all proceedings in a book to be kept for that purpose 
and authenticate records of the Corporation.  The Secretary shall give, or 
cause to be given notice of all meetings of the shareholders and Board of 
Directors.  The Secretary shall keep in safe custody the seal of the 
Corporation, and when authorized by the Board of Directors or otherwise 
directed, affix the seal to any instrument requiring it.  The Secretary shall 
perform all other duties that may be assigned by the Board of Directors, the 
Chairman of the Board, or the President.  The Secretary may appoint, pursuant 
to Section 3.02 (with the approval of the Chairman of the Board) one or more 
assistant secretaries who shall perform all duties delegated to them by the 
Secretary, the President, the Chairman of the Board or the Board of 
Directors.  The Secretary and Assistant Secretaries, in addition to their 
other powers and duties, shall have the authority to execute powers of 
attorney on behalf of the Corporation.  In the absence of the Secretary or in 
the event of the Secretary's inability or refusal to act, the duties of the 
Secretary shall be performed and the powers of the Secretary may be exercised 
by such Assistant Secretary as shall be designated by the Chairman of the 
Board of Directors.  If there shall be a vacancy in the office of Assistant 
Secretary, such person shall be designated by the Chairman of the Board of 
Directors and shall perform the duties and exercise the powers of Assistant 
Secretary.

    Section 3.03.  APPOINTED OFFICERS:  The Chairman of the Board without 
further approval, and the President and the managers of corporate staff 
departments and the Secretary may appoint (with the prior approval of the 
Chairman of the Board), assistant vice presidents, assistant treasurers, 
assistant secretaries and other appropriate titled officers to assist them in 
their respective duties. Unless otherwise provided by the officer making the 
appointment, the powers and duties of the appointed officers shall be those 
approved by the Chairman of the Board and on file with the Secretary.

                                   ARTICLE 4.

                           SECURITIES AND REGISTRATION
                              AND TRANSFER THEREOF

    Section 4.01.  CERTIFICATES:  All certificates of stock and other 
securities of this corporation shall be signed by the President or Executive 
Vice-President and the Secretary or an Assistant Secretary of the corporation 
or a facsimile thereof.

    Section 4.02.  TRANSFER AGENT AND REGISTRAR:  The Board of Directors may 
from time to time appoint one or more Transfer Agents and one or more 
Registrars for the capital stock and other securities of the corporation.  
The signatures of the President or Executive Vice President and the Secretary 
or an Assistant Secretary upon a certificate may be facsimiles if the 
certificate is countersigned by a Transfer Agent, or registered by a 
Registrar, other than the corporation itself or an employee of the 
corporation.

6


<PAGE>

    Section 4.03.  TRANSFER:  Title to a certificate and to the interest in 
this corporation represented thereby can be transferred only:  (a) by 
delivery of the certificate endorsed either in blank or to a specified person 
by the person appearing on the certificate to be the owner of the interest 
represented thereby, or (b) by delivery of the certificate and a separate 
document containing a written assignment of the certificate or a power of 
attorney to sell, assign or transfer the same or the interest represented 
thereby, signed by the person appearing on the certificate to be the owner of 
the interest represented thereby.  Such assignment or power of attorney may 
be either in blank or to a specified person.

    Section 4.04.  NECESSITY FOR REGISTRATION:  Prior to due presentment for
registration upon the books of the corporation of a transfer of a security of 
this corporation, the corporation or thus agent for purposes of registering 
transfers of its securities may treat the registered owner of the security as 
the person exclusively entitled to vote, to receive any notices, to receive 
payment of any interest on a security, or of any ordinary, extraordinary, 
partial liquidating, final liquidating, or other dividend, or of any other 
distribution, whether paid in cash or in securities or in any other form, or 
otherwise to exercise or enjoy any or all of the rights and powers of an 
owner.

    Section 4.05.  CLOSING TRANSFER BOOKS:  For the purpose of determining 
the registered owners of stock or other securities entitled to notice of or 
to vote at any meeting of the shareholders or any adjournment thereof, or to 
receive payment of any interest on a security, or of any ordinary, 
extraordinary, partial liquidating, final liquidating, or other dividend, or 
of any other distribution, whether paid in cash or in securities or in any 
other form, or otherwise to exercise or enjoy any or all of the rights and 
powers of any owner, or in order to make a determination of registered owners 
for any other proper purpose, the Board of Directors may provide that the 
transfer books shall be closed for a period of 30 days.  If the transfer 
books shall be closed to the purpose of determining the registered owners 
entitled to notice of or to vote at a meeting of the shareholders or an 
adjournment thereof, such books shall be closed for a period of 30 days 
immediately preceding such meeting.

    Section 4.06.  FIXING RECORD DATE:  In lieu of closing the transfer 
books, the Board of Directors may fix in advance a date as record date for 
any determination of registered owners for which the transfer books might 
have been closed as provided in Section 4.05 above, such date to be 30 days 
and, in case of a meeting of shareholders, 30 days prior to the date on which 
the particular action which requires such date on which the particular action 
which requires such determination of registered owners is to be taken.

    Section 4.07.  LOST CERTIFICATES:  In case of the loss or destruction of 
a certificate of stock or other security in this corporation, a duplicate 
certificated may be issued in its place upon such terms as the Board of 
Directors shall prescribe.

7


<PAGE>

                                   ARTICLE 5.     

                                WAIVER OF NOTICE

    Whenever any notice is required to be given to any shareholder or director
of the corporation by these Bylaws or the Articles of Incorporation, or by 
the corporation laws of the State of Oregon, a waiver thereof in writing, 
signed by the person or persons entitled to such notice, whether before or 
after the time stated therein, shall be deemed equivalent to the required 
notice.  Presence of a director at any meeting shall constitute a waiver of 
any notice require for such meeting, except where a director attends a 
meeting for the express purpose of objecting to the transaction of any 
business because the meeting is not lawfully called or convened.

                                   ARTICLE 6.     
      
                             ACTION WITHOUT MEETING

    Any action required or permitted to be taken at a meeting of the directors
or shareholders of this corporation, or any other action which may be taken 
at a meeting of the directors or shareholders, may be taken without a meeting 
if a consent in writing setting forth the action so taken shall be signed by 
all directors or all shareholders holding stock entitled to vote with respect 
to the subject matter thereof.  Such consent shall have the same force and 
effect as a majority vote of such directors or shareholders and may be stated 
as such in any article or document filed with the Corporation Commissioner of 
the State of Oregon, any other governmental authority, or any person or 
entity.

                                   ARTICLE 7.     

                          INDEMNIFICATION AND INSURANCE

    Section 7.01.  NON-DERIVATIVE ACTIONS:  Subject to the provisions of 
Sections 7.03 and 7.06 below, the Board of Directors may elect to have to 
corporation indemnify any person who was or is a party or is threatened to be 
made a party who was or is a party or is threatened to be made party to any 
threatened, pending or completed action, suit or proceeding, whether civil, 
criminal, administrative, or investigative (other than an action by or in the 
right of the corporation) by reason of or arising from the fact that he is or 
was a director or officer of the corporation or one of its subsidiaries, or 
is or was serving at the request of the corporation as a director, officer, 
partner or trustee of another corporation, partnership, joint venture, trust 
or other enterprise, against expenses (including attorney fees), judgements, 
fines and amounts paid in settlement actually and reasonably incurred by him 
in connection with such action, suit or proceeding if (I) he acted in good 
faith and in a manner he reasonably believed to be in or not apposed to the 
best interests of the corporation and, with respect to any criminal action or 
proceeding, he had no reasonable cause to believe his conduct was unlawful, 
or (ii) his act or omission giving rise to such action, suit or proceeding is 
ratified, adopted or confirmed by the corporation or one 

8


<PAGE>

of its subsidiaries or the benefit thereof received by the corporation or one 
of its subsidiaries.  The termination of any action, suit or proceeding by 
judgement, order, settlement, conviction, or upon a plea of nolo contendere 
or its equivalent, shall not, of itself, create a presumption that the person 
did not act in good faith and in a manner which he reasonably believed to be 
in or not apposed to the best interests of the corporation and, with respect 
to any criminal action or proceeding, and no reasonable cause to believe that 
his conduct was unlawful, and settlement shall not constitute any evidence of 
any of the foregoing.

    Section 7.02.  DERIVATIVE ACTIONS:  Subject to the provisions of Sections 
7.03, 7.05, and 7.06, below, the corporation may, at the discretion of the 
Board of Directors, indemnify any person who was or is a party or is 
threatened to be made a party to any threatened, pending or completed action 
or suit by or in the right of the corporation to produce a judgement in its 
favor by reason of or arising from the fact that he is or was a director or 
officer of the corporation of one of its subsidiaries, or is or was serving 
at the request of the corporation as a director, officer, partner, or trustee 
of another corporation, partnership, joint venture, trust or other 
enterprise, against expenses (including attorney fees) actually and 
reasonably incurred by him in connection with the defense or settlement of 
such action or suit if he (I) acted in good faith and in a manner he 
reasonably believed to be in or not opposed to the best interests of the 
corporation, or (ii) his act or omission giving rise to such action or suit 
is ratified, adopted or confirmed by the corporation or one of its 
subsidiaries or the benefit thereof received by the corporation or one of its 
subsidiaries; provided, however, that no indemnification shall be made in 
respect of any claim, issue or matter as to which such person shall have been 
adjudged to be liable for gross negligence or deliberate misconduct in the 
performance of his duty to the corporation unless and only to the extent that 
the court in which action or suit was brought shall determine upon 
application that, despite the adjudication of liability but in view of all 
the circumstances of the case, such person is fairly and reasonably entitled 
to indemnity for such expenses which the court shall deem proper.

    Section 7.03.  DETERMINATION OF RIGHT TO INDEMNIFICATION IN CERTAIN 
CASES: Subject to the provisions of Sections 7.05 and 7.06 below, at the 
discretion of the Board of Directors, indemnification under Sections 7.01 and 
7.03 of this Article may be made by the corporation unless either the 
stockholders of the corporation, or those members of the Board of Directors 
who were not parties to such action, suit or proceeding expressly determine 
by majority vote that such indemnification is not proper under the 
circumstances because the person(s) to be indemnified has (have) not met the 
applicable standard of conduct set forth in Sections 7.01 or 7.02.

    Section 7.04.  INDEMNIFICATION OF PERSONS OTHER THAN OFFICERS OR 
DIRECTORS: In the event any person not included among those referred to in 
Section 7.01 or 7.02 of this Article was or is a party or is threatened to be 
made a party to any threatened, pending or completed action, suit or 
proceeding of a type referred to in Section 7.01 or 7.02 of this Article by 
reason of or arising from the fact that he is or was an employee or agent 
(including attorneys) of the corporation or one of its subsidiaries, or is or 
was serving at the request of the corporation as an employee or agent 
(including attorney) of another corporation, partnership, joint venture, 
trust or other enterprise, the Board of Directors of the corporation by a 
majority vote (whether 

9


<PAGE>

or not such majority consists in whole or in part of directors who were 
parties to such action, suit or proceeding) or the stockholders of the 
corporation by a majority vote of the outstanding shares may, but shall not 
be required to, grant to such person a right of indemnification to the extent 
described in Section 7.01 or 7.02 of this Article as if he were an officer or 
director referred to therein, provided that such person meets the applicable 
standard of conduct set forth in such Sections. Furthermore, the Board of 
Directors may designate by resolution in advance of any action, suit or 
proceeding, those employees or agents (including attorneys) who may have 
rights of indemnification granted to officers and directors under this 
Article.

    Section 7.05.  SUCCESSFUL DEFENSE:  If the Board of Directors elects to 
have the corporation provide indemnification, notwithstanding any other 
provision of Sections 7.01, 7.02, 7.03, or 7.04 of this Article, but subject 
to the provisions of Section 7.06 below, to the extent a director, officer, 
employee or agent (including attorneys) is successful on the merits or 
otherwise in defense of any action, suit or proceeding referred to in 
Sections 7.01, 7.02 or 7.04 of this Article, or in defense of any claim, 
issue or matter therein, at the discretion of the Board of Directors, said 
person may be indemnified against expenses (including attorney fees) actually 
and reasonably incurred by him in connection therewith.

    Section 7.06.  CONDITION PRECEDENT TO INDEMNIFICATION UNDER SECTIONS 
7.01. 7.02 OR 7.05:  Any person who desires to receive the benefits which may 
be conferred by Sections 7.01, 7.02 or 7.05 of this Article shall promptly 
notify the corporation that he or she has been named a defendant to an 
action, suit or proceeding of a type referred to in Sections 7.01 or 7.02 and 
that said person wisher to receive indemnification under Sections 7.01, 7.02 
or 7.05 of the Article.  The notice shall be in writing and mailed, via 
registered or certified mail, return receipt requested, to the President of 
the corporation at the executive offices of the corporation or, in the event 
the notice is from the President, to the Secretary of the Corporation.

    Section 7.07.  UNDERTAKING:  At the discretion of the Board of Directors, 
expenses incurred by a person to be indemnified under this Article in 
defending a civil, criminal, administrative or investigative action, suit or 
proceeding (including all appeals) or threat thereof, may be paid by the 
corporation in advance of the final disposition of such action, suit or 
proceeding as authorized in Section 7.03 upon receipt of an undertaking by or 
on behalf of such person to repay such expenses if it shall ultimately be 
determined that he is not entitled to be indemnified by the corporation. 

    Section 7.08.  INSURANCE:  The Board of Directors may direct the 
corporation to purchase and maintain insurance on behalf of any person who is 
or was a director or officer of the corporation or one of its subsidiaries or 
is or was serving at the request of the corporation as a director or officer 
of another corporation, partnership, joint venture, trust or other enterprise 
against any liability asserted against him and incurred by him an any such 
capacity, or arising out of his status as such, whether or not the 
corporation would have the power to indemnify him against such liability 
under the provisions of this Article or under the Oregon Business Corporation 
Act.

10


<PAGE>

    Section 7.09.  PURPOSE AND EXCLUSIVITY:  The indemnification referred to 
in the various Sections of this Article shall be deemed to be in addition to 
and not in lieu of any other rights to which those indemnified may be 
entitled under any statute, rule or law or equity, agreement, vote of the 
stockholders or Board of Directors or otherwise.  The purpose of this Article 
is to augment, pursuant to ORS 57.260(3) the other provisions of ORS 57.255 
and 57.260.

    Section 7.010. SEVERABILITY:  If any part of this Article shall be found, 
in any action, suit or proceeding, to be invalid or ineffective, the validity 
and the effect of the remaining parts shall not be affected.

                                   ARTICLE 8.     

                                 CORPORATE SEAL

The size and style of the corporate seal is shown by the impression on the 
margin hereof.

                                  ARTICLE 9.     

                        REIMBURSEMENT OF CERTAIN PAYMENTS

    Any payments made to an officer or director of this corporation, including
payments made as salary, commission, bonus, interest, rent or travel or 
entertainment expense incurred by him, which shall be disallowed in whole or 
in part as a deductible expense by the Internal Revenue Service, shall be 
reimbursed by such officer or director to this corporation to the full extent 
of such disallowance.  It shall be the duty of the directors, as a Board, to 
enforce payment of each such amount disallowed.  If the Board of Directors 
shall determine it necessary or desirable, amounts may be withheld from the 
future compensation payments of an officer or director sufficient to equal 
the amount of any disallowed payments made to him, in lieu of reimbursement 
by him of such amounts.

                                   ARTICLE 10.    

                                   AMENDMENTS

    The Bylaws of this corporation may be altered, amended or repealed by a
two-thirds affirmative vote of the directors, or by an affirmative vote of 
shareholders holding two-thirds of the shares entitled to vote, at any 
regular meeting or at any special meeting called for that purpose, provided 
notice of the proposed change is given in the notice of the meeting or notice 
thereof is waived in writing.

11




<PAGE>

                                                                 

         VOID AFTER 5:00 P.M. PACIFIC TIME ON ____________________, 2002

                        WARRANTS TO PURCHASE COMMON STOCK


W_____                         _________ Warrants
 
                                 ANTIVIRALS INC.

                                 CUSIP _________


THIS CERTIFIES THAT




or registered assigns, is the registered holder of the number of Warrants 
("Warrants") set forth above.  Each Warrant entitles the holder thereof to 
purchase from AntiVirals, Inc., a corporation incorporated under the laws of 
the State of Oregon ("Company"), subject to the terms and conditions set 
forth hereinafter and in the Warrant Agreement hereinafter more fully 
described (the "Warrant Agreement") referred to, one fully paid and 
non-assessable share of Common Stock, $.0001 par value, of the Company 
("Common Stock") upon presentation and surrender of this Warrant Certificate 
with the instructions for the registration and delivery of Common Stock 
filled in, at any time prior to 5:00 p.m., Pacific Time, on 
______________________________, 2002 or, if such Warrant is redeemed as 
provided in the Warrant Agreement, at any time prior to the effective time of 
such redemption, at the stock transfer office in _________________________, 
of ________________________________, Warrant Agent of the Company ("Warrant 
Agent"), or of its successor warrant agent or, if there be no successor 
warrant agent, at the corporate offices of the Company, and upon payment of 
the Exercise Price (as defined in the Warrant
 Agreement) and any applicable 
taxes paid either in cash, or by certified or official bank check, payable in 
lawful money of the United States of America to the order of the Company.  
Each Warrant initially entitles the holder to purchase one share of Common 
Stock for $__________.  The number and kind of securities or other property 
for which the Warrants are exercisable are subject to further adjustment in 
certain events, such as mergers, splits, stock dividends, recapitalizations 
and the like, to prevent dilution.  The Company may redeem any or all 
outstanding and unexercised Warrants at any time if the Daily Price has 
exceeded $__________ for 20 consecutive trading days immediately preceding 
the date of notice of such redemption, upon 30 days' notice, at a price equal 
to $0.25 per Warrant.  For the purpose of the foregoing sentence, the term 
"Daily Price" shall mean, for any relevant day, the closing bid price on that 
day as reported by the principal exchange or quotation system on which prices 
for the Common Stock are reported.  All Warrants not theretofore exercised or 
redeemed will expire on ______________________________, 2002.

Page i


<PAGE>

         This Warrant Certificate is subject to all of the terms, provisions
and conditions of the Warrant Agreement, dated as of __________, 1997 
("Warrant Agreement"), between the Company and the Warrant Agent, to all of 
which terms, provisions and conditions the registered holder of this Warrant 
Certificate consents by acceptance hereof.  The Warrant Agreement is 
incorporated herein by reference and made a part hereof and reference is made 
to the Warrant Agreement for a full description of the rights, limitations of 
rights, obligations, duties and immunities of the Warrant Agent, the Company 
and the holders of the Warrant Certificates.  Copies of the Warrant Agreement 
are available for inspection at the stock transfer office of the Warrant 
Agent or may be obtained upon written request addressed to the Company at One 
S.W. Columbia, Suite 1105, Portland, Oregon  97258, Attention: Chief 
Executive Officer.

         The Company shall not be required upon the exercise of the Warrants
evidenced by this Warrant Certificate to issue fractions of Warrants, Common 
Stock or other securities, but shall make adjustment therefor in cash on the 
basis of the current market value of any fractional interest as provided in 
the Warrant Agreement.

         In certain cases, the sale of securities by the Company upon exercise
of Warrants would violate the securities laws of the United States, certain 
states thereof or other jurisdictions.  The Company has agreed to use its 
best efforts to cause a registration statement to continue to be effective 
during the term of the Warrants with respect to such sales under the 
Securities Act of 1933, as amended, and to take such action under the laws of 
various states as may be required to cause the sale of securities upon 
exercise to be lawful. However, the Company will not be required to honor the 
exercise of Warrants if, in the opinion of the Board of Directors, upon 
advice of counsel, the sale of securities upon such exercise would be 
unlawful.  In certain cases, the Company may, but is not required to, 
purchase Warrants submitted for exercise for a cash price equal to the 
difference between the market price of the securities obtainable upon such 
exercise and the exercise price of such Warrants.

         This Warrant Certificate, with or without other Certificates, upon
surrender to the Warrant Agent, any successor warrant agent or, in the 
absence of any successor warrant agent, at the corporate offices of the 
Company, may be exchanged for another Warrant Certificate or Certificates 
evidencing in the aggregate the same number of Warrants as the Warrant 
Certificate or Certificates so surrendered.  If the Warrants evidenced by 
this Warrant Certificate shall be exercised in part, the holder hereof shall 
be entitled to receive upon surrender hereof another Warrant Certificate or 
Certificates evidencing the number of Warrants not so exercised.

         No holder of this Warrant Certificate, as such, shall be entitled to
vote, receive dividends or be deemed the holder of Common Stock or any other
securities of the Company which may at any time be issuable on the exercise
hereof for any purpose whatever, nor shall anything contained in the Warrant
Agreement or herein be construed to confer upon the holder of this Warrant
Certificate, as such, any of the rights of a stockholder of the Company or any
right to vote for the election of directors or upon any matter submitted to
stockholders at any meeting thereof or give or withhold consent to any corporate
action (whether upon any matter submitted to stockholders at any meeting
thereof, or give or withhold consent to any merger, recapitalization, issuance
of stock, reclassification of stock, change of par value or change of 

Page ii


<PAGE>

stock to no par value, consolidation, conveyance or otherwise) or to receive 
notice of meetings or other actions affecting stockholders (except as 
provided in the Warrant Agreement) or to receive dividends or subscription 
rights or otherwise until the Warrants evidenced by this Warrant Certificate 
shall have been exercised and the Common Stock purchasable upon the exercise 
thereof shall have become deliverable as provided in the Warrant Agreement.

         If this Warrant Certificate shall be surrendered for exercise within
any period during which the transfer books for the Company's Common Stock or 
other class of stock purchasable upon the exercise of the Warrants evidenced 
by this Warrant Certificate are closed for any purpose, the Company shall not 
be required to make delivery of certificates for shares purchasable upon such 
transfer until the date of the reopening of said transfer books.

         Every holder of this Warrant Certificate by accepting the same
consents and agrees with the Company, the Warrant Agent, and with every other 
holder of a Warrant Certificate that:

    (a)  this Warrant Certificate is transferable on the registry books of the
Warrant Agent only upon the terms and conditions set forth in the Warrant 
Agreement, and

    (b)  the Company and the Warrant Agent may deem and treat the person in
whose name this Warrant Certificate is registered as the absolute owner 
hereof (notwithstanding any notation of ownership or other writing thereon 
made by anyone other than the Company or the Warrant Agent) for all purposes 
whatever and neither the Company nor the Warrant Agent shall be affected by 
any notice to the contrary.

         The Company shall not be required to issue or deliver any certificate
for shares of Common Stock or other securities upon the exercise of Warrants 
evidenced by this Warrant Certificate until any tax which may be payable in 
respect thereof by the holder of this Warrant Certificate pursuant to the 
Warrant Agreement shall have been paid, such tax being payable by the holder 
of this Warrant Certificate at the time of surrender.

         This Warrant Certificate shall not be valid or obligatory for any
purpose until it shall have been countersigned by the Warrant Agent.

Page iii


<PAGE>

         WITNESS the facsimile signatures of the proper officers of the Company
and its corporate seal.

          Dated:  ______________________________, 1997.


                                          ANTIVIRALS INC.



                                          By: ______________________________
                                                  Chief Executive Officer


                                          Attest: __________________________
                                                         Secretary


Countersigned

________________________


By:_____________________
    Authorized Officer

Page iv




<PAGE>
                                WARRANT AGREEMENT



                                     between



                                 ANTIVIRALS INC.

                                       and

               __________________________________________________



                          Dated as of ___________, 1997




<PAGE>

         This Agreement, dated as of ________, 1997, is between AntiVirals
Inc., an Oregon corporation (the "Company"), and _______________, a
__________________ (the "Warrant Agent").

         The Company, at or about the time that it is entering into this
Agreement, proposes to issue and sell to public investors up to 1,500,000 
Units ("Units").  Each Unit consists of one share of common stock, $.0001 par 
value, of the Company ("Common Stock") and one Warrant (collectively, the 
"Warrants"), each Warrant exercisable to purchase one share of Common Stock 
for $____, upon the terms and conditions and subject to adjustment in certain 
circumstances, all as set forth in this Agreement.

         The Company proposes to issue to the Representative of the
Underwriters in the public offering of Units referred to above warrants to 
purchase up to 150,000 additional Units.

         The Company wishes to retain the Warrant Agent to act on behalf of the
Company, and the Warrant Agent is willing so to act, in connection with the 
issuance, transfer, exchange and replacement of the certificates evidencing 
the Warrants to be issued under this Agreement (the "Warrant Certificates") 
and the exercise of the Warrants;

         The Company and the Warrant Agent wish to enter into this
 Agreement to
set forth the terms and conditions of the Warrants and the rights of the 
holders thereof ("Warrantholders") and to set forth the respective rights and 
obligations of the Company and the Warrant Agent.  Each Warrantholder is an 
intended beneficiary of this Agreement with respect to the rights of 
Warrantholders herein.


         NOW, THEREFORE, in consideration of the premises and the mutual
agreements herein set forth, the parties hereto agree as follows: 


Section 1.   APPOINTMENT OF WARRANT AGENT

             The Company appoints the Warrant Agent to act as agent for the 
Company in accordance with the instructions in this Agreement and the Warrant 
Agent accepts such appointment.


Section 2.   DATE, DENOMINATION AND EXECUTION OF WARRANT CERTIFICATES

             The Warrant Certificates (and the Form of Election to Purchase 
and the Form of Assignment to be printed on the reverse thereof) shall be in 
registered form only and shall be substantially of the tenor and purport 
recited in Exhibit A hereto, and may have such letters, numbers or other 
marks of identification or designation and such legends, summaries or 

1 of 19


<PAGE>

endorsements printed, lithographed or engraved thereon as the Company may 
deem appropriate and as are not inconsistent with the provisions of this 
Agreement, or as may be required to comply with any law, or with any rule or 
regulation made pursuant thereto, or with any rule or regulation of any stock 
exchange on which the Common Stock or the Warrants may be listed or any 
automated quotation system, or to conform to usage.  Each Warrant Certificate 
shall entitle the registered holder thereof, subject to the provisions of 
this Agreement and of the Warrant Certificate, to purchase, on or before the 
close of business on __________, 2002 (the "Expiration Date"), one fully paid 
and non-assessable share of Common Stock for each Warrant evidenced by such 
Warrant Certificate, subject to adjustments as provided in Section 6 hereof, 
for $__________ (the "Exercise Price").  Each Warrant Certificate issued as a 
part of a Unit offered to the public as described in the recitals, above, 
shall be dated __________, 1997; each other Warrant Certificate shall be 
dated the date on which the Warrant Agent receives valid issuance 
instructions from the Company or a transferring holder of a Warrant 
Certificate or, if such instructions specify another date, such other date.

             For purposes of this Agreement, the term "close of business" on 
any given date shall mean 5:00 p.m., Pacific Time, on such date; provided, 
however, that if such date is not a business day, it shall mean 5:00 p.m., 
Pacific Time, on the next succeeding business day.  For purposes of this 
Agreement, the term "business day" shall mean any day other than a Saturday, 
Sunday, or a day on which banking institutions in New York are authorized or 
obligated by law to be closed.

             Each Warrant Certificate shall be executed on behalf of the 
Company by the Chairman of the Board or its President or a Vice President, 
either manually or by facsimile signature printed thereon, and have affixed 
thereto the Company's seal or a facsimile thereof which shall be attested by 
the Secretary or an Assistant Secretary of the Company, either manually or by 
facsimile signature.  Each Warrant Certificate shall be manually 
countersigned by the Warrant Agent and shall not be valid for any purpose 
unless so countersigned. In case any officer of the Company who shall have 
signed any Warrant Certificate shall cease to be such officer of the Company 
before countersignature by the Warrant Agent and issue and delivery thereof 
by the Company, such Warrant Certificate, nevertheless, may be countersigned 
by the Warrant Agent, issued and delivered with the same force and effect as 
though the person who signed such Warrant Certificate had not ceased to be 
such officer of the Company.


Section 3.   SUBSEQUENT ISSUE OF WARRANT CERTIFICATES

             Subsequent to their original issuance, no Warrant Certificates 
shall be reissued except (i) Warrant Certificates issued upon transfer 
thereof in accordance with Section 4 hereof, (ii) Warrant Certificates issued 
upon any combination, split-up or exchange of Warrant Certificates pursuant 
to Section 4 hereof, (iii) Warrant Certificates issued in replacement of 
mutilated, destroyed, lost or stolen Warrant Certificates pursuant to Section 
5 hereof, (iv) Warrant Certificates issued upon the partial exercise of 
Warrant Certificates pursuant to Section 7 hereof, and (v) Warrant 
Certificates issued to reflect any adjustment or change in the Exercise Price 
or the number or kind of shares purchasable thereunder pursuant to Section 22 
hereof.  The Warrant Agent is hereby irrevocably authorized to countersign 
and deliver, in 

2 of 19


<PAGE>

accordance with the provisions of said Sections 4, 5, 7 and 22, the new 
Warrant Certificates required for purposes thereof, and the Company, whenever 
required by the Warrant Agent, will supply the Warrant Agent with Warrant 
Certificates duly executed on behalf of the Company for such purposes.


Section 4.   TRANSFERS AND EXCHANGES OF WARRANT CERTIFICATES

             The Warrant Agent will keep or cause to be kept books for 
registration of ownership and transfer of the Warrant Certificates issued 
hereunder.  Such registers shall show the names and addresses of the 
respective holders of the Warrant Certificates and the number of Warrants 
evidenced by each such Warrant Certificate.

             The Warrant Agent shall, from time to time, register the transfer 
of any outstanding Warrants upon the books to be maintained by the Warrant 
Agent for that purpose, upon surrender of the Warrant Certificate evidencing 
such Warrants, with the Form of Assignment duly filled in and executed with 
such signature guaranteed by a banking institution or NASD member and such 
supporting documentation as the Warrant Agent or the Company may reasonably 
require, to the Warrant Agent at its stock transfer office in 
_________________________ at any time on or before the Expiration Date, and 
upon payment to the Warrant Agent for the account of the Company of an amount 
equal to any applicable transfer tax. Payment of the amount of such tax may 
be made in cash, or by certified or official bank check, payable in lawful 
money of the United States of America to the order of the Company.

             Upon receipt of a Warrant Certificate, with the Form of Assignment
duly filled in and executed, accompanied by payment of an amount equal to any 
applicable transfer tax, the Warrant Agent shall promptly cancel the 
surrendered Warrant Certificate and countersign and deliver to the transferee 
a new Warrant Certificate for the number of full Warrants transferred to such 
transferee; PROVIDED, HOWEVER, that in case the registered holder of any 
Warrant Certificate shall elect to transfer fewer than all of the Warrants 
evidenced by such Warrant Certificate, the Warrant Agent in addition shall 
promptly countersign and deliver to such registered holder a new Warrant 
Certificate or Certificates for the number of full Warrants not so 
transferred.

             Any Warrant Certificate or Certificates may be exchanged at the 
option of the holder thereof for another Warrant Certificate or Certificates 
of different denominations, of like tenor and representing in the aggregate 
the same number of Warrants, upon surrender of such Warrant Certificate or 
Certificates, with the Form of Assignment duly filled in and executed, to the 
Warrant Agent, at any time or from time to time after the close of business 
on the date hereof and prior to the close of business on the Expiration Date. 
 The Warrant Agent shall promptly cancel the surrendered Warrant Certificate 
and deliver the new Warrant Certificate pursuant to the provisions of this 
Section.

3 of 19


<PAGE>

Section 5.   MUTILATED, DESTROYED, LOST OR STOLEN WARRANT CERTIFICATES

             Upon receipt by the Company and the Warrant Agent of evidence
reasonably satisfactory to them of the loss, theft, destruction or mutilation 
of any Warrant Certificate, and in the case of loss, theft or destruction, of 
indemnity or security reasonably satisfactory to them, and reimbursement to 
them of all reasonable expenses incidental thereto, and, in the case of 
mutilation, upon surrender and cancellation of the Warrant Certificate, the 
Warrant Agent shall countersign and deliver a new Warrant Certificate of like 
tenor for the same number of Warrants.


Section 6.   ADJUSTMENTS OF NUMBER AND KIND OF SHARES PURCHASABLE AND EXERCISE
             PRICE

             The number and kind of securities or other property purchasable 
upon exercise of a Warrant shall be subject to adjustment from time to time 
upon the occurrence, after the date hereof, of any of the following events:

    A.   In case the Company shall (1) pay a dividend in, or make a
distribution of, shares of capital stock on its outstanding Common Stock, (2) 
subdivide its outstanding shares of Common Stock into a greater number of 
such shares or (3) combine its outstanding shares of Common Stock into a 
smaller number of such shares, the total number of shares of Common Stock 
purchasable upon the exercise of each Warrant outstanding immediately prior 
thereto shall be adjusted so that the holder of any Warrant Certificate 
thereafter surrendered for exercise shall be entitled to receive at the same 
aggregate Exercise Price the number of shares of capital stock (of one or 
more classes) which such holder would have owned or have been entitled to 
receive immediately following the happening of any of the events described 
above had such Warrant been exercised in full immediately prior to the record 
date with respect to such event.  Any adjustment made pursuant to this 
Subsection shall, in the case of a stock dividend or distribution, become 
effective as of the record date therefor and, in the case of a subdivision or 
combination, be made as of the effective date thereof.  If, as a result of an 
adjustment made pursuant to this Subsection, the holder of any Warrant 
Certificate thereafter surrendered for exercise shall become entitled to 
receive shares of two or more classes of capital stock of the Company, the 
Board of Directors of the Company (whose determination shall be conclusive 
and shall be evidenced by a Board resolution filed with the Warrant Agent) 
shall determine the allocation of the adjusted Exercise Price between or 
among shares of such classes of capital stock.

    B.   In the event of a capital reorganization or a reclassification of the
Common Stock (except as provided in Subsection A. above or Subsection E. 
below), any Warrantholder, upon exercise of Warrants, shall be entitled to 
receive, in substitution for the Common Stock to which he would have become 
entitled upon exercise immediately prior to such reorganization or 
reclassification, the shares (of any class or classes) or other securities or 
property of the Company (or cash) that he would have been entitled to receive 
at the same aggregate Exercise Price upon such reorganization or 
reclassification if such Warrants had been exercised immediately prior to the 
record date with respect to such event; and in any such case, appropriate 
provision (as determined by the Board of Directors of the Company, whose 
determination shall be conclusive and shall be evidenced by a certified Board 
resolution filed 

4 of 19


<PAGE>

with the Warrant Agent) shall be made for the application of this Section 6 
with respect to the rights and interests thereafter of the Warrantholders 
(including but not limited to the allocation of the Exercise Price between or 
among shares of classes of capital stock), to the end that this Section 6 
(including the adjustments of the number of shares of Common Stock or other 
securities purchasable and the Exercise Price thereof) shall thereafter be 
reflected, as nearly as reasonably practicable, in all subsequent exercises 
of the Warrants for any shares or securities or other property (or cash) 
thereafter deliverable upon the exercise of the Warrants.

    C.   Whenever the number of shares of Common Stock or other securities
purchasable upon exercise of a Warrant is adjusted as provided in this 
Section 6, the Company will promptly file with the Warrant Agent a 
certificate signed by a Chairman or co-Chairman of the Board or the President 
or a Vice President of the Company and by the Treasurer or an Assistant 
Treasurer or the Secretary or an Assistant Secretary of the Company setting 
forth the number and kind of securities or other property purchasable upon 
exercise of a Warrant, as so adjusted, stating that such adjustments in the 
number or kind of shares or other securities or property conform to the 
requirements of this Section 6, and setting forth a brief statement of the 
facts accounting for such adjustments. Promptly after receipt of such 
certificate, the Company, or the Warrant Agent at the Company's request, will 
deliver, by first-class, postage prepaid mail, a brief summary thereof (to be 
supplied by the Company) to the registered holders of the outstanding Warrant 
Certificates; PROVIDED, HOWEVER, that failure to file or to give any notice 
required under this Subsection, or any defect therein, shall not affect the 
legality or validity of any such adjustments under this Section 6; and 
PROVIDED, FURTHER, that, where appropriate, such notice may be given in 
advance and included as part of the notice required to be given pursuant to 
Section 12 hereof.

    D.   In case of any consolidation of the Company with, or merger of the
Company into, another corporation (other than a consolidation or merger which 
does not result in any reclassification or change of the outstanding Common 
Stock), or in case of any sale or conveyance to another corporation of the 
property of the Company as an entirety or substantially as an entirety, the 
corporation formed by such consolidation or merger or the corporation which 
shall have acquired such assets, as the case may be, shall execute and 
deliver to the Warrant Agent a supplemental warrant agreement providing that 
the holder of each Warrant then outstanding shall have the right thereafter 
(until the expiration of such Warrant) to receive, upon exercise of such 
Warrant, solely the kind and amount of shares of stock and other securities 
and property (or cash) receivable upon such consolidation, merger, sale or 
transfer by a holder of the number of shares of Common Stock of the Company 
for which such Warrant might have been exercised immediately prior to such 
consolidation, merger, sale or transfer.  Such supplemental warrant agreement 
shall provide for adjustments which shall be as nearly equivalent as may be 
practicable to the adjustments provided in this Section.  The above provision 
of this Subsection shall similarly apply to successive consolidations, 
mergers, sales or transfers.

         The Warrant Agent shall not be under any responsibility to determine
the correctness of any provision contained in any such supplemental warrant 
agreement relating to either the kind or amount of shares of stock or 
securities or property (or cash) purchasable by holders of Warrant 
Certificates upon the exercise of their Warrants after any such 
consolidation, merger, sale or transfer or of any adjustment to be made with 
respect thereto, but subject to the 

5 of 19


<PAGE>

provisions of Section 20 hereof, may accept as conclusive evidence of the 
correctness of any such provisions, and shall be protected in relying upon, a 
certificate of a firm of independent certified public accountants (who may be 
the accountants regularly employed by the Company) with respect thereto.

    E.   Irrespective of any adjustments in the number or kind of shares
issuable upon exercise of Warrants, Warrant Certificates theretofore or 
thereafter issued may continue to express the same price and number and kind 
of shares as are stated in the similar Warrant Certificates initially 
issuable pursuant to this Warrant Agreement.

    F.   The Company may retain a firm of independent public accountants of
recognized standing, which may be the firm regularly retained by the Company, 
selected by the Board of Directors of the Company or the Executive Committee 
of said Board, and not disapproved by the Warrant Agent, to make any 
computation required under this Section, and a certificate signed by such 
firm shall, in the absence of fraud or gross negligence, be conclusive 
evidence of the correctness of any computation made under this Section.

    G.   For the purpose of this Section, the term "Common Stock" shall mean
(i) the class of stock designated as Common Stock in the Articles of 
Incorporation of the Company, as amended, at the date of this Agreement, or 
(ii) any other class of stock resulting from successive changes or 
reclassification of such Common Stock consisting solely of changes in par 
value, or from par value to no par value, or from no par value to par value.  
In the event that at any time as a result of an adjustment made pursuant to 
this Section, the holder of any Warrant thereafter surrendered for exercise 
shall become entitled to receive any shares of capital stock of the Company 
other than shares of Common Stock, thereafter the number of such other shares 
so receivable upon exercise of any Warrant shall be subject to adjustment 
from time to time in a manner and on terms as nearly equivalent as 
practicable to the provisions with respect to the Common Stock contained in 
this Section, and all other provisions of this Agreement, with respect to the 
Common Stock, shall apply on like terms to any such other shares.

    H.   The Company may, from time to time and to the extent permitted by law,
reduce the exercise price of the Warrants by any amount for a period of not 
less than 20 days.  If the Company so reduces the exercise price of the 
Warrants, it will give not less than 15 days' notice of such decrease, which 
notice may be in the form of a press release, and shall take such other steps 
as may be required under applicable law in connection with any offers or 
sales of securities at the reduced price.


Section 7.   EXERCISE AND REDEMPTION OF WARRANTS

             Unless the Warrants have been redeemed as provided in this 
Section 7, the registered holder of any Warrant Certificate may exercise the 
Warrants evidenced thereby, in whole at any time or in part from time to time 
at or prior to the close of business, on the Expiration Date, subject to the 
provisions of Section 9, at which time the Warrant Certificates shall be and 
become wholly void and of no value.  Warrants may be exercised by their 
holders or redeemed by the Company as follows: 

6 of 19


<PAGE>

    A.   Exercise of Warrants shall be accomplished upon surrender of the
Warrant Certificate evidencing such Warrants, with the Form of Election to 
Purchase on the reverse side thereof duly filled in and executed, to the 
Warrant Agent at its stock transfer office in _________________________, 
together with payment to the Company of the Exercise Price (as of the date of 
such surrender) of the Warrants then being exercised and an amount equal to 
any applicable transfer tax and, if requested by the Company, any other taxes 
or governmental charges which the Company may be required by law to collect 
in respect of such exercise.  Payment of the Exercise Price and other amounts 
may be made by wire transfer of good funds, or by certified or bank cashier's 
check, payable in lawful money of the United States of America to the order 
of the Company.  No adjustment shall be made for any cash dividends, whether 
paid or declared, on any securities issuable upon exercise of a Warrant.

    B.   Upon receipt of a Warrant Certificate, with the Form of Election to
Purchase duly filled in and executed, accompanied by payment of the Exercise 
Price of the Warrants being exercised (and of an amount equal to any 
applicable taxes or government charges as aforesaid), the Warrant Agent shall 
promptly request from the Transfer Agent with respect to the securities to be 
issued and deliver to or upon the order of the registered holder of such 
Warrant Certificate, in such name or names as such registered holder may 
designate, a certificate or certificates for the number of full shares of the 
securities to be purchased, together with cash made available by the Company 
pursuant to Section 8 hereof in respect of any fraction of a share of such 
securities otherwise issuable upon such exercise.  If the Warrant is then 
exercisable to purchase property other than securities, the Warrant Agent 
shall take appropriate steps to cause such property to be delivered to or 
upon the order of the registered holder of such Warrant Certificate.  In 
addition, if it is required by law and upon instruction by the Company, the 
Warrant Agent will deliver to each Warrantholder a prospectus which complies 
with the provisions of Section 9 of the Securities Act of 1933, as amended, 
and the Company agrees to supply Warrant Agent with sufficient number of 
prospectuses to effectuate that purpose.

    C.   In case the registered holder of any Warrant Certificate shall
exercise fewer than all of the Warrants evidenced by such Warrant 
Certificate, the Warrant Agent shall promptly countersign and deliver to the 
registered holder of such Warrant Certificate, or to his duly authorized 
assigns, a new Warrant Certificate or Certificates evidencing the number of 
Warrants that were not so exercised.

    D.   Each person in whose name any certificate for securities is issued
upon the exercise of Warrants shall for all purposes be deemed to have become 
the holder of record of the securities represented thereby as of, and such 
certificate shall be dated, the date upon which the Warrant Certificate was 
duly surrendered in proper form and payment of the Exercise Price (and of any 
applicable taxes or other governmental charges) was made; PROVIDED, HOWEVER, 
that if the date of such surrender and payment is a date on which the stock 
transfer books of the Company are closed, such person shall be deemed to have 
become the record holder of such shares as of, and the certificate for such 
shares shall be dated, the next succeeding business day on which the stock 
transfer books of the Company are open (whether before, on or after the 
Expiration Date) and the Warrant Agent shall be under no duty to deliver the 
certificate for such shares until such date.  The Company covenants and 
agrees that it shall not cause its stock 

7 of 19


<PAGE>

transfer books to be closed for a period of more than 20 consecutive business 
days except upon consolidation, merger, sale of all or substantially all of 
its assets, dissolution or liquidation or as otherwise provided by law.

    E.   The Warrants outstanding at the time of a redemption may be redeemed
at the option of the Company, in whole or in part on a pro rata basis, at any 
time if, at the time notice of such redemption is given by the Company as 
provided in Paragraph F, below, the Daily Price has exceeded $__________ for 
the 20 consecutive trading days immediately preceding the date of such 
notice, at a price equal to $0.25 per Warrant (the "Redemption Price").  For 
the purpose of the foregoing sentence, the term "Daily Price" shall mean, for 
any relevant day, the closing bid price on that day as reported by the 
principal exchange or quotation system on which prices for the Common Stock 
are reported.  On the redemption date the holders of record of redeemed 
Warrants shall be entitled to payment of the Redemption Price upon surrender 
of such redeemed Warrants to the Company at the principal office of the 
Warrant Agent in _________________________.

    F.   Notice of redemption of Warrants shall be given at least 30 days prior
to the redemption date by mailing, by registered or certified mail, return 
receipt requested, a copy of such notice to the Warrant Agent and to all of 
the holders of record of Warrants at their respective addresses appearing on 
the books or transfer records of the Company or such other address designated 
in writing by the holder of record to the Warrant Agent not less than 40 days 
prior to the redemption date.

    G.   From and after the redemption date, all rights of the Warrantholders
(except the right to receive the Redemption Price) shall terminate, but only 
if (a) no later than one day prior to the redemption date the Company shall 
have irrevocably deposited with the Warrant Agent as paying agent a 
sufficient amount to pay on the redemption date the Redemption Price for all 
Warrants called for redemption and (b) the notice of redemption shall have 
stated the name and address of the Warrant Agent and the intention of the 
Company to deposit such amount with the Warrant Agent no later than one day 
prior to the redemption date.

    H.   The Warrant Agent shall pay to the holders of record of redeemed
Warrants all monies received by the Warrant Agent for the redemption of 
Warrants to which the holders of record of such redeemed Warrants who shall 
have surrendered their Warrants are entitled.

    I.   Any amounts deposited with the Warrant Agent that are not required for
redemption of Warrants may be withdrawn by the Company.  Any amounts 
deposited with the Warrant Agent that shall be unclaimed after six months 
after the redemption date may be withdrawn by the Company, and thereafter the 
holders of the Warrants called for redemption for which such funds were 
deposited shall look solely to the Company for payment.  The Company shall be 
entitled to the interest, if any, on funds deposited with the Warrant Agent 
and the holders of redeemed Warrants shall have no right to any such interest.

    J.   If the Company fails to make a sufficient deposit with the Warrant
Agent as provided above, the holder of any Warrants called for redemption may 
at the option of the holder (a) by notice to the Company declare the notice 
of redemption a nullity as to such holder, 

8 of 19


<PAGE>

or (b) maintain an action against the Company for the Redemption Price.  If 
the holder brings such an action, the Company will pay reasonable attorneys' 
fees of the holder.  If the holder fails to bring an action against the 
Company for the Redemption Price within 60 days after the redemption date, 
the holder shall be deemed to have elected to declare the notice of 
redemption to be a nullity as to such holder and such notice shall be without 
any force or effect as to such holder.  Except as otherwise specifically 
provided in this Paragraph J, a notice of redemption, once mailed by the 
Company as provided in Paragraph F shall be irrevocable.


Section 8.   FRACTIONAL INTERESTS

             The Company shall not be required to issue any Warrant Certificate
evidencing a fraction of a Warrant or to issue fractions of shares of 
securities on the exercise of the Warrants.  If any fraction (calculated to 
the nearest one-hundredth) of a Warrant or a share of securities would, 
except for the provisions of this Section, be issuable on the exercise of any 
Warrant, the Company shall, at its option, either purchase such fraction for 
an amount in cash equal to the current value of such fraction computed on the 
basis of the closing market price (as quoted on NASDAQ) on the trading day 
immediately preceding the day upon which such Warrant Certificate was 
surrendered for exercise in accordance with Section 7 hereof or issue the 
required fractional Warrant or share.  By accepting a Warrant Certificate, 
the holder thereof expressly waives any right to receive a Warrant 
Certificate evidencing any fraction of a Warrant or to receive any fractional 
share of securities upon exercise of a Warrant, except as expressly provided 
in this Section 8.


Section 9.   RESERVATION OF EQUITY SECURITIES

             The Company covenants that it will at all times reserve and keep
available, free from any pre-emptive rights, out of its authorized and 
unissued equity securities, solely for the purpose of issue upon exercise of 
the Warrants, such number of shares of equity securities of the Company as 
shall then be issuable upon the exercise of all outstanding Warrants ("Equity 
Securities").  The Company covenants that all Equity Securities which shall 
be so issuable shall, upon such issue, be duly authorized, validly issued, 
fully paid and non-assessable.

             The Company covenants that if any equity securities, required to 
be reserved for the purpose of issue upon exercise of the Warrants hereunder, 
require registration with or approval of any governmental authority under any 
federal or state law before such shares may be issued upon exercise of 
Warrants, the Company will use all commercially reasonable efforts to cause 
such securities to be duly registered, or approved, as the case may be, and, 
to the extent practicable, take all such action in anticipation of and prior 
to the exercise of the Warrants, including, without limitation, filing any 
and all post-effective amendments to the Company's Registration Statement on 
Form SB-2 (Registration No. __________) necessary to permit a public offering 
of the securities underlying the Warrants at any and all times during the 
term of this Agreement, PROVIDED, HOWEVER, that in no event shall such 
securities be issued, and the Company is authorized to refuse to honor the 
exercise of any Warrant, if such exercise would result in the opinion of the 
Company's Board of Directors, upon advice of counsel, in the 

9 of 19


<PAGE>

violation of any law; and PROVIDED FURTHER that, in the case of a Warrant 
exercisable solely for securities listed on a securities exchange or for 
which there are at least two independent market makers, in lieu of obtaining 
such registration or approval, the Company may elect to redeem Warrants 
submitted to the Warrant Agent for exercise for a price equal to the 
difference between the aggregate low asked price, or closing price, as the 
case may be, of the securities for which such Warrant is exercisable on the 
date of such submission and the Exercise Price of such Warrants; in the event 
of such redemption, the Company will pay to the holder of such Warrants the 
above-described redemption price in cash within 10 business days after 
receipt of notice from the Warrant Agent that such Warrants have been 
submitted for exercise.


Section 10.  REDUCTION OF CONVERSION PRICE BELOW PAR VALUE

             Before taking any action that would cause an adjustment pursuant 
to Section 6 hereof reducing the portion of the Exercise Price required to 
purchase one share of capital stock below the then par value (if any) of a 
share of such capital stock, the Company will use its best efforts to take 
any corporate action which, in the opinion of its counsel, may be necessary 
in order that the Company may validly and legally issue fully paid and 
non-assessable shares of such capital stock.


Section 11.  PAYMENT OF TAXES

             The Company covenants and agrees that it will pay when due and 
payable any and all federal and state documentary stamp and other original 
issue taxes which may be payable in respect of the original issuance of the 
Warrant Certificates, or any shares of Common Stock or other securities upon 
the exercise of Warrants.  The Company shall not, however, be required (i) to 
pay any tax which may be payable in respect of any transfer involved in the 
transfer and delivery of Warrant Certificates or the issuance or delivery of 
certificates for Common Stock or other securities in a name other than that 
of the registered holder of the Warrant Certificate surrendered for purchase 
or (ii) to issue or deliver any certificate for shares of Common Stock or 
other securities upon the exercise of any Warrant Certificate until any such 
tax shall have been paid, all such tax being payable by the holder of such 
Warrant Certificate at the time of surrender.


Section 12.  NOTICE OF CERTAIN CORPORATE ACTION

             In case the Company after the date hereof shall propose (i) to 
offer to the holders of Common Stock, generally, rights to subscribe to or 
purchase any additional shares of any class of its capital stock, any 
evidences of its indebtedness or assets, or any other rights or options or 
(ii) to effect any reclassification of Common Stock (other than a 
reclassification involving merely the subdivision or combination of 
outstanding shares of Common Stock) or any capital reorganization, or any 
consolidation or merger to which the Company is a party and for which 
approval of any stockholders of the Company is required, or any sale, 
transfer or other disposition of its property and assets substantially as an 
entirety, or the liquidation, voluntary 

10 of 19


<PAGE>

or involuntary dissolution or winding-up of the Company, then, in each such 
case, the Company shall file with the Warrant Agent and the Company, or the 
Warrant Agent on its behalf, shall mail (by first-class, postage prepaid 
mail) to all registered holders of the Warrant Certificates notice of such 
proposed action, which notice shall specify the date on which the books of 
the Company shall close or a record be taken for such offer of rights or 
options, or the date on which such reclassification, reorganization, 
consolidation, merger, sale, transfer, other disposition, liquidation, 
voluntary or involuntary dissolution or winding-up shall take place or 
commence, as the case may be, and which shall also specify any record date 
for determination of holders of Common Stock entitled to vote thereon or 
participate therein and shall set forth such facts with respect thereto as 
shall be reasonably necessary to indicate any adjustments in the Exercise 
Price and the number or kind of shares or other securities purchasable upon 
exercise of Warrants which will be required as a result of such action.  Such 
notice shall be filed and mailed in the case of any action covered by clause 
(i) above, at least 10 days prior to the record date for determining holders 
of the Common Stock for purposes of such action or, if a record is not to be 
taken, the date as of which the holders of shares of Common Stock of record 
are to be entitled to such offering; and, in the case of any action covered 
by clause (ii) above, at least 20 days prior to the earlier of the date on 
which such reclassification, reorganization, consolidation, merger, sale, 
transfer, other disposition, liquidation, voluntary or involuntary 
dissolution or winding-up is expected to become effective and the date on 
which it is expected that holders of shares of Common Stock of record on such 
date shall be entitled to exchange their shares for securities or other 
property deliverable upon such reclassification, reorganization, 
consolidation, merger, sale, transfer, other disposition, liquidation, 
voluntary or involuntary dissolution or winding-up.

             Failure to give any such notice or any defect therein shall not 
affect the legality or validity of any transaction listed in this Section 12.


Section 13.  DISPOSITION OF PROCEEDS ON EXERCISE OF WARRANT CERTIFICATES, ETC.

             The Warrant Agent shall account promptly to the Company with 
respect to Warrants exercised and concurrently pay to the Company all moneys 
received by the Warrant Agent for the purchase of securities or other 
property through the exercise of such Warrants.

             The Warrant Agent shall keep copies of this Agreement available 
for inspection by Warrantholders during normal business hours at its stock 
transfer office.  Copies of this Agreement may be obtained upon written 
request addressed to the Warrant Agent at its stock transfer office in 
_________________________.


Section 14.  WARRANTHOLDER NOT DEEMED A STOCKHOLDER

             No Warrantholder, as such, shall be entitled to vote, receive
dividends or be deemed the holder of Common Stock or any other securities of 
the Company which may at any time be issuable on the exercise of the Warrants 
represented thereby for any purpose whatever, nor shall anything contained 
herein or in any Warrant Certificate be construed to confer upon 

Page 11 of 19


<PAGE>

any Warrantholder, as such, any of the rights of a stockholder of the Company 
or any right to vote for the election of directors or upon any matter 
submitted to stockholders at any meeting thereof, or to give or withhold 
consent to any corporate action (whether upon any recapitalization, issuance 
of stock, reclassification of stock, change of par value or change of stock 
to no par value, consolidation, merger, conveyance or otherwise), or to 
receive notice of meetings or other actions affecting stockholders (except as 
provided in Section 12 hereof), or to receive dividend or subscription 
rights, or otherwise, until such Warrant Certificate shall have been 
exercised in accordance with the provisions hereof and the receipt of the 
Exercise Price and any other amounts payable upon such exercise by the 
Warrant Agent.


Section 15.  RIGHT OF ACTION

             All rights of action in respect to this Agreement are vested in 
the respective registered holders of the Warrant Certificates; and any 
registered holder of any Warrant Certificate, without the consent of the 
Warrant Agent or of any other holder of a Warrant Certificate, may, in his 
own behalf for his own benefit, enforce, and may institute and maintain any 
suit, action or proceeding against the Company suitable to enforce, or 
otherwise in respect of, his right to exercise the Warrants evidenced by such 
Warrant Certificate, for the purchase of shares of the Common Stock in the 
manner provided in the Warrant Certificate and in this Agreement.


Section 16.  AGREEMENT OF HOLDERS OF WARRANT CERTIFICATES

             Every holder of a Warrant Certificate by accepting the same 
consents and agrees with the Company, the Warrant Agent and with every other 
holder of a Warrant Certificate that:

    A.   The Warrant Certificates are transferable on the registry books of the
Warrant Agent only upon the terms and conditions set forth in this Agreement;
and

    B.   The Company and the Warrant Agent may deem and treat the person in
whose name the Warrant Certificate is registered as the absolute owner of the 
Warrant (notwithstanding any notation of ownership or other writing thereon 
made by anyone other than the Company or the Warrant Agent) for all purposes 
whatever and neither the Company nor the Warrant Agent shall be affected by 
any notice to the contrary.


Section 17.  CANCELLATION OF WARRANT CERTIFICATES

             In the event that the Company shall purchase or otherwise acquire 
any Warrant Certificate or Certificates after the issuance thereof, such 
Warrant Certificate or Certificates shall thereupon be delivered to the 
Warrant Agent and be canceled by it and retired.  The Warrant Agent shall 
also cancel any Warrant Certificate delivered to it for exercise, in whole or 
in part, or delivered to it for transfer, split-up, combination or exchange.  
Warrant Certificates so 

Page 12 of 19


<PAGE>

canceled shall be delivered by the Warrant Agent to the Company from time to 
time, or disposed of in accordance with the instructions of the Company.


Section 18.  CONCERNING THE WARRANT AGENT

             The Company agrees to pay to the Warrant Agent from time to time, 
on demand of the Warrant Agent, reasonable compensation for all services 
rendered by it hereunder and also its reasonable expenses, including counsel 
fees, and other disbursements incurred in the administration and execution of 
this Agreement and the exercise and performance of its duties hereunder.  The 
Company also agrees to indemnify the Warrant Agent for, and to hold it 
harmless against, any loss, liability or expense, incurred without gross 
negligence, bad faith or willful misconduct on the part of the Warrant Agent, 
arising out of or in connection with the acceptance and administration of 
this Agreement.


Section 19.  MERGER OR CONSOLIDATION OR CHANGE OF NAME OF WARRANT AGENT

             Any corporation into which the Warrant Agent may be merged or with
which it may be consolidated, or any corporation resulting from any merger or 
consolidation to which the Warrant Agent shall be a party, or any corporation 
succeeding to the corporate trust business of the Warrant Agent, shall be the 
successor to the Warrant Agent hereunder without the execution or filing of 
any paper or any further act on the part of any of the parties hereto, 
provided that such corporation would be eligible for appointment as a 
successor warrant agent under the provisions of Section 21 hereof.  In case 
at the time such successor to the Warrant Agent shall succeed to the agency 
created by this Agreement, any of the Warrant Certificates shall have been 
countersigned but not delivered, any such successor to the Warrant Agent may 
adopt the countersignature of the original Warrant Agent and deliver such 
Warrant Certificates so countersigned; and in case at that time any of the 
Warrant Certificates shall not have been countersigned, any successor to the 
Warrant Agent may countersign such Warrant Certificates either in the name of 
the predecessor Warrant Agent or in the name of the successor Warrant Agent; 
and in all such cases such Warrant Certificates shall have the full force 
provided in the Warrant Certificates and in this Agreement.

             In case at any time the name of the Warrant Agent shall be changed 
and at such time any of the Warrant Certificates shall have been 
countersigned but not delivered, the Warrant Agent may adopt the 
countersignature under its prior name and deliver Warrant Certificates so 
countersigned; and in case at that time any of the Warrant Certificates shall 
not have been countersigned, the Warrant Agent may countersign such Warrant 
Certificates either in its prior name or in its changed name; and in all such 
cases such Warrant Certificates shall have the full force provided in the 
Warrant Certificates and in this Agreement.

Page 13 of 19


<PAGE>

Section 20.  DUTIES OF WARRANT AGENT

             The Warrant Agent undertakes the duties and obligations imposed by
this Agreement upon the following terms and conditions, by all of which the 
Company and the holders of Warrant Certificates, by their acceptance thereof, 
shall be bound:

    A.   The Warrant Agent may consult with counsel satisfactory to it (who may
be counsel for the Company or the Warrant Agent's in-house counsel), and the 
opinion of such counsel shall be full and complete authorization and 
protection to the Warrant Agent as to any action taken, suffered or omitted 
by it in good faith and in accordance with such opinion; PROVIDED, HOWEVER, 
that the Warrant Agent shall have exercised reasonable care in the selection 
of such counsel. Fees and expenses of such counsel, to the extent reasonable, 
shall be paid by the Company.

    B.   Whenever in the performance of its duties under this Agreement, the
Warrant Agent shall deem it necessary or desirable that any fact or matter be 
proved or established by the Company prior to taking or suffering any action 
hereunder, such fact or matter (unless other evidence in respect thereof be 
herein specifically prescribed) may be deemed to be conclusively proved and 
established by a certificate signed by a Chairman or co-Chairman of the Board 
or the President or a Vice President or the Secretary of the Company and 
delivered to the Warrant Agent; and such certificate shall be full 
authorization to the Warrant Agent for any action taken or suffered in good 
faith by it under the provisions of this Agreement in reliance upon such 
certificate.

    C.   The Warrant Agent shall be liable hereunder only for its own gross
negligence, bad faith or willful misconduct.

    D.   The Warrant Agent shall not be liable for or by reason of any of the
statements of fact or recitals contained in this Agreement or in the Warrant 
Certificates (except its countersignature on the Warrant Certificates and 
such statements or recitals as describe the Warrant Agent or action taken or 
to be taken by it) or be required to verify the same, but all such statements 
and recitals are and shall be deemed to have been made by the Company only.

    E.   The Warrant Agent shall not be under any responsibility in respect of
the validity of this Agreement or the execution and delivery hereof (except 
the due execution hereof by the Warrant Agent) or in respect of the validity 
or execution of any Warrant Certificate (except its countersignature 
thereof); nor shall it be responsible for any breach by the Company of any 
covenant or condition contained in this Agreement or in any Warrant 
Certificate; nor shall it be responsible for the making of any change in the 
number of shares of Common Stock for which a Warrant is exercisable required 
under the provisions of Section 6 or responsible for the manner, method or 
amount of any such change or the ascertaining of the existence of facts that 
would require any such adjustment or change (except with respect to the 
exercise of Warrant Certificates after actual notice of any adjustment of the 
Exercise Price); nor shall it by any act hereunder be deemed to make any 
representation or warranty as to the authorization or reservation of any 
shares of Common Stock to be issued pursuant to this Agreement or any 

Page 14 of 19


<PAGE>

Warrant Certificate or as to whether any shares of Common Stock will, when 
issued, be validly issued, fully paid and non-assessable.

    F.   The Warrant Agent shall be under no obligation to institute any
action, suit or legal proceeding or take any other action likely to involve 
expense unless the Company or one or more registered holders of Warrant 
Certificates shall furnish the Warrant Agent with reasonable security and 
indemnity for any costs and expenses which may be incurred.  All rights of 
action under this Agreement or under any of the Warrants may be enforced by 
the Warrant Agent without the possession of any of the Warrants or the 
production thereof at any trial or other proceeding relative thereto, and any 
such action, suit or proceeding instituted by the Warrant Agent shall be 
brought in its name as Warrant Agent, and any recovery of judgment shall be 
for the ratable benefit of the registered holders of the Warrant 
Certificates, as their respective rights or interests may appear.

    G.   The Warrant Agent and any stockholder, director, officer or employee
of the Warrant Agent may buy, sell or deal in any of the Warrants or other 
securities of the Company or become pecuniarily interested in any transaction 
in which the Company may be interested, or contract with or lend money to or 
otherwise act as fully and freely as though it were not Warrant Agent under 
this Agreement.  Nothing herein shall preclude the Warrant Agent from acting 
in any other capacity for the Company or for any other legal entity.

    H.   The Warrant Agent is hereby authorized and directed to accept
instructions with respect to the performance of its duties hereunder from a 
Chairman or co-Chairman of the Board or President or a Vice President or the 
Secretary or the Controller of the Company, and to apply to such officers for 
advice or instructions in connection with the Warrant Agent's duties, and it 
shall not be liable for any action taken or suffered or omitted by it in good 
faith in accordance with instructions of any such officer.

    I.   The Warrant Agent will not be responsible for any failure of the
Company to comply with any of the covenants contained in this Agreement or in 
the Warrant Certificates to be complied with by the Company.

    J.   The Warrant Agent may execute and exercise any of the rights or powers
hereby vested in it or perform any duty hereunder either itself or by or 
through its attorneys, agents or employees and the Warrant Agent shall not be 
answerable or accountable for any act, default, neglect or misconduct of any 
such attorneys, agents or employees or for any loss to the Company resulting 
from such neglect or misconduct; PROVIDED, HOWEVER, that reasonable care 
shall have been exercised in the selection and continued employment of such 
attorneys, agents and employees.

    K.   The Warrant Agent will not incur any liability or responsibility to
the Company or to any holder of any Warrant Certificate for any action taken, 
or any failure to take action, in reliance on any notice, resolution, waiver, 
consent, order, certificate, or other paper, document or instrument 
reasonably believed by the Warrant Agent to be genuine and to have been 
signed, sent or presented by the proper party or parties.

Page 15 of 19


<PAGE>

    L.   The Warrant Agent will act hereunder solely as agent of the Company in
a ministerial capacity, and its duties will be determined solely by the 
provisions hereof.  The Warrant Agent will not be liable for anything which 
it may do or refrain from doing in connection with this Agreement except for 
its own negligence, bad faith or willful conduct.


Section 21.  CHANGE OF WARRANT AGENT

             The Warrant Agent may resign and be discharged from its duties 
under this Agreement upon 30 days' prior notice in writing mailed, by 
registered or certified mail, to the Company.  The Company may remove the 
Warrant Agent or any successor warrant agent upon 30 days' prior notice in 
writing, mailed to the Warrant Agent or successor warrant agent, as the case 
may be, by registered or certified mail.  If the Warrant Agent shall resign 
or be removed or shall otherwise become incapable of acting, the Company 
shall appoint a successor to the Warrant Agent and shall, within 15 days 
following such appointment, give notice thereof in writing to each registered 
holder of the Warrant Certificates. If the Company shall fail to make such 
appointment within a period of 15 days after giving notice of such removal or 
after it has been notified in writing of such resignation or incapacity by 
the resigning or incapacitated Warrant Agent, then the Company agrees to 
perform the duties of the Warrant Agent hereunder until a successor Warrant 
Agent is appointed.  After appointment and execution of a copy of this 
Agreement in effect at that time, the successor Warrant Agent shall be vested 
with the same powers, rights, duties and responsibilities as if it had been 
originally named as Warrant Agent without further act or deed; but the former 
Warrant Agent shall deliver and transfer to the successor Warrant Agent, 
within a reasonable time, any property at the time held by it hereunder, and 
execute and deliver any further assurance, conveyance, act or deed necessary 
for the purpose.  Failure to give any notice provided for in this Section, 
however, or any defect therein shall not affect the legality or validity of 
the resignation or removal of the Warrant Agent or the appointment of the 
successor warrant agent, as the case may be.


Section 22.  ISSUANCE OF NEW WARRANT CERTIFICATES

             Notwithstanding any of the provisions of this Agreement or the 
several Warrant Certificates to the contrary, the Company may, at its option, 
issue new Warrant Certificates in such form as may be approved by its Board 
of Directors to reflect any adjustment or change in the Exercise Price or the 
number or kind of shares purchasable under the several Warrant Certificates 
made in accordance with the provisions of this Agreement.


Section 23.  NOTICES

             Notice or demand pursuant to this Agreement to be given or made 
on the Company by the Warrant Agent or by the registered holder of any 
Warrant Certificate shall be sufficiently given or made if sent by 
first-class or registered mail, postage prepaid, addressed (until another 
address is filed in writing by the Company with the Warrant Agent) as 
follows: 

Page 16 of 19


<PAGE>

     AntiVirals Inc.
     One S.W. Columbia, Suite 1105
     Portland, OR  97258

         Subject to the provisions of Section 21, any notice pursuant to this
Agreement to be given or made by the Company or by the holder of any Warrant 
Certificate to or on the Warrant Agent shall be sufficiently given or made if 
sent by first-class or registered mail, postage prepaid, addressed (until 
another address is filed in writing by the Warrant Agent with the Company) as 
follows:

     _____________________________________
     _____________________________________
     _____________________________________
     Attention: Corporate Trust Department

         Any notice or demand authorized to be given or made to the registered
holder of any Warrant Certificate under this Agreement shall be sufficiently 
given or made if sent by first-class or registered mail, postage prepaid, to 
the last address of such holder as it shall appear on the registers 
maintained by the Warrant Agent.


Section 24.  MODIFICATION OF AGREEMENT

             The Warrant Agent may, without the consent or concurrence of the
Warrantholders, by supplemental agreement or otherwise, concur with the 
Company in making any changes or corrections in this Agreement that the 
Warrant Agent shall have been advised by counsel (who may be counsel for the 
Company) are necessary or desirable to cure any ambiguity or to correct any 
defective or inconsistent provision or clerical omission or mistake or 
manifest error herein contained, or to make any other provisions in regard to 
matters or questions arising hereunder and which shall not be inconsistent 
with the provisions of the Warrant Certificates and which shall not adversely 
affect the interests of the Warrantholders.  As of the date hereof, this 
Agreement contains the entire and only agreement, understanding, 
representation, condition, warranty or covenant between the parties hereto 
with respect to the matters herein, supersedes any and all other agreements 
between the parties hereto relating to such matters, and may be modified or 
amended only by a written agreement signed by both parties hereto pursuant to 
the authority granted by the first sentence of this Section.


Section 25.  SUCCESSORS

             All the covenants and provisions of this Agreement by or for the
benefit of the Company or the Warrant Agent shall bind and inure to the 
benefit of their respective successors and assigns hereunder.

Page 17 of 19

<PAGE>

Section 26.  OREGON CONTRACT

             This Agreement and each Warrant Certificate issued hereunder 
shall be deemed to be a contract made under the laws of the state of Oregon 
and for all purposes shall be construed in accordance with the laws of said 
State.


Section 27.  TERMINATION

             This Agreement shall terminate as of the close of business on the
Expiration Date, or such earlier date upon which all Warrants shall have been 
exercised or redeemed, except that the Warrant Agent shall account to the 
Company as to all Warrants outstanding and all cash held by it as of the 
close of business on the Expiration Date.


Section 28.  BENEFITS OF THIS AGREEMENT

             Nothing in this Agreement or in the Warrant Certificates shall be
construed to give to any person or corporation other than the Company, the 
Warrant Agent, and their respective successors and assigns hereunder and the 
registered holders of the Warrant Certificates any legal or equitable right, 
remedy or claim under this Agreement; but this Agreement shall be for the 
sole and exclusive benefit of the Company, the Warrant Agent, their 
respective successors and assigns hereunder and the registered holders of the 
Warrant Certificates.


Section 29.  DESCRIPTIVE HEADINGS

             The descriptive headings of the several sections of this Agreement
are inserted for convenience only and shall not control or affect the meaning 
or construction of any of the provisions hereof.


Page 18 of 19


<PAGE>

Section 30.  COUNTERPARTS

             This Agreement may be executed in any number of counterparts, 
each of which shall be an original, but such counterparts shall together 
constitute one and the same instrument.

             IN WITNESS WHEREOF, the parties hereto have caused this Agreement
to be duly executed, all as of the day and year first above written.


                                             ANTIVIRALS INC.



                                             By: ____________________________
                                             Title:
                                             
                                             ________________________________

                                             
                                             By: ____________________________
                                             Title:
                                             

Page 19 of 19


<PAGE>


                                                                      EXHIBIT A

         VOID AFTER 5:00 P.M. PACIFIC TIME ON ____________________, 2002

                        WARRANTS TO PURCHASE COMMON STOCK


W_____                         _________ Warrants
 
                                 ANTIVIRALS INC.

                                 CUSIP _________


THIS CERTIFIES THAT




or registered assigns, is the registered holder of the number of Warrants 
("Warrants") set forth above.  Each Warrant entitles the holder thereof to 
purchase from AntiVirals, Inc., a corporation incorporated under the laws of 
the State of Oregon ("Company"), subject to the terms and conditions set 
forth hereinafter and in the Warrant Agreement hereinafter more fully 
described (the "Warrant Agreement") referred to, one fully paid and 
non-assessable share of Common Stock, $.0001 par value, of the Company 
("Common Stock") upon presentation and surrender of this Warrant Certificate 
with the instructions for the registration and delivery of Common Stock 
filled in, at any time prior to 5:00 p.m., Pacific Time, on 
______________________________, 2002 or, if such Warrant is redeemed as 
provided in the Warrant Agreement, at any time prior to the effective time of 
such redemption, at the stock transfer office in _________________________, 
of ________________________________, Warrant Agent of the Company ("Warrant 
Agent"), or of its successor warrant agent or, if there be no successor 
warrant agent, at the corporate offices of the Company, and upon payment of 
the Exercise Price (as defined in the Warrant Agreement) and any applicable 
taxes paid either in cash, or by certified or official bank check, payable in 
lawful money of the United States of America to the order of the Company.  
Each Warrant initially entitles the holder to purchase one share of Common 
Stock for $__________.  The number and kind of securities or other property 
for which the Warrants are exercisable are subject to further adjustment in 
certain events, such as mergers, splits, stock dividends, recapitalizations 
and the like, to prevent dilution.  The Company may redeem any or all 
outstanding and unexercised Warrants at any time if the Daily Price has 
exceeded $__________ for 20 consecutive trading days immediately preceding 
the date of notice of such redemption, upon 30 days' notice, at a price equal 
to $0.25 per Warrant.  For the purpose of the foregoing sentence, the term 
"Daily Price" shall mean, for any relevant day, the closing bid price on that 
day as reported by the principal exchange or quotation system on which prices 
for the Common Stock are reported.  All Warrants not theretofore exercised or 
redeemed will expire on ______________________________, 2002.


Page i


<PAGE>

         This Warrant Certificate is subject to all of the terms, provisions
and conditions of the Warrant Agreement, dated as of __________, 1997 
("Warrant Agreement"), between the Company and the Warrant Agent, to all of 
which terms, provisions and conditions the registered holder of this Warrant 
Certificate consents by acceptance hereof.  The Warrant Agreement is 
incorporated herein by reference and made a part hereof and reference is made 
to the Warrant Agreement for a full description of the rights, limitations of 
rights, obligations, duties and immunities of the Warrant Agent, the Company 
and the holders of the Warrant Certificates.  Copies of the Warrant Agreement 
are available for inspection at the stock transfer office of the Warrant 
Agent or may be obtained upon written request addressed to the Company at One 
S.W. Columbia, Suite 1105, Portland, Oregon  97258, Attention: Chief 
Executive Officer.

         The Company shall not be required upon the exercise of the Warrants
evidenced by this Warrant Certificate to issue fractions of Warrants, Common 
Stock or other securities, but shall make adjustment therefor in cash on the 
basis of the current market value of any fractional interest as provided in 
the Warrant Agreement.

         In certain cases, the sale of securities by the Company upon exercise
of Warrants would violate the securities laws of the United States, certain 
states thereof or other jurisdictions.  The Company has agreed to use its 
best efforts to cause a registration statement to continue to be effective 
during the term of the Warrants with respect to such sales under the 
Securities Act of 1933, as amended, and to take such action under the laws of 
various states as may be required to cause the sale of securities upon 
exercise to be lawful. However, the Company will not be required to honor the 
exercise of Warrants if, in the opinion of the Board of Directors, upon 
advice of counsel, the sale of securities upon such exercise would be 
unlawful.  In certain cases, the Company may, but is not required to, 
purchase Warrants submitted for exercise for a cash price equal to the 
difference between the market price of the securities obtainable upon such 
exercise and the exercise price of such Warrants.

         This Warrant Certificate, with or without other Certificates, upon
surrender to the Warrant Agent, any successor warrant agent or, in the 
absence of any successor warrant agent, at the corporate offices of the 
Company, may be exchanged for another Warrant Certificate or Certificates 
evidencing in the aggregate the same number of Warrants as the Warrant 
Certificate or Certificates so surrendered.  If the Warrants evidenced by 
this Warrant Certificate shall be exercised in part, the holder hereof shall 
be entitled to receive upon surrender hereof another Warrant Certificate or 
Certificates evidencing the number of Warrants not so exercised.

          No holder of this Warrant Certificate, as such, shall be entitled to
vote, receive dividends or be deemed the holder of Common Stock or any other
securities of the Company which may at any time be issuable on the exercise
hereof for any purpose whatever, nor shall anything contained in the Warrant
Agreement or herein be construed to confer upon the holder of this Warrant
Certificate, as such, any of the rights of a stockholder of the Company or any
right to vote for the election of directors or upon any matter submitted to
stockholders at any meeting thereof or give or withhold consent to any corporate
action (whether upon any matter submitted to stockholders at any meeting
thereof, or give or withhold consent to any merger, recapitalization, issuance
of stock, reclassification of stock, change of par value or change of 

Page ii


<PAGE>

stock to no par value, consolidation, conveyance or otherwise) or to receive 
notice of meetings or other actions affecting stockholders (except as 
provided in the Warrant Agreement) or to receive dividends or subscription 
rights or otherwise until the Warrants evidenced by this Warrant Certificate 
shall have been exercised and the Common Stock purchasable upon the exercise 
thereof shall have become deliverable as provided in the Warrant Agreement.

         If this Warrant Certificate shall be surrendered for exercise within
any period during which the transfer books for the Company's Common Stock or 
other class of stock purchasable upon the exercise of the Warrants evidenced 
by this Warrant Certificate are closed for any purpose, the Company shall not 
be required to make delivery of certificates for shares purchasable upon such 
transfer until the date of the reopening of said transfer books.

         Every holder of this Warrant Certificate by accepting the same
consents and agrees with the Company, the Warrant Agent, and with every other 
holder of a Warrant Certificate that:

    (a)  this Warrant Certificate is transferable on the registry books of the
Warrant Agent only upon the terms and conditions set forth in the Warrant 
Agreement, and

    (b)  the Company and the Warrant Agent may deem and treat the person in
whose name this Warrant Certificate is registered as the absolute owner 
hereof (notwithstanding any notation of ownership or other writing thereon 
made by anyone other than the Company or the Warrant Agent) for all purposes 
whatever and neither the Company nor the Warrant Agent shall be affected by 
any notice to the contrary.

         The Company shall not be required to issue or deliver any certificate
for shares of Common Stock or other securities upon the exercise of Warrants 
evidenced by this Warrant Certificate until any tax which may be payable in 
respect thereof by the holder of this Warrant Certificate pursuant to the 
Warrant Agreement shall have been paid, such tax being payable by the holder 
of this Warrant Certificate at the time of surrender.

         This Warrant Certificate shall not be valid or obligatory for any
purpose until it shall have been countersigned by the Warrant Agent.


Page iii


<PAGE>

         WITNESS the facsimile signatures of the proper officers of the Company
and its corporate seal.

          Dated:  ______________________________, 1997.


                                          ANTIVIRALS INC.


                                          By: ______________________________
                                                  Chief Executive Officer


                                          Attest: _________________________
                                                         Secretary


Countersigned

_____________________________


By: _________________________
        Authorized Officer


Page iv





<PAGE>
                      THIS WARRANT HAS NOT BEEN REGISTERED
                        UNDER THE SECURITIES ACT OF 1933
                             AND IS NOT TRANSFERABLE
                            EXCEPT AS PROVIDED HEREIN

                                 ANTIVIRALS INC.

                                PURCHASE WARRANT

                                   Issued to:

                        PAULSON INVESTMENT COMPANY, INC.

                            Exercisable to Purchase

                                  150,000 Units


                                       of


                                 ANTIVIRALS INC.


                           Void after _________, 2002


<PAGE>

     This is to certify that, for value received and subject to the terms and
conditions set forth below, the Warrantholder (hereinafter defined) is entitled
to purchase, and the Company promises and agrees to sell and issue to the
Warrantholder, at any time on or after _________, 1997 and on or
before___________, 2002, up to 150,000 Units (hereinafter defined) at the
Exercise Price (hereinafter defined).

     This Warrant Certificate is issued subject to the following terms and
conditions:

     1.   DEFINITIONS OF CERTAIN TERMS.  Except as may be otherwise clearly
required by the context, the following terms have the following meanings:

          (a)  "Act" means the Securities Act of 1933, as amended.

          (b)  "Closing Date" means the date on which the Offering is closed.

          (c)  "Commission" means the Securities and Exchange Commission.

          (d)  "Common Stock" means the common stock, $.0001 par value, of the
Company.

          (e)  "Company" means AntiVirals Inc., an Oregon corporation.

          (f)  "Company's Expenses" means any and all expenses
 payable by the
Company or the Warrantholder in connection with an offering described in
Section 6 hereof, except Warrantholder's Expenses.

          (g)  "Effective Date" means the date on which the Registration
Statement is declared effective by the Commission.

          (h)  "Exercise Price" means the price at which the Warrantholder may
purchase one complete Unit (or Securities obtainable in lieu of one complete
Unit) upon exercise of Warrants as determined from time to time pursuant to the
provisions hereof.  The initial Exercise Price is $_____ per Unit.  If a Warrant
is exercised for a component of a Unit or Units, then the price payable in
connection with such exercise shall be determined by allocating $0.001 to the
Unit Warrant and the balance of the Exercise Price to the share of Common Stock,
or, in each case, to any securities obtainable in addition to or in lieu of such
share of Unit Warrant or Common Stock by virtue of the application of Section 3
of this Warrant.

          (i)  "Offering" means the public offering of Units made pursuant to
the Registration Statement.


Page 2 of 9


<PAGE>

          (j)  "Participating Underwriter" means any underwriter participating
in the sale of the Securities pursuant to a registration under Section 6 of this
Warrant Certificate.

          (k)  "Registration Statement" means the Company's registration
statement (File No. _____) as amended on the Closing Date.

          (l)  "Rules and Regulations" means the rules and regulations of the
Commission adopted under the Act.

          (m)  "Securities" means the securities obtained or obtainable upon
exercise of the Warrant or securities obtained or obtainable upon exercise,
exchange, or conversion of such securities.

          (n)  "Unit" means, as the case may require, either one of the Units
offered to the Public pursuant to the Registration Statement or one of the Units
obtainable on exercise of a Warrant.

          (o)  "Unit Warrant" means a Common Stock purchase warrant included as
a component of a Unit.

          (p)  "Warrant Certificate" means a certificate evidencing the Warrant.

          (q)  "Warrantholder" means a record holder of the Warrant or
Securities.  The initial Warrantholder is Paulson Investment Company, Inc.

          (r)  "Warrantholder's Expenses" means the sum of (i) the aggregate
amount of cash payments made to an underwriter, underwriting syndicate, or agent
in connection with an offering described in Section 6 hereof multiplied by a
fraction the numerator of which is the aggregate sales price of the Securities
sold by such underwriter, underwriting syndicate, or agent in such offering and
the denominator of which is the aggregate sales price of all of the securities
sold by such underwriter, underwriting syndicate, or agent in such offering and
(ii) all out-of-pocket expenses of the Warrantholder, except for the fees and
disbursements of one firm retained as legal counsel for the Warrantholder that
will be paid by the Company.

          (s)  "Warrant" means the warrant evidenced by this certificate, any
similar certificate issued in connection with the Offering, or any certificate
obtained upon transfer or partial exercise of the Warrant evidenced by any such
certificate.

     2.   EXERCISE OF WARRANTS.  All or any part of the Warrant may be exercised
commencing on the first anniversary of the Effective Date and ending at
5:00 p.m. Pacific Time on the fifth anniversary of the Effective Date by
surrendering this Warrant Certificate, together with appropriate instructions,
duly executed by the Warrantholder or by its duly authorized attorney, at the
office of the Company, One S.W. Columbia, Suite 1105, Portland, Oregon 97258, or
at such other office or agency as the Company may designate.  Upon receipt of
notice of exercise, the Company shall immediately instruct its transfer agent to
prepare certificates for


Page 3 of 9


<PAGE>

the Securities to be received by the Warrantholder upon completion of the
Warrant exercise.  When such certificates are prepared, the Company shall notify
the Warrantholder and deliver such certificates to the Warrantholder or as per
the Warrantholder's instructions immediately upon payment in full by the
Warrantholder, in lawful money of the United States, of the Exercise Price
payable with respect to the Securities being purchased.  If the Warrantholder
shall represent and warrant that all applicable registration and prospectus
delivery requirements for their sale have been complied with upon sale of the
Securities received upon exercise of the Warrant, such certificates shall not
bear a legend with respect to the Securities Act of 1933.

     If fewer than all the Securities purchasable under the Warrant are
purchased, the Company will, upon such partial exercise, execute and deliver to
the Warrantholder a new Warrant Certificate (dated the date hereof), in form and
tenor similar to this Warrant Certificate, evidencing that portion of the
Warrant not exercised.  The Securities to be obtained on exercise of the Warrant
will be deemed to have been issued, and any person exercising the Warrants will
be deemed to have become a holder of record of those Securities, as of the date
of the payment of the Exercise Price.

     3.   ADJUSTMENTS IN CERTAIN EVENTS.  The number, class, and price of
Securities for which this Warrant Certificate may be exercised are subject to
adjustment from time to time upon the happening of certain events as follows:

          (a)  If the outstanding shares of the Company's Common Stock are
divided into a greater number of shares or a dividend in stock is paid on the
Common Stock, the number of shares of Common Stock for which the Warrant is then
exercisable will be proportionately increased and the Exercise Price will be
proportionately reduced; and, conversely, if the outstanding shares of Common
Stock are combined into a smaller number of shares of Common Stock, the number
of shares of Common Stock for which the Warrant is then exercisable will be
proportionately reduced and the Exercise Price will be proportionately
increased.  The increases and reductions provided for in this subsection 3(a)
will be made with the intent and, as nearly as practicable, the effect that
neither the percentage of the total equity of the Company obtainable on exercise
of the Warrants nor the price payable for such percentage upon such exercise
will be affected by any event described in this subsection 3(a).

          (b)  In case of any change in the Common Stock through merger,
consolidation, reclassification, reorganization, partial or complete
liquidation, purchase of substantially all the assets of the Company, or other
change in the capital structure of the Company, then, as a condition of such
change, lawful and adequate provision will be made so that the holder of this
Warrant Certificate will have the right thereafter to receive upon the exercise
of the Warrant the kind and amount of shares of stock or other securities or
property to which he would have been entitled if, immediately prior to such
event, he had held the number of shares of Common Stock obtainable upon the
exercise of the Warrant. In any such case, appropriate adjustment will be made
in the application of the provisions set forth herein with respect to the rights
and interest thereafter of the Warrantholder, to the end that the provisions set
forth herein will thereafter be applicable, as nearly as reasonably may be, in
relation to any shares of stock or other property thereafter deliverable upon
the exercise of the Warrant.  The Company will not permit any


Page 4 of 9


<PAGE>

change in its capital structure to occur unless the issuer of the shares of
stock or other securities to be received by the holder of this Warrant
Certificate, if not the Company, agrees to be bound by and comply with the
provisions of this Warrant Certificate.

          (c)  When any adjustment is required to be made in the number of
shares of Common Stock, other securities, or the property purchasable upon
exercise of the Warrant, the Company will promptly determine the new number of
such shares or other securities or property purchasable upon exercise of the
Warrant and (i) prepare and retain on file a statement describing in reasonable
detail the method used in arriving at the new number of such shares or other
securities or property purchasable upon exercise of the Warrant and (ii) cause a
copy of such statement to be mailed to the Warrantholder within thirty (30) days
after the date of the event giving rise to the adjustment.

          (d)  No fractional shares of Common Stock or other securities will be
issued in connection with the exercise of the Warrant, but the Company will pay,
in lieu of fractional shares, a cash payment therefor on the basis of the mean
between the bid and asked prices of the Common Stock in the over-the-counter
market or the closing price on a national securities exchange on the day
immediately prior to exercise.

          (e)  If securities of the Company or securities of any subsidiary of
the Company are distributed pro rata to holders of Common Stock, such number of
securities will be distributed to the Warrantholder or his assignee upon
exercise of his rights hereunder as such Warrantholder or assignee would have
been entitled to if this Warrant Certificate had been exercised prior to the
record date for such distribution.  The provisions with respect to adjustment of
the Common Stock provided in this Section 3 will also apply to the securities to
which the Warrantholder or his assignee is entitled under this subsection 3(e).

          (f)  Notwithstanding anything herein to the contrary, there will be no
adjustment made hereunder on account of the sale of the Common Stock or other
Securities purchasable upon exercise of the Warrant.

     4.   RESERVATION OF SECURITIES.  The Company agrees that the number of
shares of Common Stock, Unit Warrants or other Securities sufficient to provide
for the exercise of the Warrant upon the basis set forth above will at all times
during the term of the Warrant be reserved for exercise.

     5.   VALIDITY OF SECURITIES.  All Securities delivered upon the exercise of
the Warrant will be duly and validly issued in accordance with their terms, and
the Company will pay all documentary and transfer taxes, if any, in respect of
the original issuance thereof upon exercise of the Warrant.

     6.   REGISTRATION OF SECURITIES ISSUABLE ON EXERCISE OF WARRANT
          CERTIFICATE.

          (a)  The Company will register the Securities with the Commission
pursuant to the Act so as to allow the unrestricted sale of the Securities to
the public from time to time


Page 5 of 9



<PAGE>

commencing on the first anniversary of the Effective Date and ending at 5:00
p.m. Pacific Time on the fifth anniversary of the Effective Date (the
"Registration Period").  The Company will also file such applications and other
documents necessary to permit the sale of the Securities to the public during
the Registration Period in those states in which the Units were qualified for
sale in the Offering or such other states as the Company and the Warrantholder
agree to.  In order to comply with the provisions of this Section 6(a), the
Company is not required to file more than one registration statement.  No
registration right of any kind, "piggyback" or otherwise, will last longer than
five years from the Closing Date.

          (b)  The Company will pay all of the Company's Expenses and each
Warrantholder will pay its pro rata share of the Warrantholder's Expenses
relating to the registration, offer, and sale of the Securities.

          (c)  Except as specifically provided herein, the manner and conduct of
the registration, including the contents of the registration, will be entirely
in the control and at the discretion of the Company.  The Company will file such
post-effective amendments and supplements as may be necessary to maintain the
currency of the registration statement during the period of its use.  In
addition, if the Warrantholder participating in the registration is advised by
counsel that the registration statement, in their opinion, is deficient in any
material respect, the Company will use its best efforts to cause the
registration statement to be amended to eliminate the concerns raised.

          (d)  The Company will furnish to the Warrantholder the number of
copies of a prospectus, including a preliminary prospectus, in conformity with
the requirements of the Act, and such other documents as it may reasonably
request in order to facilitate the disposition of Securities owned by it.

          (e)  The Company will, at the request of Warrantholders holding at
least 50 percent of the then outstanding Warrants, (i) furnish an opinion of the
counsel representing the Company for the purposes of the registration pursuant
to this Section 6, addressed to the Warrantholders and any Participating
Underwriter, (ii) furnish an appropriate letter from the independent public
accountants of the Company, addressed to the Warrantholders and any
Participating Underwriter, and (iii) make representations and warranties to the
Warrantholders and any Participating Underwriter.  A request pursuant to this
subsection (e) may be made on three occasions.  The documents required to be
delivered pursuant to this subsection (e) will be dated within ten days of the
request and will be, in form and substance, equivalent to similar documents
furnished to the underwriters in connection with the Offering, with such changes
as may be appropriate in light of changed circumstances.

     7.   INDEMNIFICATION IN CONNECTION WITH REGISTRATION.

          (a)       If any of the Securities are registered, the Company will
indemnify and hold harmless each selling Warrantholder, any person who controls
any selling Warrantholder within the meaning of the Act, and any Participating
Underwriter against any losses, claims, damages, or liabilities, joint or
several, to which any Warrantholder, controlling person, or


Page 6 of 9


<PAGE>

Participating Underwriter may be subject under the Act or otherwise; and it will
reimburse each Warrantholder, each controlling person, and each Participating
Underwriter for any legal or other expenses reasonably incurred by the
Warrantholder, controlling person, or Participating Underwriter in connection
with investigating or defending any such loss, claim, damage, liability, or
action, insofar as such losses, claims, damages, or liabilities, joint or
several (or actions in respect thereof), arise out of or are based upon any
untrue statement or alleged untrue statement of any material fact contained, on
the effective date thereof, in any such registration statement or any
preliminary prospectus or final prospectus, or any amendment or supplement
thereto, or arise out of or are based upon the omission or alleged omission to
state therein a material fact required to be stated therein or necessary to make
the statements therein not misleading; PROVIDED, HOWEVER, that the Company will
not be liable in any case to the extent that any loss, claim, damage, or
liability arises out of or is based upon any untrue statement or alleged untrue
statement or omission or alleged omission made in any registration statement,
preliminary prospectus, final prospectus, or any amendment or supplement
thereto, in reliance upon and in conformity with written information furnished
by a Warrantholder for use in the preparation thereof.  The indemnity agreement
contained in this subparagraph (a) will not apply to amounts paid to any
claimant in settlement of any suit or claim unless such payment is first
approved by the Company, such approval not to be unreasonably withheld.

          (b)  Each selling Warrantholder, as a condition of the Company's
registration obligation, will indemnify and hold harmless the Company, each of
its directors, each of its officers who have signed any registration statement
or other filing or any amendment or supplement thereto, and any person who
controls the Company within the meaning of the Act, against any losses, claims,
damages, or liabilities to which the Company or any such director, officer, or
controlling person may become subject under the Act or otherwise, and will
reimburse any legal or other expenses reasonably incurred by the Company or any
such director, officer, or controlling person in connection with investigating
or defending any such loss, claim, damage, liability, or action, insofar as such
losses, claims, damages, or liabilities (or actions in respect thereof) arise
out of or are based upon any untrue or alleged untrue statement of any material
fact contained in said registration statement, any preliminary or final
prospectus, or other filing, or any amendment or supplement thereto, or arise
out of or are based upon the omission or the alleged omission to state therein a
material fact required to be stated therein or necessary to make the statements
therein not misleading, but only to the extent that such untrue statement or
alleged untrue statement or omission or alleged omission was made in said
registration statement, preliminary or final prospectus, or other filing, or
amendment or supplement, in reliance upon and in conformity with written
information furnished by such Warrantholder for use in the preparation thereof;
PROVIDED, HOWEVER, that the indemnity agreement contained in this
subparagraph (b) will not apply to amounts paid to any claimant in settlement of
any suit or claim unless such payment is first approved by the Warrantholder,
such approval not to be unreasonably withheld.

          (c)  Promptly after receipt by an indemnified party under
subparagraphs (a) or (b) above of notice of the commencement of any action, such
indemnified party will, if a claim in respect thereof is to be made against an
indemnifying party, notify the indemnifying party of the commencement thereof;
but the omission to notify the indemnifying party will not relieve


Page 7 of 9


<PAGE>

it from any liability that it may have to any indemnified party otherwise than
under subparagraphs (a) and (b).


          (d)  If any such action is brought against any indemnified party and
it notifies an indemnifying party of the commencement thereof, the indemnifying
party will be entitled to participate in, and, to the extent that it may wish,
jointly with any other indemnifying party similarly notified, to assume the
defense thereof, with counsel satisfactory to such indemnified party; and after
notice from the indemnifying party to such indemnified party of its election to
assume the defense thereof, the indemnifying party will not be liable to such
indemnified party for any legal or other expenses subsequently incurred by such
indemnified party in connection with the defense thereof other than reasonable
costs of investigation.

     8.   RESTRICTIONS ON TRANSFER. This Warrant Certificate and the Warrant may
not be sold, transferred, assigned or hypothecated for a one-year period after
the Effective Date except to underwriters of the Offering or to individuals who
are either a partner or an officer of such an underwriter or by will or by
operation of law.  The Warrant may be divided or combined, upon request to the
Company by the Warrantholder, into a certificate or certificates evidencing the
same aggregate number of Warrants.

     9.   NO RIGHTS AS A SHAREHOLDER.  Except as otherwise provided herein, the
Warrantholder will not, by virtue of ownership of the Warrant, be entitled to
any rights of a shareholder of the Company but will, upon written request to the
Company, be entitled to receive such quarterly or annual reports as the Company
distributes to its shareholders.

     10.  NOTICE.  Any notices required or permitted to be given hereunder will
be in writing and may be served personally or by mail; and if served will be
addressed as follows:

     If to the Company:

                         One S.W. Columbia, Suite 1105
                         Portland, Oregon 97258
                         Attention:  Chief Executive Officer

     If to the Warrantholder:

                         at the address furnished by the
                         Warrantholder to the Company for
                         the purpose of notice.

     Any notice so given by mail will be deemed effectively given 48 hours after
mailing when deposited in the United States mail, registered or certified mail,
return receipt requested, postage prepaid and addressed as specified above.  Any
party may by written notice to the other specify a different address for notice
purposes.


Page 8 of 9


<PAGE>

     11.  APPLICABLE LAW.  This Warrant Certificate will be governed by and
construed in accordance with the laws of the state of Oregon, without reference
to conflict of laws principles thereunder.  All disputes relating to this
Warrant Certificate shall be tried before the courts of Oregon located in
Multnomah County, Oregon to the exclusion of all other courts that might have
jurisdiction.

     Dated as of _________________, 1997



ANTIVIRALS INC.


By:  ___________________________________
Its: ___________________________________


     Agreed and accepted as of ____________________, 1997.

PAULSON INVESTMENT COMPANY, INC.



By:  ___________________________________
Its: ___________________________________



Page 9 of 9




<PAGE>

                                 ANTIVIRALS INC.

                          REGISTRATION RIGHTS AGREEMENT



                                   DATED AS OF

                    _________________________________, 19___


<PAGE>

                          REGISTRATION RIGHTS AGREEMENT



     THIS REGISTRATION RIGHTS AGREEMENT is entered into as of May 20, 1992, by
and between ANTIVIRALS, INC., an Oregon corporation (the "Company"), and Ice
Bear, Inc., an Alaska corporation ("Ice Bear").

                                    RECITALS

     Ice Bear is purchasing 65,790 shares of the Company's Common Stock (the
"Common Stock") and a warrant dated as of May 20, 1992 for an additional 658,000
shares of Common Stock.  The execution by the Company of this Agreement is a
condition to such purchase of the Common Stock and the Warrant.

                                    AGREEMENT

     NOW, THEREFORE, for good and valuable consideration, the receipt of which
is hereby acknowledged, the parties hereto agree as follows:

     1.   DEFINITIONS.  For purposes of this Agreement:

          (a)    The term "register," "registered," and "registration" refer
to a registration effected by preparing and filing a registration statement or
similar document in compliance with the Securities Act of 1933, as amended (the
"Act"), and the declaration or ordering of effectiveness of such registration
statement or document;

          (b)    The term "Registrable Securities" means (i) the 65,790
shares of the Company's Common Stock purchased under the Common Stock and
Warrant
 Purchase Agreement dated as of May 20, 1992, (ii) the Common Stock of
the Company issuable or issued upon exercise of the Warrant, and (iii) any
Common Stock of the Company issued as (or issuable upon the conversion or
exercise of any warrant, right or other security which is issued as) a dividend
or other distribution with respect to, or in exchange for or in replacement of,
such Common Stock and Warrant, excluding in all cases, however, any Registrable
Securities sold by a person in a transaction in which its rights under this
Agreement are not assigned;

          (c)    The number of shares of "Registrable Securities then
outstanding" shall be determined by the number of shares of Common Stock
outstanding which are, and the number of shares of Common Stock issuable
pursuant to then exercisable or convertible securities which are, Registrable
Securities; and 

                                       1

<PAGE>

          (d)    The term "Holder" means any person owning or having the
right to acquire Registrable Securities who is a party to this Agreement as of
the date hereof or who may be added as a party hereto pursuant to the terms of
this Agreement, and any assignee thereof in accordance with Section 9.

     2.   COMPANY REGISTRATION.  If (but without any obligation to do so)
the Company proposes to register (including for this purpose a registration
effected by the Company for shareholders other than the Holders) any of its
stock or other securities under the Act in connection with the public offering
of such securities solely for cash (other than a registration relating solely to
the sale of securities to participants in a Company employee stock plan), the
Company shall, at each such time, promptly give each Holder written notice of
such registration.  Upon the written request of each Holder given within 20 days
after mailing of such notice by the Company, the Company shall, subject to the
provisions of Section 6, cause to be registered under the Act all of the
Registrable Securities that each such Holder has requested to be registered.

     3.   FURNISH INFORMATION.  It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this Agreement with
respect to any selling Holder that such selling Holder shall furnish to the
Company such information regarding itself, the Registrable Securities held by it
and the intended method of disposition of such securities as shall be reasonably
required to effect the registration of its Registrable Securities and to execute
such documents in connection with such registration as the Company may
reasonably request.

     4.   EXPENSES OF COMPANY REGISTRATION.  The Company shall bear and pay
all expenses incurred in connection with any registration, filing or
qualification of Registrable Securities with respect to the registrations
pursuant to Section 2 for each Holder, including, without limitation, all
registration, filing and qualification fees, printing and accounting fees, and
the fees and disbursements of counsel for the Company and of one counsel for the
Holders; provided, however, that the selling Holders shall bear the expenses of
any underwriting discounts and commissions relating to the Registrable
Securities.

     5.   UNDERWRITING REQUIREMENTS.  The Company shall not be required
under Section 2 to include any of the Holders' securities in an underwritten
offering of the Company's securities unless such Holders accept the terms of the
underwriting as agreed upon between the Company and the underwriters selected by
it, assuming usual and customary underwriting terms.  If the total amount of
securities, including Registrable Securities, requested by shareholders to be
included in such offering exceeds the amount of securities that the underwriters
reasonably believe compatible with the success of the offering, then the Company
shall be required to include in the offering only that number of such
securities, including Registrable Securities, which the underwriters believe
will not jeopardize the success of the offering (the securities so included to
be apportioned pro rata among the selling shareholders according to the total
amount of securities otherwise entitled to be included therein owned by each
selling shareholder or in such other proportions as shall mutually be agreed to
by such selling shareholders), but in no event shall the amount of securities of
the selling Holders included in the offering be reduced

                                       2

<PAGE>

below 25% of the total amount of securities included in such offering, unless 
such offering is the initial public offering of the Company's securities, in 
which case the selling Holders may be excluded if the underwriters make the 
determination described above and provided no other shareholder's securities 
are included.

     6.   DELAY OF REGISTRATION.  No Holder shall have any right to obtain
or seek an injunction restraining or otherwise delaying any such registration as
the result of any controversy that might arise with respect to the
interpretation or implementation of this Agreement.

     7.   INDEMNIFICATION.  In the event any Registrable Securities are included
in a registration statement under this Agreement:

          (a)    To the extent permitted by law, the Company will indemnify
and hold harmless each Holder, the partners, officers, agents, employees and
directors of each Holder, any underwriter (as defined in the Act) for such
Holder and each person, if any, who controls such Holder or underwriter within
the meaning of the Act or the Securities Exchange Act of 1934, as amended (the
"1934 Act"), against any losses, claims, damages or liabilities (joint or
several) to which they may become subject under the Act, the 1934 Act or other
federal or state law, insofar as such losses, claims, damages or liabilities (or
actions in respect thereof) arise out of or are based upon any of the following
statements, omissions or violations (collectively, a "Violation"):  (i) any
untrue statement or alleged untrue statement of a material fact contained in
such registration statement, including any preliminary prospectus or final
prospectus contained therein or any amendments or supplements thereto, (ii) the
omission or alleged omission to state therein a material fact required to be
stated therein, or necessary to make the statements therein not misleading, or
(iii) any violation or alleged violation by the Company of the Act, the 1934
Act, any state securities law or any rule or regulation promulgated under the
Act, the 1934 Act or any state securities law; and the Company will reimburse
each such Holder, partner, officer, agent, employee or director, underwriter or
controlling person for any legal or other expenses reasonably incurred by them
in connection with investigating or defending any such loss, claim, damage,
liability or action; provided, however, that the indemnity agreement contained
in this Section 7(a) shall not apply to amounts paid in settlement of any such
loss, claim, damage, liability or action if such settlement is effected without
the consent of the Company, which consent shall not be unreasonably withheld,
nor shall the Company be liable in any such case for any such loss, claim,
damage, liability or action to the extent that it arises out of or is based upon
a Violation which occurs in reliance upon and in conformity with written
information furnished expressly for use in connection with such registration by,
or on behalf of, any such Holder, underwriter or controlling person.

          (b)    To the extent permitted by law, each selling Holder will
indemnify and hold harmless the Company, each of its officers, directors, agents
or employees, each person, if any, who controls the Company within the meaning
of the Act, any underwriter and any other Holder selling securities in such
registration statement or any of its partners, agents, employees, directors or
officers or any person who controls such Holder, against any losses, claims,
damages or liabilities (joint or several) to which the Company or any such
director, partner,

                                       3

<PAGE>

agent, employee, officer, controlling person, or underwriter, or other such 
Holder or director, officer, partner, agent, employee or controlling person 
may become subject, under the Act, the 1934 Act or other federal or state 
law, insofar as such losses, claims, damages or liabilities (or actions in 
respect thereof) arise out of or are based upon any Violation, in each case 
to the extent (and only to the extent) that such Violation occurs in reliance 
upon and in conformity with written information furnished by, or on behalf 
of, such Holder expressly for use in connection with such registration; and 
each such Holder will reimburse any legal or other expenses reasonably 
incurred by the Company or any such partner, agent, employee, director, 
officer, controlling person, underwriter or other Holder, in connection with 
investigating or defending any such loss, claim, damage, liability or action; 
provided, however, that the indemnity agreement contained in this Section 
7(b) shall not apply to amounts paid in settlement of any such loss, claim, 
damage, liability or action if such settlement is effected without the 
consent of the Holder, which consent shall not be unreasonably withheld; and 
provided, further, that each selling Holder shall be liable under this 
Section 7(b) for only that amount of losses, claims, damages and liabilities 
as does not exceed the proceeds to such selling Holder as a result of such 
registration.

          (c)    Promptly after receipt by an indemnified party under this
Section 7 of notice of the commencement of any action (including any
governmental action), such indemnified party will, if a claim in respect thereof
is to be made against any indemnifying party under this Section 7 deliver to the
indemnifying party a written notice of the commencement thereof and the
indemnifying party shall have the right to participate in, and, to the extent
the indemnifying party so desires, jointly with any other indemnifying party
similarly notified, to assume the defense thereof with counsel mutually
satisfactory to the parties; provided, however, that an indemnified party shall
have the right to retain its own counsel, with the fees and expenses to be paid
by the indemnifying party, if, in the opinion of counsel for the indemnifying
party, representation of such indemnified party by the counsel retained by the
indemnifying party would be inappropriate due to actual or potential differing
interests between such indemnified party and any other party represented by such
counsel in such proceeding.  The failure to deliver written notice to the
indemnifying party within a reasonable period of time of the commencement of any
such action shall relieve such indemnifying party of any liability to the
indemnified party under this Section 7 to the extent materially prejudicial to
its ability to defend such action, but the omission so to deliver written notice
to the indemnifying party will not relieve it of any liability that it may have
to any indemnified party otherwise than under this Section 7.

     8.   REPORTS UNDER THE ACT.  With a view to making available to the
Holders the benefits of SEC Rule 144 promulgated under the Act and any other
rule or regulation of the SEC that may at any time permit a Holder to sell
securities of the Company to the public without registration or pursuant to a
registration on Form S-3, the Company agrees to:

          (a)    make and keep public information available, as those terms
are understood and defined in SEC Rule 144, at all times after 90 days after the
effective date of the first registration statement filed by the Company for the
offering of its securities to the general public;

                                       4

<PAGE>

          (b)    take such action, including the voluntary registration of
its Common Stock under Section 12 of the 1934 Act, as is necessary to enable the
Holders to utilize Form S-3 for the sale of their Registrable Securities, such
action to be taken as soon as practicable after the end of the fiscal year in
which the first registration statement filed by the Company for the offering of
its securities to the general public is declared effective;

          (c)    file with the SEC in a timely manner all reports and other
documents required of the Company under the Act and the 1934 Act; and

          (d)    furnish to any Holder, so long as the Holder owns any
Registrable Securities, forthwith upon request (i) a written statement by the
Company that it has complied with the reporting requirements of SEC Rule 144 (at
any time after 90 days after the effective date of the first registration
statement filed by the Company), the Act and the 1934 Act (at any time after it
has become subject to such reporting requirements), or that it qualifies as a
registrant whose securities may be resold pursuant to Form S-3 (at any time
after it so qualifies), (ii) a copy of the most recent annual or quarterly
report of the Company and such other reports and documents so filed by the
Company, and (iii) such other information as may be reasonably requested in
availing any Holder of any rule or regulation of the SEC which permits the
selling of any such securities without registration or pursuant to such form.

     9.   ASSIGNMENT OF REGISTRATION RIGHTS.  The rights to cause the
Company to register Registrable Securities pursuant to this Agreement may be
assigned by a Holder to a transferee or assignee of such securities who shall,
upon such transfer or assignment, be deemed a "Holder" under this Agreement,
provided the Company is, within a reasonable period of time after such transfer,
furnished with written notice of the name and address of such transferee or
assignee and the securities with respect to which such registration rights are
being assigned; provided, further, that such assignment shall be effective only
if immediately following such transfer the further disposition of such
securities by the transferee or assignee is restricted under the Act.

     10.  "MARKET STAND-OFF" AGREEMENT.  The Holders hereby agree that they
shall not, to the extent requested by the Company and an underwriter of Common
Stock (or other securities) of the Company, sell or otherwise transfer or
dispose (other than to donees who agree to be similarly bound) of any
Registrable Securities for up to 90 days following the effective date of a
registration statement of the Company filed under the Act; provided, however,
that all officers and directors of the Company and all other persons with
registration rights (whether or not pursuant to this Agreement) enter into
similar agreements.

     In order to enforce the foregoing covenant, the Company may impose
stop-transfer instructions with respect to the Registrable Securities of the
Holders (and the shares or securities of every other person subject to the
foregoing restriction) until the end of such period.

     11.  NOTICES.  Unless otherwise provided, any notice required or
permitted under this Agreement shall be given in writing and shall be deemed
effectively given upon personal

                                       5


<PAGE>

delivery to the party to be notified or upon deposit with the United States 
Post Office, postage prepaid, registered or certified with return receipt 
requested and addressed to the party to be notified at the address indicated 
for such party on the signature page hereof or on Schedule A hereto, or at 
such other address as such party may designate by ten days' advance written 
notice to the other parties given in the foregoing manner.

     12.  AMENDMENTS AND WAIVER.  Any term of this Agreement may be amended
and the observance of any term may be waived (either generally or in a
particular instance and either retroactively or prospectively) only with the
written consent of the Company and the holders of a majority of the shares of
Common Stock that are Registrable Securities themselves or upon which
Registrable Securities are based.  Additional Holders may be added to this
Agreement with such consent by amending Schedule A hereto and adding a signature
page executed by such additional Holder.

     13.  TERMINATION.  The registration rights described in Section 2
shall terminate fifteen years after the effective date of the Company's first
registration statement for a public offering of securities of the Company to the
general public.

     14.  SEVERABILITY.  If one or more provisions of this Agreement are
held to be unenforceable under applicable law, such provision shall be excluded
from this Agreement, and the balance of this Agreement shall be interpreted as
if such provision were so excluded and shall be enforceable in accordance with
its terms.

     15.  GOVERNING LAW.  This Agreement shall be governed by and construed
under the laws of the State of Oregon as applied to agreements among Oregon
residents entered into and to be performed entirely within the State of Oregon.

     16.  COUNTERPARTS.  This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

                                       6

<PAGE>

     17.  ENTIRE AGREEMENT.  This Agreement constitutes the full and entire
understanding and agreement between the parties with respect to the subject
matter hereof and supersedes all prior agreements with respect to the subject
matter hereof.


                                       ANTIVIRALS INC., an Oregon corporation


                                       By____________________________________
                                          Its________________________________

                                       Address:  One S.W. Columbia Avenue
                                                 Suite 1105
                                                 Portland, OR  97238



                                       ICE BEAR, INC., an Alaska corporation


                                       By____________________________________
                                          Its________________________________












                                       7

<PAGE>

                                   SCHEDULE A



NAME                                                        ADDRESS
- -------------------------------------------------------------------------------


Ice Bear, Inc., an Alaska corporation                       10800 N.E. Eighth
                                                            Suite 415
                                                            Bellevue, WA  98004





<PAGE>
                                                                       Exhibit A





THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AND
APPLICABLE STATE SECURITIES LAWS. 


                          ----------------------------

                                ANTIVIRALS, INC.

                          ----------------------------


                                PURCHASE WARRANTS

                             Exercisable to Purchase
                             Shares of Common Stock
                                       of
                                Antivirals, Inc.


<PAGE>

This is to certify that, for value received and subject to the terms and
conditions set forth below, the Warrantholder is entitled to purchase, and the
Company promises and agrees to sell and issue to the Warrantholder, at any time
on or after March 21, 1988, up to 1,800,000 shares of its Common Stock at a
price of $0.0001 per share.

     This Warrant Certificate is issued subject to the following terms and
conditions: 

     1.        DEFINITION OF CERTAIN TERMS.  Except as may be otherwise clearly
required by the context, the following terms shall have the following meanings: 

          (a)       "Act" shall mean the Securities Act of 1933, as amended.

          (b)       "Agreement" shall mean the Agreement, dated July 20, 1992,
between the Company and Oregon Resource and Technology Development Corporation. 

          (c)       "Commission" shall mean the Securities and Exchange
Commission. 

          (d)       "Common Stock" shall mean the Common Stock of the Company. 

          (e)       "Company" shall mean Antivirals, Inc., an Oregon
corporation. 

          (f)       "Purchase Price" shall mean the price at which a
Warrantholder
 may purchase one share of Common stock (or Securities obtainable
in lieu of one share of Common Stock) upon exercise of Warrants as determined
from time to time pursuant to the provisions hereof. 

          (g)       "Register," "registered" and "registration" shall mean a
registration effected by preparing and filing a registration statement in
compliance with the Act and the declaration or ordering of effectiveness of such
registration statement. 

          (h)       "Registrable Securities" shall mean (1) the Common Stock
issuable upon conversion of the Securities and (2) any Common Stock of the
Company issued as (or issuable upon the conversion or exercise of any warrant,
right or other security which is issued as) a dividend or other distribution
with respect to, or in exchange for or in replacement of, the Securities,
excluding in all cases, however, any Registrable Securities sold by a person in
a transaction in which his or her rights under Section 6 herein are not
assigned. 

          (i)       "Registration Expenses" shall mean all expenses incurred by
the Company in complying with Section 6 of this Warrant Certificate, including
without limitation all registration and filing fees, printing expenses, fees and
disbursements of counsel for the Company, and blue sky fees and expenses. 

          (j)       "Rules and Regulations" shall mean the rules and regulations
of the Commission adopted under the Act. 

2


<PAGE>

          (k)       "Securities" shall mean the securities obtained or
obtainable upon exercise of the Warrants or securities obtained or obtainable
upon exercise, exchange or conversion of such securities. 

          (l)       "Selling Expenses" shall mean all underwriting discounts and
selling commissions applicable to the sale of Securities of a Warrantholder and
all fees and disbursements of counsel for such Warrantholder. 

          (m)       "Shares" shall mean shares of the Common Stock issued or
issuable upon exercise of the Warrants. 

          (n)       "Ten Percent Shareholder" shall mean any person who is
directly or indirectly the beneficial owner of more than ten percent (10%) of
all of the outstanding capital stock of the Company, determined on a Common
Stock equivalent basis. 

          (o)       "Warrant Certificate" shall mean a certificate evidencing
Warrants. 

          (p)       "Warrantholder" shall mean a record holder of Warrants or
Securities. 

          (q)       "Warrants" shall mean the warrants evidenced by this
certificate or any certificate obtained upon transfer or partial exercise of
Warrants evidenced by any such certificate. 

     2.        EXERCISE AND REDEMPTION OF WARRANTS. 

          (a)       All or any part of the Warrants may be exercised by
surrendering this Warrant Certificate, together with appropriate instructions,
duly executed by the Warrantholder or by its duly authorized attorney, at the
office of the Company set forth in Section 11 hereof or at such other office or
agency the Company designates, accompanied by payment in full, in lawful money
of the United States, of the Purchase Price for the Warrants being exercised. 
The Securities to be obtained on exercise of the Warrants shall be deemed to
have been issued, and any person exercising the Warrants shall be deemed to have
become a holder of record of those Securities, as of the date of the surrender
of this Warrant Certificate and the payment of the Purchase Price. 

          (b)       If fewer than all the Warrants evidenced by this Warrant
Certificate are exercised or redeemed, the Company will, upon such exercise or
redemption, execute and deliver to the Warrantholder a new Warrant Certificate
(dated the date of issuance thereof), in form and tenor similar to this Warrant
Certificate, evidencing the Warrants not exercised, surrendered or redeemed. 

          (c)       No fractional shares of Common Stock or other securities
will be issued in connection with the exercise of any Warrants, but the Company
shall pay, in lieu of fractional shares, a cash payment therefor on the basis of
the Purchase Price of the Common Stock or 

3


<PAGE>

other securities on the date immediately prior to the exercise as determined 
by its board of directors. 

     3.        ADJUSTMENTS IN CERTAIN EVENTS.  The number, class and price of
Securities for which this Warrant Certificate may be exercised are subject to
adjustment from time to time upon the happening of certain events as follows: 

          (a)       If the outstanding shares of the Company's Common stock 
are divided into a greater number of shares or a dividend in stock is paid on 
the Common Stock, the number of Shares obtainable on exercise of the Warrants 
shall be proportionately increased and the Purchase Price in effect 
immediately prior to such subdivision or at the record date of such dividend 
shall, simultaneously with the effectiveness of such subdivision or 
immediately after the record date of such dividend, be proportionately 
reduced; and, conversely, if the outstanding shares of Common Stock are 
combined into a smaller number of shares of Common Stock, the number of 
shares of Common stock obtainable upon exercise of the warrant shall be 
proportionately reduced and the Purchase Price in effect immediately prior to 
such combination shall, simultaneously with the effectiveness of such 
combination, be proportionately increased.  The increases and reductions 
provided for in this subsection 3(a) shall be made with the intent and, as 
nearly as practicable, the effect that neither the percentage of the total 
equity of the Company obtainable on exercise of the Warrants nor the price 
payable for such percentage upon such exercise shall be affected by any event 
described in this subsection 3(a). 

          (b)       In case of any change in the securities of the Company
through merger, consolidation, reclassification, reorganization, partial or
complete liquidation, or other change in the capital structure of the Company
(not including the issuance of additional shares of Securities by the Company
other than by stock split or stock dividend), then, as a condition of the change
in the capital structure of the Company, lawful and adequate provision shall be
made so that the holder of this Warrant Certificate will have the right
thereafter to receive upon the exercise of the Warrants the kind and amount of
shares of stock or other securities or property to which he would have been
entitled if, immediately prior to such merger, consolidation, reclassification,
reorganization, recapitalization, or other change in the capital structure, he
had held the number of shares of Common Stock obtainable upon the exercise of
the Warrants.  In any such case, appropriate adjustment shall be made in the
application of the provisions set forth herein with respect to the rights and
interest thereafter of the Warrantholder, to the end that the provisions set
forth herein shall thereafter be applicable, as nearly as reasonably may be, in
relation to any shares of stock or other property thereafter deliverable upon
the exercise of the Warrants. 

          (c)       When any adjustment is required to be made in the number of
Shares, other securities, or the property purchasable upon exercise of the
Warrants, the Company shall promptly determine the new number of shares or other
securities or property purchasable upon exercise of the Warrants and (i) prepare
and retain on file a statement describing in reasonably detail the method used
in arriving at the new number of shares or other securities or property
purchasable upon exercise of the Warrants and (ii) cause a copy of such
statement to be mailed 

4


<PAGE>

to the Warrantholder within thirty (30) days after the date when the event 
giving rise to the adjustment occurred. 

          (d)       If preferred securities of the Company or securities of any
subsidiary of the Company are distributed pro rata to holders of any or all of
the Company's securities, such number of securities shall be distributed to the
Warrantholder or his assignee upon exercise of his rights hereunder as such
Warrantholder or assignee would have been entitled to if this Warrant
Certificate had been exercised prior to such distribution.  The provisions with
respect to adjustment of the Common stock provided in this Section 3 shall also
apply to the preferred securities and securities of any subsidiary to which the
Warrantholder or his assignee shall be entitled under this subsection (d). 

          (e)       Notwithstanding anything herein to the contrary, there shall
be no adjustment made hereunder on account of the sale and issuance of the
Shares or Securities purchasable upon exercise of the Warrants. 

     4.        RESERVATION OF SHARES.  The Company agrees that the number of
shares of Common Stock or other securities sufficient to provide for the
exercise of the Warrants upon the basis set forth above shall at all times
during the term of the Warrants be reserved for exercise. 

     5.        VALIDITY OF SECURITIES.  All securities delivered upon the
exercise of the Warrants shall be duly and validly issued in accordance with
their terms, and the Company will pay all documentary and transfer taxes, if
any, in respect of the original issuance thereof upon exercise of the Warrants. 

     6.        REGISTRATION RIGHTS.

          6.1       COMPANY REGISTRATION. 

          (a)       If at any time the Company determines to register any of its
Common Stock for sale to the general public solely for cash on a form that would
also permit sale of the Registrable Securities, either for its own account or
the account of a security holder or holders exercising demand registration
rights, the Company will (i) promptly give to each Warrantholder written notice
thereof and (ii) use its best efforts to include in such registrations and in
any related underwriting all Registrable Securities specified in a written
request by any Warrantholders (which request shall state the intended method of
distribution of the Securities), received by the Company within 15 business days
after receipt of such written notice from the Company by any Warrantholder,
except as set forth in subsection (b) below. 

          (b)      If the registration of which the Company gives notice under
this Section 6 is for a registered public offering involving an underwriting,
the Company will so advise the Warrantholders as part of the written notice
given to such Warrantholders pursuant to subsection (a) above.  In such event
the right of any Warrantholder to registration pursuant to this Section 6 

5


<PAGE>

will be conditioned on such Warrantholder's participation in such 
underwriting and the inclusion of such Warrantholder's shares in the 
underwriting to the extent provided herein.  All Warrantholders proposing to 
distribute shares through such underwriting will (together with the Company 
and the other holders distributing their securities through such 
underwriting) enter into an underwriting agreement in customary form with the 
underwriter or underwriters selected for such underwriting by the Company.  
Notwithstanding any other provision of this Section 6, if the underwriter of 
the offering determines that marketing factors require a limitation on the 
number of shares to be sold for the account of security holders, the Company 
will be required to include in the relevant offering and registration under 
this Section 6 only so many of such shares as the underwriter believes in 
good faith would not adversely affect the distribution of the securities to 
be offered and registered (the shares so included to be apportioned pro rata 
among all security holders to be included in the registration statement 
according to their respective holdings of shares). 

          6.2            EXPENSES.

          (a)      All incremental Registration Expenses incurred as a result
of any Securities being included in a registration pursuant to Section 6.1 shall
be borne by the Warrantholders on a pro rata basis according to the number of
shares included in such registration. 

          (b)      All Selling Expenses shall be borne by the holder of the
Securities so registered. 

          (c)      Notwithstanding any other provision of this Section 6.2, the
provisions of this Section~6.2 shall be deemed amended to incorporate and comply
with the provisions of any applicable state securities laws, regulations and
administrative policies. 

          6.3            PROCEDURES.  Whenever required under Section 6.1 of
this Warrant Certificate to use its best efforts to effect the registration of
any of the Securities, the Company will, as expeditiously as reasonably
possible: (a) prepare and file with the Commission a registration statement with
respect to such Securities and use its best efforts to cause such registration
statement to become and remain effective, (b) prepare and file with the
Commission such amendments and supplements to such registration statement and
the prospectus used in connection therewith as may be necessary to comply with
the provisions of the Act with respect to the disposition of all securities
covered by such registration statement, (c) furnish to each Warrantholder with
respect to whom Securities are included in such registration statement a
prospectus and such other documents as the Warrantholder reasonably may require
to facilitate the disposition of such Securities, (d) use its reasonable efforts
to register and qualify the Securities covered by such registration statement
under such other securities or blue sky laws of such jurisdictions as reasonably
are appropriate for the distribution of the Securities covered by such
registration statement; provided, however, that the Company will not be required
in connection therewith or as a condition thereto to qualify to do business or
to file a general consent to service of process in any state or jurisdiction
unless the Company is already subject to service in such jurisdiction and
provided further that in connection with any proposed 

6


<PAGE>

registration, the Company will in no event be obligated to cause any such 
registration to remain effective for more than 90 days. 

          6.4            INFORMATION FROM WARRANTHOLDER.  Each Warrantholder
whose shares are included in any registration under Section 6.1 of this Warrant
Certificate will promptly furnish in writing to the Company such information
regarding such Warrantholder and the distribution proposed by such Warrantholder
as the Company may request in writing and as may be required in connection with
any registration, qualification, or compliance referred to in Section 6.1, and
to execute such documents in connection with such registration as the Company
may reasonably request.  Each Warrantholder shall furnish any information
required by this Section 6.4 within 15 business days of the Company's written
request therefor. 

          6.5            ASSIGNMENT.  Subject to compliance with the
restrictions on transfer set forth in Sections 7 and 8 hereof, each
Warrantholder's registration rights under Section 6.1 of this Warrant
Certificate may be assigned by such Warrantholder to a transferee or assignee of
the Securities if the Company is given written notice of the transfer, stating
the name and address of said transferee or assignee and identifying the
Securities with respect to which such registration rights are being assigned;
provided, however, that such assignment shall be effective only if immediately
following such transfer the further disposition of such Securities by the
transferee or assignee is restricted under the Act and applicable state
securities laws. 

          6.6            STAND-OFF AGREEMENT.  No Warrantholder who participates
in the registration, if so requested by the Company and an underwriter of
securities of the Company, will sell or otherwise transfer or dispose of any
other securities of the Company held by such Warrantholder other than pursuant
to the registration statement during the 30-day period preceding and the 120-day
period following and including the effective date of a registration statement;
provided, however, that such Warrantholder's agreement in this Section 6.6 will
only apply (a) to the first two such registration statements of the Company
including shares or securities to be sold on the Company's behalf to the general
public in an underwritten offering and (b) if all officers and directors of the
Company enter into similar agreements in writing in a form satisfactory to the
Company and such underwriter covering shares of the Common stock (or other
securities) owned by them.  The Company may impose stop transfer instructions
with respect to the securities subject to the restriction in this Section 6.6
until the end of the 120-day period. 

          6.7            INDEMNIFICATION IN CONNECTION WITH REGISTRATION. 

          (a)       If any of the Registrable Securities are registered, to the
extent permitted by law, the Company will indemnify and hold harmless each
selling Warrantholder, any person who controls any selling Warrantholder within
the meaning of the Act, any underwriter for a selling Warrantholder and any
person who controls such underwriter within the meaning of the Act (collectively
with the underwriter, a "Participating Underwriter") against any losses, claims,
damages, or liabilities, joint or several, to which any Warrantholder,
controlling person, or Participating Underwriter may be subject under the Act or
otherwise; and it will reimburse each 

7


<PAGE>

Warrantholder, each controlling person, and each Participating Underwriter 
for any legal or other expenses reasonably incurred by the Warrantholder, 
controlling person, or Participating Underwriter in connection with 
investigating or defending any such loss, claim, damage, liability, or 
action, insofar as such losses, claims, damages, or liabilities, joint or 
several (or actions in respect thereof), arise out of or are based upon any 
of the following statements, omissions or violations (collectively or 
separately, a "Violation"): (i) any untrue statement or alleged untrue 
statement of any material fact contained, on the effective date thereof, in 
any such registration statement or any preliminary prospectus or final 
prospectus, or ~ny amendment or supplement thereto, (ii) the omission or 
alleged omission to state therein a material fact required to be stated 
therein or necessary to make the statements therein not misleading or (iii) 
any violation or alleged violation by the Company of the Act, the 1934 Act, 
any state securities law, or any rule or regulation promulgated under the 
Act, the 1934 Act or any state securities law; provided, however, that the 
Company will not be liable in any case to the extent that any loss, claim, 
damage, or liability arises out of or is based upon any untrue statement or 
alleged untrue statement or omission or alleged omission made in any 
registration statement, preliminary prospectus, final prospectus, or any 
amendment or supplement thereto, in reliance upon and in conformity with 
written information furnished by a Warrantholder for use in the preparation 
thereof and provided further, that if any losses, claims, damages or 
liabilities arise out of or are based upon an untrue statement, alleged 
untrue statement, omission or alleged omission contained in any preliminary 
prospectus which did not appear in the final prospectus, the Company shall 
not have any liability with respect thereto to (i) the selling Warrantholder 
or any person who controls such selling Warrantholder within the meaning of 
the Act, if the selling Warrantholder delivered a copy of the preliminary 
prospectus to the person alleging such losses, claims, damages or liabilities 
and failed to deliver a copy of the final prospectus, as amended or 
supplement if it has been amended or supplemented, to such person at or prior 
to the written confirmation of the sale to such person or (ii) any 
Participating Underwriter, if such Participating Underwriter delivered a copy 
of the preliminary prospectus to the person alleging such losses, claims, 
damages or liabilities and failed to deliver a copy of the final prospectus, 
as amended or supplemented if it has been amended or supplemented, to such 
person at or prior to the written confirmation of the sale to such person.  
The indemnity agreement contained in this subsection (a) shall not apply to 
amounts paid to any claimant in settlement of any suit or claim unless 
such-payment is first approved by the Company, such approval not to be 
unreasonably withheld. 

          (b)       Each selling Warrantholder, to the extent permitted by law
and as a condition of the Company's registration obligation, will indemnify and
hold harmless the Company, each of the Company's directors, each of the
Company's officers who have signed any registration statement or other filing or
any amendment or supplement thereto, any person who controls the Company within
the meaning of the Act, each other Selling Warrantholder or any other person
participating as a selling shareholder in the registration (collectively, a
"Selling Shareholder"), any person who controls any such Selling shareholder
within the meaning of the Act, and any Participating Underwriter against any
losses, claims, damages, or liabilities to which the Company or any such
director, officer, Selling Shareholder, Participating Underwriter or controlling
person may become subject under the Act or otherwise, and will reimburse any

8


<PAGE>

legal or other expenses reasonably incurred by the Company or any such 
director, officer, Selling Shareholder, Participating Underwriter, or 
controlling person in connection with investigating or defending any such 
loss, claim, damage, liability, or action insofar as such losses, claims, 
damages, or liabilities (or actions in respect thereof) arise out of or are 
based upon any Violation but only to the extent that such Violation was made 
in said registration statement, preliminary or final prospectus, or other 
filing, or amendment or supplement, in reliance upon and in conformity with 
written information furnished by such Warrantholder for use in the 
preparation thereof; provided, however, that the indemnity agreement 
contained in this subsection (b) shall not apply to amounts paid to any 
claimant in settlement of any suit or claim unless such payment is first 
approved by the Warrantholder, such approval not to be unreasonably withheld. 

          (c)       Promptly after receipt by an indemnified party under
subsections (a) or (b) above of written notice of the commencement of any
action, such indemnified party will, if a claim in respect thereof is to be made
against an indemnifying party, deliver to the indemnifying party written notice
of the commencement thereof.  The failure to notify an indemnifying party
promptly of the commencement of any such action, if prejudicial to the ability
of the indemnifying party to defend the action, shall relieve the indemnifying
party of any liability to the indemnified party pursuant to this Section 6; but
the omission to notify the indemnifying party will not relieve it from any
liability which it may have to any indemnified party otherwise than under
subsections (a) and (b). 

          (d)       If any such action is brought against any indemnified party
and it notifies in writing an indemnifying party of the commencement thereof,
the indemnifying party will be entitled to participate in, and, to the extent
that it may wish, jointly with any other indemnifying party similarly notified,
to assume the defense thereof, with counsel satisfactory to such indemnified
party; and after notice from the indemnifying party to such indemnified party of
its election to assume the defense thereof, the indemnifying party will not be
liable to such indemnified party for any legal or other expenses subsequently
incurred by such indemnified party in connection with the defense thereof other
than reasonable costs of investigation. 

          (e)       The obligations of the Company and the Warrantholder under
this Section 6.7 shall survive the redemption and conversion, if any, of the
Common Stock, the completion of any offering of Registrable Securities in a
registration statement under this Section 6, and otherwise. 

          6.8            DELAY OF REGISTRATION.  No Warrantholder shall have any
right to obtain or seek an injunction restraining or otherwise delaying any such
registration as a result of any controversy that might arise with respect to the
interpretation or implementation of this Section 6. 

          6.9            RESERVATION OF RIGHTS.  Nothing herein contained shall
prevent or limit the Company from granting similar registration rights in
subsequent financings to any other person or entity on terms no more favorable
and with no greater priority than those granted herein. 

9


<PAGE>

     7.        RESTRICTIONS ON TRANSFER.  This Warrant Certificate, the
Warrants, and the Securities are transferable.  Prior to any proposed transfer,
the Company must be given written notice of the transfer, stating the name and
address of the proposed transferee, and identifying the securities to be
transferred, the proposed transferee must agree in writing to comply with the
terms of this Warrant Certificate; and the Company must receive an opinion of
counsel, in form and substance and from counsel satisfactory to the Company, to
the effect that the proposed transfer is in compliance with applicable federal
and state securities laws. 

     8.        RIGHTS OF FIRST REFUSAL.  Notwithstanding any other provision of
this Warrant Certificate, in the event a Warrantholder shall propose to accept
one or more bona fide offers from any persons to purchase the Warrants or the
Securities issuable thereunder from the Warrantholder, the Warrantholder shall
promptly notify the Company of the terms and conditions of such offer or offers,
and the Warrantholder shall not transfer any of the Warrants or the Securities
for consideration unless the Warrantholder first offers to sell the Warrant or
Securities on identical terms and conditions pursuant to this Section 8 and such
offer is not accepted. 

          (a)       All offers shall be made in writing and shall include the
number of Warrants or Securities offered, the terms of transfer, including the
price or consideration to be received, and any related arrangements or
understandings that may have a bearing on the terms of the offer.  All offers
pursuant to this Section 8 shall be made first to the Company, and if not
accepted by the Company within 20 days, to the Ten Percent Shareholders, which
holders shall have an additional 20 days to accept the offer. 

          (b)       Within 20 days of receipt of an offer pursuant to this
Section 8, the Company may purchase any or all of the Warrants or Securities
offered by written notice to the Warrantholder.  The Company may assign its
Right of First Refusal to a new shareholder if, after the acceptance of the
offer by the new shareholder, it would be a Ten Percent Shareholder.  To the
extent not accepted by the Company within 20 days, the Warrantholder shall
immediately offer any and all of the remaining Warrants or Securities to the Ten
Percent Shareholders.  Within 20 days after receipt of such offer, any Ten
Percent Shareholder may purchase any and all of the Warrants or Securities
offered.  If Ten Percent Shareholders subscribe in the aggregate for more
Warrants or Securities than are offered, they will be sold to Ten Percent
Shareholder by the Warrantholder as directed in writing by the Company. 

          (c)      The purchase price for Warrants or Securities shall be paid
in lawful money of the United States.  The total purchase price shall be paid by
the Company or Ten Percent Shareholders within one year of the acceptance of the
offer. 

          (d)      For 30 days following the earlier to occur of (i) expiration
of the final offer period or (ii) the written rejection of the offer by the
Company and all Ten Percent Shareholders, the Warrantholder may sell the
Warrants or Securities to the bona fide offeree or offerees on the same terms as
offered to the Company and the Ten Percent Shareholders. 

10


<PAGE>

     9.        SALE OR LIQUIDATION.  In the event of a voluntary or involuntary
sale or liquidation of the Company or its assets, the Warrantholder shall have
no rights as a creditor of the Company, rather the Warrantholder's liquidation
rights and position shall be equivalent, on a pro-rata basis, to the rights and
position of the holders of the Common Stock. 

     10.       NO RIGHTS AS A SHAREHOLDER.  Except as otherwise provided herein,
the Warrantholder shall not, by virtue of ownership of Warrants, be entitled to
any rights of a shareholder of the Company, but shall be entitled to receive
such quarterly or annual reports as the Company shall distribute to its
shareholders. 

     11.       NOTICE.  Any notices required or permitted to be given hereunder
shall be in writing and may be served personally or by mail; and if served shall
be addressed as follows: 

     If to the Company: 

          249 S.W. Avery 
          Corvallis, OR 97333 
          ATTENTION: PRESIDENT

     If to the Warrantholder: 

          1934 N.E. Broadway 
          Portland, OR 97232 

     Any notice so given by mail shall be deemed effectively given 48 hours
after mailing when deposited in the United States mail, registered or certified
mail, return receipt requested, postage prepaid and addressed as specified
above.  Any party may by written notice to the other specify a different address
for notice purposes.

11


<PAGE>

     12.       APPLICABLE LAW.  This Warrant Certificate shall be governed by
and construed in accordance with the laws of Oregon. 

          Dated as of _________________________, 1992.

                                         ANTIVIRALS, INC.



                                         By:
                                             ----------------------------------
                                             Denis Burger, PhD, President


                                         OREGON RESOURCE AND TECHNOLOGY 
                                         DEVELOPMENT CORPORATION



                                         By:
                                             ----------------------------------
                                             John A. Beaulieu, President


12



<PAGE>

                                 ANTIVIRALS INC.
                            1992 STOCK INCENTIVE PLAN



     1.   PURPOSE.  The purpose of this Stock Incentive Plan (the "Plan")
is to enable ANTIVIRALS Inc. (the "Company") to attract and retain the services
of (1) selected employees, officers and directors of the Company or of any
subsidiary of the Company and (2) selected nonemployee agents, consultants,
advisors, persons involved in the sale or distribution of the Company's products
and independent contractors of the Company or any subsidiary.

     2.   SHARES SUBJECT TO THE PLAN.  Subject to adjustment as provided
below and in paragraph 14, the shares to be offered under the Plan shall consist
of Common Stock of the Company, and the total number of shares of Common Stock
that may be issued under the Plan shall not exceed 4,000,000 shares.  The shares
issued under the Plan may be authorized and unissued shares or reacquired
shares.  If an option, stock appreciation right or performance unit granted
under the Plan expires, terminates or is cancelled, the unissued shares subject
to such option, stock appreciation right or performance unit shall again be
available under the Plan.  If shares sold or awarded as a bonus under the Plan
are forfeited to the Company or repurchased by the Company, the
 number of shares
forfeited or repurchased shall again be available under the Plan.

     3.   EFFECTIVE DATE AND DURATION OF PLAN.

          (a)    EFFECTIVE DATE.  The Plan shall become effective as of
June 3, 1992.  No option, stock appreciation right or performance unit granted
under the Plan to an officer who is subject to Section 16(b) of the Securities
Exchange Act of 1934, as amended (an "Officer") or a director shall become
exercisable, however, until the Plan is approved by the affirmative vote of the
holders of a majority of the shares of Common Stock represented at a
shareholders meeting at which a quorum is present and any such awards under the
Plan prior to such approval shall be conditioned on and subject to such
approval.  Subject to this limitation, options, stock appreciation rights and
performance units may be granted and shares may be awarded as bonuses or sold
under the Plan at any time after the effective date and before termination of
the Plan.

          (b)    DURATION.  The Plan shall continue in effect until all
shares available for issuance under the Plan have been issued and all
restrictions on such shares have lapsed.  The Board of Directors may suspend or
terminate the Plan at any time except with respect to options, performance units
and shares subject to restrictions then outstanding under the Plan.  Termination
shall not affect any outstanding options, any right of the Company to repurchase
shares or the forfeitability of shares issued under the Plan.

                                       1


<PAGE>

     4.   ADMINISTRATION.

          (a)    BOARD OF DIRECTORS.  The Plan shall be administered by the
Board of Directors of the Company, which shall determine and designate from time
to time the individuals to whom awards shall be made, the amount of the awards
and the other terms and conditions of the awards.  Subject to the provisions of
the Plan, the Board of Directors may from time to time adopt and amend rules and
regulations relating to administration of the Plan, advance the lapse of any
waiting period, accelerate any exercise date, waive or modify any restriction
applicable to shares (except those restrictions imposed by law) and make all
other determinations in the judgment of the Board of Directors necessary or
desirable for the administration of the Plan.  The interpretation and
construction of the provisions of the Plan and related agreements by the Board
of Directors shall be final and conclusive.  The Board of Directors may correct
any defect or supply any omission or reconcile any inconsistency in the Plan or
in any related agreement in the manner and to the extent it shall deem expedient
to carry the Plan into effect, and it shall be the sole and final judge of such
expediency.

          (b)    COMMITTEE.  The Board of Directors may delegate to a
committee of the Board of Directors or specified officers of the Company, or
both (the "Committee") any or all authority for administration of the Plan.  If
authority is delegated to a Committee, all references to the Board of Directors
in the Plan shall mean and relate to the Committee except (i) as otherwise
provided by the Board of Directors, (ii) that only the Board of Directors may
amend or terminate the Plan as provided in paragraphs 3 and 16 and (iii) that a
Committee including officers of the Company shall not be permitted to grant
options to persons who are officers of the Company.  If awards are to be made
under the Plan to Officers or directors, authority for selection of Officers and
directors for participation and decisions concerning the timing, pricing and
amount of a grant or award, if not determined under a formula meeting the
requirements of Rule 16b-3 under the Securities Exchange Act of 1934, as
amended, shall be delegated to a committee consisting of two or more
disinterested directors.

     5.   TYPES OF AWARDS; ELIGIBILITY.  The Board of Directors may, from
time to time, take the following action, separately or in combination, under the
Plan:  (i) grant Incentive Stock Options, as defined in Section 422 of the
Internal Revenue Code of 1986, as amended (the "Code"), as provided in
paragraphs 6(a) and 6(b); (ii) grant options other than Incentive Stock Options
("Non-Statutory Stock Options") as provided in paragraphs 6(a) and 6(c);
(iii) award stock bonuses as provided in paragraph 7; (iv) sell shares subject
to restrictions as provided in paragraph 8; (v) grant stock appreciation rights
as provided in paragraph 9; (vi) grant cash bonus rights as provided in
paragraph 10; (vii) grant performance units as provided in paragraph 11 and
(viii) grant foreign qualified awards as provided in paragraph 12.  Any such
awards may be made to employees, including employees who are officers or
directors, and to other individuals described in paragraph 1 who the Board of
Directors believes have made or will make an important contribution to the
Company or any subsidiary of the Company; provided, however, that only employees
of the Company shall be eligible to receive Incentive Stock Options under the
Plan.  The Board of Directors shall select the individuals to whom awards shall
be made and shall specify the action taken with respect to each individual to
whom an

                                       2

<PAGE>

award is made.  At the discretion of the Board of Directors, an individual 
may be given an election to surrender an award in exchange for the grant of a 
new award.

     6.   OPTION GRANTS.

          (a)    GENERAL RULES RELATING TO OPTIONS.

                 (i)    TERMS OF GRANT.  The Board of Directors may grant
options under the Plan.  With respect to each option grant, the Board of
Directors shall determine the number of shares subject to the option, the option
price, the period of the option, the time or times at which the option may be
exercised and whether the option is an Incentive Stock Option or a Non-Statutory
Stock Option.  At the time of the grant of an option or at any time thereafter,
the Board of Directors may provide that an optionee who exercised an option with
Common Stock of the Company shall automatically receive a new option to purchase
additional shares equal to the number of shares surrendered and may specify the
terms and conditions of such new options.

                 (ii)   EXERCISE OF OPTIONS.  Except as provided in
paragraph 6(a)(iv) or as determined by the Board of Directors, no option granted
under the Plan may be exercised unless at the time of such exercise the optionee
is employed by or in the service of the Company or any subsidiary of the Company
and shall have been so employed or provided such service continuously since the
date such option was granted.  Absence on leave or on account of illness or
disability under rules established by the Board of Directors shall not, however,
be deemed an interruption of employment or service for this purpose.  Unless
otherwise determined by the Board of Directors, vesting of options shall not
continue during an absence on leave (including an extended illness) or on
account of disability.  Except as provided in paragraphs 6(a)(iv), 14 and 15,
options granted under the Plan may be exercised from time to time over the
period stated in each option in such amounts and at such times as shall be
prescribed by the Board of Directors, provided that options shall not be
exercised for fractional shares.  Unless otherwise determined by the Board of
Directors, if the optionee does not exercise an option in any one year with
respect to the full number of shares to which the optionee is entitled in that
year, the optionee's rights shall be cumulative and the optionee may purchase
those shares in any subsequent year during the term of the option.  Unless
otherwise determined by the Board of Directors, if an Officer exercises an
option within six months of the grant of the option, the shares acquired upon
exercise of the option may not be sold until six months after the date of grant
of the option.

                 (iii)  NONTRANSFERABILITY.  Each Incentive Stock Option
and, unless otherwise determined by the Board of Directors with respect to an
option granted to a person who is neither an Officer nor a director of the
Company, each other option granted under the Plan by its terms shall be
nonassignable and nontransferable by the optionee, either voluntarily or by
operation of law, except by will or by the laws of descent and distribution of
the state or country of the optionee's domicile at the time of death or, for
options other than Incentive Stock Options, pursuant to a qualified domestic
relations order as defined under the Code or Title I of the Employee Retirement
Income Security Act.

                                       3

<PAGE>

                 (iv)   TERMINATION OF EMPLOYMENT OR SERVICE.

                        (A)     GENERAL RULE.  Unless otherwise determined by
     the Board of Directors, in the event the employment or service of the
     optionee with the Company or a subsidiary terminates for any reason
     other than because of physical disability or death as provided in
     subparagraphs 6(a)(iv)(B) and (C), the option may be exercised at any
     time prior to the expiration date of the option or the expiration of
     30 days after the date of such termination, whichever is the shorter
     period, but only if and to the extent the optionee was entitled to
     exercise the option at the date of such termination.

                        (B)     TERMINATION BECAUSE OF TOTAL DISABILITY. Unless
     otherwise determined by the Board of Directors, in the event of the 
     termination of employment or service because of total disability,
     the option may be exercised at any time prior to the expiration date
     of the option or the expiration of 12 months after the date of such
     termination, whichever is the shorter period, but only if and to the
     extent the optionee was entitled to exercise the option at the date of
     such termination.  The term "total disability" means a mental or
     physical impairment which is expected to result in death or which has
     lasted or is expected to last for a continuous period of 12 months or
     more and which causes the optionee to be unable, in the opinion of the
     Company and two independent physicians, to perform his or her duties
     as an employee, director, officer or consultant of the Company and to
     be engaged in any substantial gainful activity.  Total disability
     shall be deemed to have occurred on the first day after the Company
     and the two independent physicians have furnished their opinion of
     total disability to the Company.

                        (C)     TERMINATION BECAUSE OF DEATH.  Unless
     otherwise determined by the Board of Directors, in the event of the
     death of an optionee while employed by or providing service to the
     Company or a subsidiary, the option may be exercised at any time prior
     to the expiration date of the option or the expiration of 12 months
     after the date of death, whichever is the shorter period, but only if
     and to the extent the optionee was entitled to exercise the option at
     the date of death and only by the person or persons to whom such
     optionee's rights under the option shall pass by the optionee's will
     or by the laws of descent and distribution of the state or country of
     domicile at the time of death.

                        (D)     AMENDMENT OF EXERCISE PERIOD APPLICABLE TO
     TERMINATION.  The Board of Directors at the time of grant or at any
     time thereafter, may extend the 30-day and 12-month exercise periods
     any length of time not longer than the original expiration date of the
     option, and may increase the portion of an option that is exercisable,
     subject to such terms and conditions as the Board of Directors may
     determine.

                                       4

<PAGE>

                        (E)     FAILURE TO EXERCISE OPTION.  To the extent
     that the option of any deceased optionee or of any optionee whose
     employment or service terminates is not exercised within the
     applicable period, all further rights to purchase shares pursuant to
     such option shall cease and terminate.

                 (v)    PURCHASE OF SHARES.  Unless the Board of Directors
determines otherwise, shares may be acquired pursuant to an option granted under
the Plan only upon receipt by the Company of notice in writing from the optionee
of the optionee's intention to exercise, specifying the number of shares as to
which the optionee desires to exercise the option and the date on which the
optionee desires to complete the transaction, and if required in order to comply
with the Securities Act of 1933, as amended, containing a representation that it
is the optionee's present intention to acquire the shares for investment and not
with a view to distribution.  Unless the Board of Directors determines
otherwise, on or before the date specified for completion of the purchase of
shares pursuant to an option, the optionee must have paid the Company the full
purchase price of such shares in cash (including, with the consent of the Board
of Directors, cash that may be the proceeds of a loan from the Company) or, with
the consent of the Board of Directors, in whole or in part, in Common Stock of
the Company valued at fair market value, restricted stock, performance units or
other contingent awards denominated in either stock or cash, promissory notes
and other forms of consideration.  The fair market value of Common Stock
provided in payment of the purchase price shall be determined by the Board of
Directors.  If the Common Stock of the Company is not publicly traded on the
date the option is exercised, the Board of Directors may consider any valuation
methods it deems appropriate and may but is not required to, obtain one or more
independent appraisals of the Company.  If the Common Stock of the Company is
publicly traded on the date the option is exercised, the fair market value of
Common Stock provided in payment of the purchase price shall be the closing
price of the Common Stock as reported in THE WALL STREET JOURNAL on the trading
day preceding the date the option is exercised, or such other reported value of
the Common Stock as shall be specified by the Board of Directors.  No shares
shall be issued until full payment for the shares has been made.  With the
consent of the Board of Directors, an optionee may request the Company to apply
automatically the shares to be received upon the exercise of a portion of a
stock option (even though stock certificates have not yet been issued) to
satisfy the purchase price for additional portions of the option.  Each optionee
who has exercised an option shall immediately upon notification of the amount
due, if any, pay to the Company in cash amounts necessary to satisfy any
applicable federal, state and local tax withholding requirements.  If additional
withholding is or becomes required beyond any amount deposited before delivery
of the certificates, the optionee shall pay such amount to the Company on
demand.  If the optionee fails to pay the amount demanded, the Company may
withhold that amount from other amounts payable by the Company to the optionee,
including salary, subject to applicable law.  With the consent of the Board of
Directors an optionee may satisfy this obligation, in whole or in part, by
having the Company withhold from the shares to be issued upon the exercise that
number of shares that would satisfy the withholding amount due or by delivering
to the Company Common Stock to satisfy the withholding amount.  Upon the
exercise of an option, the number of shares reserved for issuance under the Plan
shall be reduced by the number of shares issued upon exercise of the option.

                                       5

<PAGE>


          (b)    INCENTIVE STOCK OPTIONS.  Incentive Stock Options shall be
subject to the following additional terms and conditions:

                 (i)    LIMITATION ON AMOUNT OF GRANTS.  No employee may be
granted Incentive Stock Options under the Plan if the aggregate fair market
value, on the date of grant, of the Common Stock with respect to which Incentive
Stock Options are exercisable for the first time by that employee during any
calendar year under the Plan and under any other incentive stock option plan
(within the meaning of Section 422 of the Code) of the Company or any parent or
subsidiary of the Company exceeds $100,000.

                 (ii)   LIMITATIONS ON GRANTS TO 10 PERCENT SHAREHOLDERS.  An
Incentive Stock Option may be granted under the Plan to an employee possessing
more than 10 percent of the total combined voting power of all classes of stock
of the Company or of any parent or subsidiary of the Company only if the option
price is at least 110 percent of the fair market value of the Common Stock
subject to the option on the date it is granted, as described in
paragraph 6(b)(iv), and the option by its terms is not exercisable after the
expiration of five years from the date it is granted.

                 (iii)  DURATION OF OPTIONS.  Subject to paragraphs 6(a)(ii) 
and 6(b)(ii), Incentive Stock Options granted under the Plan shall continue 
in effect for the period fixed by the Board of Directors, except that no 
Incentive Stock Option shall be exercisable after the expiration of 10 years 
from the date it is granted.

                 (iv)   OPTION PRICE.  The option price per share shall be
determined by the Board of Directors at the time of grant.  Except as provided
in paragraph 6(b)(ii), the option price shall not be less than 100 percent of
the fair market value of the Common Stock covered by the Incentive Stock Option
at the date the option is granted.  The fair market value shall be determined by
the Board of Directors.  If the Common Stock of the Company is not publicly
traded on the date the option is granted, the Board of Directors may consider
any valuation methods it deems appropriate and may, but is not required to,
obtain one or more independent appraisals of the Company.  If the Common Stock
of the Company is publicly traded on the date the option is exercised, the fair
market value shall be deemed to be the closing price of the Common Stock as
reported in THE WALL STREET JOURNAL on the day preceding the date the option is
granted, or if there has been no sale on that date, on the last preceding date
on which a sale occurred, or such other value of the Common Stock as shall be
specified by the Board of Directors.

                 (v)    LIMITATION ON TIME OF GRANT.  No Incentive Stock Option
shall be granted on or after the tenth anniversary of the effective date of the
Plan.

                 (vi)   CONVERSION OF INCENTIVE STOCK OPTIONS.  The Board of
Directors may at any time without the consent of the optionee convert an
Incentive Stock Option to a Non-Statutory Stock Option.

                                       6

<PAGE>

          (c)    NON-STATUTORY STOCK OPTIONS.  Non-Statutory Stock Options
shall be subject to the following terms and conditions in addition to those set
forth in Section 6(a) above:

                 (i)    OPTION PRICE.  The option price for Non-Statutory Stock
Options shall be determined by the Board of Directors at the time of grant and
may be any amount determined by the Board of Directors.

                 (ii)   DURATION OF OPTIONS.  Non-Statutory Stock Options
granted under the Plan shall continue in effect for the period fixed by the
Board of Directors.

     7.   STOCK BONUSES.  The Board of Directors may award shares under the
Plan as stock bonuses.  Shares awarded as a bonus shall be subject to the terms,
conditions, and restrictions determined by the Board of Directors.  The
restrictions may include restrictions concerning transferability and forfeiture
of the shares awarded, together with such other restrictions as may be
determined by the Board of Directors.  If shares are subject to forfeiture, all
dividends or other distributions paid by the Company with respect to the shares
shall be retained by the Company until the shares are no longer subject to
forfeiture, at which time all accumulated amounts shall be paid to the
recipient.  The Board of Directors may require the recipient to sign an
agreement as a condition of the award, but may not require the recipient to pay
any monetary consideration other than amounts necessary to satisfy tax
withholding requirements.  The agreement may contain any terms, conditions,
restrictions, representations and warranties required by the Board of Directors.
The certificates representing the shares awarded shall bear any legends required
by the Board of Directors.  Unless otherwise determined by the Board of
Directors, shares awarded as a stock bonus to an Officer may not be sold until
six months after the date of the award.  The Company may require any recipient
of a stock bonus to pay to the Company in cash upon demand amounts necessary to
satisfy any applicable federal, state or local tax withholding requirements.  If
the recipient fails to pay the amount demanded, the Company may withhold that
amount from other amounts payable by the Company to the recipient, including
salary or fees for services, subject to applicable law.  With the consent of the
Board of Directors, a recipient may deliver Common Stock to the Company to
satisfy this withholding obligation.  Upon the issuance of a stock bonus, the
number of shares reserved for issuance under the Plan shall be reduced by the
number of shares issued.

     8.   RESTRICTED STOCK.  The Board of Directors may issue shares under
the Plan for such consideration (including promissory notes and services) as
determined by the Board of Directors.  Shares issued under the Plan shall be
subject to the terms, conditions and restrictions determined by the Board of
Directors.  The restrictions may include restrictions concerning
transferability, repurchase by the Company and forfeiture of the shares issued,
together with such other restrictions as may be determined by the Board of
Directors.  If shares are subject to forfeiture or repurchase by the Company,
all dividends or other distributions paid by the Company with respect to the
shares shall be retained by the Company until the shares are no longer subject
to forfeiture or repurchase, at which time all accumulated amounts shall be paid
to the recipient.  All Common Stock issued pursuant to this paragraph 8 shall be
subject to a purchase agreement, which shall be executed by the Company and the
prospective recipient of

                                       7

<PAGE>

the shares prior to the delivery of certificates representing such shares to 
the recipient.  The purchase agreement may contain any terms, conditions, 
restrictions, representations and warranties required by the Board of 
Directors.  The certificates representing the shares shall bear any legends 
required by the Board of Directors.  Unless otherwise determined by the Board 
of Directors, shares issued under this paragraph 8 to an Officer may not be 
sold until six months after the shares are issued.  The Company may require 
any purchaser of restricted stock to pay to the Company in cash upon demand 
amounts necessary to satisfy any applicable federal, state or local tax 
withholding requirements.  If the purchaser fails to pay the amount demanded, 
the Company may withhold that amount from other amounts payable by the 
Company to the purchaser, including salary, subject to applicable law.  With 
the consent of the Board of Directors, a purchaser may deliver Common Stock 
to the Company to satisfy this withholding obligation.  Upon the issuance of 
restricted stock, the number of shares reserved for issuance under the Plan 
shall be reduced by the number of shares issued.

     9.   STOCK APPRECIATION RIGHTS.

          (a)    GRANT.  Stock appreciation rights may be granted under the
Plan by the Board of Directors, subject to such rules, terms, and conditions as
the Board of Directors prescribes.

          (b)    EXERCISE.

                 (i)    Each stock appreciation right shall entitle the holder,
upon exercise, to receive from the Company in exchange therefor an amount equal
in value to the excess of the fair market value on the date of exercise of one
share of Common Stock of the Company over its fair market value on the date of
grant (or, in the case of a stock appreciation right granted in connection with
an option, the excess of the fair market value of one share of Common Stock of
the Company over the option price per share under the option to which the stock
appreciation right relates), multiplied by the number of shares covered by the
stock appreciation right or the option, or portion thereof, that is surrendered.
No stock appreciation right shall be exercisable at a time that the amount
determined under this subparagraph is negative.  Payment by the Company upon
exercise of a stock appreciation right may be made in Common Stock valued at
fair market value, in cash, or partly in Common Stock and partly in cash, all as
determined by the Board of Directors.

                 (ii)   A stock appreciation right shall be exercisable only at
the time or times established by the Board of Directors.  If a stock
appreciation right is granted in connection with an option, the following rules
shall apply:  (1) the stock appreciation right shall be exercisable only to the
extent and on the same conditions that the related option could be exercised;
(2) upon exercise of the stock appreciation right, the option or portion thereof
to which the stock appreciation right relates terminates; and (3) upon exercise
of the option, the related stock appreciation right or portion thereof
terminates.  Unless otherwise determined by the Board of Directors, no stock
appreciation right granted to an Officer or director may be exercised during the
first six months following the date it is granted.

                                       8

<PAGE>

                 (iii)  The Board of Directors may withdraw any stock
appreciation right granted under the Plan at any time and may impose any
conditions upon the exercise of a stock appreciation right or adopt rules and
regulations from time to time affecting the rights of holders of stock
appreciation rights.  Such rules and regulations may govern the right to
exercise stock appreciation rights granted prior to adoption or amendment of
such rules and regulations as well as stock appreciation rights granted
thereafter.

                 (iv)   For purposes of this paragraph 9, the fair market value
of the Common Stock shall be determined as of the date the stock appreciation
right is exercised, under the methods set forth in paragraph 6(b)(iv).

                 (v)    No fractional shares shall be issued upon exercise of a
stock appreciation right. In lieu thereof, cash may be paid in an amount equal
to the value of the fraction or, if the Board of Directors shall determine, the
number of shares may be rounded downward to the next whole share.

                 (vi)   Each stock appreciation right granted in connection
with an Incentive Stock Option, and unless otherwise determined by the Board of
Directors with respect to a stock appreciation right granted to a person who is
neither an Officer nor a director of the Company, each other stock appreciation
right granted under the Plan by its terms shall be nonassignable and
nontransferable by the holder, either voluntarily or by operation of law, except
by will or by the laws of descent and distribution of the state or country of
the holder's domicile at the time of death, and each stock appreciation right by
its terms shall be exercisable during the holder's lifetime only by the holder;
provided, however, that a stock appreciation right not granted in connection
with an Incentive Stock Option shall also be transferable pursuant to a
qualified domestic relations order as defined under the Code or Title I of the
Employee Retirement Income Security Act.

                 (vii)  Each participant who has exercised a stock 
appreciation right shall, upon notification of the amount due, pay to the 
Company in cash amounts necessary to satisfy any applicable federal, state 
and local tax withholding requirements.  If the participant fails to pay the 
amount demanded, the Company may withhold that amount from other amounts 
payable by the Company to the participant including salary, subject to 
applicable law.  With the consent of the Board of Directors a participant may 
satisfy this obligation, in whole or in part, by having the Company withhold 
from any shares to be issued upon the exercise that number of shares that 
would satisfy the withholding amount due or by delivering Common Stock to the 
Company to satisfy the withholding amount.

                 (viii) Upon the exercise of a stock appreciation right for 
shares, the number of shares reserved for issuance under the Plan shall be 
reduced by the number of shares issued.  Cash payments of stock appreciation 
rights shall not reduce the number of shares of Common Stock reserved for 
issuance under the Plan.

                                       9

<PAGE>

     10.  CASH BONUS RIGHTS.

          (a)    GRANT.  The Board of Directors may grant cash bonus rights
under the Plan in connection with (i) options granted or previously granted,
(ii) stock appreciation rights granted or previously granted, (iii) stock
bonuses awarded or previously awarded and (iv) shares sold or previously sold
under the Plan.  Cash bonus rights will be subject to rules, terms and
conditions as the Board of Directors may prescribe.  Unless otherwise determined
by the Board of Directors with respect to a cash bonus right granted to a person
who is neither an Officer nor a director of the Company, each cash bonus right
granted under the Plan by its terms shall be nonassignable and nontransferable
by the holder, either voluntarily or by operation of law, except by will or by
the laws of descent and distribution of the state or country of the holder's
domicile at the time of death or pursuant to a qualified domestic relations
order as defined under the Code or Title I of the Employee Retirement Income
Security Act.  The payment of a cash bonus shall not reduce the number of shares
of Common Stock reserved for issuance under the Plan.

          (b)    CASH BONUS RIGHTS IN CONNECTION WITH OPTIONS.  A cash bonus
right granted in connection with an option will entitle an optionee to a cash
bonus when the related option is exercised (or terminates in connection with the
exercise of a stock appreciation right related to the option) in whole or in
part.  If an optionee purchases shares upon exercise of an option and does not
exercise a related stock appreciation right, the amount of the bonus shall be
determined by multiplying the excess of the total fair market value of the
shares to be acquired upon the exercise over the total option price for the
shares by the applicable bonus percentage.  If the optionee exercises a related
stock appreciation right in connection with the termination of an option, the
amount of the bonus shall be determined by multiplying the total fair market
value of the shares and cash received pursuant to the exercise of the stock
appreciation right by the applicable bonus percentage.  The bonus percentage
applicable to a bonus right shall be determined from time to time by the Board
of Directors but shall in no event exceed 75 percent.

          (c)    CASH BONUS RIGHTS IN CONNECTION WITH STOCK BONUS.  A cash
bonus right granted in connection with a stock bonus will entitle the recipient
to a cash bonus payable when the stock bonus is awarded or restrictions, if any,
to which the stock is subject lapse.  If bonus stock awarded is subject to
restrictions and is repurchased by the Company or forfeited by the holder, the
cash bonus right granted in connection with the stock bonus shall terminate and
may not be exercised.  The amount and timing of payment of a cash bonus shall be
determined by the Board of Directors.

          (d)    CASH BONUS RIGHTS IN CONNECTION WITH STOCK PURCHASES.  A
cash bonus right granted in connection with the purchase of stock pursuant to
paragraph 8 will entitle the recipient to a cash bonus when the shares are
purchased or restrictions, if any, to which the stock is subject lapse.  Any
cash bonus right granted in connection with shares purchased pursuant to
paragraph 8 shall terminate and may not be exercised in the event the shares are
repurchased by the Company or forfeited by the holder pursuant to applicable
restrictions.  The

                                       10

<PAGE>

amount of any cash bonus to be awarded and timing of payment of a cash bonus 
shall be determined by the Board of Directors.

          (e)    TAXES.  The Company shall withhold from any cash bonus paid
pursuant to paragraph 10 the amount necessary to satisfy any applicable federal,
state and local withholding requirements.

     11.  PERFORMANCE UNITS.  The Board of Directors may grant performance
units consisting of monetary units which may be earned in whole or in part if
the Company achieves certain goals established by the Board of Directors over a
designated period of time, but not in any event more than 10 years.  The goals
established by the Board of Directors may include earnings per share, return on
shareholders' equity, return on invested capital, and such other goals as may be
established by the Board of Directors.  In the event that the minimum
performance goal established by the Board of Directors is not achieved at the
conclusion of a period, no payment shall be made to the participants.  In the
event the maximum corporate goal is achieved, 100 percent of the monetary value
of the performance units shall be paid to or vested in the participants. 
Partial achievement of the maximum goal may result in a payment or vesting
corresponding to the degree of achievement as determined by the Board of
Directors.  Payment of an award earned may be in cash or in Common Stock or in a
combination of both, and may be made when earned, or vested and deferred, as the
Board of Directors determines.  Deferred awards shall earn interest on the terms
and at a rate determined by the Board of Directors.  Unless otherwise determined
by the Board of Directors with respect to a performance unit granted to a person
who is neither an Officer nor a director of the Company, each performance unit
granted under the Plan by its terms shall be nonassignable and nontransferable
by the holder, either voluntarily or by operation of law, except by will or by
the laws of descent and distribution of the state or country of the holder's
domicile at the time of death or pursuant to a qualified domestic relations
order as defined under the Code or Title I of the Employee Retirement Income
Security Act.  Each participant who has been awarded a performance unit shall,
upon notification of the amount due, pay to the Company in cash amounts
necessary to satisfy any applicable federal, state and local tax withholding
requirements.  If the participant fails to pay the amount demanded, the Company
may withhold that amount from other amounts payable by the Company to the
participant, including salary or fees for services, subject to applicable law. 
With the consent of the Board of Directors a participant may satisfy this
obligation, in whole or in part, by having the Company withhold from any shares
to be issued that number of shares that would satisfy the withholding amount due
or by delivering Common Stock to the Company to satisfy the withholding amount. 
The payment of a performance unit in cash shall not reduce the number of shares
of Common Stock reserved for issuance under the Plan.  The number of shares
reserved for issuance under the Plan shall be reduced by the number of shares
issued upon payment of an award.

     12.  FOREIGN QUALIFIED GRANTS.  Awards under the Plan may be granted
to such officers and employees of the Company and its subsidiaries and such
other persons described in paragraph 1 residing in foreign jurisdictions as the
Board of Directors may determine from time to time.  The Board of Directors may
adopt such supplements to the Plan as may be necessary

                                       11

<PAGE>

to comply with the applicable laws of such foreign jurisdictions and to 
afford participants favorable treatment under such laws; provided, however, 
that no award shall be granted under any such supplement with terms which are 
more beneficial to the participants than the terms permitted by the Plan.

     13.  OPTION GRANTS TO NON-EMPLOYEE DIRECTORS.

          (a)    INITIAL GRANTS.  Each person who is or becomes a 
Non-Employee Director after June 3, 1992 shall be automatically granted an 
option to purchase 100,000 shares of Common Stock on the date he or she 
becomes a Non-Employee Director.  A "Non-Employee Director" is a director who 
is not an employee of the Company or any of its subsidiaries and has not been 
an employee of the Company or any of its subsidiaries within one year of any 
date as of which a determination of eligibility is made.

          (b)    EXERCISE PRICE.  The exercise price of an option granted
pursuant to this paragraph 13 shall be equal to the fair market value of the
Common Stock as determined in accordance with the procedure set forth in
paragraph 6(b)(iv).

          (c)    TERM OF OPTION.  The term of each option granted pursuant to
this paragraph 13 shall be 10 years from the date of grant.

          (d)    EXERCISABILITY.  Until an option expires or is terminated
and except as provided in paragraph 13(f), 14 and 15, an option granted under
this paragraph 13 shall be exercisable according to the following schedule:

          Period of Non-Employee
           Director's Continuous
         Service as a Director of
           the Company from the                Portion of Total Option
        Date the Option is Granted               Which is Exercisable 
        --------------------------             -----------------------

            Less than 12 months                           0%

              After 12 months                       25% plus 25%
                                                for each 12 months of
                                            additional continuous service
                                                 until fully vested.

          For purposes of this paragraph 13(e), a complete month shall be 
deemed to be the period which starts on the day of grant and ends on the same 
day of the following calendar month, so that each successive "complete month" 
ends on the same day of each successive calendar month (or, in respect of any 
calendar month which does not include such a day, that "complete month" shall 
end on the first day of the next following calendar month).

                                       12

<PAGE>

          (e)    TERMINATION AS A DIRECTOR.  If an optionee ceases to be a
director of the Company for any reason, including death, the option may be
exercised at any time prior to the expiration date of the option or the
expiration of 30 days (or 12 months in the event of death) after the last day
the optionee served as a director, whichever is the sooner period, but only if
and to the extent the optionee was entitled to exercise the option as of the
last day the optionee served as a director.

          (f)    NONTRANSFERABILITY.  Each option by its terms shall be
nonassignable and nontransferable by the optionee, either voluntarily or by
operation of law, except by will or by the laws of descent and distribution of
the state or country of the optionee's domicile at the time of death or pursuant
to a qualified domestic relations order as defined under the Code or Title I of
the Employee Retirement Income Security Act.

          (g)    EXERCISE OF OPTIONS.  Options may be exercised upon payment
of cash or shares of Common Stock of the Company in accordance with
paragraph 6(a)(v).  Unless otherwise determined by the Board of Directors, if an
option is exercised within six months of the date of grant, the shares acquired
upon such exercise may not be sold until six months after the date of grant.

     14.  CHANGES IN CAPITAL STRUCTURE.  If the outstanding Common Stock of
the Company is hereafter increased or decreased or changed into or exchanged for
a different number or kind of shares or other securities of the Company or of
another corporation by reason of any reorganization, merger, consolidation, plan
of exchange, recapitalization, reclassification, stock split-up, combination of
shares or dividend payable in shares, appropriate adjustment shall be made by
the Board of Directors in the number and kind of shares available for awards
under the Plan.  In addition, except with respect to transactions referred to in
paragraph 15, the Board of Directors shall make appropriate adjustment in the
number and kind of shares as to which outstanding options and stock appreciation
rights, or portions thereof then unexercised, shall be exercisable, so that the
optionee's proportionate interest before and after the occurrence of the event
is maintained.  Notwithstanding the foregoing, the Board of Directors shall have
no obligation to effect any adjustment that would or might result in the
issuance of fractional shares, and any fractional shares resulting from any
adjustment may be disregarded or provided for in any manner determined by the
Board of Directors.  Any such adjustments made by the Board of Directors shall
be conclusive.  If the shareholders of the Company receive capital stock of
another corporation ("Exchange Stock") in exchange for their shares of Common
Stock in any transaction involving a merger, consolidation or plan of exchange,
all options granted hereunder shall be converted into options to purchase shares
of Exchange Stock unless the Company and the corporation issuing the Exchange
Stock, in their sole discretion, determine that any or all such options granted
hereunder shall not be converted into options to purchase shares of Exchange
Stock but instead shall terminate in accordance with the provisions of the last
sentence of this paragraph 14.  The amount and price of converted options shall
be determined by adjusting the amount and price of the options granted hereunder
in the same proportion as used for determining the number of shares of Exchange
Stock the holders of the Common Stock receive in such merger.  In the event of
dissolution of the Company or a merger, consolidation

                                       13

<PAGE>

or plan of exchange affecting the Company to which paragraph 15 does not 
apply, in lieu of providing for options and stock appreciation rights as 
provided above in this paragraph 14, the Board of Directors may, in its sole 
discretion, provide a 30-day period prior to such event during which 
optionees shall have the right to exercise options and stock appreciation 
rights in whole or in part without any limitation on exercisability and upon 
the expiration of which 30-day period all unexercised options and stock 
appreciation rights shall immediately terminate.

     15.  ACCELERATION IN CERTAIN EVENTS.  Notwithstanding any other provisions
of the Plan, all options and stock appreciation rights outstanding under the
Plan shall immediately become exercisable in full for the remainder of their
terms at any time when any one of the following events has taken place:

          (a)    The shareholders of the Company approve one of the following
("Approved Transactions"):

                 (i)    Any consolidation, merger or plan of exchange involving
the Company ("Merger") pursuant to which Common Stock would be converted into
cash; or

                 (ii)   Any sale, lease, exchange, or other transfer (in one
transaction or a series of related transactions) of all or substantially all of
the assets of the Company or the adoption of any plan or proposal for the
liquidation or dissolution of the Company; or

          (b)    A tender or exchange offer, other than one made by the 
Company, is made for Common Stock (or securities convertible into Common 
Stock) and such offer results in a portion of those securities being 
purchased and the offeror after the consummation of the offer is the 
beneficial owner (as determined pursuant to Section 13(d) of the Securities 
Exchange Act of 1934, as amended (the "Exchange Act")), directly or 
indirectly, of at least 20 percent of the outstanding Common Stock (an 
"Offer"); or

          (c)    The Company receives a report on Schedule 13D of the
Exchange Act reporting the beneficial ownership by any person of 20 percent or
more of the Company's outstanding Common Stock, except that if such receipt
shall occur during a tender offer or exchange offer by any person other than the
Company or a wholly-owned subsidiary of the Company, Special Acceleration shall
not take place until the conclusion of such offer; or

          (d)    During any period of 12 months or less, individuals who at
the beginning of such period constituted a majority of the Board of Directors
cease for any reason to constitute a majority thereof unless the nomination or
election of such new directors was approved by a vote of at least two-thirds of
the directors then still in office who were directors at the beginning of such
period.

          All options and stock appreciation rights that are accelerated
pursuant to this paragraph 15 shall terminate upon the dissolution of the
Company or upon the consummation of any Merger pursuant to which Common Stock
would be converted to cash.  The terms used

                                       14

<PAGE>

in this paragraph 15 and not defined elsewhere in the Plan shall have the 
same meanings as such terms have in the Exchange Act and the rules and 
regulations adopted thereunder.

     16.  CORPORATE MERGERS, ACQUISITIONS, ETC.  The Board of Directors may
also grant options, stock appreciation rights, performance units, stock bonuses
and cash bonuses and issue restricted stock under the Plan having terms,
conditions and provisions that vary from those specified in this Plan provided
that any such awards are granted in substitution for, or in connection with the
assumption of, existing options, stock appreciation rights, stock bonuses, cash
bonuses, restricted stock and performance units granted, awarded or issued by
another corporation and assumed or otherwise agreed to be provided for by the
Company pursuant to or by reason of a transaction involving a corporate merger,
consolidation, acquisition of property or stock, separation, reorganization or
liquidation to which the Company or a subsidiary is a party.

     17.  AMENDMENT OF PLAN.  The Board of Directors may at any time, and
from time to time, modify or amend the Plan in such respects as it shall deem
advisable because of changes in the law while the Plan is in effect or for any
other reason.  Except as provided in paragraphs 6(a)(iv), 9, 14 and 15, however,
no change in an award already granted shall be made without the written consent
of the holder of such award.

     18.  APPROVALS.  The obligations of the Company under the Plan are
subject to the approval of state and federal authorities or agencies with
jurisdiction in the matter.  The Company will use its best efforts to take steps
required by state or federal law or applicable regulations, including rules and
regulations of the Securities and Exchange Commission and any stock exchange on
which the Company's shares may then be listed, in connection with the grants
under the Plan.  The foregoing notwithstanding, the Company shall not be
obligated to issue or deliver Common Stock under the Plan if such issuance or
delivery would violate applicable state or federal securities laws.

     19.  EMPLOYMENT AND SERVICE RIGHTS.  Nothing in the Plan or any award
pursuant to the Plan shall (i) confer upon any employee any right to be
continued in the employment of the Company or any subsidiary or interfere in any
way with the right of the Company or any subsidiary by whom such employee is
employed to terminate such employee's employment at any time, for any reason,
with or without cause, or to decrease such employee's compensation or benefits,
or (ii) confer upon any person engaged by the Company any right to be retained
or employed by the Company or to the continuation, extension, renewal, or
modification of any compensation, contract, or arrangement with or by the
Company.

     20.  RIGHTS AS A SHAREHOLDER.  The recipient of any award under the
Plan shall have no rights as a shareholder with respect to any Common Stock
until the date of issue to the recipient of a stock certificate for such shares.
Except as otherwise expressly provided in the Plan, no adjustment shall be made
for dividends or other rights for which the record date occurs prior to the date
such stock certificate is issued.

                                       15




<PAGE>
                              EMPLOYMENT AGREEMENT



     THIS EMPLOYMENT AGREEMENT ("Agreement"), made this 4th day of
November, 1996, by and between ANTIVIRALS INC., an Oregon
corporation, with its principle office at 1 SW Columbia Street, Suite 1105,
Portland, OR 97258 ("Company"), and DENIS R. BURGER, PH.D.
1 SW Columbia Street, Suite 1105, Portland, OR 97258 ("Employee").


                                    RECITALS:

     A.   Employee has been a valued employee of the Company since March, 
1991 and has served in the capacities of Chief Operating Officer, President, 
and most recently Chief Executive Officer.

     B.   The Company desires to continue Employee's employment with the 
Company as Chief Executive Officer under the terms stated in this Agreement.

                                   AGREEMENT:

     NOW, THEREFORE, in consideration of the mutual benefits contained herein,
the sufficiency of which the parties acknowledge, the parties hereby agree as
follows:

     1.   EMPLOYMENT TERM.  The term ("Term") of this Agreement shall 
commence on the date written above, and shall continue until terminated in 
accordance with Section 12.

     2.   DUTIES.  Employee shall be responsible to perform such duties as 
assigned to him from time to time by the Board of Directors of the Company 
("Board").  Employee shall be employed by the Company and shall devote his 
best efforts to
 the service of the Company throughout the Term.  Employee 
shall devote at least for (40) hours per week to the affairs of the Company.  
Employee and Company acknowledge and agree that (i) Employee may hold certain 
offices within certain entities as set forth on Exhibit A to this Agreement, 
(ii) Employee's devotion of reasonable amounts of time in such capacities, so 
long as it does not interfere with his performance of services hereunder, 
shall not conflict with the terms of this Agreement, and (iii) Exhibit A may 
be amended from time to time by agreement of the parties.

     3.   COMPENSATION.  For his services from the date of this Agreement 
until January 1, 1997 the Company shall compensate Employee at his current 
salary. Commencing January 1, 1997, the Company shall compensate Employee 
with an annual salary of $225,000, payable in accordance with Company's 
payroll practices in effect from time to time, and less amounts required to 
be withheld under applicable law and requested to be withheld by Employee.  
Employee's annual salary shall be subject to review on an annual basis.  The 
Company may but shall not be required to pay bonus compensation to Employee.  
Except as otherwise provided in this Agreement, the base salary shall be 
prorated for any period of service less than a full month. 

                                      1

<PAGE>

     4.   EXPENSES.  The Company will reimburse Employee for all expenses 
reasonably incurred by him in discharging his duties for the Company, 
conditioned upon Employee's submission of written documentation in support of 
claimed reimbursement of such expenses, and consistent with the Company's 
expense reimbursement policies in effect from time to time.

     5.   BENEFITS.  Subject to eligibility requirements, Employee shall be 
entitled to participate in such benefits plans and programs as adopted by the 
Company from time to time.

     6.   CONFIDENTIALITY.

          (a)   In the course of his employment with the Company, it is 
anticipated that Employee may acquire knowledge (both orally and in writing) 
regarding confidential affairs of the Company and confidential or proprietary 
information including: (a) matters of a technical nature, such as know-how, 
inventions, processes, products, designs, chemicals, compounds, materials, 
drawings, concepts, formulas, trade secrets, secret processes or machines, 
inventions or research projects; (b) matters of a business nature, such as 
information about costs, profits, pricing policies, markets, sales, 
suppliers, customers, plans for future development, plans for future 
products, marketing plans or strategies; and (c) other information of a 
similar nature which is not generally disclosed by the Company to the public, 
referred to collectively hereafter as "Confidential Information."  
"Confidential Information" shall not include information generally available 
to the public.  Employee agrees that during the term of this Agreement and 
thereafter, he (i) will keep secret and retain in the strictest confidence 
all Confidential Information, (ii) not disclose Confidential Information to 
anyone except employees of the Company authorized to receive it and third 
parties to whom such disclosure is specifically authorized, and (iii) not use 
any Confidential Information for any purpose other than performance of 
services under this Agreement without prior written permission from the 
Company.

          (b)   If Employee is served with any subpoena or other compulsory 
judicial or administrative process calling for production or disclosure of 
Confidential Information or if Employee is otherwise required by law or 
regulation to disclose Confidential Information, Employee will immediately, 
and prior to production or disclosure, notify the Company and provide it with 
such information as may be necessary in order that the Company may take such 
action as it deems necessary to protect its interest.

          (c)   The provisions of this paragraph 6 shall survive termination 
of this Agreement.

     7.   NONCOMPETITION.

          (a)   Employee acknowledges that the increased compensation 
reflected in this Agreement amounts to a bona fide advancement for Employee.  
In consideration of this advancement, Employee agrees that during the Term 
and for a period of two (2) years following termination of employment with 
the Company for any reason, he will not directly or indirectly engage in any 
activity directed towards (i) the development of any uncharged 
sequence-specific nucleic acid-binding agents or any nucleic acid 
purification and concentration or detection system, or (ii) the development 
of drug delivery systems related to the "molecular engine" as defined in 
patents or patent applications filed or Contemplated at any time during the 
Term.  Patents or patent 

                                      2

<PAGE>

applications "Contemplated" are those included, recorded or discussed in the 
notebooks of researchers employed by or performing services on behalf of the 
Company.  

          (b)   For a period of two (2) years, except with the express 
written consent of the Company, Employee agrees to refrain from directly or 
indirectly recruiting, hiring or assisting anyone else to hire, or otherwise 
counseling to discontinue employment with the Company, any person then 
employed by the Company or its subsidiaries or affiliates.  

          (c)   The provisions of this paragraph 7 shall survive termination 
of this Agreement and the term of employment.

     8.   COVERED WORK.

          (a)   All right, title and interest to any Covered Work that 
Employee makes or conceives (whether alone or with others) while employed by 
the Company, belong to the Company.  This Agreement operates as an actual 
assignment of all rights in Covered Work to the Company.  "Covered Work" 
means products and Inventions that relate to the actual or anticipated 
business of the Company or any of its subsidiaries or affiliates, or that 
result from or are suggested by a task assigned to Employee or work performed 
by Employee on behalf of the Company or any of its subsidiaries or 
affiliates, or that were developed in whole or in part on the Company time or 
using the Company's equipment, supplies or facilities.  "Inventions" mean 
ideas, improvements, designs, computer software, technologies, techniques, 
processes, products, chemicals, compounds, materials, concepts, drawings, 
authored works or discoveries, whether or not patentable or copyrightable, as 
well as other newly discovered or newly applied information or concepts.  
Attached hereto as Exhibit B is a description of any product or Invention in 
which Employee had or has any right, title or interest which is not included 
within the definition of "Covered Work".

          (b)   Employee shall promptly reveal all information relating to 
Covered Work and Confidential Information to an appropriate officer of the 
Company and shall cooperate with the Company, and execute such documents as 
may be necessary, in the event that the Company desires to seek copyright, 
patent or trademark protection thereafter relating to same.

          (c)   In the event that the Company requests that Employee assist 
in efforts to defend any legal claims to patents or other right, the Company 
agrees to reimburse Employee for any reasonable expenses Employee may incur 
in connection with such assistance.  This obligation to reimburse shall 
survive termination of this Agreement and the term of employment.

          (d)   The provisions of this paragraph 8 shall survive termination 
of this Agreement and the term of employment.

     9.   RETURN OF INVENTIONS, PRODUCTS AND DOCUMENTS.  Employee 
acknowledges and agrees that all Inventions, all products of the Company and 
all originals and copies of records, reports, documents, lists, drawings, 
memoranda, notes, proposals, contracts and other documentation related to the 
business of the Company or containing any information described in this 
paragraph shall be the sole and exclusive property of the Company and shall 
be returned to the Company immediately upon the termination of Employee's 
employment with the Company or upon the written request of the Company.

                                      3

<PAGE>

     10.  INJUNCTION.  Employee agrees that it would be difficult to measure 
damages to the Company from any breach by Employee of paragraph 6, 7, 8 
and/or 9 of this Agreement, and that monetary damages would be an inadequate 
remedy for any such breach.  Accordingly, Employee agrees that if Employee 
shall breach paragraph 6, 7, 8 and/or 9 of this Agreement, the Company shall 
be entitled, in addition to all other remedies it may have at law or in 
equity, to an injunction or other appropriate orders to restrain any such 
breach without showing or proving any actual damage sustained by the Company.

     11.  OBLIGATIONS TO OTHERS.  Except for items fully disclosed in writing 
to the Company, Employee represents and warrants to the Company that (i) 
Employee's employment by the Company does not violate any agreement with any 
prior employer or other person or entity, and (ii) Employee is not subject to 
any existing confidentiality or noncompetition agreement or obligation, or 
any agreement relating to the assignment of Inventions except as has been 
fully disclosed in writing to the Company.

     12.  TERMINATION.  

          (a)   Employee may voluntarily terminate his employment with the
Company upon giving the Company sixty (60) days' written notice.

          (b)   The Company may terminate Employee's employment without Cause 
(as defined below) upon giving Employee thirty (30) days written notice of 
termination.

          (c)   Employee's employment with the Company shall terminate upon the
occurrence of any one of the following:

               (1)  Employee's death;

               (2)  The effective date of a notice sent to Employee stating 
the Board's determination made in good faith and after consultation with a 
qualified physician selected by the Board, that Employee is incapable of 
performing his duties under this Agreement, with or without reasonable 
accommodation, because of a physical or mental incapacity that has prevented 
Employee from performing such full-time duties for a period of ninety (90) 
consecutive calendar days and the determination that such incapacity is 
likely to continue for a least another ninety (90) such days; and

               (3)  The effective date of a notice sent to Employee terminating
Employee's employment for Cause.

          (d)  "Cause" means the occurrence of one or more of the following
events:

               (1)  Employee's willful and repeated failure or refusal to 
comply in any material respect with the reasonable and lawful policies, 
standards or regulations from time to time established by the Company, or to 
perform his duties in accordance with this Agreement after notice to Employee 
of such failure; and

               (2)  Employee engages in criminal conduct or engages in 
conduct with respect to the Company that is dishonest, fraudulent or 
materially detrimental to the reputation, character or standing of the 
Company.

                                      4

<PAGE>

     13.  TERMINATION COMPENSATION.

          (a)   Upon Employee's voluntary termination of employment (other 
than voluntary termination after a Change of Control (as defined below)), or 
termination of Employee's employment for Cause, the Company shall pay to 
Employee all compensation due to the date of termination, but shall have no 
further obligation to Employee hereunder in respect of any period following 
termination.

          (b)   Upon the death of Employee, the Company shall pay to 
Employee's estate or such other party who shall be legally entitled thereto, 
all compensation due to the date of death, and an additional amount equal to 
compensation at the rate set forth in this Agreement from the date of death 
to the final day of the month following the month in which the death occurs.

          (c)   Upon termination of Employee's employment by the Company 
other than for Cause, and upon Employee's voluntary termination of employment 
after a Change of Control, the Company shall pay to Employee an amount equal 
to twelve (12) months' compensation calculated with reference to Employee's 
then current annual compensation (exclusive of bonuses), which amount shall 
be due and payable at termination.

          (d)   Amounts payable under this Section shall be net of amounts 
required to be withheld under applicable law and amounts requested to be 
withheld by Employee.

          (e)   Upon Termination of employment other than for Cause, all 
outstanding options granted to Employee pursuant to the Company's 1992 Stock 
Incentive Plan, which vest with the passage of time (and are not performance 
related) shall be immediately fully vested.

          (f)   As used herein, "Change of Control" means the occurrence of 
any one of the following events: (i) any Person becomes the beneficial owner 
of twenty-five percent (25%) or more of the total number of voting shares of 
the Company; (ii) any Person (other than the Persons named as proxies 
solicited on behalf of the Board of Directors of the Company) holds revocable 
or irrevocable proxies representing twenty-five percent (25%) or more of the 
total number of voting shares of the Company; (iii) any Person has commenced 
a tender or exchange offer, or entered into an agreement or received an 
option, to acquire beneficial ownership of twenty-five percent (25%) or more 
of the total number of voting shares of the Company; and (iv) as the result 
of, or in connection with, any cash tender or exchange offer, merger, or 
other business combination, sale of assets, or any combination of the 
foregoing transactions, the persons who were directors of the Company before 
such transactions shall cease to constitute at least two-thirds (2/3) of the 
Board of Directors of the Company or any successor entity.

     14.   NOTICE.  Unless otherwise provided herein, any notice, request,
certificate or instrument required or permitted under this Agreement shall be in
writing and shall be deemed "given" upon personal delivery to the party to be
notified or three business days after deposit with the United States Postal
Service, by registered or certified mail, addressed to the party to receive
notice at the address set forth above, postage prepaid.  Either party may change
its address by notice to the other party given in the manner set forth in this
Section.

     15.     ENTIRE AGREEMENT.  This Agreement constitutes the entire 
agreement between the parties and contains all the agreements between them 
with respect to the subject matter hereof.  It 

                                      5

<PAGE>

also supersedes any and all other agreements or contracts, either oral or 
written, between the parties with respect to the subject matter hereof.

     16.   MODIFICATION.  Except as otherwise specifically provided, the 
terms and conditions of this Agreement may be amended at any time by mutual 
agreement of the parties, provided that before any amendment shall be valid 
or effective, it shall have been reduced to writing and signed by an 
authorized representative of the Company and Employee.

     17.   NO WAIVER.  The failure of any party hereto exercise any right, 
power or remedy provided under this Agreement or otherwise available in 
respect hereof at law or in equity, or to insist upon compliance by any other 
party hereto with its obligations, shall not be a waiver by such party of its 
right to exercise any such or other right, power or remedy or to demand 
compliance.

     18.   SEVERABILITY.  In the event that any paragraph or provision of 
this Agreement shall be held to be illegal or unenforceable, such paragraph 
or provision shall be severed from this Agreement and the entire Agreement 
shall not fail as a result, but shall otherwise remain in full force and 
effect.

     19.   ASSIGNMENT.  This Agreement shall be binding upon and inure to the 
benefit of the Company and its successors and assigns, and shall be binding 
upon Employee, his administrators, executors, legatees, and heirs.  In that 
this Agreement is a personal services contract, it shall not be assigned by 
Employee.

     20.   DISPUTE RESOLUTION.  Except as otherwise provided in Section 10, 
the Company and Employee agree that any dispute between Employee and the 
Company or its officers, directors, employees, or agents in their individual 
or Company capacity of this Agreement, shall be submitted to a mediator for 
nonbinding, confidential mediation.  If the matter cannot be resolved with 
the aid of the mediator, the Company and Employee mutually agree to 
arbitration of the dispute. The arbitration shall be in accordance with the 
then-current Employment Dispute Resolution Rules of the American Arbitration 
Association ("AAA") before an arbitrator who is licensed to practice law in 
the State of Oregon.  The arbitration shall take place in or near Portland, 
Oregon.  Employee and the Company will share the cost of the arbitration 
equally, but each will bear their own costs and legal fees associated with 
the arbitration.  However, if any party prevails on a statutory claim which 
affords the prevailing party attorneys' fees, or if there is a written 
agreement providing for attorneys' fees, the arbitrator may award reasonable 
attorneys' fees.

           The Company and Employee agree that the procedures outlined in 
this provision are the exclusive method of dispute resolution.

     21.   ATTORNEYS' FEES.  In the event suit or action is instituted 
pursuant to Section 10 of this Agreement, the prevailing party in such 
proceeding, including any appeals thereon, shall be awarded reasonable 
attorneys' fees and costs.

     22.   APPLICABLE LAW.  This Agreement shall be construed and enforced 
under and in accordance with the laws of the State of Oregon.

     23.   COUNTERPARTS.  This Agreement may be signed in two counterparts, 
each of which shall be deemed an original and both of which shall together 
constitute one agreement.

                                      6

<PAGE>

         IN WITNESS WHEREOF, Antivirals Inc. has caused this Agreement to be 
signed by its duly authorized representative, and Employee has hereunder set 
his name as of the date of this Agreement.

         COMPANY:              ANTIVIRALS INC.


                               By: /s/ Alan P. Timmins
                                  -------------------------------------


         EMPLOYEE:                 /s/ Denis R. Burger
                                  -------------------------------------
                                  DENIS R. BURGER, PH.D.

                                      7

<PAGE>

                                    EXHIBIT A

                              LIST OF OFFICES HELD


Trinity Biotech plc                   Director
SuperGen Inc                          Director
Yamhill Valley Vineyards              President and Director
Cellegy Inc.                          Director
Sovereign Ventures LLC                Partner
Sovereign Partners LLC                Partner
Burger Family Partnership LLC         Partner


<PAGE>

                                     EXHIBIT B

                     INVENTIONS EXCLUDED FROM COVERED WORKS





<PAGE>

                              EMPLOYMENT AGREEMENT



     THIS EMPLOYMENT AGREEMENT ("Agreement"), made this 4th day of
November, 1996, by and between ANTIVIRALS INC., an Oregon
corporation, with its principle office at 1 SW Columbia Street, Suite 1105,
Portland, OR 97258 ("Company"), and JAMES SUMMERTON, PH.D.
1 SW Columbia Street, Suite 1105, Portland, OR 97258 ("Employee").



                                    RECITALS:

     A.   Employee has been a valued employee of the Company since 1980 and has
served in the capacities of Founder, President, Chief Executive Officer and
Chief Scientific Officer.

     B.   The terms of Employee's employment with the Company have been as set
forth in an Employment Contract entered into by and between Employee and Company
dated June 17, 1992.

     C.   The Company desires to continue Employee's employment with the Company
as President and Chief Scientific Officer under the terms stated in this
Agreement.

                                   AGREEMENT:

     NOW, THEREFORE, in consideration of the mutual benefits contained herein,
the sufficiency of which the parties acknowledge, the parties hereby agree as
follows:

     1.   EMPLOYMENT TERM.  The term ("Term") of this Agreement shall commence
on the date written above, and shall continue until terminated in accordance
with Section 12.

     2.   DUTIES.  Employee shall be responsible to perform
 such duties as
assigned to him from time to time by the Board of Directors of the Company
("Board").  Employee shall be employed by the Company and shall devote his best
efforts to the service of the Company throughout the Term.  Employee shall
devote at least for (40) hours per week to the affairs of the Company.  Employee
and Company acknowledge and agree that (i) Employee may hold certain offices
within certain entities as set forth on Exhibit A to this Agreement, (ii)
Employee's devotion of reasonable amounts of time in such capacities, so long as
it does not interfere with his performance of services hereunder, shall not
conflict with the terms of this Agreement, and (iii) Exhibit A may be amended
from time to time by agreement of the parties.

     3.   COMPENSATION.  For his services from the date of this Agreement until
January 1, 1997 the Company shall compensate Employee at his current salary.
Commencing January 1, 1997, the Company shall compensate Employee with an annual
salary of $150,000, payable in accordance with Company's payroll practices in
effect from time to time, and less amounts required to be withheld under
applicable law and requested to be withheld by Employee.  Employee's annual
salary shall be subject to review on an annual basis.  The Company may but shall
not be required to pay bonus compensation to Employee.  Except as otherwise
provided in this Agreement, the base salary shall be prorated for any period of
service less than a full month.


1


<PAGE>

     4.   EXPENSES.  The Company will reimburse Employee for all expenses
reasonably incurred by him in discharging his duties for the Company,
conditioned upon Employee's submission of written documentation in support of
claimed reimbursement of such expenses, and consistent with the Company's
expense reimbursement policies in effect from time to time.

     5.   BENEFITS.  Subject to eligibility requirements, Employee shall be
entitled to participate in such benefits plans and programs as adopted by the
Company from time to time.

     6.   CONFIDENTIALITY.

          (a)  In the course of his employment with the Company, it is
anticipated that Employee may acquire knowledge (both orally and in writing)
regarding confidential affairs of the Company and confidential or proprietary
information including: (a) matters of a technical nature, such as know-how,
inventions, processes, products, designs, chemicals, compounds, materials,
drawings, concepts, formulas, trade secrets, secret processes or machines,
inventions or research projects; (b) matters of a business nature, such as
information about costs, profits, pricing policies, markets, sales, suppliers,
customers, plans for future development, plans for future products, marketing
plans or strategies; and (c) other information of a similar nature which is not
generally disclosed by the Company to the public, referred to collectively
hereafter as "Confidential Information."  "Confidential Information" shall not
include information generally available to the public.  Employee agrees that
during the term of this Agreement and thereafter, he (i) will keep secret and
retain in the strictest confidence all Confidential Information, (ii) not
disclose Confidential Information to anyone except employees of the Company
authorized to receive it and third parties to whom such disclosure is
specifically authorized, and (iii) not use any Confidential Information for any
purpose other than performance of services under this Agreement without prior
written permission from the Company.  Notwithstanding the foregoing, Employee as
General Partner of ANTI-GENE DEVELOPMENT GROUP ("AGDG") is authorized to
disclose and use Confidential Information, to the extent permitted under the
terms of the Technology Transfer Agreement between the Company and AGDG, and any
amendments to that Technology Transfer Agreement.

          (b)  If Employee is served with any subpoena or other compulsory
judicial or administrative process calling for production or disclosure of
Confidential Information or if Employee is otherwise required by law or
regulation to disclose Confidential Information, Employee will immediately, and
prior to production or disclosure, notify the Company and provide it with such
information as may be necessary in order that the Company may take such action
as it deems necessary to protect its interest.

          (c)  The provisions of this paragraph 6 shall survive termination of
this Agreement.

     7.   NONCOMPETITION.

          (a)  Employee acknowledges that the increased compensation reflected
in this Agreement amounts to a bona fide advancement for Employee.  In
consideration of this advancement, Employee agrees that during the Term and for
a period of two (2) years following termination of employment with the Company
for any reason, he will not directly or indirectly engage in any activity
directed towards (i) the development of any uncharged sequence-specific nucleic
acid-binding agents or any nucleic acid purification and concentration or
detection system,

2


<PAGE>

or (ii) the development of drug delivery systems related to the "molecular
engine" as defined in patents or patent applications filed or Contemplated at
any time during the Term.  Patents or patent applications "Contemplated" are
those included, recorded or discussed in the notebooks of researchers employed
by or performing services on behalf of the Company.  Nothing contained here
shall preclude Employee's engaging in activities that are both (A) related only
to agents, compounds, techniques, processes or technologies licensed by the
Company to AGDG, and (B) performed on behalf of AGDG or for some other entity in
which Employee has a controlling interest.  Nothing contained herein shall limit
the scope or operation of Section 6 of this Agreement.

          (b)  For a period of one (1) year, except with the express written
consent of the Company, Employee agrees to refrain from directly or indirectly
recruiting, hiring or assisting anyone else to hire, or otherwise counseling to
discontinue employment with the Company, any person then employed by the Company
or its subsidiaries or affiliates.

          (c)  The provisions of this paragraph 7 shall survive termination of
this Agreement and the term of employment.

     8.   COVERED WORK.

          (a)  All right, title and interest to any Covered Work that Employee
makes or conceives (whether alone or with others) while employed by the Company,
belong to the Company.  This Agreement operates as an actual assignment of all
rights in Covered Work to the Company.  "Covered Work" means products and
Inventions that relate to the actual or anticipated business of the Company or
any of its subsidiaries or affiliates, or that result from or are suggested by a
task assigned to Employee or work performed by Employee on behalf of the Company
or any of its subsidiaries or affiliates, or that were developed in whole or in
part on the Company time or using the Company's equipment, supplies or
facilities.  The contents of Employee's notebooks prepared during the course of
his employment with the Company contain a comprehensive description of all of
Employee's Covered Work.  "Inventions" mean ideas, improvements, designs,
computer software, technologies, techniques, processes, products, chemicals,
compounds, materials, concepts, drawings, authored works or discoveries, whether
or not patentable or copyrightable, as well as other newly discovered or newly
applied information or concepts.  Attached hereto as Exhibit B is a description
of any product or Invention in which Employee had or has any right, title or
interest which is not included within the definition of "Covered Work".

          (b)  Employee shall promptly reveal all information relating to
Covered Work and Confidential Information via entry of such information into the
Company's notebooks and confirmation of such entry by an appropriate officer of
the Company via the witnessing and review of such notebooks and shall cooperate
with the Company, and execute such documents as may be necessary, in the event
that the Company desires to seek copyright, patent or trademark protection
thereafter relating to same.

          (c)  In the event that the Company requests that Employee assist in
efforts to defend any legal claims to patents or other right, the Company agrees
to reimburse Employee for any reasonable expenses Employee may incur in
connection with such assistance.  This obligation to reimburse shall survive
termination of this Agreement and the term of employment.

3


<PAGE>

          (d)  The provisions of this paragraph 8 shall survive termination of
this Agreement and the term of employment.

     9.   RETURN OF INVENTIONS, PRODUCTS AND DOCUMENTS.  Employee acknowledges
and agrees that all Inventions, all products of the Company and all originals
and copies of records, reports, documents, lists, drawings, memoranda, notes,
proposals, contracts and other documentation related to the business of the
Company or containing any information described in this paragraph shall be the
sole and exclusive property of the Company and shall be returned to the Company
immediately upon the termination of Employee's employment with the Company or
upon the written request of the Company.  Notwithstanding the foregoing, in
recognition of the emotional and historical interest which the Employee's
notebooks have to Employee, the Company agrees that when the Employee leaves the
Company the Employee may have and own a true and accurate copy of those
notebooks in which he personally made entries during his employment with the
Company, and ten (10) years after Employee terminates employment with the
Company it is agreed that said original notebooks will be given to Employee to
have and own.  The Company may retain a true, accurate and complete copy of said
notebooks.  If the original notebooks are needed at any time in connection with
patent applications, patent litigation or other legitimate Company business,
Employee will immediately upon Company's request, make them available to the
Company for the period during with they are needed.

     10.  INJUNCTION.  Employee agrees that it would be difficult to measure
damages to the Company from any breach by Employee of paragraph 6, 7, 8 and/or 9
of this Agreement, and that monetary damages would be an inadequate remedy for
any such breach.  Accordingly, Employee agrees that if Employee shall breach
paragraph 6, 7, 8 and/or 9 of this Agreement, the Company shall be entitled, in
addition to all other remedies it may have at law or in equity, to an injunction
or other appropriate orders to restrain any such breach without showing or
proving any actual damage sustained by the Company.

     11.  OBLIGATIONS TO OTHERS.  Except for items fully disclosed in writing to
the Company, Employee represents and warrants to the Company that (i) Employee's
employment by the Company does not violate any agreement with any prior employer
or other person or entity, and (ii) Employee is not subject to any existing
confidentiality or noncompetition agreement or obligation, or any agreement
relating to the assignment of Inventions except as has been fully disclosed in
writing to the Company.

     12.  TERMINATION.

          (a)  Employee may voluntarily terminate his employment with the
Company upon giving the Company sixty (60) days' written notice.

          (b)  The Company may terminate Employee's employment without Cause (as
defined below) upon giving Employee thirty (30) days written notice of
termination.

          (c)  Employee's employment with the Company shall terminate upon the
occurrence of any one of the following:

               (1)  Employee's death;

4


<PAGE>

               (2)  The effective date of a notice sent to Employee stating the
Board's determination made in good faith and after consultation with a qualified
physician selected by the Board, that Employee is incapable of performing his
duties under this Agreement, with or without reasonable accommodation, because
of a physical or mental incapacity that has prevented Employee from performing
such full-time duties for a period of ninety (90) consecutive calendar days and
the determination that such incapacity is likely to continue for a least another
ninety (90) such days; and

               (3)  The effective date of a notice sent to Employee terminating
Employee's employment for Cause.

          (d)  "Cause" means the occurrence of one or more of the following
events:

               (1)  Employee's willful and repeated failure or refusal to comply
in any material respect with the reasonable and lawful policies, standards or
regulations from time to time established by the Company, or to perform his
duties in accordance with this Agreement after notice to Employee of such
failure; and

               (2)  Employee engages in criminal conduct or engages in conduct
with respect to the Company that is dishonest, fraudulent or materially
detrimental to the reputation, character or standing of the Company.

     13.  TERMINATION COMPENSATION.

          (a)  Upon termination of Employee's employment for Cause, the Company
shall pay to Employee all compensation due to the date of termination, but shall
have no further obligation to Employee hereunder in respect of any period
following termination.

          (b)  Upon the death of Employee, the Company shall pay to Employee's
estate or such other party who shall be legally entitled thereto, all
compensation due to the date of death, and an additional amount equal to
compensation at the rate set forth in this Agreement from the date of death to
the final day of the month following the month in which the death occurs.

          (c)  Upon termination of Employee's employment by the Company other
than for Cause, and upon Employee's voluntary termination of employment after a
Change of Control, the Company shall pay to Employee an amount equal to twelve
(12) months' compensation calculated with reference to Employee's then current
annual compensation (exclusive of bonuses), which amount shall be due and
payable at termination.

          (d)  Amounts payable under this Section shall be net of amounts
required to be withheld under applicable law and amounts requested to be
withheld by Employee.

          (e)  Upon Termination of employment other than for Cause, all
outstanding options granted to Employee pursuant to the Company's 1992 Stock
Incentive Plan, which vest with the passage of time (and are not performance
related) shall be immediately fully vested.

          (f)  In recognition of the Employee's substantial contributions to the
Company and because many of the Employee's personal books and other information
sources, including Nucleic Acids Abstracts, have been made available for Company
use since 1980, it is agreed that upon

5


<PAGE>

termination of employment, Employee has the right to take and own the books,
papers, file cabinets, and such other items in his office as approved by the
Company, as well as the full set of Nucleic Acids Abstracts in the Company's
possession at the time of Employee's termination of employment.  (In no event
shall employee be entitled to originals of patent records.)  In addition,
Employee's original notebooks are to remain in the possession of the Company for
ten (10) years from the date of Employee's termination, after which they are to
be conveyed to Employee, subject to the provisions of Section 9.

          (g)  As used herein, "Change of Control" means the occurrence of any
one of the following events: (i) any Person becomes the beneficial owner of
twenty-five percent (25%) or more of the total number of voting shares of the
Company; (ii) any Person (other than the Persons named as proxies solicited on
behalf of the Board of Directors of the Company) holds revocable or irrevocable
proxies representing twenty-five percent (25%) or more of the total number of
voting shares of the Company; (iii) any Person has commenced a tender or
exchange offer, or entered into an agreement or received an option, to acquire
beneficial ownership of twenty-five percent (25%) or more of the total number of
voting shares of the Company; and (iv) as the result of, or in connection with,
any cash tender or exchange offer, merger, or other business combination, sale
of assets, or any combination of the foregoing transactions, the persons who
were directors of the Company before such transactions shall cease to constitute
at least two-thirds (2/3) of the Board of Directors of the Company or any
successor entity.

     14.  CONSULTING AGREEMENT.  For a period of two (2) years following
termination of Employee's employment, Employee shall provide up to ten (10)
hours per week of consulting services to Company.  As consideration for those
consulting services, Employee shall be compensated at the rate of $75,000 per
year, less amounts required to be withheld by law and requested to be withheld
by Employee.  The first year of this arrangement is guaranteed, and the second
year is at the Company's option at the same compensation.

     15.  NOTICE.  Unless otherwise provided herein, any notice, request,
certificate or instrument required or permitted under this Agreement shall be in
writing and shall be deemed "given" upon personal delivery to the party to be
notified or three business days after deposit with the United States Postal
Service, by registered or certified mail, addressed to the party to receive
notice at the address set forth above, postage prepaid.  Either party may change
its address by notice to the other party given in the manner set forth in this
Section.

     16.  ENTIRE AGREEMENT.  This Agreement constitutes the entire agreement
between the parties and contains all the agreements between them with respect to
the subject matter hereof.  It also supersedes any and all other agreements or
contracts, either oral or written, between the parties with respect to the
subject matter hereof.

     17.  MODIFICATION.  Except as otherwise specifically provided, the terms
and conditions of this Agreement may be amended at any time by mutual agreement
of the parties, provided that before any amendment shall be valid or effective,
it shall have been reduced to writing and signed by an authorized representative
of the Company and Employee.

     18.  NO WAIVER.  The failure of any party hereto exercise any right, power
or remedy provided under this Agreement or otherwise available in respect hereof
at law or in equity, or to

6


<PAGE>

insist upon compliance by any other party hereto with its obligations, shall not
be a waiver by such party of its right to exercise any such or other right,
power or remedy or to demand compliance.

     19.  SEVERABILITY.  In the event that any paragraph or provision of this
Agreement shall be held to be illegal or unenforceable, such paragraph or
provision shall be severed from this Agreement and the entire Agreement shall
not fail as a result, but shall otherwise remain in full force and effect.

     20.  ASSIGNMENT.  This Agreement shall be binding upon and inure to the
benefit of the Company and its successors and assigns, and shall be binding upon
Employee, his administrators, executors, legatees, and heirs.  In that this
Agreement is a personal services contract, it shall not be assigned by Employee.

     21.  DISPUTE RESOLUTION.  Except as otherwise provided in Section 10, the
Company and Employee agree that any dispute between Employee and the Company or
its officers, directors, employees, or agents in their individual or Company
capacity of this Agreement, shall be submitted to a mediator for nonbinding,
confidential mediation.  If the matter cannot be resolved with the aid of the
mediator, the Company and Employee mutually agree to arbitration of the dispute.
The arbitration shall be in accordance with the then-current Employment Dispute
Resolution Rules of the American Arbitration Association ("AAA") before an
arbitrator who is licensed to practice law in the State of Oregon.  The
arbitration shall take place in or near Portland, Oregon.  Employee and the
Company will share the cost of the arbitration equally, but each will bear their
own costs and legal fees associated with the arbitration.  However, if any party
prevails on a statutory claim which affords the prevailing party attorneys'
fees, or if there is a written agreement providing for attorneys' fees, the
arbitrator may award reasonable attorneys' fees.

          The Company and Employee agree that the procedures outlined in this
provision are the exclusive method of dispute resolution.

     22.  ATTORNEYS' FEES.  In the event suit or action is instituted pursuant
to Section 10 of this Agreement, the prevailing party in such proceeding,
including any appeals thereon, shall be awarded reasonable attorneys' fees and
costs.

     23.  APPLICABLE LAW.  This Agreement shall be construed and enforced under
and in accordance with the laws of the State of Oregon.

     24.  COUNTERPARTS.  This Agreement may be signed in two counterparts, each
of which shall be deemed an original and both of which shall together constitute
one agreement.

7


<PAGE>

         IN WITNESS WHEREOF, Antivirals Inc. has caused this Agreement to be
signed by its duly authorized representative, and Employee has hereunder set his
name as of the date of this Agreement.


     COMPANY:              ANTIVIRALS INC.


                           By: /s/ Alan P. Timmins
                               _________________________________________________



     EMPLOYEE:               /s/ James Summerton
                             __________________________________________________
                             JAMES SUMMERTON, PH.D.

8


<PAGE>

                                    EXHIBIT A

                              LIST OF OFFICES HELD

ANTI-GENE DEVELOPMENT GROUP, or a licensee thereof


<PAGE>


                                    EXHIBIT B

                     INVENTIONS EXCLUDED FROM COVERED WORKS





<PAGE>
                              EMPLOYMENT AGREEMENT



     THIS EMPLOYMENT AGREEMENT ("Agreement"), made this 4th day of 
November, 1996, by and between ANTIVIRALS INC., an Oregon corporation,
with its principle office at 1 SW Columbia Street, Suite 1105, 
Portland, OR 97258 ("Company"), and ALAN P. TIMMINS 1 SW Columbia Street,
Suite 1105, Portland, OR 97258 ("Employee").


                                    RECITALS:

     A.   Employee has been a valued employee of the Company since September,
1992 and has served in the capacities of Chief Financial Officer and Chief
Operating Officer.

     B.   The terms of Employee's employment with the Company have been as set
forth in an Employment Contract entered into by and between Employee and Company
in September, 1992 ("Prior Agreement").

     C.   The Company desires to continue Employee's employment with the Company
as Chief Operating Officer and Chief Financial Officer under the terms stated in
this Agreement.

                                   AGREEMENT:

     NOW, THEREFORE, in consideration of the mutual benefits contained herein,
the sufficiency of which the parties acknowledge, the parties hereby agree as
follows:

     1.   EMPLOYMENT TERM.  The term ("Term") of this Agreement shall commence
on the date written above, and shall continue until terminated in accordance
with Section 12.

     2.   DUTIES.  Employee shall be responsible
 to perform such duties as
assigned to him from time to time by the Board of Directors of the Company
("Board").  Employee shall be employed by the Company and shall devote his best
efforts to the service of the Company throughout the Term.  Employee shall
devote at least for (40) hours per week to the affairs of the Company.  Employee
and Company acknowledge and agree that (i) Employee may hold certain offices
within certain entities as set forth on Exhibit A to this Agreement, (ii)
Employee's devotion of reasonable amounts of time in such capacities, so long as
it does not interfere with his performance of services hereunder, shall not
conflict with the terms of this Agreement, and (iii) Exhibit A may be amended
from time to time by agreement of the parties.

     3.   COMPENSATION.  For his services from the date of this Agreement until
January 1, 1997 the Company shall compensate Employee at his current salary. 
Commencing January 1, 1997, the Company shall compensate Employee with an annual
salary of $135,000, payable in accordance with Company's payroll practices in
effect from time to time, and less amounts required to be withheld under
applicable law and requested to be withheld by Employee.  Employee's annual
salary shall be subject to review on an annual basis.  The Company may but shall
not be required to pay 

                                      1

<PAGE>

bonus compensation to Employee.  Except as otherwise provided in this 
Agreement, the base salary shall be prorated for any period of service less 
than a full month. 

     4.   EXPENSES.  The Company will reimburse Employee for all expenses
reasonably incurred by him in discharging his duties for the Company,
conditioned upon Employee's submission of written documentation in support of
claimed reimbursement of such expenses, and consistent with the Company's
expense reimbursement policies in effect from time to time.

     5.   BENEFITS.  Subject to eligibility requirements, Employee shall be
entitled to participate in such benefits plans and programs as adopted by the
Company from time to time.

     6.   CONFIDENTIALITY.

          (a)  In the course of his employment with the Company, it is
anticipated that Employee may acquire knowledge (both orally and in writing)
regarding confidential affairs of the Company and confidential or proprietary
information including: (a) matters of a technical nature, such as know-how,
inventions, processes, products, designs, chemicals, compounds, materials,
drawings, concepts, formulas, trade secrets, secret processes or machines,
inventions or research projects; (b) matters of a business nature, such as
information about costs, profits, pricing policies, markets, sales, suppliers,
customers, plans for future development, plans for future products, marketing
plans or strategies; and (c) other information of a similar nature which is not
generally disclosed by the Company to the public, referred to collectively
hereafter as "Confidential Information."  "Confidential Information" shall not
include information generally available to the public.  Employee agrees that
during the term of this Agreement and thereafter, he (i) will keep secret and
retain in the strictest confidence all Confidential Information, (ii) not
disclose Confidential Information to anyone except employees of the Company
authorized to receive it and third parties to whom such disclosure is
specifically authorized, and (iii) not use any Confidential Information for any
purpose other than performance of services under this Agreement without prior
written permission from the Company.

          (b)  If Employee is served with any subpoena or other compulsory
judicial or administrative process calling for production or disclosure of
Confidential Information or if Employee is otherwise required by law or
regulation to disclose Confidential Information, Employee will immediately, and
prior to production or disclosure, notify the Company and provide it with such
information as may be necessary in order that the Company may take such action
as it deems necessary to protect its interest.

          (c)  The provisions of this paragraph 6 shall survive termination of
this Agreement.

     7.   NONCOMPETITION.

          (a)  Employee acknowledges that pursuant to the terms of the Prior
Agreement, Employee was precluded from engaging in any activity directed toward
the development of any uncharged sequence-specific nucleic acid-binding agents
or any nucleic acid purification and concentration or detection system, for a
period of two (2) years following termination of his employment with the
Company.  Employee agrees to continue to be bound by this restriction.

                                      2

<PAGE>

          (b)  Employee further acknowledges that the increased compensation 
reflected in this Agreement amounts to a bona fide advancement for Employee.  
In consideration of this advancement, Employee further agrees that during the 
Term and for a period of two (2) years following termination of employment 
with the Company for any reason, he will not directly or indirectly engage in 
any activity directed towards the development of drug delivery systems 
related to the "molecular engine" as defined in patents or patent 
applications filed or Contemplated at any time during the Term.  As used 
herein, the agents compounds, techniques, processes and/or technologies as to 
which patents are "Contemplated" are those included, recorded or discussed in 
the notebooks of researchers employed by or performing services on behalf of 
the Company.  

          (c)  For a period of two (2) years, except with the express written
consent of the Company, Employee agrees to refrain from directly or indirectly
recruiting, hiring or assisting anyone else to hire, or otherwise counseling to
discontinue employment with the Company, any person then employed by the Company
or its subsidiaries or affiliates.  

          (d)  The provisions of this paragraph 7 shall survive termination of
this Agreement and the term of employment.

     8.   COVERED WORK.  

          (a)  All right, title and interest to any Covered Work that Employee
makes or conceives (whether alone or with others) while employed by the Company,
belong to the Company.  This Agreement operates as an actual assignment of all
rights in Covered Work to the Company.  "Covered Work" means products and
Inventions that relate to the actual or anticipated business of the Company or
any of its subsidiaries or affiliates, or that result from or are suggested by a
task assigned to Employee or work performed by Employee on behalf of the Company
or any of its subsidiaries or affiliates, or that were developed in whole or in
part on the Company time or using the Company's equipment, supplies or
facilities.  "Inventions" mean ideas, improvements, designs, computer software,
technologies, techniques, processes, products, chemicals, compounds, materials,
concepts, drawings, authored works or discoveries, whether or not patentable or
copyrightable, as well as other newly discovered or newly applied information or
concepts.  Attached hereto as Exhibit B is a description of any product or
Invention in which Employee had or has any right, title or interest which is not
included within the definition of "Covered Work".

          (b)  Employee shall promptly reveal all information relating to
Covered Work and Confidential Information to an appropriate officer of the
Company and shall cooperate with the Company, and execute such documents as may
be necessary, in the event that the Company desires to seek copyright, patent or
trademark protection thereafter relating to same.

          (c)  In the event that the Company requests that Employee assist in
efforts to defend any legal claims to patents or other right, the Company agrees
to reimburse Employee for any reasonable expenses Employee may incur in
connection with such assistance.  This obligation to reimburse shall survive
termination of this Agreement and the term of employment.

          (d)  The provisions of this paragraph 8 shall survive termination of
this Agreement and the term of employment.

                                      3

<PAGE>

     9.   RETURN OF INVENTIONS, PRODUCTS AND DOCUMENTS.  Employee 
acknowledges and agrees that all Inventions, all products of the Company and 
all originals and copies of records, reports, documents, lists, drawings, 
memoranda, notes, proposals, contracts and other documentation related to the 
business of the Company or containing any information described in this 
paragraph shall be the sole and exclusive property of the Company and shall 
be returned to the Company immediately upon the termination of Employee's 
employment with the Company or upon the written request of the Company.

     10.  INJUNCTION.  Employee agrees that it would be difficult to measure 
damages to the Company from any breach by Employee of paragraph 6, 7, 8 
and/or 9 of this Agreement, and that monetary damages would be an inadequate 
remedy for any such breach.  Accordingly, Employee agrees that if Employee 
shall breach paragraph 6, 7, 8 and/or 9 of this Agreement, the Company shall 
be entitled, in addition to all other remedies it may have at law or in 
equity, to an injunction or other appropriate orders to restrain any such 
breach without showing or proving any actual damage sustained by the Company.

     11.  OBLIGATIONS TO OTHERS.  Except for items fully disclosed in writing 
to the Company, Employee represents and warrants to the Company that (i) 
Employee's employment by the Company does not violate any agreement with any 
prior employer or other person or entity, and (ii) Employee is not subject to 
any existing confidentiality or noncompetition agreement or obligation, or 
any agreement relating to the assignment of Inventions except as has been 
fully disclosed in writing to the Company.

     12.  TERMINATION.  

          (a)  Employee may voluntarily terminate his employment with the
Company upon giving the Company sixty (60) days' written notice.

          (b)  The Company may terminate Employee's employment without Cause (as
defined below) upon giving Employee thirty (30) days written notice of
termination.

          (c)  Employee's employment with the Company shall terminate upon the
occurrence of any one of the following:

               (1)  Employee's death;

               (2)  The effective date of a notice sent to Employee stating 
the Board's determination made in good faith and after consultation with a 
qualified physician selected by the Board, that Employee is incapable of 
performing his duties under this Agreement, with or without reasonable 
accommodation, because of a physical or mental incapacity that has prevented 
Employee from performing such full-time duties for a period of ninety (90) 
consecutive calendar days and the determination that such incapacity is 
likely to continue for a least another ninety (90) such days; and

               (3)  The effective date of a notice sent to Employee 
terminating Employee's employment for Cause.

          (d)  "Cause" means the occurrence of one or more of the following
events:

                                      4

<PAGE>

               (1)  Employee's willful and repeated failure or refusal to comply
in any material respect with the reasonable and lawful policies, standards or
regulations from time to time established by the Company, or to perform his
duties in accordance with this Agreement after notice to Employee of such
failure; and

               (2)  Employee engages in criminal conduct or engages in conduct
with respect to the Company that is dishonest, fraudulent or materially
detrimental to the reputation, character or standing of the Company.

     13.  TERMINATION COMPENSATION.

          (a)  Upon Employee's voluntary termination of employment (other than
voluntary termination after a Change of Control (as defined below)), or
termination of Employee's employment for Cause, the Company shall pay to
Employee all compensation due to the date of termination, but shall have no
further obligation to Employee hereunder in respect of any period following
termination.

          (b)  Upon the death of Employee, the Company shall pay to Employee's
estate or such other party who shall be legally entitled thereto, all
compensation due to the date of death, and an additional amount equal to
compensation at the rate set forth in this Agreement from the date of death to
the final day of the month following the month in which the death occurs.

          (c)  Upon termination of Employee's employment by the Company other
than for Cause, and upon Employee's voluntary termination of employment after a
Change of Control, the Company shall pay to Employee an amount equal to twelve
(12) months' compensation calculated with reference to Employee's then current
annual compensation (exclusive of bonuses), which amount shall be due and
payable at termination.

          (d)  Amounts payable under this Section shall be net of amounts
required to be withheld under applicable law and amounts requested to be
withheld by Employee.

          (e)  Upon Termination of employment other than for Cause, all
outstanding options granted to Employee pursuant to the Company's 1992 Stock
Incentive Plan, which vest with the passage of time (and are not performance
related) shall be immediately fully vested.

          (f)  As used herein, "Change of Control" means the occurrence of any
one of the following events: (i) any Person becomes the beneficial owner of
twenty-five percent (25%) or more of the total number of voting shares of the
Company; (ii) any Person (other than the Persons named as proxies solicited on
behalf of the Board of Directors of the Company) holds revocable or irrevocable
proxies representing twenty-five percent (25%) or more of the total number of
voting shares of the Company; (iii) any Person has commenced a tender or
exchange offer, or entered into an agreement or received an option, to acquire
beneficial ownership of twenty-five percent (25%) or more of the total number of
voting shares of the Company; and (iv) as the result of, or in connection with,
any cash tender or exchange offer, merger, or other business combination, sale
of assets, or any combination of the foregoing transactions, the persons who
were directors of the Company before such transactions shall cease to constitute
at least two-thirds (2/3) of the Board of Directors of the Company or any
successor entity.

                                      5

<PAGE>

     14.  NOTICE.  Unless otherwise provided herein, any notice, request,
certificate or instrument required or permitted under this Agreement shall be in
writing and shall be deemed "given" upon personal delivery to the party to be
notified or three business days after deposit with the United States Postal
Service, by registered or certified mail, addressed to the party to receive
notice at the address set forth above, postage prepaid.  Either party may change
its address by notice to the other party given in the manner set forth in this
Section.

     15.  ENTIRE AGREEMENT.  This Agreement constitutes the entire agreement
between the parties and contains all the agreements between them with respect to
the subject matter hereof.  It also supersedes any and all other agreements or
contracts, either oral or written, between the parties with respect to the
subject matter hereof.

     16.  MODIFICATION.  Except as otherwise specifically provided, the terms
and conditions of this Agreement may be amended at any time by mutual agreement
of the parties, provided that before any amendment shall be valid or effective,
it shall have been reduced to writing and signed by an authorized representative
of the Company and Employee.

     17.  NO WAIVER.  The failure of any party hereto exercise any right, power
or remedy provided under this Agreement or otherwise available in respect hereof
at law or in equity, or to insist upon compliance by any other party hereto with
its obligations, shall not be a waiver by such party of its right to exercise
any such or other right, power or remedy or to demand compliance.

     18.  SEVERABILITY.  In the event that any paragraph or provision of this
Agreement shall be held to be illegal or unenforceable, such paragraph or
provision shall be severed from this Agreement and the entire Agreement shall
not fail as a result, but shall otherwise remain in full force and effect.

     19.  ASSIGNMENT.  This Agreement shall be binding upon and inure to the
benefit of the Company and its successors and assigns, and shall be binding upon
Employee, his administrators, executors, legatees, and heirs.  In that this
Agreement is a personal services contract, it shall not be assigned by Employee.

     20.  DISPUTE RESOLUTION.  Except as otherwise provided in Section 10, the
Company and Employee agree that any dispute between Employee and the Company or
its officers, directors, employees, or agents in their individual or Company
capacity of this Agreement, shall be submitted to a mediator for nonbinding,
confidential mediation.  If the matter cannot be resolved with the aid of the
mediator, the Company and Employee mutually agree to arbitration of the dispute.
The arbitration shall be in accordance with the then-current Employment Dispute
Resolution Rules of the American Arbitration Association ("AAA") before an
arbitrator who is licensed to practice law in the State of Oregon.  The
arbitration shall take place in or near Portland, Oregon.  Employee and the
Company will share the cost of the arbitration equally, but each will bear their
own costs and legal fees associated with the arbitration.  However, if any party
prevails on a statutory claim which affords the prevailing party attorneys'
fees, or if there is a written agreement providing for attorneys' fees, the
arbitrator may award reasonable attorneys' fees.

          The Company and Employee agree that the procedures outlined in this
provision are the exclusive method of dispute resolution.

                                      6

<PAGE>

     21.  ATTORNEYS' FEES.  In the event suit or action is instituted pursuant
to Section 10 of this Agreement, the prevailing party in such proceeding,
including any appeals thereon, shall be awarded reasonable attorneys' fees and
costs.

     22.  APPLICABLE LAW.  This Agreement shall be construed and enforced under
and in accordance with the laws of the State of Oregon.

     23.  COUNTERPARTS.  This Agreement may be signed in two counterparts, each
of which shall be deemed an original and both of which shall together constitute
one agreement.


         IN WITNESS WHEREOF, Antivirals Inc. has caused this Agreement to be
signed by its duly authorized representative, and Employee has hereunder set his
name as of the date of this Agreement.


     COMPANY:                  ANTIVIRALS INC.


                               By: /s/ Denis R. Burger
                                  --------------------------------------



     EMPLOYEE:                    /s/ Alan P. Timmins
                                  --------------------------------------
                                  ALAN P. TIMMINS

                                      7

<PAGE>

                                    EXHIBIT A

                              LIST OF OFFICES HELD

                                   SCHEDULE A

<PAGE>

                                    EXHIBIT B

                     INVENTIONS EXCLUDED FROM COVERED WORKS

                                   SCHEDULE B




<PAGE>



                                 EMPLOYMENT AGREEMENT



    THIS EMPLOYMENT AGREEMENT ("Agreement"), made this 4th day of
November, 1996, by and between ANTIVIRALS INC., an Oregon
corporation, with its principle office at 1 SW Columbia Street, Suite 1105,
Portland, OR 97258 ("Company"), and DWIGHT WELLER, PH.D.
1 SW Columbia Street, Suite 1105, Portland, OR 97258 ("Employee").



                                      RECITALS:

     A.  Employee has been a valued employee of the Company since September,
1992 and has served in the capacity of Vice President of Research and
Development. 

     B.  The terms of Employee's employment with the Company have been as set
forth in an Employment Contract entered into by and between Employee and Company
in September, 1992 ("Prior Agreement").

     C.  The Company desires to continue Employee's employment with the Company
Vice President of Research and Development under the terms stated in this
Agreement.

                                      AGREEMENT:

     NOW, THEREFORE, in consideration of the mutual benefits contained herein,
the sufficiency of which the parties acknowledge, the parties hereby agree as
follows:

     1.  EMPLOYMENT TERM.  The term ("Term") of this Agreement shall commence
on the date written above, and shall continue until terminated in accordance
with Section 12.

     2.  DUTIES.  Employee shall be responsible to perform
 such duties as
assigned to him from time to time by the Board of Directors of the Company
("Board").  Employee shall be employed by the Company and shall devote his best
efforts to the service of the Company throughout the Term.  Employee shall
devote at least for (40) hours per week to the affairs of the Company.  Employee
and Company acknowledge and agree that (i) Employee may hold certain offices
within certain entities as set forth on Exhibit A to this Agreement, (ii)
Employee's devotion of reasonable amounts of time in such capacities, so long as
it does not interfere with his performance of services hereunder, shall not
conflict with the terms of this Agreement, and (iii) Exhibit A may be amended
from time to time by agreement of the parties.

     3.  COMPENSATION.  For his services from the date of this Agreement until
January 1, 1997 the Company shall compensate Employee at his current salary. 
Commencing January 1, 1997, the Company shall compensate Employee with an annual
salary of $135,000, payable in accordance with Company's payroll practices in
effect from time to time, and less amounts required to be withheld under
applicable law and requested to be withheld by Employee.  Employee's annual
salary shall be subject to review on an annual basis.  The Company may but shall
not be required to pay

                                        -1-

<PAGE>


bonus compensation to Employee.  Except as otherwise provided in this 
Agreement, the base salary shall be prorated for any period of service less 
than a full month. 

     4.  EXPENSES.  The Company will reimburse Employee for all expenses
reasonably incurred by him in discharging his duties for the Company,
conditioned upon Employee's submission of written documentation in support of
claimed reimbursement of such expenses, and consistent with the Company's
expense reimbursement policies in effect from time to time.

     5.  BENEFITS.  Subject to eligibility requirements, Employee shall be
entitled to participate in such benefits plans and programs as adopted by the
Company from time to time.

     6.  CONFIDENTIALITY.

         (a)  In the course of his employment with the Company, it is 
anticipated that Employee may acquire knowledge (both orally and in writing) 
regarding confidential affairs of the Company and confidential or proprietary 
information including: (a) matters of a technical nature, such as know-how, 
inventions, processes, products, designs, chemicals, compounds, materials, 
drawings, concepts, formulas, trade secrets, secret processes or machines, 
inventions or research projects; (b) matters of a business nature, such as 
information about costs, profits, pricing policies, markets, sales, 
suppliers, customers, plans for future development, plans for future 
products, marketing plans or strategies; and (c) other information of a 
similar nature which is not generally disclosed by the Company to the public, 
referred to collectively hereafter as "Confidential Information."  
"Confidential Information" shall not include information generally available 
to the public.  Employee agrees that during the term of this Agreement and 
thereafter, he (i) will keep secret and retain in the strictest confidence 
all Confidential Information, (ii) not disclose Confidential Information to 
anyone except employees of the Company authorized to receive it and third 
parties to whom such disclosure is specifically authorized, and (iii) not use 
any Confidential Information for any purpose other than performance of 
services under this Agreement without prior written permission from the 
Company.

         (b)  If Employee is served with any subpoena or other compulsory 
judicial or administrative process calling for production or disclosure of 
Confidential Information or if Employee is otherwise required by law or 
regulation to disclose Confidential Information, Employee will immediately, 
and prior to production or disclosure, notify the Company and provide it with 
such information as may be necessary in order that the Company may take such 
action as it deems necessary to protect its interest.

         (c)  The provisions of this paragraph 6 shall survive termination of
this Agreement.

     7.  NONCOMPETITION.

         (a)  Employee acknowledges that pursuant to the terms of the Prior
Agreement, Employee was precluded from engaging in any activity directed toward
the development of any uncharged sequence-specific nucleic acid-binding agents
or any nucleic acid purification and concentration or detection system, for a
period of two (2) years following termination of his employment with the
Company.  Employee agrees to continue to be bound by this restriction relating


                                        -2-

<PAGE>


to development of any unchanged sequence-specific nucleic acid-binding agents 
or any nucleic acid purification and concentration or detection system using 
uncharged agents.

         (b)  Employee further acknowledges that the increased compensation 
reflected in this Agreement amounts to a bona fide advancement for Employee.  
In consideration of this advancement, Employee further agrees that during the 
Term and for a period of two (2) years following termination of employment 
with the Company for any reason, he will not directly or indirectly engage in 
any activity directed towards the development of drug delivery systems 
related to the "molecular engine" as defined in patents or patent 
applications filed or Contemplated at any time during the Term.  Patents or 
patent applications "Contemplated" are those included, recorded or discussed 
in the notebooks of researchers employed by or performing services on behalf 
of the Company.  

         (c)  For a period of two (2) years, except with the express written 
consent of the Company, Employee agrees to refrain from directly or 
indirectly recruiting, hiring or assisting anyone else to hire, or otherwise 
counseling to discontinue employment with the Company, any person then 
employed by the Company or its subsidiaries or affiliates.  

         (d)  The provisions of this paragraph 7 shall survive termination of
this Agreement and the term of employment.

    8.   COVERED WORK.  

         (a)  All right, title and interest to any Covered Work that Employee 
makes or conceives (whether alone or with others) while employed by the 
Company, belong to the Company.  This Agreement operates as an actual 
assignment of all rights in Covered Work to the Company.  "Covered Work" 
means products and Inventions that relate to the actual or anticipated 
business of the Company or any of its subsidiaries or affiliates, or that 
result from or are suggested by a task assigned to Employee or work performed 
by Employee on behalf of the Company or any of its subsidiaries or 
affiliates, or that were developed in whole or in part on the Company time or 
using the Company's equipment, supplies or facilities.  "Inventions" mean 
ideas, improvements, designs, computer software, technologies, techniques, 
processes, products, chemicals, compounds, materials, concepts, drawings, 
authored works or discoveries, whether or not patentable or copyrightable, as 
well as other newly discovered or newly applied information or concepts.  
Attached hereto as Exhibit B is a description of any product or Invention in 
which Employee had or has any right, title or interest which is not included 
within the definition of "Covered Work".

         (b)  Employee shall promptly reveal all information relating to 
Covered Work and Confidential Information to an appropriate officer of the 
Company and shall cooperate with the Company, and execute such documents as 
may be necessary, in the event that the Company desires to seek copyright, 
patent or trademark protection thereafter relating to same.

         (c)  In the event that the Company requests that Employee assist in
efforts to defend any legal claims to patents or other right, the Company agrees
to reimburse Employee for any reasonable expenses Employee may incur in
connection with such assistance.  This obligation to reimburse shall survive
termination of this Agreement and the term of employment.


                                        -3-


<PAGE>

         (d)  The provisions of this paragraph 8 shall survive termination of
this Agreement and the term of employment.

    9.   RETURN OF INVENTIONS, PRODUCTS AND DOCUMENTS.  Employee acknowledges
and agrees that all Inventions, all products of the Company and all originals
and copies of records, reports, documents, lists, drawings, memoranda, notes,
proposals, contracts and other documentation related to the business of the
Company or containing any information described in this paragraph shall be the
sole and exclusive property of the Company and shall be returned to the Company
immediately upon the termination of Employee's employment with the Company or
upon the written request of the Company.

    10.  INJUNCTION.  Employee agrees that it would be difficult to measure
damages to the Company from any breach by Employee of paragraph 6, 7, 8 and/or 9
of this Agreement, and that monetary damages would be an inadequate remedy for
any such breach.  Accordingly, Employee agrees that if Employee shall breach
paragraph 6, 7, 8 and/or 9 of this Agreement, the Company shall be entitled, in
addition to all other remedies it may have at law or in equity, to an injunction
or other appropriate orders to restrain any such breach without showing or
proving any actual damage sustained by the Company.

    11.  OBLIGATIONS TO OTHERS.  Except for items fully disclosed in writing to
the Company, Employee represents and warrants to the Company that (i) Employee's
employment by the Company does not violate any agreement with any prior employer
or other person or entity, and (ii) Employee is not subject to any existing
confidentiality or noncompetition agreement or obligation, or any agreement
relating to the assignment of Inventions except as has been fully disclosed in
writing to the Company.

    12.  TERMINATION.  

         (a)  Employee may voluntarily terminate his employment with the
Company upon giving the Company sixty (60) days' written notice.

         (b)  The Company may terminate Employee's employment without Cause (as
defined below) upon giving Employee thirty (30) days written notice of
termination.

         (c)  Employee's employment with the Company shall terminate upon the
occurrence of any one of the following:

              (1)  Employee's death;

              (2)  The effective date of a notice sent to Employee stating the
Board's determination made in good faith and after consultation with a qualified
physician selected by the Board, that Employee is incapable of performing his
duties under this Agreement, with or without reasonable accommodation, because
of a physical or mental incapacity that has prevented Employee from performing
such full-time duties for a period of ninety (90) consecutive calendar days and
the determination that such incapacity is likely to continue for a least another
ninety (90) such days; and

              (3)  The effective date of a notice sent to Employee terminating
Employee's employment for Cause.


                                        -4-



<PAGE>

         (d)  "Cause" means the occurrence of one or more of the following
events:

              (1)  Employee's willful and repeated failure or refusal to comply
in any material respect with the reasonable and lawful policies, standards or
regulations from time to time established by the Company, or to perform his
duties in accordance with this Agreement after notice to Employee of such
failure; and

              (2)  Employee engages in criminal conduct or engages in conduct
with respect to the Company that is dishonest, fraudulent or materially
detrimental to the reputation, character or standing of the Company.

    13.  TERMINATION COMPENSATION.

         (a)  Upon Employee's voluntary termination of employment (other than
voluntary termination after a Change of Control (as defined below)), or
termination of Employee's employment for Cause, the Company shall pay to
Employee all compensation due to the date of termination, but shall have no
further obligation to Employee hereunder in respect of any period following
termination.

         (b)  Upon the death of Employee, the Company shall pay to Employee's
estate or such other party who shall be legally entitled thereto, all
compensation due to the date of death, and an additional amount equal to
compensation at the rate set forth in this Agreement from the date of death to
the final day of the month following the month in which the death occurs.

         (c)  Upon termination of Employee's employment by the Company other
than for Cause, and upon Employee's voluntary termination of employment after a
Change of Control, the Company shall pay to Employee an amount equal to twelve
(12) months' compensation calculation with reference to Employee's then current
annual compensation (exclusive of bonuses), which amount shall be due and
payable at termination.

         (d)  Amounts payable under this Section shall be net of amounts
required to be withheld under applicable law and amounts requested to be
withheld by Employee.

         (e)  Upon Termination of employment other than for Cause, all
outstanding options granted to Employee pursuant to the Company's 1992 Stock
Incentive Plan, which vest with the passage of time (and are not performance
related) shall be immediately fully vested.

         (f)  As used herein, "Change of Control" means the occurrence of any
one of the following events: (i) any Person becomes the beneficial owner of
twenty-five percent (25%) or more of the total number of voting shares of the
Company; (ii) any Person (other than the Persons named as proxies solicited on
behalf of the Board of Directors of the Company) holds revocable or irrevocable
proxies representing twenty-five percent (25%) or more of the total number of
voting shares of the Company; (iii) any Person has commenced a tender or
exchange offer, or entered into an agreement or received an option, to acquire
beneficial ownership of twenty-five percent (25%) or more of the total number of
voting shares of the Company; and (iv) as the result of, or in connection with,
any cash tender or exchange offer, merger, or other business combination, sale
of assets, or any combination of the foregoing transactions, the persons who
were directors of the


                                        -5-

<PAGE>


Company before such transactions shall cease to constitute at least 
two-thirds (2/3) of the Board of Directors of the Company or any successor 
entity.

    14.  NOTICE.  Unless otherwise provided herein, any notice, request,
certificate or instrument required or permitted under this Agreement shall be in
writing and shall be deemed "given" upon personal delivery to the party to be
notified or three business days after deposit with the United States Postal
Service, by registered or certified mail, addressed to the party to receive
notice at the address set forth above, postage prepaid.  Either party may change
its address by notice to the other party given in the manner set forth in this
Section.

    15.  ENTIRE AGREEMENT.  This Agreement constitutes the entire agreement
between the parties and contains all the agreements between them with respect to
the subject matter hereof.  It also supersedes any and all other agreements or
contracts, either oral or written, between the parties with respect to the
subject matter hereof.

    16.  MODIFICATION.  Except as otherwise specifically provided, the terms
and conditions of this Agreement may be amended at any time by mutual agreement
of the parties, provided that before any amendment shall be valid or effective,
it shall have been reduced to writing and signed by an authorized representative
of the Company and Employee.

    17.  NO WAIVER.  The failure of any party hereto exercise any right, power
or remedy provided under this Agreement or otherwise available in respect hereof
at law or in equity, or to insist upon compliance by any other party hereto with
its obligations, shall not be a waiver by such party of its right to exercise
any such or other right, power or remedy or to demand compliance.

    18.  SEVERABILITY.  In the event that any paragraph or provision of this
Agreement shall be held to be illegal or unenforceable, such paragraph or
provision shall be severed from this Agreement and the entire Agreement shall
not fail as a result, but shall otherwise remain in full force and effect.

    19.  ASSIGNMENT.  This Agreement shall be binding upon and inure to the
benefit of the Company and its successors and assigns, and shall be binding upon
Employee, his administrators, executors, legatees, and heirs.  In that this
Agreement is a personal services contract, it shall not be assigned by Employee.

    20.  DISPUTE RESOLUTION.  Except as otherwise provided in Section 10, the
Company and Employee agree that any dispute between Employee and the Company or
its officers, directors, employees, or agents in their individual or Company
capacity of this Agreement, shall be submitted to a mediator for nonbinding,
confidential mediation.  If the matter cannot be resolved with the aid of the
mediator, the Company and Employee mutually agree to arbitration of the dispute.
The arbitration shall be in accordance with the then-current Employment Dispute
Resolution Rules of the American Arbitration Association ("AAA") before an
arbitrator who is licensed to practice law in the State of Oregon.  The
arbitration shall take place in or near Portland, Oregon.  Employee and the
Company will share the cost of the arbitration equally, but each will bear their
own costs and legal fees associated with the arbitration.  However, if any party
prevails on a statutory claim which affords the prevailing party attorneys'
fees, or if there is a written agreement providing for attorneys' fees, the
arbitrator may award reasonable attorneys' fees.


                                        -6-

<PAGE>


         The Company and Employee agree that the procedures outlined in this
provision are the exclusive method of dispute resolution.

    21.  ATTORNEYS' FEES.  In the event suit or action is instituted pursuant
to Section 10 of this Agreement, the prevailing party in such proceeding,
including any appeals thereon, shall be awarded reasonable attorneys' fees and
costs.

    22.  APPLICABLE LAW.  This Agreement shall be construed and enforced under
and in accordance with the laws of the State of Oregon.

    23.  COUNTERPARTS.  This Agreement may be signed in two counterparts, each
of which shall be deemed an original and both of which shall together constitute
one agreement.


         IN WITNESS WHEREOF, Antivirals Inc. has caused this Agreement to be
signed by its duly authorized representative, and Employee has hereunder set his
name as of the date of this Agreement.


         COMPANY:                     ANTIVIRALS INC.


                                      By: /s/ Alan P. Timmins
                                           ___________________________________



         EMPLOYEE:                         /s/ Dwight Weller
                                           ___________________________________
                                           DWIGHT WELLER, PH.D.


                                        -7-


<PAGE>


                                      EXHIBIT A

                                 LIST OF OFFICES HELD



<PAGE>

                                      EXHIBIT B

                        INVENTIONS EXCLUDED FROM COVERED WORKS





<PAGE>

                         TECHNOLOGY TRANSFER AGREEMENT


         This Technology Transfer Agreement, dated February 9, 1992 (this
"Agreement"), is by and between ANTI-GENE DEVELOPMENT GROUP, an Oregon limited
partnership ("Seller"), and ANTIVIRALS Inc., an Oregon corporation ("Buyer"). 

                                    RECITALS

    A.   Seller is the owner of certain patents, patent applications, and other
intellectual property rights, all of which are more fully described in this
Agreement (collectively, the "Intellectual Property"). 

    B.   Buyer intends to offer to issue 3,300 shares of Buyer's common stock
in exchange for each limited partnership interest in Seller (the "Exchange
Offer"). 

    C.   Following completion of the Exchange Offer, Seller wishes to transfer,
and Buyer wishes to obtain, the right, title, and interest of Seller in and to
the Intellectual Property. 

    D.   Following the transfer, Buyer wishes to grant certain rights to Seller
with respect to the Intellectual Property. 

                                   AGREEMENT

         In consideration of the above and of the promises and covenants 
contained herein, the parties agree as follows: 

                                   SECTION 1
                                  DEFINITIONS

         As used in this Agreement, the following terms shall have the
following meanings: 

         1.1       "Buyer Affiliate" shall mean Buyer's Licensees, other than
Seller, and any entity other than
 Seller that controls, is controlled by, or is
under common control with Buyer or Buyer's Licensees. 

         1.2       "Closing" and "Closing Date" shall have the meanings set
forth in Section 2.1. 

         1.3       "Copyrights" shall mean all of Seller's rights under United
States or foreign copyright laws with respect to any work of authorship used by
Seller in connection with Seller's research and development and other business
operations prior to the Closing Date.


1


<PAGE>

         1.4       "Exchange Offer" shall mean the offer by Buyer to exchange
3,300 shares of Buyer's common stock for each limited partnership interest in
Seller.

         1.5       "Intellectual Property" shall mean all Patents, Patent
Applications, Trademarks, Trademark Applications, Copyrights, and all other
Technology owned or controlled by Seller as of the date of this Agreement.

         1.6       "Interests" shall mean the limited partnership interests in
Seller. 

         1.7       "Licensee" shall mean any person, corporation, or other
entity other than Buyer or Seller that obtains a License. 

         1.8       "License" shall mean a right granted by Buyer or a Buyer
Affiliate to an entity to: (a) make a Product; (b) make a Product and use that
Product; (c) make a Product and sell that Product; (d) have a Product made on
behalf of said entity and use that Product; (e) have a Product made on behalf of
said entity and sell that Product; or (f) use a method claimed in a Patent.

         1.9       "Partners" shall mean the partners in Seller as of the
effective date of the Exchange Offer. 

         1.10      "Patent Applications" shall mean the applications described
in Schedule 1.10 attached. 

         1.11      "Patents" shall mean the patents listed on Schedule 1.11
attached, and any patents issuing from any Patent Applications and Planned
Applications.  "Patents" shall also include all continuations,
continuations-in-part, divisions, reissues, patents of addition, renewals, any
foreign counterparts of any such Patents, Patent Applications, and Planned
Applications.

         1.12      "Planned Applications" shall mean the planned patent
applications covering the conceptions and inventions partially or fully reduced
to practice owned by Seller and  listed in Schedule 1.12. 

         1.13      "Product" shall mean any product the sale of which would
infringe one or more valid claims of any Patent in the absence of this
Agreement. 

         1.14      "Purchase Price" shall have the meaning set forth in
Section 4. 

         1.15      "Sales" shall mean the total worldwide sales of Products by
Buyer and Buyer Affiliates to Unaffiliated Entities at the Gross Invoice Amount
minus returns, where returns comprise compensation to the purchaser of the
Product for Products returned to Buyer or the Buyer Affiliate.  "Gross Invoice
Amount" shall mean all money and other valuable consideration paid to Buyer and
Buyer Affiliates in exchange for Products.  Transfers between Buyer and Buyer
Affiliates or between Buyer Affiliates shall not be deemed Sales.  In the event

2


<PAGE>

Buyer or a Buyer Affiliate makes or has made a Product for the Buyer's or Buyer
Affiliate's own use, each manufacture shall be considered a Sale and the amount
of the Sale shall be based upon the average price at which such Product or the
most nearly equivalent Product was sold by Buyer or Buyer Affiliates during the
six months preceding the date of manufacture.

         1.16      "Technology" shall mean conceptions, inventions,
discoveries, improvements, trade secrets, formulas, techniques, processes, and
know how, whether or not patented and whether or not reduced to practice, and
any copies of documents, or other materials describing or relating to the
foregoing, conceived, created, used, or developed by or on behalf of Seller
prior to the Closing Date which relate to nucleic acid binding polymers,
subunits useful for assembly of said polymers, methods of preparation,
purification, and characterization of said subunits and polymers, modifications
and adducts to said subunits and polymers, and uses and applications of said
subunits and polymers.

         1.17      "Trademark Applications" shall mean the Trademark
Applications identified on Schedule 1.17 attached.

         1.18      "Trademarks" shall means the trademarks and trademark
registrations identified on Schedule 1.18 attached and the goodwill associated
therewith.

         1.19      "Unaffiliated Entity" shall mean any entity other than Buyer
and Buyer Affiliates.

                                   SECTION 2
                       TRANSFER OF INTELLECTUAL PROPERTY

         2.1       CLOSING.  The closing of the transactions contemplated by
this Agreement (the "Closing") shall take place at 10 a.m. on the date that is
ten business days after the date that all conditions to Closing are satisfied
(other than those conditions that by their terms are to occur at the Closing),
unless another date and time are agreed to in writing by the parties.  The
Closing shall take place at the offices of Stoel Rives Boley Jones & Grey, 900
SW Fifth Avenue, Portland, Oregon, or such other reasonable location as shall be
specified by Buyer.  The date of the Closing is hereafter referred to as the
Closing Date. 

         2.2       LIQUIDATION OF INTERESTS.  Subject to all of the terms and
conditions of this Agreement, on the Closing Date, Buyer shall tender to Seller
Buyer's Interests for liquidation and Seller shall distribute to Buyer in
liquidation of Buyer's Interests an undivided interest in the Intellectual
Property.  The ratio of the undivided interest conveyed to the whole of the
Intellectual Property shall be the same as the ratio of the liquidated Interests
to the number of Interests outstanding on the Closing Date before liquidation of
Buyer's Interests. 

         2.3       SALE OF REMAINDER.  Subject to all of the terms and
conditions of this Agreement, on the Closing Date, contemporaneously with the
distribution described in Section 2.2, Seller shall sell, convey, assign,
transfer and deliver to Buyer, and Buyer shall 

3


<PAGE>

purchase and accept from Seller, all right, title and interest of Seller in 
and to the undivided interest in the Intellectual Property retained by Seller 
after the liquidating distribution described in Section 2.2.

                                   SECTION 3
                       LIMITED ASSUMPTION OF LIABILITIES

         Buyer shall assume all ongoing expenses associated with Patent
Applications, Planned Applications, Trademark Applications, Patents and
Trademarks including expenses associated with the filing of applications,
continuations, continuations-in-part, responses to offices actions, payment of
issue and maintenance fees, and prosecution of such infringement claims as Buyer
elects to pursue.  Other than the foregoing, Buyer will not assume and will not
be liable for any liabilities of Seller, known or unknown, contingent or
absolute, accrued or otherwise, and the Intellectual Property shall be
transferred to Buyer free of all liabilities, obligations, security interests,
mortgages, pledges, conditional sales agreements or other liens and
encumbrances. 

                                   SECTION 4
                                 CONSIDERATION

         4.1       REDEMPTION OF INTERESTS.  The consideration for distribution
of an undivided interest in the Intellectual Property pursuant to Section 2.2
shall be Buyer's Interests liquidated by Seller pursuant to that section. 

         4.2       SALE OF REMAINDER.  As consideration for the transfer of the
remainder of the Intellectual Property pursuant to Section 2.3, Buyer shall pay
the purchase price ("Purchase Price") set forth in this Section 4.2 pursuant to
the terms set forth in this Section 4. 

              (a)       If no Interests of Buyer are liquidated pursuant to
Section 2.2, the Purchase Price shall be as follows:  Subject to Sections 4.6
and 4.7, Buyer shall pay Seller eight (8) percent of the amount of the total
Sales of each Product Buyer and any Buyer Affiliates sell to any Unaffiliated
Entity after the Closing Date.  For purposes of this Section 4, transfers from
Buyer to a Buyer Affiliate or vice versa and transfers between Buyer Affiliates
shall not be deemed Sales.

              (b)       If Seller does distribute an undivided interest in the
Intellectual Property to Buyer in liquidation of its Interests pursuant to
Section 2.2, the Purchase Price set forth in Section 4.2(a) shall be reduced pro
rata to reflect Seller's reduced ownership interest in the Intellectual Property
resulting from the liquidating distribution.  By way of example, if Buyer
tenders for liquidation fifty (50.0000) percent of the Interests outstanding as
of the Closing, Seller shall distribute in liquidation of Buyer's Interests an
undivided one-half ownership interest in the Intellectual Property and Seller
will retain an undivided one-half ownership interest.  The Purchase Price shall
be reduced by half so that Buyer will pay four (4.00000) percent of the total
Sales of Products under Section 4.2(a). 

4


<PAGE>

         4.3       REPORTS.  Within thirty (30) days after the end of each
calendar quarter, for so long as Products are covered by unexpired Patents,
Buyer shall provide Seller with a written report setting forth the total amount
of each Product sold by Buyer and Buyer Affiliates during the quarter, to whom
the Products were sold, the gross invoice amount for each Sale, and the amount
of any returns.  At the time the report is made, Buyer shall pay Seller any
amounts payable pursuant to this Section 4.

         4.4       RECORDS.  Buyer shall maintain records concerning Sales of
Products sufficient to enable Seller to verify the amounts payable under this
Agreement.  Seller shall have the right, through an independent auditor, to
examine such records that concern Sales of Products up to four times in any
given year.  Seller shall bear all expenses associated with such audits. 
         4.5       LATE PAYMENTS.  If Buyer fails to make any Purchase Price
payment owing to Seller when due, Buyer shall pay Seller interest on the amount
past due at a rate equal to the "Prime Rate" in effect at the time when payment
is due, plus 7.5 percent per annum The "Prime Rate" shall be the announced
"prime rate" at First Interstate Bank of Oregon or its successors. 

         4.6       COMMENCEMENT OF PAYMENT OBLIGATIONS.  Notwithstanding
anything in this Agreement to the contrary, the first two hundred million
dollars ($200,000,000) in total cumulative worldwide Sales by Buyer and Buyer
Affiliates collectively are exempt from Purchase Price Payments Buyer shall be
obligated under this Section 4 to make Purchase Price payments only on those
Sales subsequent to the initial cumulative two hundred million dollars in exempt
Sales by Buyer and Buyer Affiliates. 

         4.7       TERMINATION OF PAYMENT OBLIGATIONS.  Buyer's obligation to
make Purchase Price payments for any given Product shall end upon the expiration
of all Patents containing claims that cover that Product.  Buyer's obligation to
make Purchase Price Payments shall terminate completely upon expiration of the
last Patent to expire. 

         4.8       PAYMENT DISPUTES. 

                   (a) Any dispute between the parties concerning payment of
Purchase Price payments shall be settled by binding arbitration in accordance
with the rules of the American Arbitration Association.  The arbitration shall
be held in Portland, Oregon before three (3) arbitrators who are knowledgeable
about the industry and markets for the Products Judgment upon the arbitrators'
award may be entered in any court having jurisdiction.  This agreement to
arbitrate shall apply only to disputes concerning Purchase Price payments, and
shall not prevent either party from seeking judicial relief in connection with
other matters relating to this Agreement.  The prevailing party in any such
arbitration proceeding shall be entitled to recover reasonable costs and
attorneys fees at the arbitration and in connection with any judicial proceeding
to enforce the arbitration award.



5


<PAGE>

                   (b) If Seller believes Buyer has refused to make Purchase
Price payments in bad faith, Seller may request that the arbitrators make a
finding of Buyer's bad faith refusal to pay.  The parties agree that such a
finding of bad faith shall not be made unless there is clear and convincing
evidence that Seller knew the payment was owing and refused to make the payment.
Seller may appeal any finding of bad faith to any court having jurisdiction and
the court shall review any finding of bad faith de novo. 

                   (c) If the arbitrators make a finding of bad faith under
Section 4.8(b) in two (2) separate proceedings relating to two (2) separate
payment disputes involving the same Product, and neither finding is reversed on
appeal, Seller shall have the right, upon notice to Buyer, to require Buyer to
convey back to Seller at no cost to Seller any Patent covering the Product. 
Upon receipt of such notice, Buyer shall execute such documents as Seller may
reasonably request to convey Buyer's rights in the Patent to Seller. 

                                   SECTION 5
                    REPRESENTATIONS AND WARRANTIES OF BUYER

         Buyer represents and warrants to Seller as follows: 

         5.1       ORGANIZATION AND STANDING.  Buyer is a corporation duly
organized and validly existing under the laws of the State of Oregon. 

         5.2       AUTHORIZATION AND BINDING OBLIGATION.  Buyer has full
corporate power and authority to enter into and perform this Agreement and the
transactions contemplated hereby.  The execution, delivery and performance of
this Agreement by Buyer have been duly and validly authorized by all necessary
corporate action on the part of Buyer.  This Agreement has been duly executed
and delivered by Buyer and constitutes the valid, binding and enforceable
obligation of Buyer except as the provisions of this Agreement may be rendered
unenforceable by applicable bankruptcy, insolvency, reorganization, moratorium
or other similar laws affecting creditor's rights generally or the application
of general principles of equity (regardless of whether enforcement is considered
in a proceeding in equity or at law). 

         5.3       ABSENCE OF CONFLICTING AGREEMENTS OR REQUIRED CONSENTS.  The
execution, delivery and performance of this Agreement by Buyer (i) do not
require the consent, approval, authorization, order or other action of, nor any
filing with, any third party, including, without limitation, (A) any party to
any contract, loan or credit agreement, instrument, commitment, understanding or
other agreement to which Buyer is a party or (B) any court, administrative
agency or other governmental authority; (ii) will not violate any provisions of
the Articles of Incorporation or Bylaws of Buyer; (iii) will not violate any
law, judgment, order, injunction, decree, rule, regulation or ruling of any
governmental authority applicable to Buyer; and (iv) will not, either alone or
with the giving of notice or the passage of time or both, conflict with,
constitute grounds for termination of, result in breach of the terms, conditions
or provisions of, or constitute a default under, any agreement, instrument,
license or permit that 


6


<PAGE>

is individually or in the aggregate material to the transactions contemplated 
hereby and to which Buyer is now subject.  

         5.4       NO BROKERS.  Neither Buyer, any officer or director of
Buyer, nor any employee or shareholder of Buyer has employed any broker, finder
or investment banker or incurred any liability for any commission, brokerage or
investment banking fee or finder's fee in connection with the transactions
contemplated by this Agreement.

                                   SECTION 6
                    REPRESENTATIONS AND WARRANTIES OF SELLER

         Seller represents and warrants to Buyer as follows:

         6.1       ORGANIZATION AND STANDING.  Seller is a limited partnership
duly organized and validly existing under the laws of the State of Oregon.

         6.2       AUTHORIZATION AND BINDING OBLIGATION.  Seller has full power
and authority to enter into and perform this Agreement and the transactions
contemplated hereby.  The execution, delivery and performance of this Agreement
by Seller have been duly and validly authorized by all necessary action on the
part of Seller.  This Agreement has been duly executed and delivered by Seller
and constitutes the valid, binding and enforceable obligation of Seller except
as the provisions of this Agreement may be rendered unenforceable by applicable
bankruptcy, insolvency, reorganization, moratorium or other similar laws
affecting creditor's rights generally or the application of general principles
of equity (regardless of whether enforcement is considered in a proceeding in
equity or at law).

         6.3       ABSENCE OF CONFLICTING AGREEMENTS OR REQUIRED CONSENTS.  
The execution, delivery and performance of this Agreement by Seller (i) do not
require the consent, approval, authorization, order or other action of, nor any
filing with, any third party, including, without limitation, (A) any party to
any contract, loan or credit agreement, instrument, commitment, understanding or
other agreement to which Seller is a party or (B) any court, administrative
agency or other governmental authority; (ii) will not violate any provisions of
the partnership agreement of Seller; (iii) will not violate any law, judgment,
order, injunction, decree, rule, regulation or ruling of any governmental
authority applicable to Seller; (iv) will not, either alone or with the giving
of notice or the passage of time or both, conflict with, constitute grounds for
termination of, result in a breach of the terms, conditions or provisions of, or
constitute a default under, any agreement, instrument, license or permit that is
individually or in the aggregate material to the transactions contemplated
hereby and to which Seller is now subject; and (v) will not result in the
creation of any lien, charge or encumbrance on any of the Intellectual Property.

         6.4       OWNERSHIP OF INTELLECTUAL PROPERTY.  Except as set forth in
Schedule 6.4 to this Agreement, Seller owns valid, unrestricted, enforceable and
exclusive rights for the use of the Intellectual Property.  Seller has delivered
to Buyer copies of all documents establishing 

7


<PAGE>

the rights of Seller to the Intellectual Property.  Schedules 1.10, 1.11, 
1.12, 1.17 and 1.18 respectively list all patent applications, patents, 
planned patent applications, trademark applications, and trademarks owned by 
Seller.

         6.5       ABSENCE OF INFRINGEMENT.  Except as set forth in Schedule
6.5 to this Agreement, to the best of Seller's knowledge, the use by Seller of
the Intellectual Property has not created any conflict with or infringement upon
any intellectual property rights of third parties, and Seller has not been
notified of any such conflicts or infringement claims. 

         6.6       ABSENCE OF ENCUMBRANCES.  Except as set forth in Schedule 6.6
to this Agreement, none of the Intellectual Property is subject to any security
interest, mortgage, pledge, conditional sales agreement~ or other lien or
encumbrance. 

         6.7       NUMBER OF PARTNERSHIP INTERESTS.  On the Closing Date, the
number of partnership interests outstanding will be the number reflected in
Seller's books and records as of that date. 

         6.8       LITIGATION AND ADMINISTRATIVE PROCEEDINGS.  Except as set
forth in Schedule 6.8 to this Agreement, there is no litigation, proceeding or
investigation pending or, to the best of Seller's knowledge threatened, against
Seller in any federal, state or local court or before any administrative agency
individually or in the aggregate material to the transactions contemplated
hereby, including, without limitation, any proceeding that seeks to enjoin or
prohibit or otherwise questions the validity of any action taken or to be taken
pursuant to or in connection with this Agreement. 

         6.9       NO BROKERS.  Neither Seller, any officer or director of
Seller, nor any employee or partner of Seller has employed any broker, finder or
investment banker or incurred any liability for any commission, brokerage or
investment banking fee or finder's fee in connection with the transactions
contemplated by this Agreement. 

         6.10      DISCLOSURE.  No representation or warranty made by Seller
herein, or in any schedule referred to herein, or in any certificate delivered
or to be delivered in connection with the transactions contemplated by this
Agreement, contains or will contain any untrue statement of a material fact or
omits or will omit to state any material fact necessary to make the statement
not misleading. 

                                   SECTION 7
                              COVENANTS OF SELLER

         7.1       PRE-CLOSING COVENANTS.  Seller covenants and agrees that,
between the date hereof and the Closing Date, except as contemplated by this
Agreement or with the prior written consent of Buyer, Seller will conduct its
business and operations in accordance with the following: 


8


<PAGE>

                   (a) Seller will not enter into any contract or commitment
relating to the Intellectual Property or incur any obligations (including
obligations relating to the borrowing of money of guaranteeing of indebtedness)
with respect to the Intellectual Property. 

                   (b) Seller will not create, assume or permit to exist any
mortgage, pledge, lien or any charge or encumbrance or rights affecting any of
the Intellectual Property. 

                   (c) Seller will not sell, assign, license or otherwise
transfer or dispose of any of the Intellectual Property. 

                   (d) Seller will use its best efforts not to cause or
permit, by any act or failure to act, any action which would impair or lessen
the value of the Intellectual Property. 

                   (e) Seller will not create or issue any Interests prior to
Closing beyond those outstanding as of the date of this Agreement. 

                   (f) From the date of this Agreement to the Closing Date,
Seller will give to Buyer and its counsel, accountants, and other authorized
representatives reasonable access during normal business hours to the books and
records of Seller relating to the Intellectual Property and will furnish to
Buyer and its authorized representatives all information relating to the
Intellectual Property as they may reasonably request. 

                   (g) Seller will notify Buyer of any material litigation or
administrative proceeding pending or, to its knowledge, threatened against it or
involving the Intellectual Property. 

         7.2       CLOSING COVENANT.  On the Closing Date, Seller shall redeem
the Interests and shall transfer, convey, assign and deliver to Buyer the
Intellectual Property as provided in Section 2 of this Agreement. 

         7.3       POST-CLOSING COVENANTS.  After the Closing, Seller agrees
that it will take such actions and execute and deliver to Buyer such further
instruments of assignment, conveyance and transfer as, in the reasonable opinion
of counsel for Buyer, may be necessary to ensure complete and evidence the full
and effective transfer of the Intellectual Property to Buyer pursuant to this
Agreement.

         7.4       CONFIDENTIALITY.  Both prior to and after the Closing,
Seller will maintain the confidentiality of all Technology that is not in the
public domain; provided that Seller's obligations under this Section 7.4 shall
not apply to Technology to which Seller obtains ownership pursuant to
Section 4.8 or pursuant to the License and Option Agreement described in
Section 9.1; and provided further that Seller may not disclose Technology which
is not in the public domain unless: (a) the disclosed has entered into a written
agreement acceptable to Buyer under which the disclosed agrees to restrictions
on disclosure, use, and transfer of the Technology; and (b) Buyer has consented
in writing to the disclosure, which consent shall not 

9


<PAGE>

be unreasonably withheld The parties agree that Buyer may withhold consent if 
the proposed disclosed is an actual or potential competitor of Buyer and that 
such refusal to consent shall be reasonable 

                                   SECTION 8
                               COVENANTS OF BUYER

         8.1       FILING, PROSECUTION, MAINTENANCE AND DEFENSE OF PATENTS. 
Buyer shall use its best efforts to file and prosecute the Planned Applications
and the Patent Applications, to maintain the Planned Applications, the Patent
Applications, and the Patents, and to bear the full cost of said maintenance. 
Buyer shall use its best efforts to prosecute the infringement of Patents and
shall bear the cost associated with such prosecution, provided that Buyer shall
have sole discretion with respect to what action it elects to take with respect
to such prosecution.  In the event Buyer is unable to or elects not to continue
the prosecution or maintenance of a Patent Application, Planned Application, or
Patent, or if Buyer otherwise acts or fails to act in such a manner as to result
in de facto abandonment of a Patent Application, Planned Application, or Patent,
Buyer shall notify Seller of this fact in a timely manner.  To the extent
Buyer's decision not to prosecute or maintain an Application or a Patent is
based upon a decision by Buyer to abandon the Application or Patent, or
otherwise results in de facto abandonment of the Application or Patent, Buyer
agrees to convey all right, title, and interest in such Application or Patent to
Seller at no cost to Seller.  Buyer further agrees to provide Seller with copies
of all office actions by the United States and any foreign patent offices
concerning Planned Applications and Patent Applications within two weeks of
receipt by Buyer of such office action and to provide in a timely manner a copy
of Buyer's response to each such office action. 

         8.2       NOTICES.  Buyer and Buyer Affiliates shall include on all
Products sold labels containing appropriate trademark and patent notifications. 

         8.3       CONFIDENTIALITY.  Both prior to and after the Closing, Buyer
will maintain the confidentiality of all Technology that is not in the public
domain; provided that Buyer's obligations under this Section 8.3 shall not apply
to disclosures made pursuant to an appropriate confidentiality agreement to the
extent Buyer, in its sole discretion, determines such disclosures to be
appropriate to exploitation of the Technology. 

                                   SECTION 9
                                JOINT COVENANTS

         9.1       LICENSE AND OPTION AGREEMENT.  On the Closing Date, Buyer
and Seller shall execute a License and Option Agreement in substantially the
form shown in Schedule 9.1. 

         9.2       NO INCONSISTENT ACTION.  Seller and Buyer will not take any
action inconsistent with their obligations under this Agreement or which could
hinder or delay the consummation of the transactions contemplated by this
Agreement. 


10


<PAGE>

         9.3       PROVISION OF INFORMATION AND FILING OF PLANNED APPLICATIONS. 
Seller shall provide Buyer with copies of appropriate documents and other
materials necessary to complete preparation of the Planned Applications listed
in Schedule 1.12, and Buyer will use reasonable efforts to file such
applications in a timely manner and carry out such other steps as are necessary
in order to obtain patents on the basis of such applications.  Both parties
shall execute such documents and take such actions as the other party may
reasonably request to facilitate the prosecution of the Planned Applications. 

         9.4       PROSECUTION OF INFRINGEMENT.  Both parties shall cooperate
in the prosecution of any infringement of any Patents; provided, however, that
Buyer shall have the sole right to control the prosecution and settlement of any
claim of infringement and shall have sole discretion with respect to such
prosecution for so long as Buyer remains the owner of the Patent in question In
the event that Seller elects to assist in the prosecution of any infringement,
Seller shall have the right to share in any resulting recovery or settlement pro
rata based upon the percentage established under Section 4 for the Purchase
Price payments and shall have the right to share in any award of legal expenses
and fees pro rata based upon Seller's share of such expenses and fees incurred. 

         9.5       CANCELLATION OF PRIOR AGREEMENTS.  Effective as of the
Closing, the License Agreements between the parties dated November 1, 1991 and
November 4, 1991 are cancelled and superseded by this Agreement. 

                                   SECTION 10
                       CONDITIONS TO OBLIGATIONS OF BUYER

         The obligations of Buyer hereunder are, at its option, subject to
satisfaction, at or prior to the Closing Date, of each of the following
conditions: 

         10.1      REPRESENTATIONS, WARRANTIES, COVENANTS. 

                   (a) All representations and warranties of Seller made in
this Agreement, or in any schedule or certificate delivered pursuant hereto,
shall be true and complete on and as of the Closing Date with the same force and
effect as if made on and as of that date. 

                   (b) All of the terms, covenants and conditions to be
complied with and performed by Seller on or prior to the Closing Date shall have
been complied with or performed by Seller. 

                   (c) Buyer shall have received a certificate of Seller
executed by the General Partner of Seller and dated as of the Closing Date, to
the effect that the representations and warranties of Seller contained in this
Agreement, are true and complete on and as of the Closing Date as though made on
and as of the Closing Date, and that Seller has complied with or performed all
terms, covenants and conditions to be complied with or performed by Seller on or
prior to the Closing Date. 

11


<PAGE>

         10.2      THIRD PARTY CONSENTS.  Seller shall have obtained such third
party consents and made such filings or registrations with or notifications to,
or received such consents, approvals or authorizations of, all federal, state
and local and foreign authorities, required for consummation of the transactions
contemplated by this Agreement, in each case on terms and conditions that are
satisfactory to Buyer in its sole discretion.

         10.3      ADVERSE PROCEEDINGS.  No suit, action, claim or proceeding
shall have been instituted or threatened against, and no order, decree or
judgment of any court, agency or other governmental authority shall have been
rendered against, Buyer or Seller to restrain or prohibit, or obtain damages in
respect of, this Agreement or the transactions contemplated by this Agreement. 

         10.4      NO MATERIAL ADVERSE CHANGE.  There shall not have been any
material adverse change in the Intellectual Property. 

         10.5      COMPLETION OF EXCHANGE OFFER.  The Exchange Offer shall have
been completed pursuant to its terms. 

         10.6      REDEMPTION OF INTERESTS.  Seller shall have redeemed the
Interests Tendered by Buyer pursuant to Section 2.2. 

         10.7      INSTRUMENTS OF CONVEYANCE AND TRANSFER.  Seller shall have
sold, conveyed, assigned, transferred and delivered to Buyer all right, title
and interest of Seller in and to the Intellectual Property by the execution and
delivery to Buyer of assignment documents prepared by Buyer and satisfactory in
form and substance to Seller and shall have otherwise done all things necessary
or desirable in the reasonable judgment of Buyer to place Buyer in ownership and
control of the Intellectual Property, free and clear of any security interest,
mortgage, pledge, conditional sales agreement, or other lien or encumbrance
other than any security interest, mortgage, pledge, conditional sales agreement
or other lien or encumbrance imposed on the Intellectual Property by or through
Buyer. 

         10.8      OPINION OF COUNSEL.  Counsel to Seller shall have delivered
an opinion dated as of the Closing Date substantially in the form of Schedule
10.8. 

         10.9      SATISFACTION OF COUNSEL.  All actions and proceedings
required to be carried out by this Agreement, or incidental hereto, all
documents and instruments to be delivered hereunder, or incidental hereto and
all other relevant legal matters shall be reasonably satisfactory in all
respects to counsel for Buyer. 

                                   SECTION 11
                      CONDITIONS TO OBLIGATIONS OF SELLER

         The obligations of Seller hereunder are, at its option, subject to
satisfaction, at or prior to the Closing Date, of each of the following
conditions: 

12


<PAGE>

         11.1      REPRESENTATIONS, WARRANTIES AND COVENANTS. 

                   (a) All representations and warranties of Buyer made in
this Agreement, or in any certificate delivered pursuant hereto, shall be true
and complete on and as of the Closing Date with the same force and effect as if
made on and as of that date.

                   (b) All of the terms, covenants and conditions to be
complied with and performed by Buyer on or prior to the Closing Date shall have
been complied with or performed by Buyer.

                   (c) Seller shall have received a certificate of Buyer,
dated as of the Closing Date, executed by the President or other authorized
officer of Buyer, to the effect that the representations and warranties of Buyer
contained in this Agreement are true and complete on and as of the Closing Date
as though made on and as of the Closing Date and that Buyer has complied with or
performed all terms, covenants and conditions to be complied with or performed
by Buyer on or prior to the Closing Date. 

         11.2      COMPLETION OF EXCHANGE OFFER.  The Exchange Offer shall have
been completed pursuant to its terms. 

                                   SECTION 12
                                  TERMINATION

         12.1      TERMINATION BY BUYER.  This Agreement may be terminated by
Buyer upon notice to Seller if: 

                   (a) The Closing shall not have occurred on or before
July 1, 1993; 

                   (b) Any representation of warranty of Seller shall prove
false in any material respect; 

                   (c) Seller shall (i) apply for or consent to the
appointment of, or the taking of possession by, a receiver, custodian, trustee
or liquidator of itself or of all of its property, (ii) make a general
assignment for the benefit of its creditors, (iii) commence a voluntary case
under the Federal Bankruptcy Code (as now or hereafter in effect), (iv) be
adjudicated a bankrupt or insolvent, (v) file a petition seeking to take
advantage of any other law relating to bankruptcy, insolvency, reorganization,
winding-up or composition or adjustment of debts, (vi) fail to controvert in a
timely and appropriate manner, or acquiesce in writing to, any petition filed
against it in an involuntary case under such Bankruptcy Code, or (vii) take any
action for the purpose of effecting any of the foregoing; 

                   (d) A proceeding or case shall be commenced, without the
application or consent of Seller, in any court of competent jurisdiction seeking
(i) the liquidation, reorganization, dissolution or winding-up or the
composition or readjustment of debts, of Seller, 

13


<PAGE>

(ii) the appointment of a trustee, receiver, custodian, liquidator or the 
like of Seller, or of all of any substantial part of its assets or (iii) similar
relief in respect of Seller under any law relating to bankruptcy, insolvency, 
reorganization, winding-up or composition or adjustment of debts; or 

                   (e) On the Closing Date any condition precedent to the
obligations of Buyer set forth in this Agreement shall not have been satisfied
and Buyer shall not have previously waived such condition. 

         12.2      TERMINATION BY SELLER.  This agreement may be terminated by
Seller, if not then in default, upon notice to Buyer if:

                   (a) The Closing shall not have occurred on or before
July 1, 1993; 

                   (b) Any representation or warranty of Buyer shall prove
false in any material respect; or 

                   (c) Buyer shall (i) apply for or consent to the appointment
of, or the taking of possession by, a receiver, custodian, trustee or liquidator
of itself or all of its property, (ii) make a general assignment for the benefit
of creditors, (iii) commence a voluntary case under the federal Bankruptcy Code
(as now or hereafter in effect), (iv) be adjudicated a bankrupt or insolvent,
(v) file a petition seeking to take advantage of any other law relating to
bankruptcy, insolvency, reorganization, winding-up or composition or adjustment
of debts, (vi) fail to controvert in a timely and appropriate manner, or
acquiesce in writing to, any petition filed against it in an involuntary case
under such Bankruptcy Code, or (vii) take any action for the purpose of
effecting any of the foregoing; 

                   (d) A proceeding or case shall be commenced, without the
application or consent of Buyer in any court of competent jurisdiction seeking
(i) the liquidation, reorganization, dissolution or winding-up or the
composition or readjustment of debts, of Buyer, (ii) the appointment of a
trustee, receiver, custodian, liquidator or the like of Buyer, or of all or any
substantial part of its assets or (iii) similar relief in respect of Buyer under
any law relating to bankruptcy, insolvency, reorganization, winding-up or
composition or adjustment of debts; or 

                   (e) On the Closing Date any condition precedent to the
obligations of Buyer set forth in this Agreement shall not have been satisfied
and Seller shall not have previously waived such condition.

         12.3      EFFECT OF CLOSING.  The termination provisions of this
Section 12 shall cease upon the Closing. 




14


<PAGE>

                                   SECTION 13
                             DISCLAIMER OF WARRANTY

         Seller makes no warranty whatsoever with respect to the safety,
efficacy, or utility of the Intellectual Property, the Patents, or the Products
or as to the validity or utility of any claims in any Planned Applications,
Patent Applications, or Patents.  Buyer acknowledges that it has made its own
assessment of and is satisfied with the value of the Intellectual Property. 

                                   SECTION 14
                                OTHER PROVISIONS

         14.1      SURVIVAL.  The conditions to closing contained in
Sections 10 and 11 and the termination provisions of Section 12 shall be
extinguished in the Closing.  All other provisions of this Agreement, including,
without limitation, the representations and warranties of the parties, shall
survive the Closing and continue in full force and effect. 

         14.2      CHOICE OF LAW.  The construction and performance of this
Agreement will be governed by the laws of the state of Oregon (except for choice
of law provisions thereof). 

         14.3      EXPENSES.  Each party to this Agreement shall pay its own
expenses incident to the negotiation, execution, delivery and performance of
this Agreement 

         14.4      NOTICES.  Any notice or other communication required or
permitted under this Agreement shall be in writing (which may take the form of a
telecopy communication) and shall be sent by certified mail, return receipt
requested, or by confirmed telecopier or hand delivery: 

    If to Buyer, to the following address:

              ANTIVIRALS Inc.
              One Southwest Columbia, Suite 1105
              Portland, Oregon 97204
              Telecopy: (503) 227-0,51
              Attention: President

    With a copy to:

              Stoel Rives Boley Jones & Grey
              900 SW Fifth Avenue, Suite 2300
              Portland, Oregon 97204
              Telecopy: (503) 220-2480
              Attention: E. Walter Van Valkenburg


15


<PAGE>

    If to Seller, to the following address:

              ANTI-GENE DEVELOPMENT GROUP
              P.O. Box 2210
              Corvallis, Oregon 97339
              Telecopy: (503) 754-3545
              Attention: James E. Summerton, Ph.D

    With a copy to: 

              James E. Summerton
              ANTI-GENE DEVELOPMENT GROUP
              1935 N.W. Larch
              Corvallis, OR 97330

Unless otherwise provided in this Agreement, all notices and communications
shall be deemed to have been duly given or made (i) when delivered by hand,
(ii) five business days after being deposited in the mail, postage prepaid,
as.registered or certified mail, return receipt requested, or (iii) when
telecopied, receipt acknowledged.  The address or telecopy numbers to which
notices or other communications shall be directed may be changed from time to
time by any party by giving written notice to the other parties of the
substitute address or telecopy number. 

         14.5      ATTORNEY FEES.  If a suit or action is filed by either party
to enforce the provisions of this Agreement, or otherwise with respect to the
subject matter of this Agreement, the prevailing party shall be entitled to
recover reasonable attorneys' fees and expenses (including, but not limited to
those fees and expenses permitted or defined by statute) as fixed by the trial
court, and if any appeal is taken from the decision of the trial court, as
affixed by the appellate court.  For purposes of this Agreement, the term
"prevailing party" shall be deemed to include a party that successfully opposes
a petition for review filed by an appellate court. 

         14.6      SUCCESSORS AND ASSIGNS.  This Agreement will be binding upon
and inure to the benefit of each of the parties and its successors and assigns;
provided that no party may assign its rights under this Agreement without the
consent of the other party, which consent shall not unreasonably be withheld. 

         14.7      AMENDMENT.  No supplement, modification or amendment of, or
waiver with respect to, this Agreement shall be binding unless executed in
writing.  This Agreement may be modified, amended or terminated upon the written
agreement of both parties.

         14.8      CONSENTS.  Any consent required by this Agreement shall be
effective only if given in a writing executed by the party giving the consent. 



16


<PAGE>

         14.9      HEADINGS.  The headings in this Agreement are solely for
convenience of reference and shall not limit or otherwise affect the meaning of
this Agreement. 

         14.10          SEVERABILITY.  If any part of this Agreement is found
invalid or unenforceable, it shall be enforced to the maximum extent permitted
by law, and other parts of this Agreement will remain in force. 

         14.11          ENTIRE AGREEMENT.  This Agreement, including the
License and Option Agreement comprising Schedule 9.1, constitutes the entire
agreement pertaining to the subject matter hereof and supersedes all prior
agreements and understandings of the parties in connection herewith.  No
covenant, representation or condition not expressed in this Agreement will
affect or be effective to interpret, change or restrict, the express provisions
of this Agreement. 

         14.12          COUNTERPARTS.  This Agreement may be executed in
counterparts, each of which will be considered an original, but all of which
together will constitute the Same instrument 

         IN WITNESS WHEREOF, the parties hereto have executed this Technology
Transfer Agreement the day and year first above written.

                                        ANTIVIRALS Inc. 


                                        By:
                                           -------------------------------------
                                              Denis Burger, Ph.D, President


                                        ANTI-GENE DEVELOPMENT GROUP


                                        By:
                                           -------------------------------------
                                              James E. Summerton, Ph.D,
                                              General Partner



17


<PAGE>

                                 Schedule 1.10

                       UNITED STATES PATENT APPLICATIONS


Application No. 944,707 for "Polynucleotide Assay Reagent and Method" (Filed
December 18, 1986).

Application No. 454,056 for "Alpha-Morpholino Ribonucleoside Derivatives and
Polymers Thereof" (Filed December 20, 1989). 

Application No. 799,681 for "Uncharged Morpholino Based Polymers Having
Phosphorous Linked Chiral Intersubunit Linkages" (Filed November 21, 1991). 

Application No. 880,883 for "Uncharged Polynucleotide-Binding Polymers n (Filed
May 8, 1992). 

Application No. 979,158 for "Sequence Specific Binding Polymers for Duplex
Nucleic Acids" (Filed November 23, 1992). 

Application No. 988,451 for "Uncharged Morpholino-Based Polymers Having
Phosphorous Containing Chiral Intersubunit Linkages" (Filed December 10, 1992). 

                          FOREIGN PATENT APPLICATIONS

Application No. 869025957 (Europe) for "Polynucleotide Assay Reagent and Method"
(Filed March 14, 1986). 

Application No. 869021899 (Europe) for "Stereoregular Polynucleotide-Binding
Polymers" (Filed March 14, 1986). 

Application No. 61-502179 (Japan) for "Polynucleotide Assay Reagent and Method"
(Filed March 14, 1986). 

Application No. 61-501967 (Japan) for "Stereoregular Polynucleotide-Binding
Polymer" (Filed March 14, 1986). 

Application No. 92/05208 (PCT) for "Sequence Specific Binding Polymers for
Duplex Nucleic Acids" (Filed June 18, 1992). 

Application No. 81109326 (Taiwan) for "Sequence Specific Binding Polymers for
Duplex Nucleic Acids" (Filed November 21, 1992). 



                                        1


<PAGE>

Application No. 20698691 (Canada) for "Uncharged Morpholino-Based Polymers
Having Phosphorous-Containing Chiral Intersubunit Linkages" (Filed December 20,
1990). 

Application No. 3502891 (Japan) for "Uncharged Morpholino-Based Polymers Having
Phosphorous Containing Chiral Intersubunit Linkages" (Filed December 20, 1990). 

Application No. 71642/91 (Australia) for "Uncharged Morpholino-Based Polymers
Having Phosphorous-Containing Chiral Intersubunit Linkages" (Filed December 20,
1990). 

Application No. 919020859 (EPO) for "Uncharged Morpholino-Based Polymers Having
Phosphorous-Containing Chiral Intersubunit Linkages" (Filed December 20, 1990). 

Application No. 92701479 (Korea) for "Uncharged Morpholino-Based Polymers Having
Phosphorous-Containing Chiral Intersubunit Linkages" (Filed December 20, 1990). 

Application No. 20699060 (Canada) for "Uncharged Morpholino-Based Polymers
Having Achiral Intersubunit Linkagesll (Filed December 20, 1990). 

Application No. 3502893 (Japan) for "Uncharged Morpholino-Based Polymers Having
Achiral Intersubunit Linkages" (Filed December 20, 1990). 

Application No. 71587/91 (Australia) for "Uncharged Morpholino-Based Polymers
Having Achiral Intersubunit Linkages" (Filed December 20, 1990). 

Application No. 919024018 (EPO) for "Uncharged Morpholino-Based Polymers Having
Achiral Intersubunit Linkages" (Filed December 20, 1990). 

Application No. 92701480 (Korea) for "Uncharged Morpholino-Based Polymers Having
Achiral Intersubunit Linkages" (Filed December 20, 1990).



                                        2


<PAGE>

                                 Schedule 1.11

                             UNITED STATES PATENTS


U.S. Patent No. 5,142,047 for "Uncharged Polynucleotide-Binding Polymers"
(August 25, 1992). 

U.S. Patent No. 5,034,506 for "Uncharged Morpholino-Based Polymers having
Achiral Intersubunit Linkages" (July 23, 1991). 

U.S. Patent No. 5,166,315 for "Sequence-Specific Binding Polymers for Duplex
Nucleic Acids" (November 24, 1992). 

                                FOREIGN PATENTS


Canadian Patent No. 1,268,404 for "Polynucleotide Assay Reagent and Method."


<PAGE>

                                 Schedule 1.12

                              PLANNED APPLICATIONS


Nonionic nucleic acid-binding polymers specific for single stranded DNA.  

Single-probe diagnostic system utilizing nonionic reporter probe.

Novel adducts for improving entry of nucleic acids-binding polymers into cells.

Binding polymers having reduced sequence-specificity effective for binding
RNA:RNA duplexes.

Subunits and nucleic acids-binding polymers containing novel 6-membered
non-morpholino backbone moieties.

Continuous flow method for assembling sequence-specific nucleic acids-binding
polymers.

Purification/concentration component for use with a probe diagnostic system
which utilizes a nonionic capture probe. 

Method for conversion of biologically-synthesized DNA to a nonionic form, and
products of said conversion.


<PAGE>

                                 Schedule 1.17

                             TRADEMARK APPLICATIONS


U.S. Application No. 74-269,484 for GOOD-SENSE (Filed April 27, 1992). 

U.S. Application No. 74-269,483 for ANTI-GENE (Filed April 27, 1992). 

U.S. Application No. 74-269,482 for NEU-GENE (Filed April 27, 1992). 


<PAGE>

                                 Schedule 1.18
                                           
                                   TRADEMARKS
                                           
                                           
                                   GOOD-SENSE
                                   ANTI-GENE
                                    NEU-GENE


<PAGE>

                                  Schedule 6.4
                                           
                 EXCEPTIONS TO INTELLECTUAL PROPERTY OWNERSHIP
                                           
                                           
                                     None.


<PAGE>

                                  Schedule 6.6
                                           
                             LIENS AND ENCUMBRANCES
                                           
                                           
                                     None.


<PAGE>

                                  Schedule 6.9
                                           
                   LITIGATION AND ADMINISTRATIVE PROCEEDINGS
                                           
                                           
                                     None.


<PAGE>

                                  Schedule 9.1

                          LICENSE AND OPTION AGREEMENT


         This License and Option Agreement is by and between ANTI-GENE
DEVELOPMENT GROUP, an Oregon limited partnership ("AGD") and ANTIVIRALS Inc., an
Oregon corporation ("AVI"). 

                                    RECITALS


    A.   AGD and AVI are parties to a Technology Transfer Agreement (the
"Transfer Agreement") under which AGD has conveyed to AVI certain Technology, as
more fully described in the Transfer Agreement. 

    B.   Each party wishes to grant to the other certain rights with respect to
the Technology and Improvements thereto.

                                   AGREEMENT

         In consideration of the above and of the promises and covenants
contained herein, the parties agree as follows: 

    1.   DEFINITIONS. 

         1.1      Unless otherwise set forth in this Agreement, the terms used
in this Agreement shall have the meanings given to them in the Transfer
Agreement. 

         1.2      "AGD Affiliate" shall mean AGD Licensees, other than AVI,
and any entity other than AVI that controls, is controlled by or is under common
control with AGD. 

         1.3      "AGD Improvements n shall mean Improvements developed by AGD
after the effective date of this Agreement but before January 1, 2000, and which
AGD has the right to sublicense to AVI.

         1.4      "AGD Licensee" shall mean any person, corporation or other
entity, other than AVI, that obtains a right granted by AGD or an AGD Affiliate
to: (a) make a Proposed Product or Related Product; (b) make a Proposed Product
or Related Product and use that Proposed Product or Related Product; (c) make a
Proposed Product or Related Product and sell that Proposed Product or Related
Product; (d) have a Proposed Product or Related Product made on behalf of said
entity and use that Proposed Product or Related Product; (e) have a Proposed
Product or Related Product made on behalf of said entity and sell that Proposed
Product or Related Product; or, (f) use a method claimed in a patent covering an
AVI Improvement. 

                                        1


<PAGE>

         1.5      "AVI Affiliate" shall have the meaning given to Buyer
Affiliate" in the Transfer Agreement.

         1.6      "AVI Improvements" shall mean Improvements developed by AVI
after the effective date of this Agreement but before January 1, 2000, and which
AVI has the right to license to AGD. 

         1.7      "Improvements" shall mean documented improvements to the
Technology comprising inventions, discoveries, trade secrets, formulas,
techniques, processes, and know-how, whether or not patented and whether or not
reduced to practice, which are derived from, incorporate, or are based upon, are
adducts to, or which relate to making or using the Technology. 

         1.8      "Licensed Product" shall mean any product with respect to
which AVI obtains a license under Section 5 of this Agreement. 

         1.9      "Polymer" shall mean a single molecular specie of nucleic
acid binding polymer incorporating one or more aspects of the Technology and/or
Improvements. 

         1.10     "Proposed Product" shall have the meaning set forth in
Section 3.1.

         1.11     "Related Product" shall mean, with respect to any Proposed 
Product, all related products which have the same or similar structural type and
adducts which achieve substantially the same biological effect and which are 
targeted against the same pathogen specie or cellular gene as the Proposed 
Product.

    2.   RESEARCH AND DEVELOPMENT LICENSE TO AGDG. 

         2.1      Subject to the terms of this Agreement, AVI hereby grants to
AGD a nonexclusive, royalty free license, with the right to sublicense: (a) to
use the Technology and AVI Improvements and to make, have made, and use any
Products incorporating the Technology and AVI Improvements internally for
research and development; and (b) to make, have made, use and sell Polymers in
an amount of no more than ten (10) grams per month of each single Polymer; and
(c) to make, have made, and use subunits and adducts in amounts not to exceed
that required for assembly of said Polymers. 

         2.2      AGD may not disclose the Technology or any AVI Improvements
that are not in the public domain unless: (a) the disclosed or transferee has
entered into a written agreement acceptable to AVI under which the disclosed or
transferee agrees to restrictions on disclosure, use, and transfer of the
Technology or AVI Improvements, and (b) AVI has consented in writing to the
disclosure, use and transfer, which consent shall not be unreasonably withheld;
provided that AGD's obligation under this Section 2.2 shall not apply to
Technology or Improvements to which AGD obtains a license pursuant to Section 3
or Section 6 or to which AGD obtains ownership pursuant to section 4.8 of the
Transfer Agreement. 

                                        2


<PAGE>

         2.3      AVI shall not enter into any agreement restricting its right
to license AVI Improvements solely for the purpose of denying a license to such
AVI Improvements to AGD. 

    3.   OPTION. 

         3.1      If AGD develops or obtains-a specific prototype product 
which AVI has the right to make, use and sell and which incorporates one or 
more aspects of the Technology or Improvements and demonstrates at the 
biophysical level that said prototype product affords binding properties for 
its selected genetic target, AGD shall provide written notice (the "Notice") 
to AVI describing the product (the "Proposed Product") and shall provide AVI 
with such existing information and materials as AVI may reasonably request to 
enable AVI to evaluate the Proposed Product. 

         3.2      Within thirty (30) days after the date of the Notice
required under Section 3.1, AVI shall notify AGD: (a) that AVI intends to begin
optimization and commercialization of the Proposed Product; or (b) that AVI
elects not to commercialize the Proposed Product.  If AVI elects not to
commercialize the Proposed Product, AVI shall grant AGD an exclusive, perpetual
license, with the right to sublicense, to make, have made, use, sell, and
otherwise distribute the Proposed Product and any Related Products and to make,
have made, and use subunits and adducts in amounts not to exceed that required
for assembly of the Proposed Product and any Related Products. 

         3.3      If AVI elects to begin optimization and commercialization of
the Proposed Product, AVI shall take such steps as AVI, in its sole discretion,
considers appropriate with respect to the Proposed Product: provided, however
that AGD shall have the right, upon written notice to AVI, to obtain the license
described in Section 3.2 if neither AVI nor any AVI Affiliate achieves the
milestones set forth below by the dates indicated: 

                  (a)   Commencement of cell culture studies on the Proposed
Product: Nine (9) months from the date of AGD's Notice under Section 3.1. 

                  (b)   Commencement of pharmacokinetics and toxicology studies
of the Proposed Product: Twenty-four (24) months from the date of AGD is Notice
under Section 3.1. 

                  (c)   Commencement of clinical trials of the Proposed Product
or an optimized version thereof: thirty-six (36) months from the date of AGD's
Notice under Section 3.1. 

         3.4      For purposes of Section 3.3, a milestone shall be met for a
Proposed Product if the milestone occurs with respect to an optimized version of
the Proposed Product which has the same or similar structural type and adducts
which achieve substantially the same biological effect and which is targeted
against the same pathogen specie or cellular gene. 



                                        3


<PAGE>

         3.5      Notwithstanding anything in this Section 3 to the contrary,
AGD shall not have any rights under this Section 3 with respect to any Proposed
Product as to which AVI or any AVI Affiliate has commenced large scale
production prior to the date of AGD's Notice for so long as such large scale
production continues.  For purposes of this Section 3.5, Proposed Product
includes Related Products and "large scale production" shall mean production of
more than ten (10) grams each month. 

    4.   ROYALTIES. 

         4.1      For any license granted by AVI to AGD pursuant to Section 3
of this Agreement which covers a Proposed Product or Related Product that does
not incorporate a patented AVI Improvement, the license shall be royalty free. 

         4.2      For any license granted by AVI to AGD pursuant to Section 3
of this Agreement which covers a Proposed Product or Related Product that
incorporates a patented AVI Improvement, AGD shall pay AVI as a royalty a
percentage of the total Sales of each Proposed Product by AGD and any AGD
Affiliate, which percentages shall be equal to the applicable percentages AVI is
required to pay AGD as Purchase Price payments pursuant to the Transfer
Agreement; provided, however, that AGD's obligation to pay royalties under this
section shall be limited to Proposed Products and Related Products, the sale of
which would infringe a patent owned by AVI in the absence of this Agreement. 
For purposes of this section 4 2, "Sales" shall mean the total worldwide sales
of Proposed Products and Related Products by AGD and AGD Affiliates, subject to
the terms applicable to Sales by AVI under the Transfer Agreement. 

         4.3      AGD's obligation to pay royalties pursuant to this Section 4
shall be subject to all of the terms applicable to AVI's obligation to make
Purchase Price payments set forth in Sections 4.3, 4.4, 4.5, 4.6, and 4.8 of the
Transfer Agreement. 

    5.   LICENSE TO AVI OF AGD IMPROVEMENTS. 

         5.1      Subject to the terms of this Agreement, AGD hereby grants to
AVI a non-exclusive license, with the right to sublicense, to make, have made,
use, and sell products incorporating AGD Improvements (a "Licensed Product"). 

         5.2      AVI shall pay AGD as a royalty a percentage of the total
Sales of each Licensed Product AVI or any AVI Affiliate sells, which percentages
shall be equal to the applicable percentages AVI is required to pay AGD as
Purchase Price payments pursuant to the Transfer Agreement; provided, however,
that AVI's obligation to pay royalties under this section shall be limited to
Licensed Products the sale of which would infringe a patent owned by AGD in the
absence of this Agreement; and provided further that AVI shall have no
obligation under this Section 5.2 with respect to Licensed Products covered by
one or more 


                                        4


<PAGE>

unexpired Patents owned by AVI.  AVI's obligation with respect to Licensed 
Products covered by one or more unexpired Patents owned by AVI shall be 
limited to AVI's obligation to make Purchase Price payments pursuant to the 
Transfer Agreement. 

         5.3      AVI's obligation to pay royalties pursuant to this Section 5
shall be subject to all of the terms of AVI's obligation to make Purchase Price
payments set forth in Sections 4.3, 4.4, 4.5, 4.6 and 4.8 of the Transfer
Agreement; provided that the parties intend the exemption granted under
Section 4.6 for the first two hundred million dollars ($200,000,000) in AVI and
AVI Affiliate Sales to apply only once, so that Sales of Licensed Products under
this Section 5 shall no longer be exempt once AVI and AVI Affiliates achieve the
first two hundred million dollars in worldwide Sales of Products and Licensed
Products. 

         5.4      AVI will maintain the confidentiality of all information
about AGD Improvements that is not in the public domain unless: (a) the
disclosed has entered into a written agreement acceptable to AGD under which the
disclosed agrees to restrictions on disclosure, use, and transfer of the AGD
Improvements, and (b) AGD has consented in writing to the disclosure or
transfer, which consent shall not unreasonably be withheld. 

    6.   OBLIGATION TO EXPLOIT. 

         If after January 1, 1994, AVI and AVI Affiliates together effectively
cease development of Products based on the Technology, as evidenced by AVI, AVI
Affiliates, and/or their successors and assigns in the aggregate having for a
period of more than 180 consecutive days less than the equivalent of ten (10)
full time employees devoted to development, testing, commercialization,
production and/or sales of one or more products based on the Technology, then,
upon request by AGD, AVI will grant to AGD an exclusive royalty-free license,
with right to sublicense, to make, have made, use, sell, or otherwise distribute
the Products, to practice the Technology, and to use the Trademarks. 

    7.   DISCLAIMER OF WARRANTY. 

         Neither party makes any warranty whatsoever with respect to
Technology;and Improvements licensed pursuant to this Agreement or any Products,
Licensed Products, Proposed Products or Related Products.  Each party's rights
under this Agreement are limited to whatever rights that party has in the
Technology and Improvements transferred. 

    8.   FURTHER ASSISTANCE. 

         Each party shall take such actions and execute and deliver such other
documents as, in the reasonable opinion of counsel for the other party, may be
necessary to evidence the rights and interests of the requesting party
hereunder. 

    9.   OTHER PROVISIONS. 

                                        5


<PAGE>

         The provisions set forth in Section 14 of the Transfer Agreement are
applicable to this Agreement and are incorporated herein by reference. 

         IN WITNESS WHEREOF, the Parties hereto have executed this Agreement
effective as of __________________, 1993. 

                                        ANTIVIRALS INC. 


                                        By:
                                           -------------------------------------
                                              Denis Burger, Ph.D, President


                                        ANTI-GENE DEVELOPMENT GROUP


                                        By:
                                           -------------------------------------
                                              James E. Summerton, Ph.D,
                                              General Partner



                                        6


<PAGE>

                                 Schedule 10.8

                         OPINION OF COUNSEL FOR SELLER

                                 [Closing Date]


Antivirals Inc.
One Southwest Columbia, Suite 1105
Portland, Oregon 97204


         We have acted as counsel to Anti-Gene Development Group, an Oregon
limited partnership ("Seller") in connection with the transactions contemplated
by the Technology Transfer Agreement (the Transfer Agreement") dated as of
February 9, 1993, between Seller and Antivirals Inc. 

         We have examined originals or copies, certified or otherwise
identified to our satisfaction, of such documents, corporate records,
certificates of public officials and other instruments and have conducted such
other investigations of fact and law as we have deemed necessary.or advisable
for purposes of this opinion. 

         Upon the basis of the foregoing and subject to the qualifications
below, we are of the opinion that: 

    1.   Seller is a limited partnership duly organized and validly
existing under the laws of the state of Oregon. 

    2.   Seller has full power and authority to enter into and perform the
Transfer Agreement and the transactions contemplated thereby.  The execution,
delivery and performance of the Transfer Agreement by Seller have been duly and
validly authorized by all necessary action on the part of Seller.  The Transfer
Agreement has been duly executed and delivered by Seller and constitutes the
valid, binding and enforceable obligation of Seller except as the provisions of
the Transfer Agreement may be rendered unenforceable by applicable bankruptcy,
insolvency, reorganization, moratorium, or other similar laws affecting
creditor's rights generally or the application of general principles of equity
(regardless of whether enforcement is considered in a proceeding in equity or at
law). 

    3.   The execution, delivery and performance of the Transfer Agreement
by Seller (i) do not require the consent, approval, authorization, order or
other action of, nor any filing with, any third party, including without
limitation (A) any party to any contract, loan or credit agreement, instrument,
commitment, understanding or other agreement to which Seller is a party or
(B) any court, administrative agency or other governmental authority; (ii) will
not violate any provisions of the partnership agreement of Seller; (iii) will
not violate any law, judgment, order, 

                                        1


<PAGE>

injunction, decree, rule, regulation or ruling of any governmental authority 
applicable to Seller; (iv) will not, either alone or with the giving of 
notice or the passage of time or both, conflict with, constitute grounds for 
termination of, result in a breach of the terms, conditions or provisions of, 
or constitute a default under, any agreement, instrument, license or permit 
that is individually or in the aggregate material to the transactions 
contemplated by the Transfer Agreement and to which Seller is now subject; 
and (v) will not result in the creation of any lien, charge or encumbrance on 
any of the Intellectual Property! 

    4.   To the best of our knowledge, except as set forth in Schedule 6.4
to the Transfer Agreement, Seller owns valid, unrestricted, enforceable and
exclusive rights for the use of the Intellectual Property, Seller has delivered
to Buyer copies of all documents establishing the rights of Seller to the
Intellectual Property, and all patent applications, patents, planned patent
applications, trademark applications, and trademarks owned by Seller are
respectively listed on Schedules 1.10, l.il, 1.12, 1.17 and 1.18 to the Transfer
Agreement. 

    5.   To the best of our knowledge, the use by Seller of the
Intellectual Property has not created any conflict with or infringement upon any
intellectual property rights of third parties, and Seller has not been notified
of any such conflicts or infringement claims. 

    6.   To the best of our knowledge, none of the Intellectual Property
is subject to any security interest, mortgage, pledge, conditional sales
agreement, or other lien or encumbrance. 

    7.   To the best of our knowledge, there is no litigation, proceeding
or investigation pending or threatened against Seller in any federal, state or
local court or before any administrative agency individually or in the aggregate
material to the transactions contemplated by the Transfer Agreement, including,
without limitation, any proceeding that seeks to enjoin or prohibit or otherwise
questions the validity of any action taken or to be taken pursuant to or in
connection with the Transfer Agreement. 

         This opinion is given solely to the addressee named above and may not
be relied upon by any other person nor may it be used, circulated, quoted or
otherwise referred to other than in connection with the transactions
contemplated by the Transfer Agreement. 

                                        Very truly yours,



                                        2



<PAGE>

                  AMENDMENT TO TECHNOLOGY TRANSFER AGREEMENT
           BETWEEN ANTI-GENE DEVELOPMENT GROUP AND ANTIVIRALS INC.


This Amendment to the Technology Transfer Agreement dated February 9, 1992 but
executed on February 9, 1993 (the TT Agreement or the 1993 TT Agreement) between
ANTI-GENE DEVELOPMENT GROUP and ANTIVIRALS Inc. (Amendment) is by and between
ANTI-GENE DEVELOPMENT GROUP (AGD), an Oregon limited partnership, and ANTIVIRALS
Inc. (AVI), an Oregon corporation. 

                                    RECITALS

A.    As per the terms of the 1993 TT Agreement, hereby incorporated by
reference herein, AGD (Seller) is due Purchase Price payments from AVI (Buyer)
in the amount of 4.051 percent of Sales of Products after the first two hundred
million dollars in total cumulative worldwide Sales by Buyer and Buyer
Affiliates collectively. 

B.    AVI wishes to have Purchase Price payments reduced on Sales of
diagnostic products. 

C.    AGD wishes to receive Purchase Price payments for diagnostic products
and research products due upon AVI's sale of such products without regard to the
two hundred million dollars exemption referred to in Recital A, and otherwise
pursuant to the payment schedules and procedures set forth in this Amendment and
in the TT Agreement.

D.    AGD wishes
 to obtain from AVI a royalty-bearing license for
small-scale products and a royalty-bearing license for diagnostic products. 

                               AGREEMENT TO AMEND

In consideration of the above and as provided in Section 14.7 of the TT
Agreement, AGD and AVI agree to amend the TT Agreement as set forth below.
   

1.    TT AGREEMENT TERMS.   All capitalized terms not defined in this
Amendment shall have the meanings assigned to such terms in the TT Agreement or
its Exhibits.

2.    TT AGREEMENT DEFINITIONS.

      2.1    BUYER AFFILIATE.  Section 1.1 of the TT Agreement is hereby 
amended to read in its entirety as follows:

             "Buyer Affiliate" shall mean Buyer's Licensees and any other entity
             that controls, is controlled by, or is under common control with 
             Buyer or Buyer's Licensees, except that Seller and any direct 
             licensee of Seller shall not be deemed to be a Buyer Affiliate.


                                       1


<PAGE>

      2.2    NEW DEFINITIONS.  Section 1 of the TT Agreement is hereby 
amended to include the following definitions:

             1.20 "Therapeutic Product" shall mean a Product, as defined in 
             the TT Agreement, which is approved for use in, or is used in a 
             human or other animal to achieve a therapeutic or prophylactic 
             effect. 

             1.21 "Diagnostic Product" shall mean a Product, as defined in 
             the TT Agreement, which is approved for, or is used for detecting
             and/or quantitating in a biological specimen outside any animal 
             body one or more selected nucleic acid sequences.

             1.22 "Research Product" shall mean a Product, as defined in the 
             TT Agreement, which is not classed as a Therapeutic Product or a 
             Diagnostic Product. 

             1.23 "Small-Scale Product" shall mean a Product and AVI 
             Improvements relating thereto--including  adducts for enhancing 
             delivery and cell entry, as defined in the TT Agreement, which 
             meets all of the following requirements: 2(i) is produced in a lot
             size of less than 1 gram; 2(ii) is sold by any entity for research 
             purposes only; 

             1.24 The terms "Seller's Affiliate" and "AGD Affiliate" are 
             synonymous, and are understood and intended to mean, any entity 
             that controls, is controlled by, or is under common control with,
             AGD, but only if James E. Summerton (i) controls AGD and such AGD
             Affiliate; and (ii) is an acting key policy decision maker and
             manager of AGD and such AGD Affiliate.  For purposes of this 
             paragraph, to "control" an entity means to own greater than 50% 
             of the ownership interests with commensurate voting power in such 
             entity.

3.    TT AGREEMENT PURCHASE PRICE.  Section 4.2(b) of the TT Agreement is 
hereby amended to read in its entirety as follows:

              (b)  If Seller does distribute an undivided interest in 
      the Intellectual Property to Buyer in liquidation of its Interests 
      pursuant to Section 2.2, the Purchase Price set forth in Section 4.2(a) 
      shall be (i) with respect to Therapeutic Products, reduced pro rata to 
      reflect Seller's reduced ownership interest in the Intellectual Property 
      resulting from the liquidating distribution; and (ii) with respect to 
      Diagnostic Products and


                                       2

<PAGE>

      Research Products, a flat 2.00 percent.  By way of example, if Buyer 
      tenders for liquidation fifty (50.000) percent of the Interests 
      outstanding as of the Closing, Seller shall distribute in liquidation of 
      Buyer's Interests an undivided one-half ownership interest in the 
      Intellectual Property and Seller will retain an undivided one-half 
      ownership interest.  The Purchase Price for a Therapeutic Product shall 
      be reduced by half so that Buyer will pay four (4.00000) percent of the 
      total Sales of Products under Section 4.2(a).  The Purchase Price for a 
      Diagnostic or Research Product shall remain two (2.00000) percent 
      regardless of the Interests liquidated.

4.    RIGHT OF FIRST REFUSAL.  A new Section 4.9 is added to the TT Agreement, 
which Section reads in its entirety as follows:

      4.9  RIGHT OF FIRST REFUSAL.  Buyer shall have the right of first refusal
      to purchase a controlling interest or any interest in any AGD Affiliate 
      upon any proposed change in ownership in such entity that would result in 
      James E. Summerton losing control over such entity ("Triggering Event").  
      Transfers of interests by James E. Summerton to Summerton's children, 
      James P., Jean and/or Daniel Summerton, shall not be considered a 
      Triggering Event, and shall not give rise to Buyer's right of first 
      refusal hereunder, but transfers by such children transferees to parties 
      other than James E. Summerton would constitute a Triggering Event.  Such 
      rights of first refusal shall be exercised as follows: James E. Summerton 
      or his children transferees (hereafter "Summerton") shall give written 
      notice (the "Notice") of Summerton's desire to sell such interests prior 
      to the sale, and the parties shall seek to determine the interest price 
      as quickly as reasonably possible after such Notice.  The price of the 
      interests shall be (i) the price offered by the proposed transferee in 
      good faith and at arm's length; or (ii) if there is no proposed 
      transferee or no terms have been offered by a proposed transferee, the 
      price as determined by a neutral third party appraiser acceptable to both 
      the AGD Affiliate and Buyer; or (iii) if a price has not been determined 
      pursuant to the preceding subsections (i) or (ii), or the parties 
      otherwise agree, a price mutually agreeable to both Buyer and the AGD 
      Affiliate.  If Buyer elects not to acquire the interests specified in the 
      Notice, Summerton may sell such interests within the 60 day period 
      following the parties' determination of the interest price, provided that 
      the sale of such interests shall only occur at no less than the interest 
      price as determined according to this paragraph. Once an AGD affiliate 
      has obtained the SS license from AGD, Summerton's loss of control of AGD
      affiliate will not terminate this license.

5.    REPORTS.  Section 4.3 of the TT Agreement is hereby amended to read in its
entirety as follows:

             Within sixty (60) days after the end of each calendar quarter, 
      for so long as Products are covered by unexpired Patents, Buyer shalt 
      provide Seller with a written report setting forth the total amount of 
      each Product sold by Buyer and Buyer Affiliates during the quarter, to 
      whom the Products were sold, the gross invoice amount for each Sale, and 
      the amount of any returns.  At the time the report is made, Buyer shall 
      pay Seller any amounts payable pursuant to this Section 4. 

6.    RECORDS.  Section 4.4 of the TT Agreement is hereby amended to read in its
entirety as follows:  

             Buyer shall maintain records concerning Sales of Products 
      sufficient to enable Seller to verify the amounts payable under this 
      Agreement.  Seller shall have the right, through an independent auditor, 
      to examine such records that concern Sales of Products once in any given 
      calendar year.  Seller shall bear all expenses associated with such 
      audits.

7.    COMMENCEMENT OF PAYMENT OBLIGATIONS.  Section 4.6 of the TT Agreement is
hereby amended to read in its entirety as follows:

             The first two hundred million dollars ($200,000,000) in total 
      cumulative worldwide Sales of Therapeutic Products by Buyer and Buyer 
      Affiliates, collectively, are exempt from Purchase Price payments.  
      All Sales of Diagnostic Products and Research Products by Buyer and Buyer
      Affiliates are subject to Purchase Price Payments as of the initial Sale
      without regard to any exemption.

8.    NEW SCHEDULES.  Section 9.1 of the TT Agreement is hereby amended to read
in its entirety as follows:

             Buyer and Seller shall execute a License and Option Agreement shown
      in SCHEDULE 9.1.  In addition, the     parties hereby enter into a License
      for Small-Scale Products, attached hereto as Schedule 9.1.1 and a License 
      for  Diagnostic Products and Improvements, attached hereto as Schedule 
      9.1.2.


                                       3


<PAGE>

9.   SCHEDULE 9.1 DEFINITIONS.  Schedule 9.1, Section 1.3 of the TT Agreement 
is hereby amended to read in its entirety as follows:

           "AGD Improvements" shall mean Improvements developed by AGD after the
     effective date of this Agreement but before January 1, 1998, and which AGD 
     has the right to sublicense to AVI.

10.  SCHEDULE 9.1 AVI IMPROVEMENTS.  Schedule 9.1, Section 1.6 of the TT 
Agreement is hereby amended to read in its entirety as follows:  

           "AVI Improvements" shall mean Improvements developed by AVI after the
     effective date of this Agreement but before January 1, 1998, and which AVI
     has the right to sublicense to AGD.

11.  SCHEDULE 9.1 AGD IMPROVEMENTS.  Schedule 9.1 of the original TT Agreement
is hereby amended to include a new Section 2.4 which reads in its entirety as 
follows:

           Improvements to the Technology made by AGD and its licensees under 
     the Research and Development License to AGD will be defined as "AGD 
     Improvements" which are to be made available to AVI under the terms of
     Section 5 of this  Schedule 9.1 of the TT Agreement.

12.  SCHEDULE 9.1 CROSS LICENSES.  Section 5 of Schedule 9.1 of the original TT
Agreement is amended as follows:

     12.1.  Change in Title.  The title of Section 5 of Schedule 9.1 is hereby 
amended to read in its entirety as follows: 

            5.  License to AVI and Cross Licenses of Improvements.

     12.2.  Change in Numbering of Section 5.4.  Section 5.4 of Schedule 9.1, 
relating to the confidentiality of AGD improvements, is hereby renumbered 5.5 
and is otherwise left intact.

     12.3.  New Section 5.4.  A new Section 5.4 is hereby added to Schedule 
9.1, which reads in its entirety as follows: 

     5.4  The parties grant each other the following cross-licenses.  AGD 
     agrees to grant to AVI a royalty-free non-exclusive license to make, use,
     sell, and sublicense any improvements made by AGD before January 1, 2000 
     relating to preparation of Morpholino subunits and/or assembly of said 
     subunits into Morpholino polymers. AVI agrees to grant to AGD a 
     royalty-free non-exclusive license to make, use, sell, and sublicense any 
     improvements made by AVI before January 1, 2000 relating to preparation of
     Morpholino subunits and/or assembly of said subunits into Morpholino 
     polymers.

    IN WITNESS WHEREOF, the parties hereby execute this Amendment to the 
Technology Transfer Agreement, effective as of the later of the dates of 
signature by the representatives of AVI and AGD below. 

                                       ANTIVIRALS Inc. 


                                       By: /s/ Denis Burger
                                          ----------------------------------
                                             Denis Burger, Ph.D.
                                             Chief Executive Officer


                                       Date: 1/20/97


                                       ANTI-GENE DEVELOPMENT GROUP


                                       By: /s/ James E. Summerton
                                          ----------------------------------
                                             James E. Summerton, Ph.D.
                                             Sole General Partner


                                       4

<PAGE>

                                       Date: January 20, 1997


                                       5


<PAGE>

                                 SCHEDULE 9.1.1

                        License for Small-Scale Products

1.   SMALL-SCALE PRODUCTS LICENSE TO AGD

     AVI hereby grants to AGD a license to Small-Scale Products (SS Products),
with right to sublicense to AGD Affiliates, to make, have made, use, and sell SS
Products, and to make, have made, and use subunits and other components in
amounts not to exceed that required for assembly and use of SS Products.  This
license (the "SS Product License") is to be exclusive with respect to, and only
with respect to selling SS Products.  AGD and AGD Affiliates agree to label 
all SS products with the phrase "Not for use in humans."

2.   ROYALTY

     AGD shall pay AVI as a royalty four (4.00) percent of the total Sales of 
SS Products sold by AGD and AGD Affiliates, where Sales of SS Products shall 
mean total worldwide sales of SS Products by AGD and AGD Affiliates to any 
entity other than AGD and AGD Affiliates at the Gross Invoice Amount minus 
returns, where returns comprise compensation to the purchaser of the SS 
Product for SS Products returned to AGD or AGD Affiliates.  Gross Invoice 
Amount shall mean all money and other valuable consideration paid to AGD and 
AGD Affiliates in exchange for SS Products.

3.   INFORMATION FOR MAKING AND USING SS PRODUCTS

     Unless requested earlier by AGD, in December of 1997 AVI will convey to 
AGD written "Information for Making and Using SS Products."  This Information 
for Making and Using SS Products shall comprise the best ways known to AVI to 
make and use SS Products as of the date of conveyance of said Information for 
Making and Using SS Products.  No other rights to transfer information 
concerning any other AVI Improvements are implied or granted by this SS 
Products License.  If AGD shares information on AVI Improvements other than 
"Information for Making and Using SS Products," with a sublicensee for SS 
Products, except where expressly allowed by a separate AVI license to AGD, 
that sublicensee shall also be considered to be a Research and Development 
Licensee and any and all Improvements to the Technology made by that 
sublicensee will be defined as AGD improvements which are to be made 
available to AVI under the terms of Section 5 of Schedule 9.1 of the TT 
Agreement.

4.   CONFIDENTIALITY OF INFORMATION

     AGD may not disclose the Technology or any AVI Improvements described in 
the Information for Making and Using SS Products that are not in the public 
domain unless: (a) the recipient has entered into a written agreement 
acceptable to AVI under which the recipient agrees to restrictions on 
disclosure, use and transfer of the Technology and AVI Improvements, and (b) 
AVI has consented in writing to the disclosure, use, and transfer, which 
consent shall not be unreasonably withheld.


1


<PAGE>

5. EXEMPTION

     AVI's provision of Small-Scale Products to a for-profit entity as part of a
contract which includes testing and assessment of Products by said for-profit
entity, where said contract is for an amount not less than $100,000, shall not
be construed as infringing the "exclusive with respect to selling SS Products"
clause of this SS Products license to AGD.  It is understood that AVI is free to
provide SS Products to any of its collaborators at no charge (including, without
limitation in arrangements such as the 1995 option arrangement with Abbott
Laboratories).  Further, it is understood that AVI may sell SS Products to a
given collaborator is those sales are part of a contract with a value of not
less than $100,000 for the purchase of SS Products.

6.   EFFECTIVE DATE

     The effective date of this SS Products License shall be when both AVI and
AGD have signed the Amendment to which this is Schedule 9.1.1, except that the
exclusivity of the SS Product License granted to AGD under Section 1 above will
only become effective at the time AGD or AGD Affiliate demonstrates a capability
to prepare at lease 10 different 20-mer Morpholino polymers in a 2 week period
and two such representative Morpholino polymers exhibit on a per mass basis in a
cell-free translation system at least 60% of the efficacies of corresponding
highly-purified Morpholino polymers prepared by AVI.

7.   TERMINATION OF PAYMENT OBLIGATIONS

     AGD's obligation to make royalty payments to AVI for any given SS Product
shall end upon the expiration of all AVI patents claims that cover that SS
Product.

8.   TERMINATION OF SS PRODUCT LICENSE

     Either party may terminate this SS Products License for any material 
breach by the other party that remains uncured 90 days after that party 
receives notice of the breach from the non-breaching party, except that if a 
dispute arises with respect to AGD's payment of royalties, AVI shall be 
entitled to terminate this SS Products License only after the arbitration 
process set forth in Section 14.

9.   OBLIGATION TO EXPLOIT

     Subsequent to the year 1999 AGD must pay AVI a royalty of at least $10,000
per year for this SS Products License.  If the royalty paid is less than this
amount the exclusivity granted to AGD to the SS Product License under Section 1
shall automatically terminate.

10.  DISCLAIMER OF WARRANTY

     AVI makes no warranty whatsoever, express or implied, including without
limitation a warranty of merchantability or fitness, with respect to Technology,
AVI Improvements, or SS Products licensed to AGD pursuant to this Amendment,
which SS Products AGD takes "as is".


2


<PAGE>

11.  REPORTS

     Within sixty (60) days after the end of each calendar quarter, for so 
long a SS Products are covered by unexpired AVI Patents, AGD shalt provide 
AVI with a written report setting forth the total amount of each Product sold 
by AGD and AGD Affiliates during the quarter, the gross invoice amount for 
each Sale, and the amount of any returns. At the time the report is made, AGD 
shall pay AVI any amounts payable pursuant to this SS Products License.

12.  RECORDS

     AGD shall maintain records concerning Sales of SS Products sufficient to 
enable AVI to verify the amounts payable under this SS Products License. AVI 
shall have the right, through an independent auditor, to examine such records 
that concern Sales of SS Products once in any given year. AVI shall bear all 
expenses associated with such audits.

13.  LATE PAYMENTS

     If AGD fails to make any royalty payments due to AVI from this SS 
Products License when due, AGD shall pay AVI interest on the amount past due 
at a rate equal to the "Prime Rate" reported in the Wall Street Journal on 
the date payment is due, plus 7.5% per annum.

14.  PAYMENT DISPUTES

(a)  Any dispute between the parties concerning payment of royalty payments 
on this SS Products License shall be settled by binding arbitration in 
accordance with the rules of the American Arbitration Association. The 
arbitration shall be held in Portland, Oregon before three (3) arbitrators 
who are knowledgeable about the industry and markets for the SS Products. 
Judgment upon the arbitrators' award may be entered in any court having 
jurisdiction. This agreement to arbitrate shall apply only to disputes 
concerning royalty payments in this SS Products License and shall not prevent 
either party from seeking judicial relief in connection with other matters 
relating to this SS Product License. The prevailing party in any such 
arbitration proceeding shall be entitled to recover reasonable costs and 
attorneys fees at the arbitration and in connection with any judicial 
proceeding to enforce the arbitration award.

(b)  If AVI believes AGD has refused to make royalty payments in bad faith, 
AVI may request that the arbitrators make a finding of AGD's bad faith 
refusal to pay. The parties agree that such a finding of bad faith shall not 
be made unless there is clear and convincing evidence that AGD knew the 
payment was owing and refused to make the payment. AGD may appeal any finding 
of bad faith to any court having jurisdiction and the court shall review any 
finding of bad faith de novo.

(c)  If the arbitrators make a finding of bad faith under Section 14(b) above 
in three (3) separate proceedings relating to three (3) separate payment 
disputes involving SS Products in a single year, AVI shall have the right, 
upon notice to AGD, to terminate this SS Products License.


3


<PAGE> 

15.  CHOICE OF LAW

     The construction and performance of this SS Products License will be 
governed by the laws of the state of Oregon (except for conflicts of law 
provisions thereof.)

16.  EXPENSES

     Each party to this SS Products License shall pay its own expenses 
incident to the negotiation, execution, delivery and performance of this SS 
Products License.

17.  NOTICES

     Any notice or other communication required or permitted under this 
Agreement shall be in writing and shall be sent by certified mail, return 
receipt requested, or by hand delivery:

     If to AVI, to the following address:

                     ANTIVIRALS Inc.
                     One SW Columbia, Suite 1105
                     Portland, Oregon 97258
                     Attention: Denis Burger

     With a copy to:

                     ANTIVIRALS Inc.
                     4575 SW Research Way, Suite 200
                     Corvallis, Oregon 97333
                     Attention: Alan Timmins

     If to AGD, to the following address:
     
                     ANTI-GENE DEVELOPMENT GROUP
                     Attention: James E. Summerton
                     P.O. Box 2210
                     Corvallis, Oregon 97339

     With a copy to:

                     James E. Summerton
                     General Partner of AGDG
                     3107 N.W. Norwood Pl.
                     Corvallis, Oregon 97330

     Unless otherwise provided in this SS Products License, all notices and 
communications shall be deemed to have been duty given or made (i) When 
delivered by hand, (ii) five business days after being deposited in the U.S. 
mail, postage prepaid, as registered or certified mail, return receipt 
requested. The address to which notices or other communications shall be 
directed may be changed from time to time by any party by giving written 
notice to the other parties of the substituted address.


4


<PAGE>

18.  ATTORNEY FEES

     If a suit or action is filed by either party to enforce the provisions 
of this SS Products License, or otherwise with respect to the subject matter 
of this SS Products License, the prevailing party shall be entitled to 
recover reasonable attorneys' fees and expenses (including, but not limited 
to those fees and expenses permitted or defined by statute) as fixed by the 
trial court, and if any appeal is taken from the decision of the trial court, 
as affixed by the appellate court.

19.  SUCCESSORS AND ASSIGNS

     This SS Products License will be binding upon and inure to the benefit 
of each of the parties and its successors and assigns; provided that no party 
may assign its rights under this SS Products License agreement without the 
consent of the other party, which consent shall not unreasonably be withheld.

20.  AMENDMENT

     No supplement, modification or amendment of, or waiver with respect to, 
this SS Products License shall be binding unless executed in writing. This SS 
Product License agreement may be modified, amended, or terminated upon the 
written agreement of both parties.

21.  CONSENTS

     Any consent required by this SS Products License shall be effective only 
if given in a writing executed by the party giving the consent.

22.  HEADINGS

     The headings in this SS Products License are solely for convenience of 
reference and shall not limit or otherwise affect the meaning of this SS 
Products License.

23.  SEVERABILITY

     If any part of this SS Products License is found invalid or unforceable, 
it shall be enforced to the maximum extent permitted by law, and other parts 
of this SS Products License will remain in force.

24.  ENTIRE LICENSE

     This SS Products License, whose terms comprise Schedule 9.1.1 of the 
1997 Amendment to the 1993 TT Agreement between AGD and AVI, constitutes the 
entire license pertaining to SS Products and supersedes all prior agreements 
and understandings of the parties in connection therewith. No covenant, 
representation or condition not expressed in this SS Products License will 
affect or be effective to interpret, change or restrict, the express 
provisions of this SS Products License.


5


<PAGE>

                                 SCHEDULE 9.1.2

                License for Diagnostic Products and Improvements

1.   AVI GRANT OF DIAGNOSTIC PRODUCTS AND IMPROVEMENTS LICENSE TO AGD

     AVI grants to AGD a non-exclusive license (the "DPI license"), with right
to sublicense to AGD Affiliates, to the Diagnostic Products and AVI Improvements
relating thereto, as defined in the 1993 TT Agreement and the 1997 amendment
thereto.  The DPI license is to make, have made, use, and sell Diagnostic
Products and AVI Improvements relating thereto (DPI), and to make, have made,
and use subunits and other components of DPI in amounts not to exceed that
required for assembly and use of DPI.  AVI also grants to AGD the right to
develop and patent "undeveloped AVI ideas relating to diagnostics" (Undeveloped
Ideas), where Undeveloped Ideas are defined as AVI ideas relating to diagnostics
which have not been reduced to practice as of the effective date of this DPI
license.  This right to develop and patent Undeveloped Ideas is non-exclusive
and is only effective if "develop and patent" includes an actual reduction to
practice.  The right to develop and patent the Undeveloped Ideas shall not
eliminate AGD's responsibility to pay royalties upon the sale of any DPI as set
forth in Section 2 below.

2.   ROYALTY

     AGD shall pay AVI as a royalty four (4.00) percent of the total Sales of
DPI sold by AGD and AGD Affiliates, where Sales of DPI shall mean total
worldwide sales of DPI by AGD and AGD Affiliates to any entity other than AGD
and AGD Affiliates at the Gross Invoice Amount minus returns, where returns
comprise compensation to the purchaser of the DPI for DPI returned to AGD or AGD
Affiliates.  Gross Invoice Amount shall mean all money and other valuable
consideration paid to AGD and AGD Affiliates in exchange for DPI.

3.   INFORMATION FOR MAKING AND USING DIAGNOSTIC PRODUCTS AND AVI IMPROVEMENTS
     RELATING THERETO (DPI INFORMATION)

     Upon request by AGD, but not later than December 1997, AVI will convey to
AGD written DPI Information.  This DPI Information shall comprise only the
specific information described in Exhibit A.  No other rights to transfer
information concerning any other AVI Improvements are implied or granted by this
DPI license.  If AGD shares information on AVI Improvements other than "DPI
Information," with a sublicensee for DPI, except where expressly allowed by a
separate AVI license to AGD, that sublicense shall also be considered to be a
Research and Development licensee and any and all Improvements to the Technology
made by that sublicensee will be defined as AGD Improvements which have to be
made available to AVI under the terms of Section 5 of Schedule 9.1 of the TT
Agreement.


1


<PAGE>

4.   CONFIDENTIALITY OF DPI INFORMATION

     AGD may not disclosed the Technology or any AVI Improvements described in
the DPI Information that are not in the public domain unless: (a) the recipient
has entered into a written agreement acceptable to AVI under which the recipient
agrees to restrictions on disclosure, use and transfer of the Technology and AVI
Improvements, and (b) AVI has consented in writing to the disclosure, use, and
transfer, which consent shall not be unreasonably withheld.

5.   EFFECTIVE DATE

     The effective date of this DPI license shall be the date when both AVI and
AGD have signed the Amendment to which this is Schedule 9.1.2.

6.   TERMINATION OF PAYMENT OBLIGATIONS

     AGD's obligation to make royalty payments to AVI for any given DPI shall
end upon the expiration of all AVI patents containing claims that cover that
DPI.

7.   TERMINATION OF DPI LICENSE

     Either party may terminate this DPI License for any material breach by the
other party that remains uncured 90 days after that party receives notice of the
breach from the non-breaching party, except that if a dispute arises with
respect to AGD's payment of royalties, AVI shall be entitled to terminate this
DPI license only after the arbitration process set forth in Section 12.

8.   DISCLAIMER OF WARRANTY

     AVI makes no warranty whatsoever, express or implied, including without
limitation a warranty of merchantability or fitness, with respect to Technology,
AVI Improvements, or DPI licensed to AGD pursuant to this Amendment, which AVI
Improvements or DPI AGD takes "as is".

9.   REPORTS

     Within sixty (60) days after the end of each calendar quarter, for so long
as DPI are covered by unexpired AVI Patents, AGD shall provide AVI with a
written report setting forth the total amount of each DPI sold by AGD and AGD
Affiliates during the quarter, the gross invoice amount for each Sale, and the
amount of any returns.  At the time the report is made, AGD shall pay AVI any
amounts payable pursuant to this DPI license.

10.  RECORDS

     AGD shall maintain records concerning Sales of DPI sufficient to enable AVI
to verify the amounts payable under this DPI license.  AVI shall have the right,
through an independent auditor, to examine such records that concern Sales of
DPI once in any given year.  AVI shall bear all expenses associated with such
audits.


2


<PAGE>

11.  LATE PAYMENTS

     If AGD fails to make any royalty payments due to AVI from this DPI license
when due, AGD shall pay AVI interest on the amount past due at a rate equal to
the "Prime Rate" "Prime Rate" reported in the Wall Street Journal on the date
payment is due, plus 7.5% per annum.

12.  PAYMENT DISPUTES

(a)  Any dispute between the parties concerning payment of royalty payments on
this DPI license shall be settled by binding arbitration in accordance with the
rules of the American Arbitration Association.  The arbitration shall be held in
Portland, Oregon, before three (3) arbitrators who are knowledgeable about the
industry and markets for diagnostics.  Judgment upon the arbitrators' award may
be entered in any court having jurisdiction.  This agreement to arbitrate shall
apply only to disputes concerning royalty payments on this DPI license, and
shall not prevent either party from seeking judicial relief in connection with
other matters relating to this DPI license.  The prevailing party in any such
arbitration proceeding shall be entitled to recover reasonable costs and
attorneys fees at the arbitration and in connection with any judicial proceeding
to enforce the arbitration award.

(b)  If AVI believes AGD has refused to make royalty payments in bad faith, AVI
may request that the arbitrators make a finding of AGD's bad faith refusal to
pay.  The parties agree that such a finding of bad faith shall not be made
unless there is clear and convincing evidence that AGD knew the payment was
owing and refused to make the payment.  AGD may appeal any finding of bad faith
to any court having jurisdiction and the court shall review any finding of bad
faith de novo.

(c)  If the arbitrators make a finding of bad faith under Section Section 12(b)
above in three (3) separate proceedings relating to three (3) separate payment
disputes involving DPI in a single year.

13.  CHOICE OF LAW

     The construction and performance of this DPI license will be governed by
the laws of the state of Oregon (except for conflicts of law provisions
thereof).

14.  EXPENSES

     Each party to this DPI license shall pay its own expenses incident to the
negotiation, execution, delivery and performance of this DPI license.

15.  NOTICES

     Any notice or other communication required or permitted under this
Agreement shall be in writing and shalt be sent by certified mail, return
receipt requested, or by hand delivery.


3


<PAGE>

     If to AVI, to the following address:
                     ANTIVIRALS Inc.
                     One SW Columbia, Suite 1105
                     Portland, Oregon 97258
                     Attention: Denis Burger

     With a copy to:
                     ANTIVIRALS Inc.
                     4575 SW Research Way, Suite 200
                     Corvallis, Oregon 97333
                     Attention: Alan Timmins

     If to AGD, to the following address:
                     ANTI-GENE DEVELOPMENT GROUP
                     Attention: James E. Summerton
                     P.O. Box 2210
                     Corvallis, Oregon 97339

     With a copy to:
                     James E. Summerton
                     General Partner of AGDG
                     3107 N.W. Norwood Pl.
                     Corvallis, Oregon 97330

Unless otherwise provided in this DPI license, all notices and communications
shall be deemed to have been duly given or made (i) when delivered by hand, (ii)
five business days after being deposited in the U.S. mail, postage prepaid, as
registered or certified mail, return receipt requested.  The address to which
notices or other communications shall be directed may be changed from time to
time by any party by giving written notice to the other parties of the
substituted address.

16.  ATTORNEY FEES

     If a suit or action is filed by either party to enforce the provisions of
this DPI license, or otherwise with respect to the subject matter of this DPI
license, the prevailing party shall be entitled to recover reasonable attorneys'
fees and expenses (including, but not limited to those fees and expenses
permitted or defined by statute) as fixed by the trial court, and if any appeal
is taken from the decision of the trial court, as affixed by the appellate
court.

17.  SUCCESSORS & ASSIGNS

     This DPI license will be binding upon and inure to the benefit of each of
the parties and its successors and assigns; provided that no party may assign
its rights under this license agreement without the consent of the other party,
which consent shall not unreasonably be withheld.


4



<PAGE>

18.  AMENDMENT

     No supplement, modification or amendment of, or waiver with respect to, 
this DPI license shall be binding unless executed in writing. This DPI 
license may be modified, amended, or terminated upon the written agreement of 
both parties.

19.  CONSENTS

     Any consent required by this DPI license shall be effective only if 
given in a writing executed by the party giving the consent.

20.  HEADINGS

     The headings in this DPI license are solely for convenience of reference 
and shall not limit or otherwise affect the meaning of this DPI license.

21.  SEVERABILITY

     If any part of this DPI license if found invalid or unenforceable, it 
shall be enforced to the maximum extent permitted by law, and other parts of 
this DPI license will remain in force.

22.  ENTIRE LICENSE

     This DPI license, whose terms comprise Schedule 9.1.2 of the 1997 
Amendment to the 1993 TT Agreement between AGD and AVI, constitutes the 
entire license pertaining to DPI and supersedes all prior agreements and 
understandings of the parties in connection therewith. No covenant, 
representation or condition not expressed in this DPI license will affect or 
be effective to interpret, change or restrict, the express provisions of this 
DPI license.


5


<PAGE>

                                    EXHIBIT A

                                  DPI Information


Below is a listing of specific notebooks which comprise the agreed upon DPI 
Information. This notebook information constitutes the entire DPI Information.

Notebook Designation         Notebook Title       Dates of Entries
- --------------------         --------------       ----------------------------

J. Summerton Notebook        Diagnostics 1        Jan. 20, 1993 - May 1, 1993
J. Summerton Notebook        Diagnostics 2        May 1, 1983 - July 16, 1994
AVI 9                        Diagnostics 3        July 17, 1994 - Dec. 23, 1994
AVI 10                       Diagnostics 4        Dec. 24, 1994 - Jan. 27, 1995
AVI 29                       Diagnostics 5        Jan. 30, 1985 - Mar. 4, 1995
AVI 32                       Diagnostics 6        Mar. 4, 1995 - Apr. 4, 1995
AVI 33                       Diagnostics 7        Apr. 4, 1995 - Apr. 26, 1995
AVI 38                       Diagnostics 8        Apr. 26, 1995 - Oct. 31, 1995
AVI 57                       Diagnostics 9        Oct. 31, 1995 - Dec. 24, 1995


6


<PAGE>

ANTIVIRALS Inc. (AVI) hereby provides its consent to ANTI-GENE DEVELOPMENT 
GROUP (AGD) to allow the transfer to and use by a single sublicensee of AGD 
of "Information for Making and Using SS Products" and "DPI Information," 
where "Information for Making and Using SS Products" and "DPI Information" 
are as defined in the 1997 Amendment to the 1993 Technology Transfer 
Agreement between AGD and AVI. In return for this AVI consent to allow 
transfer to and use of said information by a sublicensee of AGD, said 
sublicensee agrees not to disclose to any other entity any of said 
information, excepting that which is already in the public domain, and to 
abide by all terms necessary for its licensor, AGD, to fulfill AGD's license 
obligations to AVI under the terms in Schedules 9.1.1 and 9.1.2 of the 1997 
Amendment to the 1993 Technology Transfer Agreement between AGD and AVI.


                                  
                                       By: /s/ Denis Burger
                                          ------------------------------------
                                          Denis Burger, Ph.D.
                                          Chief Executive Officer
                                          ANTIVIRALS Inc.


                                       Date: 1/20/97


                                       By: /s/ James E. Summerton
                                          ------------------------------------
                                          President
                                          __________ (Sublicensee of AGD)

                                          Jan. 20, 1997


7




<PAGE>

                         LICENSE AND OPTION AGREEMENT


         This License and Option Agreement is by and between ANTI-GENE 
DEVELOPMENT GROUP, an Oregon limited partnership ("AGD") and ANTIVIRALS Inc., 
an Oregon corporation ("AVI"). 

                                   RECITALS

    A.   AGD and AVI are parties to a Technology Transfer Agreement (the
"Transfer Agreement") under which AGD has conveyed to AVI certain Technology, as
more fully described in the Transfer Agreement. 

    B.   Each party wishes to grant to the other certain rights with respect to
the Technology and Improvements thereto.

                                   AGREEMENT

         In consideration of the above and of the promises and covenants
contained herein, the parties agree as follows: 

    1.   DEFINITIONS. 

         1.1   Unless otherwise set forth in this Agreement, the terms used
in this Agreement shall have the meanings given to them in the Transfer
Agreement. 

         1.2   "AGD Affiliate" shall mean AGD Licensees, other than AVI,
and any entity other than AVI that controls, is controlled by or is under common
control with AGD. 

         1.3   "AGD Improvements n shall mean Improvements developed by AGD
after the effective date of this Agreement but before January 1, 2000, and which
AGD has the right to sublicense to AVI.

         1.4   "AGD Licensee" shall mean any person, corporation or other
entity, other than AVI, that
 obtains a right granted by AGD or an AGD Affiliate
to: (a) make a Proposed Product or Related Product; (b) make a Proposed Product
or Related Product and use that Proposed Product or Related Product; (c) make a
Proposed Product or Related Product and sell that Proposed Product or Related
Product; (d) have a Proposed Product or Related Product made on behalf of said
entity and use that Proposed Product or Related Product; (e) have a Proposed
Product or Related Product made on behalf of said entity and sell that Proposed
Product or Related Product; or, (f) use a method claimed in a patent covering an
AVI Improvement. 

         1.5   "AVI Affiliate" shall have the meaning given to Buyer
Affiliate" in the Transfer Agreement.

                                       1

<PAGE>

         1.6   "AVI Improvements" shall mean Improvements developed by AVI
after the effective date of this Agreement but before January 1, 2000, and which
AVI has the right to license to AGD. 

         1.7   "Improvements" shall mean documented improvements to the
Technology comprising inventions, discoveries, trade secrets, formulas,
techniques, processes, and know-how, whether or not patented and whether or not
reduced to practice, which are derived from, incorporate, or are based upon, are
adducts to, or which relate to making or using the Technology. 

         1.8   "Licensed Product" shall mean any product with respect to
which AVI obtains a license under Section 5 of this Agreement. 

         1.9   "Polymer" shall mean a single molecular specie of nucleic
acid binding polymer incorporating one or more aspects of the Technology and/or
Improvements. 

         1.10  "Proposed Product" shall have the meaning set forth in
Section 3.1.

         1.11  "Related Product" shall mean, with respect to any Proposed
Product, all related products which have the same or similar structural type and
adducts which achieve substantially the same biological effect and which are
targeted against the same pathogen specie or cellular gene as the Proposed
Product. 

    2.   RESEARCH AND DEVELOPMENT LICENSE TO AGDG. 

         2.1   Subject to the terms of this Agreement, AVI hereby grants to
AGD a nonexclusive, royalty free license, with the right to sublicense: (a) to
use the Technology and AVI Improvements and to make, have made, and use any
Products incorporating the Technology and AVI Improvements internally for
research and development; and (b) to make, have made, use and sell Polymers in
an amount of no more than ten (10) grams per month of each single Polymer; and
(c) to make, have made, and use subunits and adducts in amounts not to exceed
that required for assembly of said Polymers. 

         2.2   AGD may not disclose the Technology or any AVI Improvements
that are not in the public domain unless: (a) the disclosed or transferee has
entered into a written agreement acceptable to AVI under which the disclosed or
transferee agrees to restrictions on disclosure, use, and transfer of the
Technology or AVI Improvements, and (b) AVI has consented in writing to the
disclosure, use and transfer, which consent shall not be unreasonably withheld;
provided that AGD's obligation under this Section 2.2 shall not apply to
Technology or Improvements to which AGD obtains a license pursuant to Section 3
or Section 6 or to which AGD obtains ownership pursuant to section 4.8 of the
Transfer Agreement. 

         2.3   AVI shall not enter into any agreement restricting its right
to license AVI Improvements solely for the purpose of denying a license to such
AVI Improvements to AGD. 

    3.   OPTION. 

                                       2

<PAGE>

         3.1   If AGD develops or obtains-a specific prototype product
which AVI has the right to make, use and sell and which incorporates one or more
aspects of the Technology or Improvements and demonstrates at the biophysical
level that said prototype product affords binding properties for its selected
genetic target, AGD shall provide written notice (the "Notice") to AVI
describing the product (the "Proposed Product") and shall provide AVI with such
existing information and materials as AVI may reasonably request to enable AVI
to evaluate the Proposed Product. 

         3.2   Within thirty (30) days after the date of the Notice
required under Section 3.1, AVI shall notify AGD: (a) that AVI intends to begin
optimization and commercialization of the Proposed Product; or (b) that AVI
elects not to commercialize the Proposed Product.  If AVI elects not to
commercialize the Proposed Product, AVI shall grant AGD an exclusive, perpetual
license, with the right to sublicense, to make, have made, use, sell, and
otherwise distribute the Proposed Product and any Related Products and to make,
have made, and use subunits and adducts in amounts not to exceed that required
for assembly of the Proposed Product and any Related Products. 

         3.3   If AVI elects to begin optimization and commercialization of
the Proposed Product, AVI shall take such steps as AVI, in its sole discretion,
considers appropriate with respect to the Proposed Product: provided, however
that AGD shall have the right, upon written notice to AVI, to obtain the license
described in Section 3.2 if neither AVI nor any AVI Affiliate achieves the
milestones set forth below by the dates indicated: 

               (a) Commencement of cell culture studies on the Proposed
Product: Nine (9) months from the date of AGD's Notice under Section 3.1. 

               (b) Commencement of pharmacokinetics and toxicology studies
of the Proposed Product: Twenty-four (24) months from the date of AGD is Notice
under Section 3.1. 

               (c) Commencement of clinical trials of the Proposed Product
or an optimized version thereof: thirty-six (36) months from the date of AGD's
Notice under Section 3.1. 

         3.4   For purposes of Section 3.3, a milestone shall be met for a
Proposed Product if the milestone occurs with respect to an optimized version of
the Proposed Product which has the same or similar structural type and adducts
which achieve substantially the same biological effect and which is targeted
against the same pathogen specie or cellular gene. 

         3.5   Notwithstanding anything in this Section 3 to the contrary,
AGD shall not have any rights under this Section 3 with respect to any Proposed
Product as to which AVI or any AVI Affiliate has commenced large scale
production prior to the date of AGD's Notice for so long as such large scale
production continues.  For purposes of this Section 3.5, Proposed Product
includes Related Products and "large scale production" shall mean production of
more than ten (10) grams each month. 

    4.   ROYALTIES. 

                                       3


<PAGE>

         4.1   For any license granted by AVI to AGD pursuant to Section 3
of this Agreement which covers a Proposed Product or Related Product that does
not incorporate a patented AVI Improvement, the license shall be royalty free. 

         4.2   For any license granted by AVI to AGD pursuant to Section 3
of this Agreement which covers a Proposed Product or Related Product that
incorporates a patented AVI Improvement, AGD shall pay AVI as a royalty a
percentage of the total Sales of each Proposed Product by AGD and any AGD
Affiliate, which percentages shall be equal to the applicable percentages AVI is
required to pay AGD as Purchase Price payments pursuant to the Transfer
Agreement; provided, however, that AGD's obligation to pay royalties under this
section shall be limited to Proposed Products and Related Products, the sale of
which would infringe a patent owned by AVI in the absence of this Agreement. 
For purposes of this section 4 2, "Sales" shall mean the total worldwide sales
of Proposed Products and Related Products by AGD and AGD Affiliates, subject to
the terms applicable to Sales by AVI under the Transfer Agreement. 

         4.3   AGD's obligation to pay royalties pursuant to this Section 4
shall be subject to all of the terms applicable to AVI's obligation to make
Purchase Price payments set forth in Sections 4.3, 4.4, 4.5, 4.6, and 4.8 of the
Transfer Agreement. 

    5.   LICENSE TO AVI OF AGD IMPROVEMENTS. 

         5.1   Subject to the terms of this Agreement, AGD hereby grants to
AVI a non-exclusive license, with the right to sublicense, to make, have made,
use, and sell products incorporating AGD Improvements (a "Licensed Product"). 

         5.2   AVI shall pay AGD as a royalty a percentage of the total
Sales of each Licensed Product AVI or any AVI Affiliate sells, which percentages
shall be equal to the applicable percentages AVI is required to pay AGD as
Purchase Price payments pursuant to the Transfer Agreement; provided, however,
that AVI's obligation to pay royalties under this section shall be limited to
Licensed Products the sale of which would infringe a patent owned by AGD in the
absence of this Agreement; and provided further that AVI shall have no
obligation under this Section 5.2 with respect to Licensed Products covered by
one or more unexpired Patents owned by AVI.  AVI's obligation with respect to
Licensed Products covered by one or more unexpired Patents owned by AVI shall be
limited to AVI's obligation to make Purchase Price payments pursuant to the
Transfer Agreement. 

         5.3   AVI's obligation to pay royalties pursuant to this Section 5
shall be subject to all of the terms of AVI's obligation to make Purchase Price
payments set forth in Sections 4.3, 4.4, 4.5, 4.6 and 4.8 of the Transfer
Agreement; provided that the parties intend the exemption granted under
Section 4.6 for the first two hundred million dollars ($200,000,000) in AVI and
AVI Affiliate Sales to apply only once, so that Sales of Licensed Products under
this Section 5 shall no longer be exempt once AVI and AVI Affiliates achieve the
first two hundred million dollars in worldwide Sales of Products and Licensed
Products. 

         5.4   AVI will maintain the confidentiality of all information
about AGD Improvements that is not in the public domain unless: (a) the
disclosed has entered into a written agreement acceptable to AGD under which the
disclosed agrees to restrictions on disclosure, use, 

                                       4


<PAGE>

and transfer of the AGD Improvements, and (b) AGD has consented in writing to 
the disclosure or transfer, which consent shall not unreasonably be withheld. 

    6.   OBLIGATION TO EXPLOIT. 

         If after January 1, 1994, AVI and AVI Affiliates together effectively
cease development of Products based on the Technology, as evidenced by AVI, AVI
Affiliates, and/or their successors and assigns in the aggregate having for a
period of more than 180 consecutive days less than the equivalent of ten (10)
full time employees devoted to development, testing, commercialization,
production and/or sales of one or more products based on the Technology, then,
upon request by AGD, AVI will grant to AGD an exclusive royalty-free license,
with right to sublicense, to make, have made, use, sell, or otherwise distribute
the Products, to practice the Technology, and to use the Trademarks. 

    7.   DISCLAIMER OF WARRANTY. 

         Neither party makes any warranty whatsoever with respect to
Technology;and Improvements licensed pursuant to this Agreement or any Products,
Licensed Products, Proposed Products or Related Products.  Each party's rights
under this Agreement are limited to whatever rights that party has in the
Technology and Improvements transferred. 

    8.   FURTHER ASSISTANCE. 

         Each party shall take such actions and execute and deliver such other
documents as, in the reasonable opinion of counsel for the other party, may be
necessary to evidence the rights and interests of the requesting party
hereunder. 

    9.   OTHER PROVISIONS. 

         The provisions set forth in Section 14 of the Transfer Agreement are
applicable to this Agreement and are incorporated herein by reference. 

         IN WITNESS WHEREOF, the Parties hereto have executed this Agreement
effective as of __________________, 1993. 

                                       ANTIVIRALS INC. 


                                       By: ----------------------------------- 
                                             Denis Burger, Ph.D, President

                                       ANTI-GENE DEVELOPMENT GROUP


                                       By: ----------------------------------- 
                                             James E. Summerton, Ph.D,
                                             General Partner

                                       5



<PAGE>

                               COMMERCIAL LEASE





                          RESEARCH WAY INVESTMENTS

                                   LANDLORD





                               ANTIVIRAL, INC.

                                    TENANT



<PAGE>
                                      LEASE



     For and in consideration of the Rent and other sums to be paid by Tenant to
Landlord under this Lease, and of the covenants and agreements hereinafter set
forth to be kept and performed by Tenant, Landlord hereby leases, to Tenant and
Tenant hereby leases from Landlord the Premises for the term, at the rental and
subject to and upon all of the terms, covenants, conditions and agreements
hereinafter set forth: 

     1.   PREMISES: 

          1.1       DESCRIPTION.  The Premises comprise the area described in
PARAGRAPH D OF THE SUMMARY OF LEASE TERMS, and are shown as crosshatched on
EXHIBIT A attached hereto and made a part hereof. 

          1.2       NET RENTABLE AREA DEFINED.  The term "Net Rentable Area" is
hereby defined for the purposes of this Lease to mean the area of space leased
by Tenant (or, in the case of the entire Building, leasable) computed by
measuring to the inside finish of permanent outer building walls, to the
Premises side of public corridors and/or other permanent partitions and to the
center of partitions which separate the adjoining rentable areas, with no
deductions for columns and projections in the Building.  On multi-tenant floors,
common corridors
 and toilets, air conditioning rooms, fan rooms, janitorial
closets, electrical and telephone closets and any other areas serving that floor
are considered common area and for purposes of this Section shall be allocated
pro rata to the tenants.  Tenant acknowledges that Tenant has measured or has
waived measurement of the Net Rentable Area of the Premises and Building and
Tenant agrees that the square footage stated in PARAGRAPH D OF THE SUMMARY OF
LEASE TERMS is the Net Rentable Area for the Premises and Building calculated on
the basis of the foregoing definition and Tenant further agrees to waive any
right to contest the amount of such square footage. 

     2.   TERM: 

          2.1       TERM.  The term of this Lease shall be for a period
commencing as of the Commencement Date (as defined in PARAGRAPH E OF THE SUMMARY
OF LEASE TERMS) and continuing to and including the Expiration Date (as defined
in PARAGRAPH E OF THE SUMMARY OF LEASE TERMS) unless sooner terminated pursuant
to this Lease. 

          2.2       DELAY IN COMMENCEMENT.  Tenant agrees that in the event of
the inability of Landlord for any reason whatsoever to deliver possession of the
Premises to Tenant on the Commencement Date, Landlord shall not be liable for
any damage suffered thereby nor shall such inability affect the validity of this
Lease or the obligations of Tenant hereunder, but in such case there shall be a
proportionate reduction in Fixed Rent and Tenant's Percentage Share of Operating
Costs and Taxes until possession of the Premises is tendered to Tenant.  No
delay in the delivery of possession shall extend the term hereof beyond the
Expiration Date. 

1


<PAGE>

          2.3       EARLY OCCUPANCY.  In the event the Premises are ready for
occupancy prior to the Commencement Date, Tenant shall have the right to take
possession of the Premises on such date as Landlord and Tenant shall agree upon
in writing, and notwithstanding the Commencement Date, the term of this Lease
and the obligation of Tenant to pay Rent and all other monetary sums to be paid
by Tenant under this Lease (whether or not payable directly to Landlord) shall
begin on such date; provided, however, that the Expiration Date in all events
shall remain unchanged. 

          2.4       ACKNOWLEDGMENT OF COMMENCEMENT DATE.  In the event the
Commencement Date is other than as specified in PARAGRAPH E OF THE SUMMARY OF
LEASE TERMS, Landlord and Tenant shall execute a written acknowledgment of the
actual date of commencement which shall be deemed to be the Commencement Date. 

          2.5       OPTION TO TERMINATE.  Landlord shall have the option to
terminate this Lease if Landlord intends to demolish or substantially alter all
or a substantial portion of the Building.  Landlord shall exercise this option
by written notice given to Tenant no less than nine (9) months prior to the
effective date of such termination. 

     3.   RENT: 

          3.1       FIXED RENT.  Tenant agrees to pay to Landlord the Fixed Rent
(as set forth in PARAGRAPH F OF THE SUMMARY OF LEASE TERMS) in equal monthly
installments in advance on the first day of each calendar month of the term of
this Lease without deduction, offset, prior notice or demand, in lawful money of
the United States, at the office of Landlord at Landlord's address for notice as
specified in PARAGRAPH M OF THE SUMMARY OF LEASE TERMS or at such other place as
designated by Landlord (the "Fixed Rent").  If the Commencement Date is not the
first day of a month, or if the Expiration Date is not the last day of a month,
a prorated monthly installment shall be paid at the then current rate for the
fractional month during which the Lease commences and/or expires.  It is the
responsibility of Tenant to ensure that the Rent arrives at the above-mentioned
place on or before the due date.  If the due date is a weekend or holiday, then
Tenant must arrange for earlier delivery.  Payments made by mail will be
considered late if they do not arrive at the place designated by Landlord on the
designated due date. 

          All amounts of Rent, including, without limitation, Fixed Rent, and
other sums due under this Lease if not paid when due shall (i) bear interest
from the due date until paid at a per annum rate equal to the lesser of (x) the
maximum rate allowed by law, or (y) fifteen percent (15%) (the "Default Rate")
until fully paid, and (ii) incur a late charge of five percent (5%) of such
unpaid amount.  Landlord and Tenant agree that the amount of such interest and
late charge is fair and reasonable compensation for costs and expenses incurred
by Landlord due to the failure by Tenant to timely make any payment of Rent or
other sums due under this Lease as such costs and expenses are extremely
difficult to estimate and ascertain. 

          3.2       CPI ADJUSTMENTS.  The amount of Fixed Rent shall be adjusted
as of the expiration of each calendar year after the calendar year in which this
Lease commences (the 

2

<PAGE>

"Adjustment Dates") to reflect any increase in the cost of living.  Each 
adjustment, if any, shall be calculated on the basis of the United States 
Department of Labor, Bureau of Labor Statistics, Consumer Price Index, All 
Item, All Urban Consumers for the region specified in PARAGRAPH G(i) OF THE 
SUMMARY OF LEASE TERMS (the "Index") as of the Commencement Date of this 
Lease. The Index for the month in which the sixtieth (60th) day preceding 
each Adjustment Date falls shall be deemed the "Adjustment Index."  The 
Adjustment Index for determining an adjustment to Fixed Rent for a specific 
Adjustment Date shall be deemed the Index on the next following Adjustment 
Date.  At the Adjustment Date, the new Fixed Rent shall be determined by 
multiplying the then current Fixed Rent by the percentage increase of the 
Adjustment Index over the Index, if any.  In no event shall the Fixed Rent as 
so adjusted be less than the Fixed Rent in effect for the month immediately 
prior to such Adjustment Date. When the new Fixed Rent is determined, 
Landlord shall give Tenant written notice of same.  If Landlord fails to give 
timely notice of the new Fixed Rent, the adjustment shall be retroactive to 
the Adjustment Date and Tenant shall pay the arrears within fifteen (15) days 
after being billed therefor.  If at any Adjustment Date, the Index is no 
longer published as described in this Section, Landlord, after consultation 
with Tenant, shall substitute the official index published by the United 
States Department of Labor, Bureau of Labor Statistics or successor or 
similar governmental agency as may then be in existence which is most nearly 
equivalent thereto. 

          3.3       MARKET VALUE RENT ADJUSTMENT.  The Fixed Rent shall be
adjusted on each Adjustment Date listed in PARAGRAPH G(ii) OF THE SUMMARY OF
LEASE TERMS to an amount equal to the then current fair market rental for the
Premises.  The Market Value Rent Adjustment is defined in and shall be
determined in accordance with the provisions of PARAGRAPH G(ii) OF THE SUMMARY
OF LEASE TERMS and the Addendum referred to therein.  In no event shall Fixed
Rent ever be reduced pursuant to the provisions of this SECTION 3.3. 

          3.4       RENT DEFINITION.  Fixed Rent, as adjusted in accordance with
the terms hereof, and any other sums due to Landlord from Tenant pursuant to
this Lease shall be deemed to be "Rent" hereunder. 

     4.   SECURITY DEPOSIT: 

          Concurrently with Tenant's execution of this Lease, Tenant shall
deposit with Landlord the Security Deposit (as set forth in PARAGRAPH H OF THE
SUMMARY OF LEASE TERMS).  The Security Deposit shall be held by Landlord as
security for the faithful performance by Tenant of all of the terms, covenants,
conditions and provisions of this Lease to be kept and performed or observed by
Tenant.  If Tenant defaults with respect to any provision of this Lease,
including, but not limited to, the provisions relating to the payment of Rent or
any other monetary sums due herewith, Landlord may (but shall not be required
to) use, apply or retain all or any part of the Security Deposit for the payment
of any Rent or other monetary sums due herewith and/or for the payment of any
other amount which Landlord may spend or become obligated by reason of Tenant's
default, or to compensate Landlord for any other loss or damage which Landlord
may suffer thereby.  If any portion of the Security Deposit is so used or
applied, Tenant shall, within ten (10) days after demand therefor, deposit cash
with Landlord in an 


3

<PAGE>

amount sufficient to restore the Security Deposit to the full amount thereof, 
and Tenant's failure to do so shall be a material breach of this Lease.  
Landlord shall not be required to keep the Security Deposit separate from its 
general accounts and/or funds.  If Tenant shall fully and faithfully perform 
all of its obligations hereunder, the Security Deposit, or any balance 
thereof that has not theretofore been applied by Landlord, shall be returned 
to Tenant, without payment of interest or other increment for its use (or, at 
Landlord's option, to the last assignee of Tenant's interest hereunder), 
within ten (10) days after the expiration of the Lease term and after Tenant 
has vacated the Premises.  In the event of termination of Landlord's interest 
in this Lease, Landlord shall transfer the Security Deposit to Landlord's 
successor in interest whereupon Landlord shall be released from any and all 
liability for the return thereof or the accounting therefor.  No trust 
relationship is created herein between Landlord and Tenant with respect to 
the Security Deposit. 

     5.   OPERATING COSTS AND REAL PROPERTY TAXES: 

          5.1       DEFINITIONS.  For purposes of this Section and Lease, the
following terms are herein defined: 

               (a)       OPERATING COSTS:  All costs and expenses of management,
ownership, operation and maintenance of the Building and Property, including by
way of illustration but not limited to, utilities; waste disposal; materials and
supplies; insurance (unless otherwise paid for by Tenant pursuant to the
provisions of SECTION 13.1 below); cost of services of independent contractors
and employees (including, without limitation, wages, salaries, employment taxes
and fringe benefits of such persons but excluding persons performing services
not uniformly available to all Building tenants), day-to-day operation,
maintenance and repair of the Premises, Building, its equipment, and the common
areas, parking areas, walkways, access ways, and landscaped areas, including,
without limitation, janitorial, gardening, security, elevator servicing,
painting, plumbing, electrical, carpentry, heating, ventilation, air
conditioning, window washing, signing and advertising; rental expense or
depreciation of personal property used in the maintenance, operation, and repair
of the Building; the cost of capital improvements to the Building (amortized in
accordance with generally accepted accounting principles together with interest
at the prevailing annual rate on the unamortized portion of such cost) made
after the date of this Lease which reduce other items of Operating Costs or are
required under any governmental law or regulation; provided, however, that
Operating Costs shall not include Real Property Taxes (as defined in
SECTION 5.1(b) below) or the taxes referred to in SECTION 5.3 below; debt
service, if any, on the Building; depreciation on the Building other than
depreciation on exterior window draperies provided by Landlord and carpeting in
public corridors and common areas; costs of Tenant's improvements; real estate
brokers' commissions; capital items other than those included in Operating Costs
above; and the cost of repairs, utilities, or extra services furnished to,
billed to and payable separately by, Tenant or any other lessee of the Building.


               (b)       REAL PROPERTY TAXES:  Includes without limitation, all
taxes, service payments levied or assessed wholly or partly in lieu of taxes,
annual or periodic license, permit, 

4


<PAGE>

inspection or use fees, excises, transit charges, housing fund assessments, 
assessments, levies, fees or charges, general and special, ordinary and 
extraordinary, unforeseen as well as foreseen, of any kind which are 
assessed, levied, charged, confirmed, or imposed by any recorded declaration 
affecting the Property or by any public authority upon the Property, the 
Building, its operation, personal property contained therein, or the Rent 
payable hereunder, (but excluding taxes referred to in SECTION 5.3 below and 
state and federal, personal or corporate income taxes measured by the net 
income of Landlord from all sources), and the cost of contesting by 
appropriate proceedings the amount or validity of any of the aforementioned 
taxes. 

          5.2       TENANT'S PERCENTAGE SHARE OF OPERATING COSTS AND TAXES. 

               (a)       In addition to the Fixed Rent payable during each
calendar year or any portion thereof, during the term of this Lease Tenant shall
pay Tenant's proportionate share of the amount of Operating Costs and Real
Property Taxes paid or incurred by Landlord in such year or any portion thereof
("Tenant's Percentage Share of Operating Costs and Taxes") (as shown in
PARAGRAPH I OF THE SUMMARY OF LEASE TERMS).  Tenant's Percentage Share of
Operating Costs and Taxes has been computed by dividing the amount of Tenant's
Net Rentable Area by the amount of Net Rentable Area for the entire Building. 
In the event that either Tenant's Net Rentable Area or the Building's Net
Rentable Area is changed, Tenant's Percentage Share of Operating Costs and Taxes
shall be appropriately adjusted by Landlord, such adjustment to be conclusive
and binding on Tenant.  If such change occurs during any calendar year, Tenant's
Percentage Share of Operating Costs and Taxes shall be determined for that
calendar year on the basis of the number of days during such calendar year each
such percentage is applicable. 

               (b)       Landlord's estimate of Tenant's Percentage Share of
Operating Costs and Taxes for the first Lease Year is set forth in PARAGRAPH I
OF THE SUMMARY OF LEASE TERMS.  On December of each calendar year or as soon
thereafter as practicable, Landlord shall give Tenant notice of its adjusted
estimate of Tenant's Percentage Share of Operating Costs and Taxes for the
succeeding calendar year.  On or before the first day of each month during the
succeeding calendar year (or in the case of the first year of the Lease, on or
before the first day of each month during such first year), Tenant shall pay to
Landlord one-twelfth (1/12) of such estimate or adjusted estimate.  If Landlord
fails to deliver such notice to Tenant in December, Tenant shall continue to pay
Tenant's Percentage Share of Operating Costs and Taxes on the basis of the prior
year's estimate until the first day of the next calendar month after such notice
is given, provided that on such date Tenant shall pay to Landlord the amount of
such estimated adjustment payable to Landlord as of January 1 of the year in
question, less any portion thereof previously paid by Tenant. 
(b)  
               (c)       Within ninety (90) days after the close of each
calendar year or as soon after such ninety (90) day period as practicable,
Landlord shall deliver to Tenant a statement of Tenant's Percentage Share of
Operating Costs and Taxes for such calendar year.  If, on the basis of such
statement, Tenant owes an amount that is more than the estimated payments for
such calendar year previously made by Tenant, Tenant shall pay the deficiency to
Landlord within fifteen (15) days after delivery of the statement.  If on the
basis of such 

5

<PAGE>

statement Tenant has paid to Landlord an amount in excess of the actual 
adjustment to be made for the preceding calendar year and Tenant is not in 
default in the performance of any of its covenants under this Lease, then 
Landlord, at its option, shall either promptly refund such excess to Tenant 
or credit the amount thereof to the Rent next becoming due from Tenant until 
such credit has been exhausted. 

               (d)       In the event of any dispute as to any amount due by
Tenant for Tenant's Percentage Share of Operating Costs and Taxes, Tenant shall
have the right upon reasonable advance written notice to inspect Landlord's
accounting records relative to Operating Costs and Real Property Taxes at the
address at which Landlord maintains its records during normal business hours at
any time within forty-five (45) days following the furnishing by Landlord to
Tenant of such statement.  If Tenant makes such timely written demand, a
certification as to the proper amount of Tenant's Percentage Share of Operating
Costs and Taxes shall be made by an independent public accountant designated by
Landlord, which certification shall be final and conclusive.  Tenant agrees to
pay the cost of such certification unless it is determined that Landlord's
original determination of Tenant's Share of Operating Costs and Taxes was in
error by more than ten percent (10%) over Tenant's actual obligation. 

               (e)       If this Lease (i) terminates on a day other than the
last day of a calendar year, the amount of Tenant's Percentage Share of
Operating Costs and Taxes payable by Tenant applicable to the calendar year in
which such termination occurs, shall be prorated on the basis which the number
of days from the commencement of such calendar year, to and including such
termination date, bears to 360; or (ii) commences on a day other than the first
day of a calendar year, the amount of Tenant's Percentage Share of Operating
Costs and Taxes payable by Tenant applicable to the calendar year in which such
commencement occurs, shall be prorated on the basis which the number of days
from the Commencement Date, to and including the last day of the calendar year
in which the Commencement Date occurs, bears to 360. 

          Tenant's obligations to pay Tenant's Percentage Share of Operating
Costs and Taxes for either year end adjustments or partial lease years as
contemplated by subparagraphs (c) and (e) above shall survive the termination or
expiration of this Lease. 

          5.3       OTHER TAXES PAYABLE BY TENANT.  Tenant shall reimburse
Landlord upon demand for, or upon Landlord's request shall pay directly to the
appropriate party or entity the amount of, any and all taxes payable by Landlord
(other than net income taxes) whether or not now customary or within the
contemplation of the parties hereto: 

               (a)       imposed upon, measured by or reasonably attributable to
     the cost or value of Tenant's equipment, furniture, fixtures and other
     personal property located on the Premises or by the cost or value of any
     leasehold improvements made in or to the Premises by or for Tenant, other
     than building standard improvements made by Landlord, if any, regardless of
     whether title to such improvements shall be in Tenant or Landlord; 

6

<PAGE>

               (b)       imposed upon or measured by the Rent payable hereunder,
     including, without limitation, any gross income tax or excise tax levied by
     the City and County in which the Premises are located, the Federal
     Government or any other governmental body with respect to the receipt of
     such rental; 

               (c)       imposed upon or with respect to the possession,
     leasing, operation, management, maintenance, alteration, repair, use or
     occupancy by Tenant of the Premises or any portion thereof; and 

               (d)       imposed upon this transaction or any document to which
     Tenant is a party creating or transferring an interest or an estate in the
     Premises. 

          In the event that it shall not be lawful for Tenant to so reimburse
Landlord, the Rent payable to Landlord under this Lease shall be revised to net
Landlord the same income after imposition of any such tax upon Landlord as would
have been received by Landlord hereunder prior to the imposition of any such
tax. 

     6.   USE:

          6.1  USE.  The Premises shall be used and occupied by Tenant for 
the purposes stated on PARAGRAPH J OF THE SUMMARY OF LEASE TERMS and for no 
other purpose without the prior written consent of Landlord. 

          6.2  SUITABILITY.  Tenant acknowledges that neither Landlord nor 
any officer, director, shareholder, employee or agent of Landlord has made 
any representation or warranty with respect to the condition of the Premises 
or the Building or with respect to the suitability of either for the conduct 
of Tenant's business, nor has Landlord agreed to undertake any modification, 
alteration or improvement to the Premises except as provided in this Lease.  
The taking of possession of the Premises by Tenant shall conclusively 
establish that the Premises and the Building were at such time in a 
satisfactory condition. 

          6.3  USES PROHIBITED. 

               (a)       Tenant shall not do or permit anything to be done in 
or about the Premises or the Building, or bring or keep or permit to be 
brought or kept anything in or about the Premises or Building, which is 
prohibited by any Law (as defined in SECTION 6.3(b) below), or which is 
prohibited by, or will in any way increase the existing rate of, cause a 
cancellation of, or otherwise affect any fire or other insurance on the 
Building, or any part thereof, or any of its contents.  

               (b)       Tenant shall at its sole cost and expense promptly
comply with all applicable covenants, conditions and restrictions now or
hereafter affecting the Premises, or the Building, or the Property, with all
laws, rules, ordinances, regulations, directives and requirements of all
federal, state, county and municipal authorities having jurisdiction over the

7

<PAGE>

Premises, or the Building, or the Property ("Laws"), including without 
limitation those relating to health, safety, noise, environmental protection, 
waste disposal, water and air quality, and other environmental matters, and 
the use, storage and disposal of Hazardous Materials, as such term is defined 
in SECTION 6.4(a) below, and with the certificate of occupancy for the 
Premises or the Building and shall not permit anything to be done on the 
Premises in violation thereof.  Upon written demand, Tenant shall discontinue 
any use of the Premises in violation of any covenants, conditions and 
restrictions, or of any Law or of the certificate of occupancy. 

               (c)       Tenant shall not do or permit anything to be done in,
or about the Premises, or the Building, or the Property which will in any way
obstruct or interfere with the rights of other tenants or occupants of the
Building, or injure or annoy them, or use or allow the Premises to be used for
any improper, immoral, unlawful or objectionable purpose, nor shall Tenant
cause, maintain or permit any nuisance in, on, or about the Premises or the
Building, or the Property nor use or permit to be used any loudspeaker, or other
device, system or apparatus which can be heard outside the Premises without the
prior written consent of Landlord.  Tenant shall not commit or suffer to be
committed any waste in or upon the Premises, the Building, or the Property. 

          6.4       TENANT'S OBLIGATIONS REGARDING ENVIRONMENTAL MATTERS. 

               (a)       Tenant shall at all times and in all respects comply
with all federal, state and local laws, ordinances and regulations (collectively
"Hazardous Materials Laws") relating to industrial hygiene, environmental
protection or the use, analysis, generation, manufacture, storage, disposal, or
transportation of any oil, gasoline and related products, flammable substance or
explosives, asbestos, radioactive materials or waste, or other hazardous, toxic,
contaminated or polluting materials, substances, chemicals, wastes or related
injurious materials, whether injurious by themselves or in combination with
other materials including, without limitation, any "hazardous substances,"
"hazardous wastes," "hazardous materials," or "toxic substances" under any such
Laws, any toxic or hazardous substance, material or waste listed in the United
States Department of Transportation Table (49 CFR 172.101) or by the
Environmental Protection Agency as a hazardous substance (40 CFR, Part 302) and
amendments thereto, or such substances, materials and wastes which are or become
regulated or listed as toxic under any applicable local, state or federal law)
(collectively, "Hazardous Materials"). 

               (b)       Tenant shall at its own expense procure, maintain in
effect and comply with all conditions of any and all permits, licenses and other
governmental and regulatory approvals required for Tenant's use of the Premises,
including, without limitation, discharge of (appropriately treated) materials or
wastes into or through any sanitary sewer serving the Premises.  Except as
discharged into the sanitary sewer in compliance with all applicable Hazardous
Materials Laws, Tenant shall cause any and all Hazardous Materials removed from
the Premises to be removed and transported solely by duly licensed haulers to
duly licensed facilities for final disposal of such materials and wastes as
required by applicable governmental agencies having responsibility for any such
removal.  Tenant shall in all respects handle, treat, deal with and manage any
and all Hazardous Materials in, on, under or about the Premises in compliance
with all applicable Hazardous Materials Laws and prudent industry practices
regarding management of such Hazardous Materials.  Upon expiration or earlier
termination of the term of this Lease, Tenant shall cause all Hazardous
Materials in excess of levels permitted by governmental authorities to be
removed from the Premises and transported for use, storage or disposal in
accordance and compliance with all applicable Hazardous Materials Laws.  Tenant
shall not take any remedial action in response to the presence of any Hazardous
Materials in or about the 

8

<PAGE>

Premises or the Building, nor enter into any settlement agreement, consent 
decree or other compromise in respect to any claims relating to any Hazardous 
Materials in any way connected with the Premises or the Building, without 
first notifying Landlord of Tenant's intention to do so and affording 
Landlord ample opportunity to appear, intervene or otherwise appropriately 
assert and protect Landlord's interest with respect thereto. 

               (c)       Tenant shall immediately notify Landlord in writing of:
(i) any enforcement, cleanup, removal or other governmental or regulatory action
instituted, completed or threatened pursuant to any Hazardous Materials Laws;
(ii) any claim made or threatened by any person against Tenant, the Premises,
the Building, or the Property relating to damage, contribution, cost recovery
compensation, loss or injury resulting from or claimed to result from any
Hazardous Materials; and (iii) any reports made to any environmental agency
arising out of or in connection with any Hazardous Materials in, on, under,
about or removed from the Premises, the Building, or the Property including any
complaints, notices, warnings or asserted violations in connection therewith. 
Tenant shall also supply to Landlord as promptly as possible, and in any event
within five (5) business days after Tenant first receives or sends the same,
copies of all claims, reports, complaints, notices, warnings or asserted
violations relating in any way to the Property, the Building, or the Premises,
or Tenant's use thereof.  Tenant shall promptly deliver to Landlord copies of
hazardous waste manifests reflecting the legal and proper disposal of all
Hazardous Materials removed from the Premises. 

               (d)       Tenant shall indemnify, defend (by counsel reasonably
acceptable to Landlord), protect, and hold Landlord, and each of Landlord's
partners, employees, agents, attorneys, lenders, successors and assigns, and the
Premises, the Building, and Property free and harmless from and against any and
all loss of rents and/or damages, claims, liabilities, penalties, liens,
judgments, forfeitures, costs, losses or expenses (including permits, and
consultants' and attorneys' fees) or death of or injury to any person or damage
to any property or the environment whatsoever, arising from or caused in whole
or in part, directly or indirectly, by (a) the presence in, on, under or about
the Premises, the Building or the Property or discharge in or from the Premises,
the Building, or the Property of any Hazardous Materials caused or contributed
to by Tenant, or Tenant's use, analysis, storage, transportation, disposal,
release, threatened release, discharge or generation of Hazardous Materials to,
in, on, under, about or from the Premises, the Building, or the Property or
(b) Tenant's failure to comply with any Hazardous Materials Laws or (c) any
storage tank brought onto the Premises, the Building or the Property by or for
Tenant.  Tenant's obligations hereunder shall include, without limitation, and
whether foreseeable or unforeseeable, all costs of any required or necessary
investigation (including consultants' and attorneys' fees and testing), repair,
cleanup or detoxification or 

9

<PAGE>

decontamination of the Premises, the Building, or the Property, and the 
preparation and implementation of any restoration, abatement, closure, 
remedial action or other required plans in connection therewith, and shall 
survive the expiration or earlier termination of the term of this Lease.  For 
purposes of the release and indemnity provisions hereof, any acts or 
omissions of Tenant, or by employees, agents, assignees, contractors or 
subcontractors of Tenant or others acting for or on behalf of Tenant (whether 
or not they are negligent, intentional, willful or unlawful) shall be 
strictly attributable to Tenant.  No termination, cancellation or release 
agreement entered into by Landlord and Tenant shall release Tenant from its 
obligations under this Lease with respect to Hazardous Materials or storage 
tanks, unless specifically so agreed in writing at the time of such 
agreement. 

     7.   SERVICES AND UTILITIES: 

          7.1       LANDLORD'S OBLIGATIONS.  Provided that Tenant is not in
default in the performance or observation of any of the terms, covenants,
conditions or provisions of this Lease to be kept and performed or observed by
it, Landlord, subject to the rules and regulations of the Building hereinafter
referred to, agrees to (i) furnish to the Premises during reasonable hours of
generally recognized business days (as determined by Landlord) water, gas,
electricity, heating and air conditioning suitable for the intended use of the
Premises; (ii) maintain and keep lighted the common stairs, entries and
bathrooms in the Building and outside lighting on the Property; (iii) make all
repairs other than those specified to be Tenant's obligation under this Lease;
and (iv) maintain and repair, other than as specified to be Tenant's obligation
under this Lease, the elevators, if any, and maintain all portions of the
Property and Building used in common by Tenant and Landlord's other tenants;
provided that such repair shall be at Tenant's cost and expense if damage
thereto is caused by the negligence of Tenant, or Tenant's employees, agents,
contractors or invitees.  Tenant agrees that at all times it will cooperate
fully with Landlord and abide by all regulations and requirements that Landlord
may prescribe for the proper functioning and protection of any of the Building's
heating, ventilation and air conditioning systems.  Whenever heat generating
machines or equipment are used in the Premises by Tenant which affect the
temperature otherwise maintained by the air conditioning system, if any,
Landlord shall have the right to install supplementary air conditioning units in
the Premises, and the cost thereof, including the cost of installation,
operation and maintenance thereof, shall be paid by Tenant to Landlord upon
demand by Landlord with interest at the Default Rate accruing from the date
Landlord incurs such costs until the time payment for same is actually received
by Landlord, and Landlord shall have (in addition to any other right or remedy
of Landlord) the same rights and remedies in the event of non-payment thereof by
Tenant as in the case of failure by Tenant to pay Rent hereunder.  To the extent
that the cost and expense incurred by Landlord in performing its obligations in
this SECTION 7.1 are not reimbursed to Landlord by insurance or individual
tenants, such costs shall be included in Operating Expenses. 

          7.2       NON-LIABILITY.  Landlord shall not be liable for, and Tenant
shall not be entitled to, any abatement or reduction of Rent by reason of
Landlord's failure to furnish any of the items Landlord is obligated to furnish
pursuant to SECTION 7.1 above when such failure 

10


<PAGE>

is caused by accident, breakage, repairs, strikes, lockouts or other labor 
disturbances or disputes of any character; by the limitation, curtailment, 
rationing or restrictions on use of electricity, gas or any other form of 
energy; or by any other cause, similar or dissimilar, beyond the reasonable 
control of Landlord; and Landlord shall not be liable under any circumstances 
for injury to or death of any person or damage to or destruction of any 
property, however occurring, through or in connection with or incidental to 
failure to furnish any of the foregoing. 

          7.3       TENANT'S OBLIGATIONS.  Tenant agrees it will not, without
the written consent of Landlord, use any apparatus or device in the Premises
(including, without limitation, electronic data processing machines, computers
or machines using current in excess of 110 volts) which will in any way increase
the amount of electricity, water or air conditioning usually furnished or
supplied to the Premises for the purposes allowed pursuant to SECTION 6.1 above
or connect with electric current (except through existing electrical outlets in
the Premises) or with water pipes any apparatus or device for the purposes of
using electric current or water.  If Tenant shall require water or electrical
current in excess of that usually furnished or supplied to the Premises as used
for the purposes allowed pursuant to SECTION 6.1 above, Tenant shall first
obtain the written consent of Landlord, and Landlord may cause an electric
current or water meter to be installed in the Premises in order to measure the
amount of electric current or water consumed for any such excess use.  The cost
of any such meter and of the installation, maintenance and repair thereof; all
charges for such excess water and electric current consumed (as shown by such
meters and at the rates then charged by the furnishing public utility); and any
additional expense incurred by Landlord in keeping account of electric current
or water so consumed shall be paid by Tenant, and Tenant agrees to pay Landlord
therefor promptly upon demand by Landlord, and Landlord shall have (in addition
to any other right or remedy of Landlord) the same rights and remedies in the
event of non-payment thereof by Tenant as in the case of failure by Tenant to
pay Rent hereunder. 

          7.4       ADDITIONAL SERVICES.  Landlord agrees to make reasonable
effort to provide utilities and services to the Premises during hours and on
days not otherwise provided in this Lease upon written request by Tenant. 
Tenant shall give reasonable notice in making such request.  Tenant agrees to
pay promptly on demand any and all costs incurred by Landlord in connection with
providing such additional services, and Landlord shall have (in addition to any
other right or remedy of Landlord) the same rights and remedies in the event of
non-payment thereof by Tenant as in the case of failure by Tenant to pay Rent
hereunder.

     8.   MAINTENANCE AND REPAIR:

          8.1       TENANT'S OBLIGATIONS.  By its execution hereof, Tenant
accepts the Premises as being in the condition in which Landlord is obligated to
deliver the Premises.  Tenant, at Tenant's sole cost and expense, shall at all
times maintain and keep the Premises in good and sanitary order, condition and
repair, including, but not limited to, the interior surfaces of the ceilings,
walls and floors, all doors, interior surface of windows (and replacement of all
cracked or broken glass), all plumbing and all electrical fixtures and special
items in excess of building standard improvements, and all equipment (including
heating, cooling, or air conditioning units) 

11


<PAGE>

installed by or at the request of Tenant.  Tenant expressly waives the 
benefits of any statute now or hereafter in effect permitting Tenant to 
repair the Premises and deduct the cost thereof from Rent otherwise due. 

          8.2       SURRENDER OF PREMISES.  Upon the Expiration Date, Tenant
shall surrender the Premises and all Alterations (as defined in SECTION 9 below)
thereto (unless designated by Landlord to be removed in accordance with
SECTION 9) to Landlord in the same condition as received, ordinary wear and tear
(except to the extent Tenant is obligated to keep the Premises in good condition
and repair) and damage thereto by fire, earthquake, acts of God or the elements
alone excepted, and shall promptly remove or cause to be removed at Tenant's
expense from the Premises and the Building any signs, notices and displays
placed by Tenant, as well as any furniture or fixtures placed therein by Tenant.
Tenant shall indemnify the Landlord against any loss, cost, liability and/or
expense (including, without limitation, attorneys' and paralegals' fees and
costs and court costs) resulting from delay by Tenant in so surrendering the
Premises and Alterations thereto, including, without limitation, any claims made
by any succeeding tenant founded on such delay. 

          8.3       REMOVAL OF FIXTURES.  Tenant agrees to repair any damage to
the Premises or the Building caused by or in connection with the removal of any
articles of personal property business or trade fixtures, movable equipment, and
cabinetwork, belonging to Tenant including without limitation thereto, repairing
the floor and patching and painting the walls where required by Landlord to
Landlord's reasonable satisfaction, all at Tenant's sole cost and expense. 

     9.   ALTERATIONS AND ADDITIONS: 

          Tenant agrees not to make or suffer to be made any alteration,
addition or improvement to or of the Premises or any part thereof
("Alterations"), without obtaining the prior written consent of Landlord.  If
Landlord consents to the making of any Alterations, they shall be made by Tenant
at its sole cost and expense.  Tenant shall use a contractor designated by
Landlord or shall obtain Landlord's prior written approval to any contractor
selected by Tenant.  Prior to commencement of any work, Tenant shall deliver to
Landlord for its approval plans and specifications for each Alteration to be
undertaken by Tenant; and, at the completion of such work, Tenant shall deliver
to Landlord a certificate from Tenant's architect or engineer stating that the
work has been completed in full compliance with such plans and specifications,
such certificate to be in form and substance reasonably satisfactory to
Landlord.  Landlord shall also have the right to impose as a condition to its
consent such requirements as Landlord may deem necessary in its sole discretion
including, without limitation, full reimbursement to Landlord of any and all
expenses incurred by Landlord in connection with the granting of its consent,
the amounts and types of liability and other insurance covering all risks
normally associated with such work and the times and dates during which the
Alterations are to be accomplished.  If Landlord is required pursuant to
applicable law or agrees to supervise such work, Tenant shall pay to Landlord a
fee in the amount of fifteen percent (15%) of the total cost of the Alterations
for its management and supervision of the progress of the work.  Tenant agrees
that in no event shall such management or supervision by Landlord impose any
obligation 


12

<PAGE>

or liability upon Landlord to Tenant as to or in connection with such work.  
All sums due and owing to contractors which have been paid by Landlord due to 
Tenant's failure to pay such sums when due, shall bear interest payable to 
Landlord at the Default Rate until fully paid.  Upon the Expiration Date, 
Tenant, at its sole cost and expense, shall promptly remove any Alterations 
designated by Landlord to be so removed and repair any damage to the Premises 
or the Building caused by such removal and any Alterations not so designated 
to be removed shall become the property of the Landlord.  Unless removed by 
Tenant prior to or on the Expiration Date, any equipment, trade fixtures, 
machinery, cabinetwork, movable furniture, or other personal property 
remaining on the Premises at the expiration or sooner termination of this 
Lease shall, in the sole option of Landlord, either (i) become the property 
of Landlord; or (ii) be removed from the Premises and discarded at Tenant's 
sole cost and expense.  It is agreed that Landlord has no obligation, and has 
made no promises, to alter, add to, remodel, improve, repair, decorate or 
paint the Premises or any part thereof and that no representations respecting 
the condition of the Premises or the Building have been made by Landlord to 
Tenant except as may be specifically set forth herein. 

     10.  ENTRY BY LANDLORD: 

               (a)       Landlord reserves, and shall at any and all times have,
the right to enter the Premises to (i) inspect them; (ii) supply any service to
be provided by Landlord to Tenant hereunder; (iii) present the Premises to
prospective purchasers, mortgagees or lessees; (iv) post notices of
non-responsibility, "For Sales" and "For Lease" signs; and (v) alter, improve or
repair the Premises and any portion of the Building all without abatement of
Rent, and may erect scaffolding and other necessary structures where reasonably
required by the character of the work to be performed, using all reasonable
efforts to provide that Tenants's use of the Premises shall not be unreasonably
interfered with thereby.  As part of the consideration for this Lease, Tenant
hereby waives any claim for damages for any injury or inconvenience to or
interference with Tenant's business, any loss of occupancy or quiet enjoyment of
the Premises, and any other loss occasioned by such entry, For each of the
aforesaid purposes, Landlord shall at all times have and retain a key with which
to unlock all doors, in, upon and about the Premises, excluding Tenant's vaults
and safes, and Landlord shall have the right to use any and all means which
Landlord may deem proper to open said doors in an emergency, in order to obtain
entry to the Premises, and any entry to the Premises obtained by Landlord by any
of said means, or otherwise, shall not under any circumstances be construed or
deemed to be a forcible or unlawful entry into, or a detainer of, or an eviction
of Tenant from, the Premises or any portion thereof.  

               (b)       Landlord shall also have the right at any time to
change the arrangement or location of or eliminate entrances or passageways,
doors and doorways, and corridors, elevators, stairs, toilets or other public or
common areas of the Building, or change the arrangement and location of or
eliminate parking areas, access ways, or landscaped areas of the Property, and
to change the name, number or designation by which the Building is commonly
known, and none of the foregoing shall be deemed an actual or constructive
eviction 

13


<PAGE>

of Tenant, nor shall it entitle Tenant to any reduction of Rent or result in 
any liability of Landlord to Tenant. 

     11.  LIENS: 

          Tenant shall keep the Premises, the Building and the land upon which
the Building is situated, free from any liens arising out of work performed,
materials furnished or obligations incurred by Tenant and shall indemnify, hold
harmless and defend Landlord from any liens and encumbrances arising out of any
work performed or materials furnished by or at the direction of Tenant.  In the
event that Tenant does not, within ten (10) days following the recording of
notice of any such lien, cause such lien to be released of record, by payment or
posting of a proper bond, Landlord shall have, in addition to all other remedies
provided herein and by law, the right, but not the obligation, to cause such
lien to be released by such means as it shall deem proper, including payment of
the claim giving rise to such lien.  All sums paid by Landlord and all expenses
incurred by it in connection therewith, including, without limitation,
attorneys' and paralegals' fees and costs and court costs, shall be payable to
Landlord by Tenant on demand with interest at the Default Rate, from the date
such expenses are incurred by Landlord to the date payment is received by
Landlord from Tenant and Landlord shall have (in addition to any other right of
remedy of Landlord) the same rights and remedies in the event of non-payment
thereof by Tenant as in the case of failure of Tenant to pay Rent hereunder. 
Landlord shall have the right- at all times to post and keep posted on the
Premises any notices permitted or required by law, or which Landlord shall deem
proper for the protection of Landlord, the Premises, the Building, the Property,
or any other party having an interest therein, or to keep same free from
mechanics' and materialmen's and similar liens.  Tenant shall give Landlord at
least ten (10) days prior written notice of the date of commencement of any
construction or other work on or to the Premises. 

     12.  INDEMNITY: 

          Landlord shall not be liable to Tenant and Tenant waives all claims
against Landlord for any injury to or death of any person or for loss of use of,
damage to, or destruction of property in or about the Premises, the Building, or
the Property by or from any cause whatsoever, including without limitation,
earthquake or earth movement, gas, fire, oil, electricity or leakage from the
roof, walls, basement or other portion of the Premises or the Building, unless
caused by the gross negligence or willful misconduct of Landlord, its agents or
employees.  Tenant agrees to hold Landlord harmless from and to indemnify and
defend Landlord against all claims, liability, damage or loss and against all
costs and expenses, including, without limitation, attorneys' and paralegals'
fees and costs and court costs in connection therewith, arising out of any
injury or death of any person or damage to or destruction of property
(i) occurring in, on or about the Premises, from any cause whatsoever,
including, without limitation, Tenant's use of the Premises, unless caused
solely by the gross negligence or willful misconduct of Landlord, its agents or
employees; or (ii) occurring in, on or about any facilities (including without
limitation elevators, stairways, passageways or hallways) the use of which
Tenant has in common with other lessees, or elsewhere in or about 

14


<PAGE>

the Property or the Building other than the Premises, when such claim, injury 
or damage is caused in whole or in part by the act, neglect, default, or 
omission of any duty by Tenant, its agents, employees, contractors, invitees, 
or subtenants or otherwise by any conduct of any of said persons in or about 
the Premises, the Building, or the Property including failure of Tenant to 
observe or perform any of its obligations under this Lease, including, 
without limitation, its obligations under SECTION 6 hereof. 

          Without in any way limiting the foregoing, Tenant specifically
acknowledges that Tenant assumes all risks in the use of any or all of the
exercise equipment or facilities in the Building; Tenant acknowledges that
neither the Landlord nor the property manager provide instruction for or
supervision of the use of the exercise equipment and facilities, and neither the
Landlord nor the property manager shall be liable for injury, death, or any
claim arising directly or indirectly out of use of the exercise equipment and
facilities.  Tenant agrees to hold Landlord harmless from and to indemnify and
defend Landlord against all claims, liability, damage, or loss and against all
costs and expenses, including, without limitation, attorneys' and paralegals'
fees and costs and court costs in connection therewith, arising out of any
injury or death of any person using the exercise equipment or facilities through
said person's association with Tenant.  Tenant further acknowledges that said
exercise equipment and/or facilities may only be used by Tenant and its
employees in common with other tenants and their employees.  Tenant shall not
permit use of the exercise equipment or facilities by Tenant's vendors, or the
family members or friends of Tenant and its employees. 

          The provisions of this SECTION 12 shall survive the termination of
this Lease with respect to any claims or liability occurring prior to such
termination. 

     13.  INSURANCE: 

          13.1      TENANT'S REQUIRED COVERAGE.  Tenant shall, at Tenant's sole
cost and expense, procure and continue in force the following policies of
insurance in the amounts set forth in PARAGRAPH K OF THE SUMMARY OF LEASE TERMS,
unless such amounts are otherwise set forth in this SECTION 13.1: 

              (i)        Liability insurance on an occurrence basis, with limits
    in an amount set forth in PARAGRAPH K OF THE SUMMARY OF LEASE TERMS, for
    claims or losses arising out of or resulting from personal injury
    (including bodily injury), death and/or property damage sustained or
    alleged to have been sustained by any person for any reason on or about the
    Premises, for liability arising out of or resulting from Tenant's covenants
    contained in SECTION 12 above to indemnify Landlord, its agents and
    employees, or for contractual liability; 

             (ii)        All risk replacement cost insurance with an agreed
    amount endorsement upon property of every description and kind owned by
    Tenant and located in the Premises and for all improvements located in the
    Premises except building standard improvements in an amount equal to 100%
    of the full replacement value thereof; 


15


<PAGE>
            (iii)        Workers' compensation insurance (including employer's
    liability insurance) in accordance with applicable law; 

             (iv)        Such other insurance as may be reasonably required by
    Landlord or by any holder of any ground or underlying lease, mortgage or
    deed of trust. 

          Not more often than every year and upon not less than sixty (60) days
prior written notice, Landlord, in its reasonable discretion, may require Tenant
to increase the insurance limits set forth in subparagraphs (i) or (ii) above. 

          13.2      LANDLORD'S REQUIRED COVERAGE.  Landlord shall procure and
continue in force the following policies of insurance in the amounts set forth
in PARAGRAPH L OF THE SUMMARY OF LEASE TERMS, the cost of same to be included in
Operating Costs: 

              (i)        Liability insurance on an occurrence basis, with limits
    in the amount set forth in PARAGRAPH L OF THE SUMMARY OF LEASE TERMS, for
    claims or losses arising out of or resulting from personal injury
    (including bodily injury), death and/or property damage sustained or
    alleged to have been sustained by any person for any reason on or about the
    Premises, for liability arising out of or resulting from Tenant's covenants
    contained in SECTION 12 above to indemnify Landlord, its agents and
    employees, or for contractual liability; 

             (ii)        Casualty insurance insuring the Building against loss
    by or damage due to risks covered by the broadest form of casualty
    insurance policy (such coverage shall include, without limitation, coverage
    against the risk of fire, lightning, extended coverage, vandalism and
    malicious mischief).  Such policy, shall also include, a rental loss
    endorsement.  Such policy, exclusive of the rental loss endorsement, shall
    be in the face amount of not less than ninety (90%) percent of the full
    value of the improvements covered thereby.  The rental loss endorsement
    shall cover Landlord's loss of rentals in an amount of not less than one
    (1) year's aggregate Rent for the Premises; 

            (iii)        Difference in conditions insurance against (1) damage
    or loss by flood if the Premises are located in an area identified by the
    Secretary of Housing and Urban Development or any successor thereto or
    other appropriate authority (governmental or private) as an area having
    special flood hazards and in which flood insurance has been made available
    under the National Flood Insurance Act of 1968 or the Flood Disaster
    Protection Act of 1973, as amended, modified, supplemented or replaced from
    time to time, on such basis as shall be required by Landlord and with
    coverage in an amount not less than as set forth in PARAGRAPH L OF THE
    SUMMARY OF LEASE TERMS, and (2) against damage or loss by earthquake with a
    deductible of not more than ten percent (10%) and with coverage in an
    amount not less than as set forth in PARAGRAPH L OF THE SUMMARY OF TERMS,
    so long as same is available at commercially reasonable rates; 

16


<PAGE>

             (iv)        Such other insurance as may be reasonably required by
    Landlord or by any holder of any ground or underlying lease, mortgage or
    deed of trust. 

          Landlord may increase the insurance limits set forth in subparagraphs
(i), (ii), or (iii) above. 

          13.3      INSURANCE POLICIES.  The minimum limits of insurance
policies as set forth in SECTION 13.1 above shall in no event limit the
liability of Tenant hereunder.  The following provisions shall apply regarding
all insurance policies Tenant is required to procure and maintain under
SECTION 13.1 above.  For any insurance policies Landlord is to procure and
maintain under SECTION 13.2 above, Landlord may, at its option, have such
policies comply with such provisions.  The aforesaid insurance shall name
Landlord as an additional insured (and, at Landlord's option, the property
manager and the holder of any mortgage or deed of trust on the Building, or any
part thereof or interest therein, as an additional insured), and shall be with
companies having a rating of not less than AAA in "Best's insurance Guide" or
another comparable rating or publication if Best's Insurance Guide is no longer
published or produced.  For any insurance policies procured by Tenant, Tenant
shall cause the insurance companies to furnish Landlord with certificates of
coverage, and shall provide that such insurance policy shall not be canceled or
subject to reduction or modification of coverage except after thirty (30) days'
prior written notice to Landlord by the insurer.  All such policies shall be
written as primary policies, not contributing with and not in excess of the
coverage which Landlord may carry and shall contain a cross-liability
endorsement stating that the rights of named insureds shall not be prejudiced by
one insured making a claim or commencing an action against another named
insured.  For any insurance policies procured by Tenant, Tenant shall, at least
thirty (30) days prior to the expiration of such policies, furnish Landlord with
renewals or binders for renewals thereof.  Tenant agrees that if Tenant does not
procure and maintain the insurance required to be procured and maintained by
Tenant pursuant to SECTION 13.1 above Landlord may (but shall not be required
to) procure said insurance on Tenant's behalf and charge Tenant the premiums
charged therefor together with the sum equal to all costs and expenses incurred
by Landlord in connection therewith (including, without limitation, costs
allocated to the use of Landlord's employees in connection therewith, including
without limitation, costs of wages for such employees) together with interest
thereon at the Default Rate, payable upon demand and upon Tenant's failure to
pay such insurance premiums and handling charge, Landlord shall have (in
addition to any other right or remedy of Landlord) the same rights and remedies
as in the case of failure by Tenant to pay Rent hereunder.  Tenant shall have
the right to provide the insurance policies required pursuant to SECTION 13.1
above pursuant to blanket policies obtained by Tenant, provided such blanket
policies expressly afford coverage to the Premises and to Landlord as required
by this Lease. 

          13.4      WAIVER OF SUBROGATION.  Landlord and Tenant each hereby
waive any and all rights of recovery against the other or against the officers,
employees, agents and representatives of the other, on account of loss or damage
occasioned to such waiving party or its property or the property of others under
its control to the extent that such loss or damage is insured against under any
fire and extended coverage insurance policy which either may have 

17


<PAGE>

in force at the time of such loss or damage.  Tenant shall, upon obtaining 
the policies of insurance required under this Lease, give notice to the 
insurance carrier or carriers that the foregoing mutual waiver of subrogation 
is contained in this Lease and shall obtain from such insurance carrier or 
carriers a waiver of any right of recovery by way of subrogation against 
Landlord. 

     14.  DAMAGE OR DESTRUCTION: 

          PARTIAL DAMAGE - INSURED.  In the event the Premises or the 
Building are partially damaged by fire or other casualty which is covered 
under fire and extended coverage insurance carried pursuant to SECTION 
13.2(1) above, Landlord shall restore such damage provided insurance proceeds 
are available to pay one hundred percent (100%) of the cost of restoration 
and provided such restoration can be completed within one hundred eighty 
(180) days after the commencement of the work thereof under the laws and 
regulations of the state, federal, county and municipal authorities having 
jurisdiction thereover and if such conditions apply so as to require Landlord 
to restore such damage, this Lease shall continue in full force and effect.  
Tenant shall be entitled to a proportionate reduction of Fixed Rent and 
Tenant's Proportionate Share of Operating Costs and Taxes while such 
restoration takes place, such proportionate reduction to be based upon the 
extent to which the restoration efforts interfere with Tenant's business in 
the Premises, provided that Tenant shall not be entitled to such reduction in 
Fixed Rent and Tenant's Proportionate Share of Operating Costs and Taxes if 
the damage is the result of negligence, default or omission of Tenant, its 
agents, employees, contractors, or invitees; and provided, further, that in 
no event shall the reduction of Fixed Rent and Tenant's Proportionate Share 
of Operating Costs and Taxes exceed the amounts received by Landlord from 
rent loss insurance.  Tenant's rights to a reduction in Fixed Rent and 
Tenant's Proportionate Share of Building Operating Costs and Taxes hereunder 
shall be Tenant's sole and exclusive remedy in connection with any such 
damage. 

          Notwithstanding the foregoing, Landlord may terminate this Lease if
such damage or casualty occurs during the last twelve (12) months of the term of
this Lease (or the term of any renewal option, if applicable) by giving Tenant
notice thereof at any time within thirty (30) days of the occurrence of such
damage or casualty and such notice shall specify the date of such termination
which date shall not be less than thirty (30) nor more than sixty (60) days
after the giving of such notice.  In the event of the giving of such notice of
termination, this Lease shall expire and all interest of Tenant in the Premises
shall terminate on the date so specified in such notice and the Rent shall be
paid to the date of such termination. 

          14.2      PARTIAL DAMAGE - UNINSURED.  In the event the Premises or
the Building are partially damaged by a risk not covered by Landlord's fire and
extended coverage insurance or the proceeds of available insurance are less than
one hundred percent (100%) of the cost of restoration, or if the restoration
cannot be completed within one hundred eighty (180) days after the commencement
of such restoration under the laws and regulations of the state, federal, county
and municipal authorities having jurisdiction thereover in the reasonable
opinion of Landlord, or if such damage occurs during the last twelve (12) months
of the term of this Lease 

18


<PAGE>

(or the term of any renewal option, if applicable), Landlord shall have the 
option either to (i) repair or restore such damage, with the Lease continuing 
in full force and effect, but the Rent to be proportionately abated as 
provided in SECTION 14.1 above; or (ii) give notice to Tenant at any time 
within thirty (30) days after the occurrence of such damage terminating this 
Lease as of a date to be specified in such notice which date shall not be 
less than thirty (30) nor more than sixty (60) days after the giving such 
notice.  In the event of the giving of such notice of termination, this Lease 
shall expire and all interest of Tenant in the Premises shall terminate on 
the date so specified in such notice and the Rent, reduced by any 
proportionate reduction in Fixed Rent and Tenant's Proportionate Share of 
Building Operating Costs and Taxes as provided for in this Section and/or 
SECTION 14.1 above, shall be paid to the date of such termination. 

          14.3      TOTAL DESTRUCTION.  In the event the Premises are totally
destroyed or the Premises cannot be restored as required herein under applicable
laws and regulations, notwithstanding the availability of insurance proceeds,
Landlord shall have the right to terminate this Lease by giving Tenant notice
thereof within thirty (30) days of date of the occurrence of such casualty
specifying the date of termination which shall not be less than thirty (30) days
nor more than sixty (60) days after the date of the delivery of such notice. 

          14.4      LANDLORD'S OBLIGATIONS.  Notwithstanding the provisions of
this Lease, Landlord shall in no event be required to repair any injury or
damage by fire or other cause whatsoever to, or to make any restoration or
replacement of, any paneling, decorations, partitions, railings, ceilings, floor
coverings, office fixtures or any other improvements or property installed in
the Premises by Tenant or at the direct or indirect expense of Tenant.  Tenant
shall be required to restore or replace same in the event of damage at its sole
cost and expense and except for abatement of Fixed Rent and Tenant's
Proportionate share of Operating Costs and Taxes, if any, Tenant shall have no
claim against Landlord for any damage, loss, liability, cost or expense incurred
by Tenant by reason of any such injury, damage or destruction to or repair or
restoration of such items. 

          14.5      TENANT'S WAIVER.  The provisions of this SECTION 14 shall
constitute the express agreement of the parties regarding damage to or
destruction of the Premises and shall supersede any statute now or hereafter in
effect. 

     15.  CONDEMNATION: 

          (a)       If all or part of the Premises shall be taken by any public
or quasi-public authority under the power of eminent domain or shall be conveyed
in lieu thereof, this Lease shall terminate as to any portion of the Premises so
taken or conveyed on the date when title or the right to possession vests in the
condemnor. 

          (b)       If (i) a part of the Premises shall be taken by any public
or quasi-public authority under the power of eminent domain or shall be conveyed
in lieu thereof; and (ii) Tenant is reasonably able to continue the operation of
Tenant's business in that portion of the Premises remaining; and (iii) Landlord
elects to restore the Premises to an architectural 


19

<PAGE>

whole, then this Lease shall remain in effect as to said portion of the 
Premises remaining, and the Fixed Rent and Tenant's Proportionate Share of 
Operating Costs and Taxes payable from the date of the taking shall be 
reduced in the same proportion as the area of the Premises taken bears to the 
total area of the Premises.  If, after a partial taking, Tenant is not 
reasonably able to continue the operation of its business in the Premises or 
Landlord elects not to restore the Premises as hereinabove described, this 
Lease may be terminated by either Landlord or Tenant by giving written notice 
to the other party within thirty (30) days of the date of the taking.  Such 
notice shall specify the date of termination which shall not be less than 
thirty (30) nor more than sixty (60) days after the date of such notice. 

          (c)       If a portion of the Building is taken, whether any portion
of the Premises is taken or not, and Landlord determines that it is not
economically feasible to continue operating the portion of the Building
remaining, then Landlord shall have the option for a period for sixty (60) days
after such taking to terminate this Lease.  If Landlord determines that it is
economically feasible to continue operating the portion of the Building
remaining after such taking, then this Lease shall remain in effect, and
Landlord at Landlord's cost shall restore the Building to an architectural
whole. 

          (d)       Landlord shall be entitled to any and all payment, income,
rent, award, or any interest thereon whatsoever which may be paid or made in
connection with such taking or conveyance, and Tenant hereby assigns any rights
to same to Landlord and Tenant shall have no claim against Landlord or otherwise
for the value of any unexpired term of this Lease.  Notwithstanding the
foregoing, to the extent that Landlord's recovery for such taking shall not be
diminished, Tenant shall have the right to make a claim for moving expenses and
for loss or damage to Tenant's trade fixtures, equipment and movable furniture. 

          (e)       No temporary taking of the Premises and/or of Tenant's
rights therein or under this Lease shall terminate this Lease or give Tenant any
right to any abatement of Rent hereunder. 

     16.  ASSIGNMENT AND SUBLETTING: 

          (a)       Tenant shall not assign, transfer, mortgage, pledge 
hypothecate or encumber this Lease or any interest therein and shall not 
sublet the Premises or any part thereof, or allow occupation or use thereof 
by any other party or entity, without the prior written consent of Landlord.  
In the event Tenant should desire to assign or transfer this Lease or sublet 
any part of the Premises, Tenant shall notify Landlord in writing 
(hereinafter referred to as "Sublet Notice") of the terms of the proposed 
assignment or transfer or subletting, at least ninety (90) days in advance of 
the date on which Tenant desires to make such assignment or transfer or 
sublease.  Landlord shall then have a reasonable period of time following 
receipt or such notice within which to notify Tenant in writing that Landlord 
elects to do one of the following: 


20


<PAGE>

               (i)       Terminate this Lease as to the space so affected as of
     the date so specified by Tenant in the Sublet Notice, in which event Tenant
     shall be relieved of all further obligations hereunder as to such space
     from and after such date; or 

              (ii)       Grant consent to Tenant to assign or transfer the Lease
     or sublet such space to the proposed assignee or transferee or sublessee on
     the terms set forth in the Sublet Notice; or 

             (iii)       Deny consent to Tenant to assign or transfer the Lease
     or sublet such space. 

          (b)       If Tenant proposes to sublease less than all of the
Premises, an election by Landlord under subparagraph (a)(i) above to terminate
this Lease with respect to such space shall not affect the force or validity of
the Lease with respect to the remainder of the Premises, provided that the Rent
payable hereunder shall be adjusted on a pro rata basis in accordance with the
reduction in the rentable area of the Premises.  If Landlord should fail to
notify Tenant in writing of its election under subparagraph (a) within the
thirty (30) day period, Landlord shall be deemed to have waived the option
described in subparagraph (a)(i), but prior written consent by Landlord of the
proposed assignee or transferee or sublessee shall still be required.  Landlord
shall have the right to require complete financial statements and business
history information (including without limitation, the name and legal
composition of the proposed assignee or transferee or sublessee and the nature
of the business proposed to be carried on in the Premises) regarding the
proposed assignee or transferee or sublessee before determining whether or not
to consent. 

          (c)       Any consideration in excess of the Fixed Rent and Tenant's
Proportionate Share of Building Operating Costs and Taxes payable hereunder
which is realized by Tenant under any sublease or assignment or transfer in
accordance with this Section shall be paid entirely to Landlord.  Landlord shall
have (in addition to any other right or remedy of Landlord) the same rights and
remedies in the event of nonpayment thereof by Tenant as in the case of failure
by Tenant to pay Rent hereunder. 

          (d)       The consent of Landlord to any assignment, transfer,
mortgage, pledge, encumbrance, hypothecation, subletting, occupation or use by
any other person or entity shall not release Tenant from any of Tenant's
obligations hereunder or discharge any liability of Tenant under this Lease, nor
shall said consent be deemed to be a consent to any subsequent similar or
dissimilar assignment, transfer, mortgage, pledge, encumbrance, hypothecation,
subletting, occupation or use by any other person or entity.  Any such
assignment, transfer, mortgage, pledge, encumbrance, hypothecation, subletting,
occupation or use by any other person or entity without such consent shall be
void and shall constitute a breach of the Lease by Tenant and shall, at the
option of Landlord, constitute a material event of default hereunder.  The
acceptance of Rent by Landlord from any other person or entity shall not be
deemed to be a waiver by Landlord of any provision of this Lease or to be a
consent to any assignment, subletting or other transfer thereof. 

21

<PAGE>
          (e)       For purposes of this SECTION 16, sales, transfers or
assignments of (i) a controlling interest in the stock of Tenant (if Tenant is a
corporation); (ii) the general partnership interest of Tenant sufficient to
materially change its general partnership composition and management (if Tenant
is a partnership); or (iii) the majority of controlling underlying beneficial
interest of Tenant (if Tenant is any other form or business entity) shall
constitute an assignment hereunder. 

          (f)       The voluntary or other surrender of this Lease or of the
Premises by Tenant or a mutual cancellation of this Lease shall not work a
merger, and at the option of Landlord any existing subleases may be terminated
or be deemed assigned to Landlord in which event the tenants under such
subleases shall become tenants of Landlord. 

          (g)       Tenant shall reimburse Landlord for all costs incurred by
Landlord in connection with its review and consideration of any proposed
assignment, transfer, mortgage, pledge, encumbrance or hypothecation of the
Lease or subletting of the Premises, or any part thereof, including without
limitation, reasonable attorneys' fees. 

     17.  MORTGAGEE/GROUND LANDLORD PROTECTION: 

          17.1      SUBORDINATION. This Lease, at the Landlord's option, shall
be subject and subordinate at all times to all ground or underlying leases which
now exist or may hereafter exist affecting the Premises, the Building or the
land upon which the Building is situated, or all of same, and to the lien of any
mortgage or deed of trust in any amount or amounts whatsoever now or hereafter
placed on or against the Building or land upon which the Building is situated,
or both, or on or against Landlord's interest or estate therein, all without the
necessity of the execution and delivery of any further instruments on the part
of Tenant to effectuate such subordination. 

          17.2      SUBORDINATION AGREEMENTS. Tenant covenants and agrees to
execute and deliver upon demand and without charge, such further instruments
evidencing subordination of this Lease to (i) any ground or underlying leases
and (ii) to the lien of any mortgages or deeds of trust, as described in
SECTION 17.1 above, as may be requested by Landlord.  Tenant hereby appoints
Landlord as Tenant's attorney-in-fact, irrevocably, to execute and deliver any
such agreements, instruments, releases or other documents. 

          17.3      FINANCIAL STATEMENTS.  If this Lease is to be subject and
subordinate to any ground or underlying lease, mortgage or deed of trust
executed after this date, within ten (10) days after Landlord's request, Tenant
shall deliver to Landlord, or to any actual or prospective ground lessor or
lender that Landlord designates, such financial statements as are reasonably
required by any holder of any underlying or ground lease or mortgage or deed of
trust (the "Holder") to verify the net worth of Tenant (or any assignee,
subtenant or guarantor of Tenant) to facilitate the financing or refinancing of
the Building, or any part 

22

<PAGE>

     18.  INSOLVENCY OR BANKRUPTCY: 

          18.1      EVENTS OF DEFAULT.  In addition to the occurrences set forth
in SECTION 19 below, the following events shall constitute a default under this
Lease: (i) Tenant admits in writing its inability to pay its debts as they
mature; (ii) Tenant makes an assignment for the benefit of creditors or takes
any other similar action for the protection or benefit of creditors;
(iii) Tenant gives notice to any governmental body of insolvency or pending
insolvency, or suspension or pending suspension of operations; (iv) Tenant files
a voluntary petition in bankruptcy or shall be adjudicated a bankrupt or
insolvent; (v) an involuntary petition in bankruptcy is filed against Tenant and
is not dismissed within sixty (60) days from the date same is filed; (vi) Tenant
files any petition or answer seeking any reorganization, arrangement,
composition, readjustment, liquidation, dissolution or other similar relief
under any present or future bankruptcy statute, regulation or law; (vii) a court
of competent jurisdiction enters an order, judgment or decree approving a
petition filed against Tenant seeking any relief described in the preceding
subparagraph (vi) and such order, judgment or decree shall remain unvacated and
unstayed for an aggregate of thirty (30) days from the date of entry thereof;
(viii) a trustee, receiver, conservator or liquidator of Tenant or of all or any
substantial part of its property or its interest in the Premises is employed or
appointed and such receivership remains undissolved for thirty (30) days; or
(ix) this Lease or any estate of Tenant hereunder is levied upon under any
attachment or execution and such attachment or execution shall remain unvacated
and unstayed for ten (10) days. 

          18.2      BANKRUPTCY.  Upon the filing of a petition by or against
Tenant under the United States Bankruptcy Code, Tenant, as debtor in possession,
and any trustee who may be appointed agree to: 

               (i)       Perform each and every obligation of Tenant under this
     Lease until such time as this Lease is either rejected or assumed by order
     of the United States Bankruptcy Court; 

              (ii)       Pay monthly in advance on the first day of each month
     as reasonable compensation for use and occupancy of the Premises the Rent
     payable hereunder and all other charges due pursuant to this Lease as said
     charges become due; 

             (iii)       Reject or assume this Lease within sixty (60) days of
     the filing of such petition under Chapter 7 of the Bankruptcy Code or
     within one hundred twenty (120) days (or such shorter term as Landlord, in
     its sole discretion, may deem reasonable so long as notice of such period
     is given) of the filing of a petition under any other Chapter; 

              (iv)       Give Landlord at least forty-five (45) days prior
     written notice of any abandonment of the Premises, any such abandonment to
     be deemed a rejection of this Lease; and 


23


<PAGE>
               (v)       Do all other things of benefit to Landlord otherwise
     required under the Bankruptcy Code. 

          Tenant, as debtor in possession, and any such trustee shall be deemed
to have rejected this Lease in the event of the failure to comply with any of
the above requirements and to have consented to the entry of an order by an
appropriate Bankruptcy Court providing all of the above, waiving notice and
hearing of the entry of same. 

     19.  DEFAULT AND REMEDIES: 

               In the event that (i) any of the events described in SECTION 
18.1 above shall occur; (ii) Tenant abandons or vacates the Premises; (iii) 
Tenant fails to pay any Rent payable hereunder when and as the same becomes 
due and payable and such failure shall continue for more than five (5) days; 
or (iv) Tenant fails to perform any other term, covenant or condition of this 
Lease and such failure continues for more than thirty (30) days after 
receiving notice thereof from Landlord, or, if such default cannot reasonably 
be cured within said thirty (30) day period, fails to commence to cure such 
default with all due diligence and dispatch within said thirty (30) day 
period, or having commenced such cure, shall fail to diligently prosecute 
such cure to completion; then Landlord, in addition to any other rights and 
remedies of Landlord at law or in equity, shall have the right to terminate 
Tenant's right to possession of the Premises and either terminate this Lease 
or have this Lease continue in full force and effect.  Should Landlord elect 
to terminate Tenant's right to possession of the Premises, then Landlord 
shall have the right of entry and may remove all persons and property from 
the Premises, subject to applicable law. Such property so removed may be 
stored in a public warehouse or elsewhere at the cost and for the account of 
Tenant.  Upon such termination, Landlord, in addition to any other rights and 
remedies provided by law, shall be entitled to recover from Tenant (i) all 
delinquent Rent, together with interest and late charges; and (ii) all costs 
and expenses of recovering possession, in restoring the Premises to good 
order and condition, or in remodeling, renovating, or preparing the Premises 
for reletting; (iii) all costs of reletting, including broker's commissions; 
(iv) the worth at the time of award of the amount by which the unpaid Rent 
for the balance of the term hereof after the time of award exceeds the amount 
of such Rent loss that the Tenant proves could be reasonably avoided; and (v) 
all other damages caused by Tenant's default.  The worth at the time of award 
of the amount referred to in this subparagraph shall be computed by 
discounting such amount at the discount rate of the Federal Reserve Bank of 
San Francisco at the time of the award plus one percent (1%).  As used 
herein, the term "time of award" shall mean either the date upon which Tenant 
pays to Landlord the amount recoverable by Landlord as hereinabove set forth 
or the date of entry of any determination, order or judgment of any court or 
other legally constituted body, or of any arbitrators determining the amount 
recoverable, whichever first occurs. 

          (b)       Should Landlord, following any breach or default of this
Lease by Tenant, elect to keep this Lease in full force and effect with Tenant
retaining the right to possession of the Premises (notwithstanding the fact that
Tenant may have abandoned the Premises), then Landlord, in addition to all other
rights and remedies Landlord may have at law or in equity, 


24


<PAGE>

shall have the right to enforce all of Landlord's rights and remedies under 
this Lease, including, but not limited to, the right to recover the 
installments of Rent as they become due under this Lease.  Notwithstanding 
any such election to have this Lease remain in full force and effect, 
Landlord may at any time thereafter elect to terminate Tenant's right to 
possession of said Premises for any previous breach or default hereunder by 
Tenant which remains uncured or for any subsequent breach or default. 

     20.  MISCELLANEOUS: 

          20.1      TRANSFER OF LANDLORD'S INTEREST.  In the event of a sale or
conveyance by Landlord of Landlord's interest in the Premises,or the Building,
or Property Landlord shall be relieved from any further obligations and
liabilities accruing hereunder (whether express or implied) in favor of Tenant
on the part of Landlord.  Tenant agrees to look solely to the successor in
interest of Landlord in and to the Property or the Building and this Lease. 
This Lease shall not be affected by any such sale and Tenant agrees to attorn to
the Landlord's successor in interest. 

          20.2      RIGHT OF LANDLORD TO PERFORM.  All terms and covenants of
this Lease to be performed or observed by Tenant shall be performed or observed
by Tenant at Tenant's expense and without any reduction of Rent.  If Tenant
fails to pay any Rent hereunder or fails to perform any other term or covenant
hereunder on its part to be performed, and such failure shall continue for ten
(10) days after written notice thereof by Landlord, Landlord, without waiving or
releasing Tenant from any obligation of Tenant hereunder, may (but shall not be
obligated to) make any such payment or perform any such other term or covenant
on Tenant's part to be performed.  All sums so paid by Landlord and all
necessary costs of such performance by Landlord, together with interest thereon
at the Default Rate from the date of such payment or performance by Landlord,
shall be paid by Tenant to Landlord on demand by Landlord, and Landlord shall
have (in addition to any other right or remedy of Landlord) the same rights and
remedies in the event of non-payment thereof by Tenant as in the case of failure
by Tenant in the payment of Rent hereunder. 

          20.3      CAPTIONS: ATTACHMENTS; DEFINED TERMS. 

               (a)       The captions of the paragraphs of this Lease are for
convenience of reference only and shall not be deemed to be relevant in
resolving any question of interpretation or construction of any section of this
Lease. 

               (b)       Exhibits attached hereto, and addendums and schedules
initialed by the parties, are deemed by attachment to constitute part of this
Lease and are incorporated herein. 

               (c)       The words "Landlord" and "Tenant," as used herein,
shall include the plural as well as the singular.  Words used in neuter gender
include the masculine and feminine and words in the masculine or feminine gender
include the neuter.  If there be more 

25


<PAGE>

than one Tenant, the obligations hereunder imposed upon Tenant shall be joint 
and several; as to a Tenant which consists of husband and wife, the 
obligations shall extend individually to their sole and separate property as 
well as community property.  The term "Landlord" shall mean only the owner or 
owners at the time in question of the fee title or a tenant's interest in a 
ground lease of the land underlying the Building.  The obligations contained 
in this Lease to be performed by Landlord shall be binding on Landlord or 
Landlord's successors and assigns only during their respective periods of 
ownership. 

          20.4      ENTIRE AGREEMENT.  This instrument together with any
exhibits and attachments hereto constitutes the entire agreement between
Landlord and Tenant relative to the Premises and this Lease and such exhibits
and attachments hereto may be modified, amended or revoked only by an instrument
in writing signed by the party to be charged thereunder.  Landlord and Tenant
hereby agree that all prior or contemporaneous agreements (whether oral or
otherwise) between and among themselves and their agents or representatives
relative to the leasing of the Premises are merged in, superseded by or revoked
by this Lease.  

          20.5      SEVERABILITY.  If any term or provision of this Lease shall,
to any extent, be determined by a court of competent jurisdiction to be invalid
or unenforceable, the remainder of this Lease shall not be affected thereby, and
each term and provision of this Lease shall be valid and be enforceable to the
fullest extent permitted by law. 

        20.6   COSTS OF SUIT. 

               (a)       If Landlord places this Lease in the hands of an
attorney for collection or enforcement of Tenant's obligations as a consequence
of Tenant's default hereunder, Tenant agrees to pay reasonable attorney fees and
expenses so incurred, even though no suit or action is filed. 

               (b)       If Tenant or Landlord shall bring any action for any
relief against the other, declaratory or otherwise, arising out of this Lease,
including, but not limited to, any suit by Landlord for the recovery of Rent or
possession of the Premises, the losing party shall pay the successful party the
court costs and reasonable attorneys' fees incurred therefor and such expenses
shall be paid whether or not such action is prosecuted to judgment. 

               (c)       Should Landlord, without fault on Landlord's part, be
made a party to any litigation instituted by Tenant or by any third party
against Tenant, or by or against any person holding under or using the Premises
by license of Tenant (for the purposes of this Section the "Licensee"), or for
the foreclosure of any lien for labor or material furnished to or for Tenant or
any Licensee or otherwise arising out of or resulting from any act or
transaction of Tenant or of any Licensee, Tenant agrees and covenants to save
and hold Landlord harmless from any judgment rendered against Landlord or the
Premises or Building or any part of either thereof, and to defend and indemnify
Landlord as to any and all costs and expenses, including attorneys' fees and
court costs, incurred by Landlord in or in connection with such litigation. 

26


<PAGE>

          20.7      TIME: JOINT AND SEVERAL LIABILITY.  Time is of the essence
as to this Lease and each and every provision thereof, except as to the
conditions relating to the delivery of possession of the Premises to Tenant. 
All the terms, covenants and conditions contained in this Lease to be performed
by either party, if such party shall consist of more than one person or
organization, shall be deemed to be joint and several, and all rights and
remedies of the parties shall be cumulative and nonexclusive of any other remedy
at law or in equity. 

          20.8      BINDING EFFECT: CHOICE OF LAW.  The parties hereto agree
that all provisions of this Lease are to be construed as both covenants and
conditions as though the words importing such covenants and conditions were used
in each separate paragraph.  Subject to any provisions hereof restricting
assignment or subletting by Tenant and subject to the provisions of SECTION 20.1
above, all of the provisions hereof shall bind and inure to the benefit of the
parties hereto and their respective heirs, legal representatives, successors and
assigns.  This Lease shall be governed by the laws of the state in which the
Premises are located. 

          20.9      WAIVER.  No covenant, term or condition or the breach
thereof shall be deemed waived, except by written consent of the party against
whom the waiver is claimed, and any waiver or the breach of any covenant, term
or condition shall not be deemed to be a waiver of any preceding or succeeding
breach of the same or any other covenant, term or condition of this Lease. 
Acceptance by Landlord of any performance by Tenant after the time the same
shall have become due (including, but not limited to, the acceptance of Rent)
shall not constitute a waiver by Landlord of the breach or default of any
covenant, term or condition of the Lease unless otherwise expressly agreed to by
Landlord in writing. 

          20.10      SURRENDER OF LEASE.  The voluntary or other surrender of
this Lease by Tenant, or a mutual cancellation thereof, shall not work a merger,
and shall, at the option of Landlord, terminate all or any existing subleases or
subtenancies, or may, at the option of Landlord operate as an assignment to it
of any or all such subleases or subtenancies. 

          20.11      RELOCATION OF THE PREMISES.  Landlord reserves the
unrestricted and unconditional right to relocate the Premises to substantially
comparable space subject to the same terms and conditions as the Premises
originally leased.  Landlord shall give Tenant written notice of its intention
to relocate the Premises, and Tenant shall complete such relocation within
ninety (90) days after receipt of such written notice.  If the improvements of
the space to which Landlord proposes to relocate Tenant are substantially
inferior than those of the Premises, or if the fixed rent of the new space is
substantially greater than the Fixed Rent, Tenant may so notify Landlord, and if
Landlord fails to offer space satisfactory to Tenant, Tenant may terminate this
Lease by written notice thereof effective as of the thirtieth (30th) day after
Landlord's initial notice.  If Landlord does relocate Tenant, then effective on
the date of such relocation this Lease shall be amended by (i) deleting the
description of the original Premises and substituting for it a description of
such comparable space, and (ii) making such other changes thereto as Landlord
reasonably requires.  Landlord agrees to reimburse Tenant for its actual moving
costs to such other space to the extent such costs are reasonable. 

27


<PAGE>

          20.12      HOLDING OVER.  Any holding over after the expiration or
other termination of the term of this Lease with the written consent of Landlord
delivered to Tenant shall be construed to be a tenancy from month-to-month on
all the terms, covenants and conditions herein specified so far as applicable,
except that the Rent (including the Fixed Rent and the Percentage Rent, if any)
shall be an amount equal to one hundred percent (100%) of the Rent otherwise
payable by Tenant immediately prior to such holding over.  Any holding over
after the expiration or other termination of the term of this Lease without the
written consent of Landlord shall be construed to be a tenancy from
month-to-month on all the terms set forth herein, except that the Rent
(including the Fixed Rent and the Percentage Rent, if any) shall be an amount
equal to two hundred percent (200%) of the Rent otherwise payable by Tenant
immediately prior to such holding over.  Acceptance by Landlord of Rent after
the expiration or termination of this Lease shall not constitute a consent by
Landlord to any such tenancy from month-to-month or result in any other tenancy
or any renewal of the term hereof.  The provisions of this paragraph are in
addition to, and do not affect, Landlord's right to re-entry or other rights
provided by this Lease or by law. 

        20.13    SIGNS. 

                 (a)     Tenant shall not place or permit to be placed in or
upon the Premises, or outside the Premises, or any part of the Building
(including, but not limited to the exterior or roof) any signs, notices, drapes,
shutters, blinds or displays of any type without the prior written consent of
Landlord. 

                 (b)     Landlord reserves the right in Landlord's sole
discretion to place and locate on the roof, exterior of the Building, and in any
area of the Building not leased to Tenant such signs, notices, displays and
similar items as Landlord deems appropriate in the proper operation of the
Building. 

          20.14  RULES AND REGULATIONS.  Tenant and Tenant's agents, 
servants, employees, visitors and licensees shall observe and comply fully 
and faithfully with the Rules and Regulations attached hereto as Exhibit B 
for the care, protection, cleanliness and operation of the Building and its 
lessees and any modification or addition thereto adopted by Landlord, 
provided Landlord shall give notice thereof to Tenant.  Landlord shall not be 
responsible to Tenant for the non-performance by any other lessee or occupant 
of the Building of any said Rules and Regulations. 

          20.15  NOTICES.  All notices, demands, requests, advice or 
designations ("Notices") which may be or are required to be given by either 
party to the other hereunder shall be in writing.  All Notices by Landlord to 
Tenant shall be sufficiently given, made or delivered if personally served on 
Tenant by leaving the same at the Premises, or if sent by United States 
certified or registered mail, postage prepaid, addressed to Tenant at 
Tenant's address as set forth in PARAGRAPH M OF THE SUMMARY OF LEASE TERMS.  
All notices by Tenant to Landlord shall be sufficiently given, made or 
delivered if personally served on Landlord or sent by United States certified 
registered mail, postage prepaid, addressed to (or in the case of personal 
delivery, 

28


<PAGE>

delivered to) Landlord at Landlord's address for notices as set forth in 
PARAGRAPH M OF THE SUMMARY OF LEASE TERMS.  Each Notice shall be deemed 
received on the date of the personal service or three (3) days after the 
mailing thereof in the manner herein provided. 

         20.16       CORPORATE AUTHORITY.  If Tenant is a corporation, each 
individual executing this Lease on behalf of said corporation represents and 
warrants that he or she is duly authorized to execute and deliver this Lease 
on behalf of said corporation in accordance with a duly adopted resolution of 
the Board of Directors of said corporation or in accordance with the Bylaws 
of said corporation, and that this Lease is binding upon said corporation in 
accordance with its terms; and at the time of execution of this Lease, Tenant 
shall deliver to Landlord a certified copy of a resolution of the Board of 
Directors of said corporation authorizing or ratifying the execution of this 
Lease.

          20.17      RECORDING.  Tenant shall not record this Lease or any
memoranda thereof without Landlord's prior written consent. 

          20.18      LIGHT AIR AND VIEW.  Tenant agrees that no diminution or
shutting off of light, air or view by any structure which may be erected
(whether or not by Landlord) on property adjacent to the Building shall in any
way affect this Lease, entitle Tenant to any reduction of Rent hereunder or
result in any liability of Landlord to Tenant. 

          20.19      NAME.  Tenant agrees that it shall not use the name of the
Building for any purpose other than as the address of the business conducted by
Tenant in the Premises without first obtaining the written consent of Landlord. 

          20.20      BROKERAGE.  Tenant covenants and represents that it has
negotiated this Lease directly with Landlord and has not acted by implication to
authorize, nor has authorized, any real estate broker, finder or salesman to act
for it in these negotiations other than the Broker (as defined in PARAGRAPH N OF
THE SUMMARY OF LEASE TERMS).  Tenant agrees to hold Landlord harmless from and
to defend and indemnify Landlord against any and all claims, cost, liability
and/or expense (including attorneys' fees and court costs) incurred by Landlord
in connection with any claim by any real estate broker or salesman or finder
(other than the Broker) for a commission or finder's fee as a result of Tenant's
entering into this Lease The provisions contained herein shall survive the
termination of this Lease 

          20.21      EXAMINATION OF LEASE.  Submission of this instrument for
examination or signature by Tenant does not constitute a reservation of or
option for a lease, and this instrument is not effective as a Lease or otherwise
until its execution and delivery by both Landlord and Tenant. 

          20.22      ESTOPPEL LETTER.  Tenant shall at any time and from time
to time within ten (10) days following request from Landlord execute,
acknowledge and deliver to Landlord a statement in writing and signed by Tenant,
(i) certifying that 

29


<PAGE>

this Lease is unmodified and in full force and effect (or, if modified, 
stating the nature of such modification and certifying that this Lease as so 
modified is in full force and effect), (ii) acknowledging that there are not, 
to Tenant's knowledge, any uncured defaults on the part of Landlord 
hereunder, or specifying such defaults if any are claimed, (iii) certifying 
the date that Tenant entered into occupancy of the Premises and that Tenant 
is open for business in the Premises, (iv) certifying the amount of the Fixed 
Rent and the date to which Rent is paid in advance, if any, (v) evidencing 
the status of this Lease as may be required either by a lender making a loan 
affecting, or a purchaser of, the Premises or the Building of any interest of 
Landlord therein, (vi) certify the amount of the Security Deposit, if any, 
(vii) certifying that all building standard improvements to be constructed in 
the Premises by Landlord, if any, are substantially completed except for 
punch list items which do not prevent Tenant from using the Premises for its 
intended use, and (viii) certifying such other matters relating to this Lease 
and/or the Premises as may be requested by either a lender making a loan to 
Landlord or a purchaser purchasing the Premises or the Building, or any 
interest of Landlord therein, from Landlord.  Any such statement may be 
relied upon by any prospective purchaser or encumbrancer of all or any 
portion of the Building or any interest therein.  Tenant shall, within ten 
(10) days following request of Landlord, deliver such other documents 
including Tenant's financial statements as are reasonably requested in 
connection with the sale of, or loan to be secured by, the Premises or 
Building or any interest therein.  Tenant's failure to deliver said statement 
in the time required shall be conclusive upon Tenant that: (i) the Lease is 
in full force and effect, without modification except as may be represented 
by Landlord; (ii) there are no uncured defaults in Landlord's performance and 
Tenant has no right of offset, counterclaim or deduction against Rent under 
the Leases; and (iii) no more than one month's Fixed Rent has been paid in 
advance. 

          20.23      NO THIRD PARTY BENEFICIARIES.  Unless otherwise expressly
specified herein, no term, covenant, condition or provision of this Lease shall
be construed to be for the benefit of any lessee (other than Tenant) or occupant
of the Building or any other third party or entity. 

          20.24      EASEMENTS.  Landlord reserves the right to grant public
utility easements and other rights on, over and under the Premises without any
abatement in Rent, provided that such rights do not unreasonably interfere with
Tenant's business operations on the Premises. 

          20.25      FORCE MAJEURE.  Landlord shall incur no liability to
Tenant, and shall not be responsible for any failure to perform any of
Landlord's obligations hereunder, if such failure is caused by reason of strike,
other labor trouble, governmental rule, regulations, ordinance, statute or
interpretation, or by fire, earthquake, civil commotion, or any and all other
causes beyond the reasonable control of Landlord.  The amount of time for
Landlord to perform any of Landlord's obligations shall be extended for the
amount of time Landlord is delayed in performing such obligation by reason of
such force majeure occurrence. 

          20.26      SURVIVAL OF OBLIGATIONS.  Any obligations of Tenant
accruing prior to the expiration of this Lease shall survive termination of this
Lease, and Tenant shall promptly perform all such obligations whether or not the
Lease term has expired. 

30


<PAGE>

     21.    EXCULPATION: 

Any liability of Landlord (including without limitation Landlord's partners and
their shareholders, affiliates, agents, and employees) to Tenant or any other
person shall be limited to the interest of Landlord in the Property.  Tenant or
any other person claiming through Tenant agrees to look solely to such interest
for the recovery of any judgment against Landlord, it being intended by the
parties that neither Landlord, its partners, and their shareholders, affiliates,
agents and employees, nor any other assets of Landlord or such partners, and
their shareholders, affiliates, agents, and employees shall be liable for any
such judgment. 

     THIS IS A LEGAL DOCUMENT.  PLEASE READ IT CAREFULLY.  IF YOU HAVE ANY
     QUESTIONS ABOUT IT, YOU SHOULD CONSULT YOUR OWN ATTORNEY.  NOTE THAT SOME
     STATES REQUIRE AN ACKNOWLEDGEMENT.

RESEARCH WAY INVESTMENTS, INC.          ANTIVIRALS, INC. 

/s/ Rex Jacobsma                        /s/ William H. Fleming
- -----------------------------------     ---------------------------------------


By: Rex Jacobsma                    By:     William H. Fleming
    -------------------------------         ------------------------------------

Its: General Partner                    Its: Director of Business Development
    -------------------------------         ------------------------------------









31

<PAGE>

                                 ACKNOWLEDGMENTS

                          FOR INDIVIDUAL ACKNOWLEDGMENT

STATE OF Oregon     )
                    ) ss.
COUNTY OF Multnomah )

          THIS IS TO CERTIFY that on this 17TH day of June, 1992, before me, 
the undersigned, a notary public in and for said State, duly commissioned and 
sworn, personally appeared William Fleming, to me known to be the individual 
described in and who executed the within and foregoing instrument, and 
acknowledged to me that said individual signed the same as said individual's 
free and voluntary act and deed for the uses and purposes therein mentioned.

          WITNESS my hand and official seal the day and year in this
certificate first above written. 


                              /s/ Janet M. Eayes
                              ------------------------------------------------
                              Notary public in and for state of Oregon,
                              residing at

                              ------------------------------------------------
                              My appointment expires 10/20/95








32

<PAGE>

                         FOR PARTNERSHIP ACKNOWLEDGMENT


STATE OF  X X X     )
                    ) ss.
COUNTY OF X X X     )

          THIS IS TO CERTIFY that on this X day of  X  , 19X, before me, the 
undersigned, a notary public in and for said State, duly commissioned and 
sworn, personally appeared Rex Jacobsma, to me known to be a general partner 
of Research Way Investments, the ____________________ partnership that 
executed the within and foregoing instrument, and acknowledged the said 
instrument to be the free and voluntary act and deed of said partnership for 
the uses and purposes therein mentioned, and on oath stated that said 
individual was authorized to execute said instrument.

          WITNESS my hand and official seal the day and year in this
certificate first above written. 



                                        X      X      X
                              ------------------------------------------------
                              Notary public in and for state of X  X,
                              residing at

                              ------------------------------------------------
                              My appointment expires X  X



33


<PAGE>

                          FOR CORPORATE ACKNOWLEDGMENT


STATE OF Oregon     )
                    ) ss.
COUNTY OF Multnomah )

          THIS IS TO CERTIFY that on this 17th day of June, 1992, before me, 
the undersigned, a notary public in and for said State, duly commissioned and 
sworn, personally appeared William Fleming, to me known to be the Director of 
AntiVirals, the corporation that executed the within and foregoing 
instrument, and acknowledged the said instrument to be the free and voluntary 
act and deed of said corporation for the uses and purposes therein mentioned, 
and on oath stated that said individual was authorized to execute said 
instrument.

          WITNESS my hand and official seal the day and year in this
certificate first above written. 



                              /s/ Janet M . Eayes
                              ------------------------------------------------
                              Notary public in and for state of Oregon,
                              residing at

                              ------------------------------------------------
                              My appointment expires 10/20/95










34

<PAGE>

                                   ADDENDUM 1
                           TO COMMERCIAL LEASE BETWEEN
                  RESEARCH WAY INVESTMENTS AND ANTIVIRALS, INC.


     1.  At Tenant's request, from time to time, Landlord will permit
Tenant access to the space between the floor of the Premises and the ceiling of
the first floor area directly below the Premises for the purpose of conducting
inspection, maintenance, and repairs to equipment and conduits.  Tenant shall
request access as far in advance of the actual inspection, repair, or
maintenance as is reasonably possible and shall coordinate the scheduling of the
access so as to minimum disturbance of the first floor tenants that may be
affected by Tenant's access to said area between the floor and the ceiling. 
Tenant shall promptly repair any damage to the floor, the ceiling below the
floor, Landlord's conduits or equipment, or the first floor tenants that is
caused by Tenant. 

     2.  Within a reasonable time of Tenant's request, Landlord shall
provide partitions/dividers for Tenant's use during the term of this Lease. 
Tenant shall install the partitions/dividers at Tenant's expense and shall
repair or replace any damaged or lost partitions/dividers during the term of
this Lease. 

     3.  Tenant shall not be obligated to pay Fixed Rent for the stairs
and stairwell in the Premises.  However, all other terms and provisions of this
Lease shall apply to the stairs and stairwell, including Tenant's obligation to
pay its Percentage Share of Operating Costs and Taxes; without limiting the
foregoing, Tenant shall be responsible for cleaning and maintaining the stairs
and stairwell in good condition throughout the term of the Lease. 

     4.  Tenant shaM have the right to cancel this Lease after Tenant has
paid Fixed Rent on the entire Premises for 48 months; provided, that Tenant
shall give Landlord a minimum of 12 months' prior written notice of Tenant's
intent to cancel, which notice shall be accompanied by a cancellation payment in
the sum of $54,000.00; and, provided further, that Tenant shall not be entitled
to cancel this Lease if Tenant is in default.

     5.  Tenant agrees to pay a leasing commission to Jacobsma & Associates 
in the amount of $34,399.80, which sum shall be paid in installment payments 
equivalent to installments of Fixed Rent on the first day of each month until 
paid in full.  Landlord shall credit Tenant with payments of Fixed Rent 
equivalent to each installment of leasing commission timely paid to Jacobsma 
& Associates.  Notwithstanding the foregoing, Tenant acknowledges that 
Jacobsma & Associates has represented only the interests of Landlord in this 
transaction and in the negotiations for this Lease; there is no fiduciary 
relationship or agency relationship between Jacobsma & Associates and Tenant. 
Tenant shall pay its Percentage Share of Operating Costs and Taxes directly 
to Landlord. 


1

<PAGE>

     6.  Tenant shall have access from the Premises to the upstairs
freight elevator and access from the shipping/receiving area to the freight
elevator on the first floor; Landlord shall have the right to change the route
of the access from time to time. 

     7.  Tenant may, at its option, extend this Lease for three additional
years beyond December 15, 1997 at a Fixed Rent rate of 78CENTS per square foot
of Net Rental Area per month; provided, that Tenant shall give Landlord prior
written notice on or before December 15, 1996, of its intent to extend the
Lease, which notice shall be accompanied by a nonrefundable payment of $20,000
to be applied toward Fixed Rent due and payable during the extended term; and,
provided further, that Tenant shall not be entitled to extend this Lease if
Tenant is in default. 

     8.  Tenant shall have a "second right of refusal" to lease other
space in the Building on the following terms and conditions: prior to Landlord
entering into a lease with a third party for space in the Building, Landlord
shall first offer such space in writing (on the same terms and conditions on
which Landlord is willing to lease to said third party) to CH2M Hill and then to
Tenant herein ("Landlord's Written Notice").  Tenant shall have 10 days, from
the date of Landlord's Written Notice, to deliver written notice to Landlord
unconditionally agreeing to lease such space on the specified terms and
conditions.  If Tenant fails to deliver said written acceptance to Landlord
within the 10-day period, Tenant shall have no further "second right of refusal"
on the space described in Landlord's Written Notice so long as Landlord
thereafter enters into a lease for said space on the terms and conditions
specified in Landlord's Written Notice or on terms and conditions more favorable
to Landlord.  Tenant acknowledges that notwithstanding Landlord's Written
Notice, CH2M Hill has a "first right of refusal" and may preempt Tenant's right
to lease such space.  Notwithstanding the foregoing, Tenant shall have no
"second right of refusal" if Tenant is in default. 

     9.  Landlord hereby agrees to pay Jacobsma & Associates a leasing
commission, if Tenant extends the Lease pursuant to SECTION 7 of this Addendum
or otherwise, as follows: 3% of Rent (Fixed Rent plus Tenant's estimated
Percentage Share of Operating Expenses and Taxes) to be paid during the extended
term of the Lease, provided that no commission shall be payable for extensions
beyond the first 10 years of Tenant's occupancy of the entire Premises; said
commission shall be due and payable in full at the commencement of the extended
term.  Landlord hereby agrees to pay Jacobsma & Associates a leasing commission
if Tenant leases additional space, pursuant to the "second right of refusal" or
otherwise, as follows: 3% of Rent (Fixed Rent plus Tenant's estimated Percentage
Share of Operating Expenses and Taxes) to be paid during the term of the lease
for the additional space, provided, that no commission shall 


2


<PAGE>

be payable for any portion of the lease term that extends beyond the first 10 
years of Tenant's occupancy of the additional space. 

RESEARCH WAY INVESTMENTS, INC.         ANTIVIRALS, INC. 


/s/ Rex Jacobsma                       /s/ William H. Fleming
- -----------------------------------    -------------------------------------

By: Rex Jacobsma                       By:  William H. Fleming
    -------------------------------         ------------------------------------

Its: General Partner                   Its: Director of Corporate Deveploment
    -------------------------------         ------------------------------------










3


<PAGE>

                                    EXHIBIT B

                                       To

                                COMMERCIAL LEASE


                              RULES AND REGULATIONS


     1.  No sidewalks, entrance, passages, courts, elevators, vestibules,
stairways, corridors or halls shall be obstructed or encumbered by Tenant or
used for any purpose other than ingress and egress to and from the Premises or
the Building and if the Premises are situated on the ground floor of the
Building.  Tenants shall further, at Tenant's own expense, keep the sidewalks
and curb directly in front of the Premises clean and free from rubbish.

     2.  No awning or other projection shall be attached to the outside
walls or windows of the Building or Premises without the prior written consent
of Landlord.  No curtains, blinds, shades, drapes or screens shall be attached
to or hung in, or used in connection with any window or door of the Premises,
without the prior written consent of Landlord.  Such awnings, projections,
curtains, blinds, shades, drapes, screens and other fixtures must be of a
quality, type, design, color, material and general appearance approved by
Landlord, and shall be attached in the manner approved by Landlord.  All
electrical fixtures hung in offices or spaces along the perimeter of the
Premises must be fluorescent, of a quality, type, design, bulb color, size and
general appearance approved by Landlord.

     3.  No sign, advertisement, notice or other lettering shall be
exhibited, inscribed, painted or affixed by Tenant on any part of the outside or
inside of the Premises or of the Building without the prior written consent of
Landlord.  In the event of the violation of the foregoing by Tenant, Landlord
may remove same without any liability, and may charge the expense incurred by
such removal to Tenant.  Interior signs on doors and the directory tablet shall
be inscribed, painted or affixed for Tenant by Landlord at the expense of
Tenant, and shall be of a quality, quantity, type, design, color, size, style,
composition, material, location and general appearance acceptable to Landlord.

     4.  The sashes, sash doors, skylights, windows and doors that reflect
or admit light or air into the halls, passageways or other public places in the
Building shall not be covered or obstructed by Tenant, nor shall any bottles,
parcels or other articles be placed on the window sills or in the public
portions of the Building. 

     5.  No show cases or other articles shall be put in front of or
affixed to any part of the exterior of the Building, nor placed in public
portion thereof without the prior written consent of Landlord. 


Page 1

<PAGE>

     6.  The water and wash closets and other plumbing fixtures shall not
be used for any purposes other than those for which they were constructed, and
no sweepings, rubbish, rags or other substances shall be thrown therein.  All
damages resulting from any misuse of the fixtures shall be borne by Tenant to
the extent that Tenant or Tenant's agents, servants, employees, contractors,
visitors or licensees shall have caused the same. 

     7.  Tenant shall not mark, paint, drill into or in any way deface any 
part of the Premises or Building.  No boring, cutting or stringing of wires 
shall be permitted, except with the prior written consent of Landlord, and as 
Landlord may direct. 

     8.  No animal or bird of any kind shall be brought into or kept in or 
about the Premises or Building. 

     9.  Tenant shall not make, or permit to be made, any unseemly or 
disturbing noises or disturb or interfere with occupants of the Building or 
neighboring buildings or premises or those having business with them.  Tenant 
shall not throw anything out of the doors, windows or skylights or down the 
passageways. 

     10.  Neither Tenant nor any of Tenant's agents, servants, employees, 
contractors, visitors or licensees shall at any time bring or keep upon the 
Premises any flammable, combustible or explosive fluid, chemical or substance 
other than those substances in reasonable quantities, customarily used in 
Tenant's operations. 

     11.  No additional locks, bolts or mail slots of any kind shall be 
placed upon any of the doors or windows by Tenant, nor shall any change be 
made in existing locks or the mechanism thereof.  Tenant must, upon the 
termination of the tenancy, restore to Landlord all keys of stores, offices 
and toilet rooms, either furnished to, or otherwise procured by Tenant, and 
in the event of the loss of any keys so furnished, Tenant shall pay to 
Landlord the cost thereof. 

     12.  All removals, or the carrying in or out of any safes, freight, 
furniture, construction material, bulky mater or heavy equipment of any 
description must take place during the hours which Landlord or its agent may 
determine from time to time.  Landlord reserves the right to prescribe the 
weight and position of all safes, which must be placed upon two-inch thick 
plank strips to distribute the weight.  The moving of safes, freight, 
furniture, fixtures, bulky matter or heavy equipment of any kind must be made 
upon previous notice to the Superintendent of the Building and in a manner 
and at times prescribed by him, and the persons employed by Tenant for such 
work are subject to Landlord's prior approval.  Landlord reserves the right 
to inspect all safes, freight or other bulky articles to be brought into the 
Building and to exclude from the Building all safes, freight or other bulky 
articles which violate any of these Rules and Regulations or the Lease of 
which these Rules and Regulations are a part. 

     13.  Tenant shall not engage janitorial or maintenance or other like 
service from any company or persons not approved by Landlord.  Landlord shall 
approve a sufficient number of 


Page 2


<PAGE>

sources of such services to provide Tenant with a reasonable selection, but 
only in such instances and to such extent as Landlord in its judgment shall 
consider consistent with security and proper operation of the Building. 

     14.  Landlord shall have the right to prohibit any advertising or 
business conducted by Tenant referring to the Building which, in Landlord's 
opinion, tends to impair the reputation of the Building or its desirability 
as a first class building for offices and/or commercial services and upon 
notice from Landlord, Tenant shall refrain from or discontinue such 
advertising. 

     15.  Landlord reserves the right (but does not have the obligation) to 
exclude from the Building between the hours of 6:00 p.m. and 8:00 a.m. on all 
days and at all hours on Saturdays, Sundays and legal holidays, all persons 
who do not present a pass to the Building or Project issued by Landlord.  
Landlord may furnish passes to Tenant so that Tenant may validate and issue 
same.  Tenant shall safeguard said passes and shall be responsible for all 
acts of persons in or about the Building or Project who possess a pass issued 
by Tenant. 

     16.  Tenant's contractors shall, while in the Building, be subject to 
and under the control and direction of the Superintendent of the Building 
(but not as agent or servant of said Superintendent of the Building or of 
Landlord). 

     17.  If the Premises is or becomes infested with vermin as a result of 
the use or any misuse or neglect of the Premises by Tenant, its agents, 
servants, employees, contractors, visitors or licensees, Tenant shall 
forthwith at Tenant's expense cause the same to be exterminated from time to 
time to the satisfaction of Landlord and shall employ such licensed 
exterminators as shall be approved in writing in advance by Landlord. 

     18.  The requirements of Tenant will be attended to only upon 
application at the office of the Landlord.  Building personnel shall not 
perform any work or do anything outside of their regular duties, unless under 
special instructions from the office of the Landlord. 

     19.  Canvassing, soliciting and peddling in the Building are prohibited 
and Tenant shall cooperate to prevent the same.

     20.  No water cooler, air conditioning unit or system or other apparatus 
shall be installed or used by Tenant without the written consent of Landlord. 

     21.  There shall not be used in any space, or in the public halls, plaza 
areas or lobbies of the Building, either by Tenant or by jobbers or others, 
in the delivery or receipt of merchandise, any hand trucks or dollies, except 
those equipped with rubber tires and sideguards. 

     22.  Tenant, Tenant's agents, servants, employees, contractors, 
licensees, or visitors shall not park any vehicles in any driveways, service 
entrances, or areas posted "No Parking" and shall comply with any other 
parking restrictions imposed by Landlord from time to time. 


Page 3

<PAGE>

     23.  Tenant shall install and maintain, at Tenant's sole cost and 
expense, an adequate visibly marked (at all times properly operational) fire 
extinguisher next to any duplicating or photocopying machine or similar heat 
producing equipment, which may or may not contain combustible material in the 
Premises. 

     24.  Tenant shall not use the name of the Building for any purpose other 
than as the address of the business to be conducted by Tenant in the 
Premises, nor shall Tenant use any picture of the Building in its 
advertising, stationery or in any other manner without the prior written 
permission of Landlord.  Landlord expressly reserves the right at any time to 
change said name without in any manner being liable to Tenant therefor.

     25.  Tenant shall not prepare any food nor do any cooking, conduct any 
restaurant, luncheonette or cafeteria for the sale or service of food or 
beverages to its employees or to others, or cause or permit any odors of 
cooking or other processes, or otherwise to emanate from the Premises.  
Tenant shall not install or permit the installation or use of any vending 
machine or permit the delivery of any food or beverage to the Premises except 
by such persons and in such manner as are approved in advance in writing by 
Landlord. 

     26.  Tenant, Tenant's agents, servants, employees, contractors, 
licensees, or visitors shall not smoke in the interior common areas of the 
Building. 

     27.  Tenant shall not use the elevator in any way which exceeds the 
posted weight limit of the elevator. 

     28.  Tenant acknowledges that the exercise equipment and facilities may 
only be used by Tenant and its employees; Tenant shall not permit the 
exercise equipment and facilities to be used by Tenant's vendors, customers, 
family members, friends, etc. 




Page 4


<PAGE>

COMMERCIAL LEASE


RESEARCH WAY INVESTMENTS

LANDLORD

ANTIVIRAL, INC.

TENANT




<PAGE>
                                COMMERCIAL LEASE


                             SUMMARY OF LEASE TERMS


A.   EXECUTION DATE:


     --------------------------------------------------------------------------

B.   LANDLORD:

     Research Way Investments, a California Limited Partnership

C.   TENANT:

     Antivirals, Inc., an Oregon corporation 

D.   PREMISES (SECTION 1, EXHIBIT A):

     Approximately 13,180 square feet (not including stairs and stairwell) of
     Net Rentable Area located on the second floor in that certain building
     located and addressed at Research Way, Corvallis, Oregon (the "Building"),
     situated on the real property described on Exhibit C ("Property").  The Net
     Rentable Area of the Building is 89,000 square feet. 

E.   TERM (SECTION 2.1):

     Commencement Date:     June 15, 1992
     Expiration Date:       December 15, 1997
     Length of Term:        5.5 Years

F.   FIXED RENT (SECTION 3.1):


     *First year: $.26 per square foot of Net
     Rentable Area per month; 
     Second year: $.52 per square foot of Net Rentable Area per month;
     Third year: $.52 per square foot of Net Rentable Area per month;
     Fourth year: $.52 per square foot of Net Rentable Area per month; 
     Fifth year through expiration date: $.78 per square foot of Net Rentable
     Area per month; 
     Tenant has paid $0 installments of Fixed Rent in advance totalling the sum
     of $0. 

G.   ADJUSTMENTS TO RENT:

       (i)  CPI Rent Adjustment Region (Section 3.2): N/A                       
                                                      --------------------------


___________________________


     * First year commences when Tenant occupies any portion of the Premises; 
Tenant pays Fixed Rent only on portions that Tenant occupies (prorated to 
nearest 100 square feet), but shall pay Fixed Rent on entire Premises 
commencing December 15, 1992 in any event.  Second year commences 12 months 
after commencement of First year, etc.  All of Tenant's other obligations in 
this Lease commence on the Commencement Date defined in Section E, 
above.

                                  -i-

<PAGE>

      (ii)  Market Value Rent Adjustment Dates (Section 3.3 and Addendum No.
            ________): N/A                                                      
                       ---------------------------------------------------------
H.   SECURITY DEPOSIT (SECTION 4):

     $25,000 00 

I.   OPERATING COSTS AND TAXES (SECTION 5.2):*

     Tenant's Percentage Share of Operating Costs and Taxes: Fourteen and
     ninety-nine hundreds percent (14.99%) 

     Estimate for First Lease Year: $56,036.40 

     * Tenant shall commence payment of its Percentage Share of Operating Costs
     and Taxes on the Commencement Date defined in Section E, above. 

J.   PERMITTED USE (SECTION 6.1):

     Pharmaceutical research and development laboratory. 

K.   TENANT'S INSURANCE REQUIREMENTS (SECTION 13.1):

       (i)  Liability:                     $5,000,000 min. 
      (ii)  All Risk Replacement Cost:     $Cost of replacement 

L.   LANDLORD'S INSURANCE REQUIREMENTS (SECTION 13.2):

       (i)  Liability:                     $5,000,000.00 
      (ii)  Casualty:                      Cost of replacement 
     (iii)  Difference in Conditions:      Actual loss of rents 

M.   ADDRESS FOR NOTICES (SECTION 20.15):

     TO LANDLORD:                        WITH COPIES TO:

     Research Way Investments            Turn-Key Property Management
     c/o Rex Jacobsma                    P.O. Box 1715
     P.O. Box 1833/1508 Olive St.        1508 Olive Street
     Paso Robles, California 93447/93446 Paso Robles, California 93447/93446
     (805) 239-3090                      (805) 2394795
     (805) 239-9088 (FAX)                (805) 239-9088 (FAX)



                                -ii-

<PAGE>

     TO TENANT:                          WITH COPIES TO:

     Antivirals, Inc.                    N/A                                   
     One SW Columbia, Suite 1105         --------------------------------------
     Portland OR 97258
     503) 227-0554
     (503) 227-0751 (FAX)

N.   BROKER(S) (SECTION 20.20):

     Broker(s): Jacobsma & Associates
     Address: P.O. Box 1833, Paso Robles, California 93447
     Party Paying Commission (Landlord or Tenant): Tenant*

     * See Addendum 1

O.   LIST OF EXHIBITS:

     EXHIBIT A - Floor Plan 
     EXHIBIT B - Rules and Regulations 
     EXHIBIT C - Real Property Description 

P.   LIST OF ADDENDA:

     Addendum 1

     The provisions of the lease identified above in parentheses are those
provisions making reference to above-described Lease Terms.  Each such reference
in the Lease shall incorporate the applicable Lease Terms.  In the event of any
conflict between the Summary of Lease Terms and the Lease, the latter shall
control.



                                       -iii-



<PAGE>

                                TABLE OF CONTENTS

ARTICLE                                                     PAGE

1.   USE AND RESTRICTIONS ON USE.. . . . . . . . . . . . . . . . . . . . . .   1

2.   TERM. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   1

3.   RENT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   2

4.   RENT ADJUSTMENTS. . . . . . . . . . . . . . . . . . . . . . . . . . . .   2

5.   REAL ESTATE TAXES.. . . . . . . . . . . . . . . . . . . . . . . . . . .   5

6.   SECURITY DEPOSIT. . . . . . . . . . . . . . . . . . . . . . . . . . . .   7

7.   ALTERATIONS.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   7

8.   REPAIR. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   8

9.   LIENS.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   9

10.  ASSIGNMENT AND SUBLETTING.. . . . . . . . . . . . . . . . . . . . . . .   9

11.  INDEMNIFICATION.  . . . . . . . . . . . . . . . . . . . . . . . . . . .  11

12.  INSURANCE.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  11

13.  WAIVER OF SUBROGATION.. . . . . . . . . . . . . . . . . . . . . . . . .  12

14.  SERVICES AND UTILITIES. . . . . . . . . . . . . . . . . . . . . . . . .  12

15.  HOLDING OVER. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14

16.  SUBORDINATION, ATTORNMENT AND NONDISTURBANCE. . . . . . . . . . . . . .  14

17.  RULES AND REGULATIONS.. . . . . . . . . . . . . . . . . . . . . . . . .  15

18.  REENTRY BY LANDLORD.. . . . . . . . . . . . . . . . . . . . . . . . . .  15

19.  DEFAULT.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16


<PAGE>

20.  REMEDIES. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17

21.  QUIET ENJOYMENT.. . . . . . . . . . . . . . . . . . . . . . . . . . . .  20

22.  DAMAGE BY FIRE, ETC.. . . . . . . . . . . . . . . . . . . . . . . . . .  20

23.  EMINENT DOMAIN. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21

24.  SALE BY LANDLORD. . . . . . . . . . . . . . . . . . . . . . . . . . . .  22

25.  ESTOPPEL CERTIFICATES.. . . . . . . . . . . . . . . . . . . . . . . . .  22

26.  SURRENDER OF PREMISES.. . . . . . . . . . . . . . . . . . . . . . . . .  23

27.  NOTICES.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24

28.  TAXES PAYABLE BY TENANT.. . . . . . . . . . . . . . . . . . . . . . . .  24

29.  RELOCATION BY TENANT. . . . . . . . . . . . . . . . . . . . . . . . . .  24

30.  DEFINED TERMS AND HEADINGS. . . . . . . . . . . . . . . . . . . . . . .  25

31.  ERISA REPRESENTATION. . . . . . . . . . . . . . . . . . . . . . . . . .  25

32.  ENFORCEABILITY. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26

33.  COMMISSIONS.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26

34.  TIME AND APPLICABLE LAW.. . . . . . . . . . . . . . . . . . . . . . . .  26

35.  SUCCESSORS AND ASSIGNS. . . . . . . . . . . . . . . . . . . . . . . . .  26

36.  ENTIRE AGREEMENT. . . . . . . . . . . . . . . . . . . . . . . . . . . .  26

37.  EXAMINATION NOT OPTION. . . . . . . . . . . . . . . . . . . . . . . . .  26

38.  RECORDATION.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27

39.  MUTUAL WAIVER OF JURY TRIAL.. . . . . . . . . . . . . . . . . . . . . .  27

40.  ATTORNEY FEES.. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27


<PAGE>

41.  CORPORATE AUTHORITY.. . . . . . . . . . . . . . . . . . . . . . . . . .  27

42.  RENT SCHEDULE.. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27

43.  FORGIVENESS OF RENT.. . . . . . . . . . . . . . . . . . . . . . . . . .  28

44.  IMPROVEMENTS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28

45.  LIMITATION OF LANDLORD'S LIABILITY. . . . . . . . . . . . . . . . . . .  28

     EXHIBIT A - LEASED PREMISES
     EXHIBIT B - RULES AND REGULATIONS
     GUARANTY


<PAGE>

                                      LEASE



     Landlord hereby leases to Tenant and Tenant
 hereby leases from Landlord 
the Premises set forth and described on the Reference Page.  The Reference 
Page including all terms defined thereon is hereby incorporated as part of 
this Lease.

1.   USE AND RESTRICTIONS ON USE.

     The Premises are to be used solely for the purposes stated on the 
Reference Page.  Tenant shall not do or permit anything to be done in or 
about the Premises which will in any way obstruct or interfere with the 
rights of other tenants or occupants of the Building or injure, annoy, or 
disturb them or allow the Premises to be used for any improper, immoral, 
unlawful, or objectionable purpose.  Tenant shall not commit or suffer the 
commission of any waste in on or about the Premises.  Tenant shall not do or 
permit anything to be done on or about the Premises or bring or keep anything 
therein which will in any way increase the rate of fire insurance upon the 
Building or any of its contents.

2.   TERM.

     The term of this Lease shall be as indicated on the Reference Page 
(unless sooner terminated as herein provided).  Tenant agrees that in the 
event of the inability of Landlord to deliver possession of the Premises on 
the Commencement Date, Landlord shall not be liable for any damage thereby, 
but Tenant shall not be liable for any rent until the time when Landlord can, 
alter notice to Tenant, deliver possession of the Premises to Tenant.  No 
such failure to give possession on the Commencement Date shall affect the 
other obligations of Tenant hereunder, nor shall such failure be construed in 
any way to extend the Term. If Landlord is unable to deliver possession of 
the Premises within ninety (90) days of the Commencement Date (other than as 
a result of strikes, shortages of materials or similar matters beyond the 
reasonable control of Landlord and Tenant is notified by Landlord in writing 
as to such delay), Tenant shall have the option to terminate this Lease 
unless said delay is as a result of:  (a) Tenant's failure to agree to plans 
and specifications; (b) Tenant's request for materials, finishes or 
installations other than Landlord's standard; (c) Tenant's change in 
architectural plans; or (d) performance or completion by a party employed by 
Tenant.  If said delay is the result of any of the foregoing, the 
Commencement Date and the payment of rent hereunder shall be accelerated by 
the number of days of such delay.

     In the event Landlord shall permit Tenant to occu